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Preface 
Coronary artery disease is a major cause of morbidity and mortality in the western 
world (1 ). Depending on the progression and severity of coronary artery disease and the 
myocardial response this may result in angina pectoris, myocardial infarction, chronic 
ischemic heart disease and cardiac death. Several techniques have been developed to evaluate 
patients with known or suspected coronary artery disease. 
In 1973, Strauss and Zaret and coworkers (2,3) hypothesized that exercise should be 
used to maximize differences in relative perfusion bet\veen normal and abnormal coronary 
vascular beds during myocardial perfusion imaging. This is a safe and simple noninvasive 
way of assessing myocardial perfusion at rest and to detect myocardial ischemia. In 1979, 
Wann and colleagues (4) demonstrated that the mechanical consequences of ischemia can be 
detected noninvasively by real-time two-dimensional stress echocardiography. Since then, 
advances in exercise and pharmacological stress protocols, developments in nuclear 
cardiology, and significant improvements in echocardiographic equipment have provided the 
foundation for the growth of myocardial stress imaging (5-11 ). 
Myocardial stress imaging has seen little to parallel its rapid development. Currently, 
noninvasive imaging of the heart using radionuclide tracers under stress and resting 
conditions and dobutamine stress echocardiography are established techniques for the 
evaluation of patients with known or suspected coronary artery disease. Myocardial stress 
imaging can be used for the detection, localization and determination of the functional 
significance of coronary heart disease, preoperative risk stratification, and assessment of 
prognosis (5-11). Furthermore, myocardial viability can be evaluated with dual-isotope 
nuclear imaging and dobutamine stress echocardiography (12,13). As a result, myocardial 
stress imaging has become the workhorse of cardiologists for the evaluation of patients with 
(suspected) ischemic heart disease. This thesis deals with myocardial stress imaging, and 
focuses on both nuclear imaging and dobutamine stress echocardiography. 
Outline of the thesis 
Part 1: Myocardial viability 
Recently, an epidemic of patients with heart failure due to coronary artery disease has 
been reported (14,16). Coronary revascularization can be an alternative treatment in selected 
patients (16, 17). Surgery in this category of patients is however associated with a higher 
morbidity and mortality, and thus a careful selection of patients who may benefit from 
revascularization is necessary (12,13). It has been demonstrated that in the presence of viable 
myocardium revascularization may improve left ventricular function, heart failure symptoms 
and prognosis (12,13,17). The first part of this thesis deals with the assessment of myocardial 
viability using dual-isotope nuclear imaging and dobutamine stress echocardiography. 
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Chapter 1 is a systematic review evaluating the value of the two modalities in the 
detection of coronary artery disease, assessment of prognosis, prediction of functional 
recovery after myocardial infarction, and prediction of recovery of function in patients with 
ischemic cardiomyopathy. In this pooled analysis, only direct comparative studies on nuclear 
imaging and stress echocardiography in the same patients were included. 
In chapter 2 the prevalence of myocardial viability in 83 patients with ischemic 
cardiomyopathy is assessed. To evaluate myocardial viability all patients underwent 
dobutamine stress echocardiography. 
Subsequently, chapter 3 evaluates the prevalence of myocardial viability in 104 
patients using dual-isotope nuclear imaging. Myocardial perfusion as the only criterion of 
viability was compared with combined perfusion and metabolic imaging. 
Next, a consecutive series of 150 patients with ischemic cardiomyopathy with chronic 
electrocardiographic Q wave infarction was studied. Myocardial viability was assessed by the 
end-diastolic wall thickness at resting echocardiography, and additional testing using stress 
echocardiography (chapter 4). 
Chapter 5 evaluates myocardial viability in Q-wave regions in consecutive series of 
148 patients with ischemic cardiomyopathy, who had heart failure as the predominant 
symptom. All 148 patients underwent echocardiography at rest to identify dysfunctional 
myocardial tissue and dual-isotope nuclear imaging to assess myocardial glucose utilization 
and metabolism. 
In chapter 6, the presence of contractile reserve in response to dobutamine infusion 
was studied in patients with stunned and hibernating myocardium. A total of 198 patients 
underwent both stress echocardiography to assess myocardial contractile reserve and dual-
isotope nuclear perfusion imaging. 
Chapter 7 describes the feasibility and image quality of dual-isotope nuclear perfusion 
imaging using acipimox in patients with diabetes mellitus. The study population consisted of 
70 patients, subsets of patients with insulin-dependent diabetes mellitus and with non-insulin 
dependent diabetes mellitus were studied. 
Our aim in chapter 8 was to assess the clinical implications of segments with intact 
perfusion without contractile reserve. A total of 114 patients with ischemic cardiomyopathy 
undergoing surgical revascularization were evaluated using nuclear perfusion imaging and 
low-dose dobutamine stress echocardiography. The findings were subsequently related to 
functional outcome, assessed 9-12 months after coronary revascularization. 
Part 2: Prognosis 
Previous studies have shown that 201Tl myocardial perfusion variables have 
incremental value for the prediction of cardiac events over clinical and exercise test 
information alone (5,6). The new technetium-99m (99mTc) labeled perfusion tracers provide 
an improved image quality, and have a much shorter half-life compared to 201 Tl (7,8). This 
thesis assesses the prognostic value of99mTc myocardial perfusion imaging. 
Chapter 9 reports on the long-term prognostic value of 99mTc-sestamibi myocardial 
perfusion imaging. The study population comprised 531 patients with limited exercise 
capacity. These patients were followed during a 8-year period after nuclear testing. 
In chapter 10 the prognostic value of dobutamine stress 99mTc-tetrofosmin myocardial 
perfusion imaging is assessed in 721 patients with known or suspected coronary artery 
disease. 
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Exercise capacity in patients with diabetes mellitus is often impaired because of non-
cardiac disease, as claudication or polyneuropathy. Chapter 11 describes the prognostic value 
of 99mTc myocardial perfusion imaging in 207 patients with diabetes mellitus unable to 
perform an exercise test. 
As described in chapter 12 our aim was to assess the incremental value of exercise 
99
mTc-tetrofosmin myocardial perfusion imaging for the prediction of cardiac events. A total 
of 655 patients performed 9mTc-tetrofosmin imaging and were followed for 4 years. 
Patients with a normal exercise 99mTc-sestamibi myocardial perfusion images were 
shown to have a favorable outcome at intermediate follow-up. Our aim was to evaluate the 
incidence and predictors of mortality during long-term follow-up after a normal exercise 
99mTc-sestarnibi study in 218 patients. 
Subsequently, we assessed the prognostic significance of reversible perfusion 
abnormalities in patients without angina during dobutamine stress 99mTc-sestamibi imaging 
(chapter 14). The study reports on cardiac events in 224 patients with completely or partially 
reversible perfusion abnormalities during 7-year follow-up. 
Part 3: New techniques 
Recently, new techniques have been proposed for non-invasive evaluation of the heart. 
In this thesis the value of hand-held ultrasound devices and the cardiac markers atrial 
natriuretic peptide and brain natriuretic peptide are evaluated. 
In chapter 15, our objective was to evaluate the influence of left ventricular 
myocardial contractile reserve on atrial natriuretic peptide and brain natriuretic peptide. 
Dobutamine stress echocardiography and plasma natriuretic peptide concentrations were 
assessed in 66 patients with a varying degree of heart failure. 
As described in chapter 16, we tested the diagnostic potential of a hand-held 
ultrasound device for screening for left ventricular hypertrophy. Hand-held echocardiography 
was performed in 100 patients with hypertension. 
Chapter 17 deals with screening for left ventricular dysfunction. The screening 
potential of an hand-carried ultrasound device for LV dysfunction was assessed. 
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Chapter 1 
Noninvasive evaluation of ischemic heart 
disease: myocardial perfusion imaging or 
stress echocardiography? 
Schinkel AFL, Bax JJ, Geleijnse ML, 
Boersma E, Elhendy A, 
Roelandt JRTC, Poldermans D 
Eur Heart J, in press 
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Review Article 
Noninvasive evaluation of ischaemic heart disease: 
myocardial perfusion imaging or stress 
echocardiography? 
A. F. L. Schinkel', J. J. Bax2 , M. L. Geleijnse1, E. Boersma', A. Elhendy1 , 
J. R. T. C. Roeland!1 and D. Poldermans1 
1 Department of Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands; 2Department of Cardiology, 
Leiden University Medical Center, Leiden, The Netherlands 
Introduction 
Stress echocardiography and myocardial perfusion im· 
aging are commonly used noninvasive imaging modali-
ties for the evaluation of ischaemic heart disease. Both 
modalities have proved clinically useful in the entire 
spectrum of coronary artery disease11- 29l. Both tech-
niques can detect coronary artery disease and provide 
prognostic informationP-ZIJ_ Both techniques can iden-
tify low-risk and high-risk subsets among patients with 
known or suspected coronary artery disease and thus 
guide patient management decisions[ls-zq_ In patients 
with acute myocardial infarction, both techniques have 
been used to identify residual viable tissue and predict 
improvement of function over timel22 "261. In patients 
with chronic ischaemicleft ventricular (LV) dysfunction, 
viability assessment with either modality can be used to 
predict improvement of function after revascularization 
and thus guide patient treatrnentl27~291. 
Hence, the use of noninvasive cardiac imaging can 
help guide management and potentially reduce health-
care costsP0l. The question remains what is the optimal 
noninvasive cardiac imaging method in which setting? 
This article evaluates the value of the two modalities in: 
(I) the detection of coronary artery disease, (2) the 
prognosis of coronary artery disease in patients with 
known or suspected coronary artery disease, (3) predic-
tion of functional recovery following acute myocardial 
infarction and ( 4) prediction of functional recovery after 
revascularization in patients with chronic ischaemic LV 
dysfunction. To provide the most objective information, 
only direct comparative studies on stress echocardiogra-
Revision submitted 27 August 2002, and accepted 28 August 2002. 
Correspondence: Don Poldermans, MD, PhD, Thoraxcenter Room 
Ba 300. Department of Cardiology, Erasmus Medical Center, Dr. 
Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. 
phy and perfusion imaging in the same patients are 
included and pooled analysis of the data was performed. 
Methods 
The available studies were identified by MEDLINE 
searches using the following key words: noninvasive 
imaging, stress echocardiography, dobutamine, dipyri-
damole, adenosine, myocardial perfusion imaging, 
technetium-99m sestamibi, technetium-99m tetrofosmin 
and thallium-201. In addition, a manual search of eight 
cardiology and nuclear medicine journals (American 
Heart Journal, American Journal of Cardiology, Circu-
lation, European Heart Journal, Heart, Journal of the 
American College of Cardiology, Journal of Nuclear 
Cardiology, Journal of Nuclear Medicine) from January 
1975 to 2001 was carried out. Only studies that per-
formed a head-to-head comparison between stress 
echocardiography and some form of nuclear imaging 
were selected. From these articles the sensitivity and 
specificity of the techniques were compared. Studies that 
did not provide this information were excluded. From 
the pooled data, weighted sensitivities and specificities 
were calculated. Comparison of sensitivities and specifi-
cities was performed using McNemar testing; a P-value 
<0·05 was considered significant. 
Results 
Detection of coronary artery disease 
Seventeen direct comparisons (1405 patients) with dif-
ferent stressors (five exercise, two adenosine, one dipy-
ridamole, eight dobutamine, and one combined 
adenosine and dobutamine) were identified (Table !). 
Pooling of the data showed a slightly higher overall 
17 
~ 
00 
Table 1 Myocardial perfusion imaging ~·s stress ec/wcardiography ilt tile diagnosis of coronary arte1y disease 
Author Year Pt• Definition of significant CAD 
Sensitivity 
Stress Tracer 
MPT Echocardiography 
Maurerlll 1981 36 ~50% stenosis Exercise TI-201 74%(17/23) 83% {19/23) 
Nguyen12J 1990 25 :2: 50% stenosis Adenosine TI-201 90% (18/20) 60% (12120) 
Galantilll 1991 53 ;;::: 70% stenosis Exercise 11-201 IOO'Yo (27/27) 53%(25/27) 
PozzoJil4 l 1991 75 :2:50% stenosis Exercise Tc-99m 84%(41/49) 71%{35/49) 
Quinones!>~ 1992 ll2 :2: 50% stenosis Exercise TI-201 76% (65/86) 74%(64/86) 
Salustri16J 1992 44 >50% stenosis Exercise Tc-99m 77% (23/30) 67%(20/30) 
Gunalpl7J 1993 27 > 50"/o stenosis Dobutaminc Tc-99m 94%(17/18) 83%(15/18) 
AmanuUah!8l 1993 40 ;;:, 50% stenosis Adenosine Tc-99m 94% (32/34) 74'Yn (25/34) 
Marwickl9l 1993 97 > 50"/o stenosis Adenosine Te-99m 86% (51/59) 58% (34/59) 
Marwickl~l 1993 97 >50% stenosis Dobutaminc Tc-99m 80"/o(47/59) 85% (50{59) 
Marwickl10l 1993 217 >50% stenosis Dobutamine Tc-99m 76% (108/142) 72% (1 02/142) 
Forsterf1 lJ 1993 21 >50% stenosis Dobutamine Tc-99m 83%(10/12) 75% (9/12) 
Scniorf12l 1994 61 > 50"/o stenosis Dobutaminc Tc-99m 95%(42/44) 93% (41144) 
Holl3J 1995 54 ;:>::50% stenosis Dobutamine Tl-201 98% (42/43) 93% (40/43) 
Kisacikl14l 1996 69 > 50"/o stenosis Dobutamine Tc-99m 96% (45/47) 94%(44/47) 
Huangl15J 1997 93 ;;:, 50% stenosis Dobutaminc 11-201 90% (60/67) 93% (62/67) 
Parodil16l 1999 101 ;;:, 50% stenosis Dipyridamole Tc-99m 79% (63/80) 78% (62/80) 
Smart[ 17] 2000 18.1 ;;:, 50% stenosis Dobutamine Tc-99m 80% (95/119) 87%(104/119) 
Pooled analysis 84'Yo (803/959) 80% (765/959) 
MPI-myocardial perfusion imaging; Tc-99m=Technetium-99m; Tl-201 =Thallium-201 chloride. 
Specificity 
MP! Echocardiography 
92% (121!3) 92% (12/13) 
100% (5/5) 100%(5/5) 
92% (24/26) 96% (25/26) 
88% (23/26) 96% (25/26) 
8l'Yo(21/26) 88% (23/26) 
86%(12/14) 71%(10114) 
88% (8/9) 88% (8/9) 
100%(6/6) 100%(6/6) 
71% (27/38) 87% (33/38) 
74% (28/38) 82%(31f38) 
67'!/o (50175) 83% {62175) 
89% (8/9) 89% (8/9) 
71%(12/17) 94% (16117) 
7.1%(8/11) 73% (8/11) 
64% (14/22) 86% (19/22) 
81%(21/26) 77% (20/26) 
90%(19/21) 76% (16/21) 
73% (47/64) 91%(58/64) 
77% (345/446) 86% (385/446) 
r angina ECG changes ~ 
1 
./ systolic dysfunct;on 
diastolic dysfunctiOn 
hypoperfusion 
flow maldistribution 
Time from onset of ischemia ---+ 
Figure 1 The ischacmic cascade represents a sequence 
of pathophysiologic events caused by coronary artery 
disease. Nuclear imaging probes an earlier event (hypo-
perfusion) in the ischaemic cascade than stress echocardi-
ography does (systolic dysfunction). 
sensitivity for myocardial perfusion imaging as com-
pared to stress echocardiography (84% vs 80%, P<0·05). 
This finding is in line with the ischaemic cascade (Fig. 1), 
since perlusion abnormalities (detected by perfusion 
imaging) proceed systolic dysfunction (detected by stress 
echocardiography)l3 1l. 
On the other hand, stress echocardiography was more 
specific compared to perfusion imaging (86% vs 77%, 
P=O·OOJ). Figure 2 demonstrates the differences in 
sensitivity and specificity of the two modalities. It should 
be noted that the gold standard for the presence/absence 
of coronary artery disease was angiography in these 
studies, which may affect specificity of the tests. In the 
majority of the studies ~50% stenosis was used as 
the definition of significant coronary artery disease. In 
the study of Marwick et a!. [9J, results were also analysed 
with a cutoff of >70% stenosis. The results were altered 
little using this cutoff, as only four patients had a 
stenosis severity of 50-70%. 
Pharmacological stress can be a useful alternative to 
exercise stress protocols in patients who are unable to 
exercise because of neurological, orthopedic, or periph-
eral vascular disease. Because wall motion abnormalities 
are a consequence of myocardial ischaemia, dobutamine 
may be more effective than vasodilator (adenosine or 
dipyridamole) stress echocardiographyP2l. In line with 
this, combined data from seven direct comparative 
studies demonstrated that dobutamine stress echocardi-
ography had a higher sensitivity for the diagnosis of 
coronary artery disease than vasodilator stress echo-
cardiography, while specificity was similar. When 
dobutamine stress echocardiography was compared to 
dobutamine or vasodilator perfusion scintigraphy, dob-
utamine echocardiography was equally sensitive but 
slightly more specific than perfusion scintigraphyl33l. 
Two subgroups of patients were analysed separately: 
hypertensive patients and female patients. In patients 
with hypertension, abnormal thallium perfusion results 
lo Echocardiography 1111 Nuclear I 
100 -
75 
~ 50 
25 
0 
Sensitivity Specificity 
Figure 2 Sensitivity and specificity of stress echocardi-
ography and nuclear imaging for the detection of coronary 
artery disease (data based on referencesl1- 171). o = 
echocardiograpby; Ill =nuclear. 
have been demonstrated in the absence of obstructive 
coronary artery disease[34· 3~1; this may lower specificity. 
Summarized data from two studies (Table 2, 286 
patients) have demonstrated a somewhat higher sensitiv-
ity for perfusion imaging compared to stress echocardi-
ography (87% vs 74%, P<0·005), and confirmed the 
lower specificity for perfusion imaging (44% vs 85%, 
P<O·OOl)l36· 37l. 
The diagnosis of coronary artery disease in women 
may be more challenging due to the lower prevalence of 
coronary artery disease. In addition, single-vessel disease 
is a common finding in women[38•39l. The accuracy of 
perfusion imaging appears to be decreased in women 
with breast tissue attenuationP9l, and the smaller LV 
chamber size in women[40l. Pooled data from three direct 
comparisons[41-43J revealed a comparable sensitivity of 
the two techniques (71% vs 80%, P=ns) (175 patients, 
Table 2) with a higher specificity of stress echocardiog-
raphy for the detection of coronary artery disease (72% 
vs 89%, P<O·Ol). Comparative studies on adenosine 
stress imaging in patients with hypertension and women 
are not available. Further research on the relative value 
of adenosine stress echocardiography and nuclear 
perfusion imaging in these subgroups is needed. 
Prognosis in coronary artery disease 
Noninvasive cardiac imaging is frequently used for risk 
stratification of patients with known or suspected cor-
onary artery disease. There are two direct comparisons 
available on the prognostic value of myocardial per-
fusion imaging and stress echocardiography. Geleijnse 
et a[.P 8l studied 220 patients with chest pain \vith 
dobutamine-atropine stress echocardiography and sim-
ultaneous technetium-99m sestamibi single photon emis-
sion computed tomography (SPECT) imaging. During 
follow-up of 31 ± 15 months, 24 patients had hard 
cardiac events (nonfatal myocardial infarction or 
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Table 2 J.l1yocardial perfusion imaging vs stress echocardiography in special patient subsets 
Definition of Sensitivity Specificity 
Author Year Pts significant Stress Tracer 
CAD MPI Echocardiography MPI Echocardiography 
Hypertension 
ElhendyP6l 1998 84 ;;:>:50% stenosis Dobutamine Tc-99m 67% (44/66) 73% (48/66) 83% (151l8) 83% (15/18) 
Fragassol37l 1999 101 >50% stenosis Dipyridamole Tc-99rn 98% (56/57) 61% (35/57) 36% (16/44) 91%(40/44) 
Fragassol'7l 1999 101 >50% stenosis Dobutamine Tc-99m 98% (56/57) 88% (50/57) 36% (16/44) 80% (35144) 
Pooled analysis 87% (156/180) 74'Yo (1331180) 44% (471106) 85% (90/106) 
Women 
Takcuchi141 l \996 61 ;;:>:50% stenosis Dobutamine Tl-201 78% (14/18) 72% (13/18) 70'Yo (30/43) 91%(39/43) 
Elhendyi"21 1998 70 ~50% stenosis Dobutamine Tc-99m 64% (29/45) 78% (35/45) 72% (18/25) 92% (23125) 
Ho1431 1998 44 ;;:>:50% stenosis Dobutamine Tl-201 79% (19124) 92% (22/24) 75% (15120) 80% (16/20) 
Pooled analysis 71%(62/87) 80% (70/87) 72% (63/88) 89% (78/88) 
MPio:=myocardial perfusion imaging; Tc-99m=Technetium-99m; Tl-201 =Thallium-201 chloride. 
cardiac death). A normal test was related to a good 
prognosis, with a low annual cardiac event rate of 0·4% 
by echocardiography and 0·5% by perfusion imaging. In 
that study, stress echocardiography and technetium-99m 
sestamibi SPECT provided comparable prognostic 
information. 
Olmos et a!Y 9l studied 248 patients who underwent 
exercise echocardiography simultaneously with thallium-
201 SPECT. During follow-up (obtained in 225 patients 
with a mean follow-up of 3·7 ± 2·0 years), 64 cardiac 
events occurred (eight nonfatal infarctions and seven 
cardiac deaths). A significant difference was observed 
between patients with normal and abnormal tests for all 
end points, including death alone, for both modalities. 
Overall cardiac event rate in patients with normal test 
results was comparable for both exercise echocardiogra-
phy and thallium-201 SPECT (1·05% vs H3%, ns). 
Annual cardiac death rate was favorably low for both 
normal echocardiography and normal SPECT imaging 
(0·08% vs 0·08%, ns). Since only two direct comparisons 
are available, more large studies are required to fully 
elucidate the relative prognostic value of myocardial 
perfusion imaging and stress echocardiography. 
Assessment of myocardial viability 
The hallmark of viability on dobutamine echocardiog-
raphy is the improvement of wall motion during the 
infusion of low-dose dobutamine {5-10 ).lg. kg- 1 
min- 1). More recent studies have employed a low-high 
dose protocol (with dosages up to 40 ).lg. kg- 1 min- 1, 
with the addition of atropine). This protocol allows 
assessment of both viability (response during low-dose 
dobutamine) and stress-induced ischaemia (response 
during high-dose dobutamine). For nuclear imaging, 
different techniques are available. Thallium-201 imaging 
can be used to evaluate perfuSion and cell membrane 
integrity. Two protocols are used mainly: rest-
redistribution imaging and stress-redistribution-
reinjection imagingl27- 29l. While rest-redistribution 
imaging provides only information on myocardial 
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viability, the reinjection protocol allows assessment of 
stress-induced ischaemia and viability. 
Technetium-99m sestamibi can be used to assess per-
fusion and intact mitochondria. Sestamibi imaging is 
performed under resting conditions; in the absence of a 
stress study, this protocol only provides information on 
viability. It has been demonstrated that the addition of 
nitrates before tracer administration enhances viability 
detectionl441. 
Glucose utilization can be evaluated with F18-
fiuorodeoxyglucose (FDG). FDG imaging can now-
adays be performed with positron emission tomography 
and SPECT. The introduction of SPECT imaging has 
contributed to a more widespread use of FDGl45l. Gen-
erally, cardiac FDG uptake is compa1ed with regional 
perfusion. Viability is defined when perfusion/FDG up-
take is normal, or when perf us ion is reduced with 
enhanced FDG uptake. 
Prediction of functional recovery after acute myocardial 
infarction 
The phenomenon of reversible dysfunction after myo-
cardial infarction, known as stunning has been well 
establishedl46.47l. The presence of viable, but stunned 
myocardium has been used to predict functional recov-
ery. Five studiesl2l-l6J with 209 patients and 958 dyssyn-
ergic myocardial segments, compared perfusion imaging 
with stress echocardiography in the same patient popu-
lation after acute myocardial infarction and aimed at the 
prediction of recovery of function (Table 3). All of these 
studies used dobutamine stress, in most studies a low 
dose dobutamine protocol was employed for echocardi-
ography. Nuclear imaging tended to have a higher 
sensitivity (although not significant), whereas stress 
echocardiography was more specific in the prediction of 
recovery of function (Fig. 3). 
Prediction of functional recovery after revascularization 
in chronic ischaemic LV dysfunction 
Table 4 shows the accuracy of different viability tech-
niques for the prediction of improvement of function 
Table 3 Prediction of recovery of function afteJ" acute myocardial i11jarctiou: myocardial perfusion imaging vs stress 
echocardiography 
Dyssynergic Sensitivity Specificity Author Year Pts Techniques 
segments MPI Echocardiography MPI Echocardiography 
ElhendyP"I 1996 32 !12 Tl-201 RR vs LDDE 77% (27/35) 77% (27/35) 57% (44177) 84% {65!77) 
Le Feuvrel231 1996 45 235 Tl-201 RI vs LDDE 54% (59/109) 53% (58/109) 88%(111/126) 95% (120/126) 
Smart1241 1997 64 399 Tl-201 RR vs HDDE 68% (140/207) 88% (183/207) 70% (1341192) 80% (1531192) 
Spinc1Jil25J 1999 49 108 Tl-201 vs LDDE 87% (53/61) 66% (40/61) 74% (35/47) 89% (42/47) 
Anselmil261 2000 19 104 Tl-201 RR vs LDDE 88% (23/26) 69%(18/26) 36% (28178) 88% (69178) 
Pooled analysis 69% (302/438) 74% (326/438) 68% (352/520) 86% (449/520) 
HDDE=low-high dose dobutamine echocardiography; LDDE=low dose dobutamine echocardiography; MPI:::myocardial perfusion 
imaging; RI=reinjection; RR=rest-redistribution; Tl-201=thallium-201 chloride. 
after revascularization129l. The nuclear imaging tech-
niques appear to have a higher sensitivity for the 
prediction of functional recovery whereas stress echocar-
diography appears more specific. Various studies have 
directly compared some form of nuclear imaging to 
stress echocardiography. Panza et af.148l have performed 
a head-to-head comparison between thallium-201 imag-
I :::J DSE II Nuclear I 
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Figure 3 Sensithity and specificity of dobutamine stress 
echocard.iography and nuclear imaging for the prediction 
of functional outcome in acute myocardial infarction (data 
based on referencesll2-Z6l). O=DSE; llll=nuclear. 
ing and dobutamine stress echocardiography in patients 
with chronic ischaemic LV dysfunction. A total of 311 
segments were analysed by both techniques; 84% of 
these were classified as viable and 16% as nonviable on 
thallium-201 imaging. The majority of the 'thallium-201 
nonviable segments' did not exhibit contractile reserve. 
However, an additional 36% of the 'thallium-201 viable 
segments' also did not exhibit contractile reserve. Thus, 
the results indicated that thallium-201 imaging was more 
sensitive than dobutamine echocardiography for the 
detection of viable tissue. Similar results were obtained 
by Cornel et af.l491 who evaluated 40 patients with 
chronic ischaemic LV dysfunction with FDG imaging 
and dobutamine echocardiography. Again, nuclear im-
aging was more sensitive for the detection of viable 
tissue as evidenced by the 27% of the dysfunctional 
segments -with FDG uptake but without contractile 
reserve (Fig. 4). 
Various studies have subsequently compared the pre-
dictive accuracy of nuclear imaging with dobutamine 
echocardiography. Currently, a total of 18 studiesi>o-o7) 
(with 563 patients) have performed a direct comparison 
between the two modalities (Table 5). Different nuclear 
techniques were used: three studies used FDG PET, five 
thallium-201 reinjection and 10 thallium-201 rest-
redistribution. Two studies used low-high dose dob-
utamine echocardiography and the remaining 16 used 
low dose dobutamine echocardiography. Pooling of 
Table 4 Accuracy of tile different viability techniques. Data based on pooled analysis 
of data available in the literature (based on refel"ellcef291) 
Technique No. studies No. of pls Sensitivity Specificity PPV 
]',"PV 
(%) (%) (%) (%) 
DSE 32 1090 81 80 77 85 
Tl-201 RR 22 557 86 59 69 80 
Tl-201 Rl 11 301 88 50 57 83 
MIBI 20 488 81 66 71 77 
FOG PET 20 598 93 58 71 86 
DSE=dobutamine stress echocardiography; FDG=F18~fiuorodeoxyglucose; MIBI=technetium-
99m sestamibi; NPV::onegativc predictive value: PET=positron emission tomography; 
PPV=positive predictive value: RR=rcst~redistribution; Rl=reinjection; Tl-201=thallium-201 
chloride. 
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Figure 4 Agreement and disagreement between FOG SPECT and low-dose dobutamine 
echocardiography in dysfunctional myocardium (reprinted with permission from 
rcferencel491). 
Tahle 5 Head-to-head comparisons between nuclear imaging and dohutamine 
eclwcardiography for t!Je prediction of improvement of regional function post-
revasculadzation (Table modified from referenC£f291) 
Author Techniques Assessing No. of pts 
Gerber[501 FDG PET vs LODE Vvs V 39 
Baerl5'1 FDG PET vs LDDE V VS V 42 
Paganol52l FDG PET vs LODE Vvs V 30 
Vanoverschelctel031 Tl-201 RI vs LDDE V+l vs V 73 
Arnesel541 Tl-201 RI vs LODE V+Ivs V 38 
Baxl551 Tl-201 RI vs LDDE V+l vs V 17 
Haquc! 5"1 TI-201 Rl vs LODE V+l vs V 26 
Kos\opou!osl'71 Tl-201 RI vs LDDE V+J vs V 31 
Marzullo150l Tl-201 RR vs LDDE Vvs V 14 
Qureshil59l Tl-201 RR vs HDDE VvsV+I 34 
Alfieri1601 Tl-201 RR vs LDDE Vvs V 13 
Perrrone-Filardi161 l Tl-201 RR vs LDDE Vvs V 18 
Chameyi62l Tl-201 RR vs LDDE Vvs V 14 
Naguehi6.1l Tl-201 RR vs HDDE VvsV+I 19 
Pacel641 Tl-201 RR vs LDDE Vvs V 46 
SeniorW'J Tl-201 RR vs LDDE V V$ V 22 
Sicari1661 Tl-201 RR vs LDDE v vs v 57 
Gunning1671 Tl-201 RR vs LDDE V VS V 30 
FDG=FlS-fluorodeoxyglucose; HDDE=low-high dose dobutamine echocardiography: l=stress-
inducible ischaemia; LDDE=low dose dobutamine echocardiography; PET=positron emission 
tomography: RI ::=reinjection; RR=rest-redistribution; Tl-201 :::thallium-201 chloride; 
V=viability.[,J 
these data yielded a higher sensitivity for nuclear imag-
ing (88% vs 76%, P<O·OS) and a higher specificity for 
dobutamine echocardiography (81% vs 53%, P<0·05). 
In eight studies (see Table 5) some form of stress 
imaging (either thallium-201 reinjection or low-high 
dose dobutamine echocardiography) was used; to make 
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the comparison more balanced (and only restricted to 
viability assessment) the analysis was repeated after 
exclusion of these eight studies. The discrepancy be-
tween nuclear imaging and dobutamine echocardiogra-
phy for the prediction of functional outcome after 
revascularization became even more outspoken (Fig. 5). 
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Figure 5 Bar graph illustrating sensitivities and specifi-
cities of nuclear imaging and dobutamiue stress echocar-
diography to predict improvement of function post-
revascularization in patients with chronic ischaemic left 
ventricular dysfunction (data based on references15(1-
sz,s8,6(0-62J). D = DSE; 1111! =nuclear. 
It is conceivable that different levels of ultrastructural 
cell damage account for this discrepancy: the inotropic 
response during dobutamine stimulation may be lost 
while more basal characteristics such as cell membrane 
integrity and glucose utilization are still intact. Besides 
prediction of improvement of function after revascular-
ization, prediction of long-tenn survival may be more 
important. Currently, no direct comparative studies are 
available on the prognostic value of nuclear imaging 
and stress echocardiography in patients with ischaemic 
cardiomyopathy. 
Recent developments: simultaneous 
assessment of function and perfusion 
Recently, different technical developments have been 
implemented in both perfusion imaging and stress 
echocardiography that further optimized the techniques. 
Myocardial perfusion imaging has been improved by the 
introduction of new cameras, imaging protocols, attenu-
ation and scatter correction[68 ' 691. For echocardiogra-
phy, second harmonic imaging has markedly improved 
endocardial border detection, which could even be fur-
ther enhanced by intravenous administration of contrast 
agents that opacify the LV cavity[70-nJ. Colour kinesis 
and tissue Doppler echocardiography may allow quan-
tification of function!73·741, which may enhance repro-
ducibility and diagnostic accuracy. 
Other recent developments have aimed at providing 
integrated information on function and perfusion. Both 
gated SPECT imaging and contrast echocardiography 
al!O\v simultaneous assessment of function and per-
fusionF5·761. Over the past 5 years ECG-gated SPECT 
has become state-of-the-art in cardiac myocardial per-
fusion imaging. Various comparative studies have dem-
onstrated excellent accuracy of gated SPECT for the 
assessment of both regional and global LV function[77J. 
Smanio and coworkers!78l have demonstrated that com-
bination of perfusion and function (assessed by gating) 
resulted in significantly higher diagnostic accuracy for 
detection/exclusion of coronary artery disease. More-
over, the integrated infonnation of function and per-
fusion allows superior prognostification in patients 
with known or suspected coronary artery disease, as 
demonstrated recently by Sharir e/ a!P91. 
Contrast echocardiography also allows simultaneous 
assessment of function and perfusion. With the intro-
duction of contrast agents that can be administered 
intravenously, the use of contrast echocardiography has 
now become feasible outside the catheterization labora-
tory. In combination with hannonic and intermittent 
imaging, quantitative assessment of perfusion has 
become possible. 
Recently, Kaul et af_[SOJ have shown an excellent 
concordance between contrast echocardiography and 
myocardial perfusion imaging. In 30 patients, the agree-
ment for detecting absence/presence of coronary artery 
disease was 86%. However. two multicentre trials have 
demonstrated a less favourable agreement between per-
fusion imaging and contrast echocardiography[Bl.H2J. 
Marwick and coworkersiBlJ showed that. for the detec-
tion of extensive perfusion defects on SPECT perfusion 
imaging, contrast echocardiography had a sensitivity 
ranging from 13% to 48% with a specificity ranging from 
63% to 100%. Jucquois et al.[82l suggested that the 
discrepancy between the two techniques could in part be 
related to attenuation artifacts on SPECT (inferior wall) 
and suboptimal visualization of the anterior and lateral 
walls by echocardiography. However, in experienced 
settings, adequate quantification of myocardial blood 
flow and quantification of coronary artery stenoses is 
possible, as demonstrated by Wei et af.!8H 41. Besides 
detection of coronary artery disease, evaluation of 
patients with acute myocardial infarction is feasible with 
contrast echocardiography and is particularly useful for 
assessment of 'the no-refiow phenomenon' after throm-
bolysis or percutaneous interventions[85· 86l. Finally, the 
feasibility of contrast echocardiog:raphy for assessment 
of viability after acute infarction[87l and in the setting of 
chronic LV dysfunction[SBJ has been demonstrated. 
Thus, in the near future, the combined assessment 
of perfusion and function by echocardiography and 
SPECT will allow a more complete assessment of 
patients with coronary artery disease. 
Clinical implications and conclusions 
Both myocardial perfusion imaging and stress echo-
cardiography have proved to be extremely useful non-
invasive tests for the evaluation of coronary artery 
disease[l-·291. Due to basic differences between the two 
tests, perfusion imaging is a sensitive test \\lith a some-
what lower specificity for the detection of coronary 
artery disease; the converse is true for stress 
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echocardiography[l-171_ This systematic review focuses 
on direct comparative studies on stress echocardiogra-
phy and perfusion imaging in order to provide the most 
objective information. Nevertheless, a potential risk of 
pooling data from different studies is to mix patients 
with different clinical characteristics and risk profile. 
Two available direct head-to-head comparative 
studies demonstrated a similar prognostic value of per-
fusion imaging and stress echocardiography. Larger 
comparisons are needed to draw further conclusions. 
For the assessment of myocardial viability after acute 
infarction the modalities seem to be equally sensitive, 
whereas stress echocardiography is the more specific 
test[22- 26l. Hence, for the early assessment of viability 
stress echocardiography may be preferable. However, 
specificity is determined by segments that are nonviable 
that do not improve in function. A lower specificity 
suggests that a substantial percentage of segments that 
are viable do not recover in function. Most studies have 
evaluated recovery of function at a rather short time-
interval after infarction ( <3 months) and longer 
follow-up may be needed. 
In patients with chronic ischaemic ventricular dys-
function, nuclear imaging has a high sensitivity for the 
detection of viable myocardium and a low specificity, 
whereas the converse is true for stress echo-
cardiography[S0·-671_ The lower specificity of nuclear im-
aging can again be an issue of duration of follow-up. 
Recent data have demonstrated that a substantial per-
centage of segments need longer time after revascular-
ization to (fully) recover in functionls 9J_ In addition, 
large direct comparative studies are required to evaluate 
the prognostic value of nuclear imaging and stress 
echocardiography in patients with chronic ischaemic left 
ventricular dysfunction. 
In conclusion, the current analysis demonstrated that 
both techniques are useful in the evaluation of patients 
with coronary artery disease, although small differences 
between accuracies exist in different settings. The most 
important factor for using a test remains the local 
expertise and availability of these imaging modalities. In 
addition, patient characteristics (habitus, acoustic win-
dow, pregnancy) may influence the choice of the tech-
nique, and finally the studies discussed generally reflect 
the experience in university centers and many of these 
studies may be influenced by selection and referral bias, 
which limits application of the results to the general 
population. 
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How Many Patients With Ischemic Cardiomyopathy 
Exhibit Viable Myocardium? 
Arend F.L. Schinkel, MD, Jeroen J. Box, MD, Eric Boersma, PhD, Abdou Elhendy, MD, 
Jos R.T.C. Roelandt, MD, and Don Poldermans, MD 
S evere left ventricular (LV) dysfunction secondary to chronic coronary artery disease is a major prob-
lem in clinical cardiology. 1 Incidence is increasing 
and the severity of LV dysfunction is related to clin-
ical outcome. L 2 Current options of treatment include 
medical therapy and heart transplantation. Transplan-
tation is associated with excellent survival, but the 
number of donor hearts is limited, and medical ther-
apy is still suboptimaL 1-·3 Coronary revascularization 
can be an alternative treatment in selected patients. 
However, surgery in these patients is associated with 
higher morbidity and mortality, and thus a careful 
selection of patients who may benefit from revascu-
larization is necessary to offset this higher risk. It has 
been demonstrated that in the presence of viable myo-
cardium, revascularization may improve LV function, 
heart failure symptoms, and prognosis.4 •5 In view of 
the rapidly increasing number of patients with isch-
emic cardiomyopathy and the suboptimal therapeutic 
options, it is of interest to know how many patients 
may be eligible (based on viability assessment) for 
coronary revascularization. This information is cur-
rently not available. To establish the prevalence of 
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myocardial viability, consecutive patients who had 
ischemic cardiomyopathy were studied with debut-
amine stress echocardiography. 
The study population comprised 83 consecutive 
patients with chronic coronary artery disease and a LV 
ejection fraction (EF) of :<:;35%, who presented with 
heart failure symptoms. Patients with primary cardio-
myopathy or significant valvular heart disease were 
not included. All patients underwent echocardiogra-
phy at rest to identify regional dysfunction, followed 
by dobutamine stress to detect residual viability in 
these regions. The local medical ethics committee 
approved the protocol and all patients gave informed 
consent. 
All echocardiograms were performed with a Sonos 
5500 imaging system (Andover, Massachusetts) with 
a 1.8-:MHz transducer using second harmonic imaging 
to optimize endocardial border visualization. After 
baseline echocardiography, dobutamine was adminis-
tered, starting at a dose of 5 p,glkg based on body 
weight per minute for 5 minutes, followed by a 10 
p..g/kg/min dose for 5 minutes (low dose). Incremental 
dobutamine doses of 10 p..gikg/min were then given at 
3-minute intervals up to a dose of 40 p,g/kg/min, and 
atropine was added, if necessary. Test end points 
were: target heart rate, extensive new wall motion 
abnormalities, ST-segment depression 2=2 mm, severe 
angina, a decrease in systolic blood pressure >40 mm 
Hg, blood pressure >2401120 mm Hg, and significant 
(supra)ventricular arrhythmia. The echocardiograms 
were digitized on optical disks and scored by 2 expe-
rienced reviewers using a 16-segment model.6 Re-
31 
-TABLE I Clinical Characteristics of 83 Patients Who 
Underwent Dobutomine Stress Echocordiogrophy 
Clinical Features No. of Patients 
Age (yrs ::':: SD) 59± 10 
Moo 70 (84%) 
Previous Ml 78(94%) 
Q-wove Ml 66(80%) 
Anterior Ml 57(69%) 
Septal Ml 15 (18%) 
lateral Ml 18 (22%) 
Inferior/posterior Ml 27 (33%) 
Previous CABG 13 (16%) 
Previous PTCA 7 (8%) 
Diabetes mellitus 13 (16%) 
Smoking previous/current 29 (35%)/30 (36%) 
Hypertension previous/current 5 (6%)/11 (13%) 
Multivessel disease 71 (66%) 
LBBB 9 (11%) 
RBBB 3 (4%) 
LVEF s:20% 19 (23%) 
LVEF >20% and s:JO% 41 (49%) 
LVEF >30% and s:35% 23 (28%) 
Dolo ore presented'" numbers[%). There were no patient. with o Ml, PTCA, 
or CABG <3 months before viability testing. 
CABG = corMory artery bypo" graft surgery; LBSS ~ left bundle bronch 
block; Ml ~ myocordiol infarction; PTCA ~ percutoneou• tr<lnoluminol core-
nory ongioplosty; RBBB ~ right bundle bronch block. 
panent was cJassmeu as v1at>1e m me presence or 2:4 
dysfunctional viable segments.7 
L VEF was assessed by radionuclide ventriculogra-
phy at rest in all patients. A small field-of-view 
gamma camera system (Orbiter, Siemens, Erlangen, 
Germany) was used; after injection of technetium-99 
m (740 MBq), radionuclide ventriculography was per-
formed at rest. L VEF was calculated by standard 
methods (Odyssey VP, Picker, Cleveland, Ohio).7 
All continuous data are expressed as mean ± SD, 
percentages are rounded. Continuous variables were 
compared using the Student's t test for unpaired sam-
ples. Differences betvleen proportions were compared 
using the chi-square test. If the distribution was not 
normal, the nonpararnetric Wilcoxon test and the 
Spearman correlation analysis was used. A p value of 
<0.05 was considered statistically significant. 
The clinical characteristics of the study population 
are listed in Table 1. Heart failure was the principal 
clinical presentation in all patients; New York Hearl 
Association (NYHA) functional class was an average 
of2.8 ± 0.6 (with 80% of the patients in NYHA class 
III or IV). L VEF was severely depressed (mean 25 ± 
7%, range 10% to 35%). Medication consisted of 
aspirin and/or oral anticoagulants (92%), angiotensin-
converting enzyme inhibitors 
(84%), f3-blockers (52%), digoxin 
Normal Dysfunctional 
(27%), diuretics (63%), and nitrates 
(70%). 
Heart rate increased from 78 ± 
hypokinetic 36% 
normal 
35% 
severe 
~hypokinesia 
13 beats/min at rest to 118 ± 17 
beats/min at peak stress (p 
<0.0001). Overall, systolic blood 
pressure did not significantly 
change during dobutarnine infusion. 
Test end points were target hearl 
rate (n = 76, 92%), severe ischemia 
on electrocardiography (n = 4, 5%). 
severe angina (n = 2, 2%), or a 
decrease in systolic blood pressure 
of>40mmHg(n= 1, 1%).Apeak 
akinesia 
dobutamine infusion dose of 40 Jl-gl 
kg/min was used in 59 patients 
(71%); 37 patients received atro-
pine. Echocardiographic analysis 
was performed on 1,328 segments 
and revealed 143 normal and 226 
mild hypokinetic segments. Of 959 
FIGURE 1. Incidence of 5 po:ttems of conlro:ctile function in 1,328 LV segments; 959 
segments (72%) were dysfunctional, ond 369 segments (28%) exhibited normal con-
lro:ctile function. 
gional wall motion and systolic wall thickening were 
scored on a 5-point scale: 1 = normal, 2 = mildly 
hypokinetic, 3 = severely hypokinetic, 4 = akinetic, 
and 5 = dyskinetic. Myocardial segments were con-
sidered normal if the regional wall motion was normal 
or mildly hypokinetic. Only dysfunctional segments 
(severe hypokinesia, akinesia, or dyskinesia at echo-
cardiography at rest) were evaluated for myocardial 
viability. Segments with an improvement, worsening, 
or a biphasic wall motion response during stress echo-
cardiography were considered viable. Segments with 
unchanged wall motion were considered nonviable. A 
32 
dysfunctional segments (72%), 484 
segments exhibited severe hypoki-
nesia, 460 segments had akinesia, and 15 had dyski-
nesia (Figure 1). Patients had an average of 11.6 ± 3.9 
dysfunctional segments. During dobutamine stress 
echocardiography, 205 dysfunctional segments exhib-
ited sustained improvement, 47 worsening, and 86 
segments had a biphasic response. Thus, a total of338 
dysfunctional segments (35%) were considered viable 
(Figure 2). Moreover, 39% of these segments demon-
strated a limited coronary flow reserve (showing direct 
worsening during dobutamine infusion or a biphasic 
response). Patients had an average of 4.1 ± 3.2 dys-
functional but viable segments; those with a L VEF 
Nonviable Viable 
rate.7•11- 15 Thus, (preoperative) via-
bility testing may guide patient man-
agement. The exact prevalence of vi-
ability among patients with heart fail-
biphasic 
ure, secondary to poor LV function in 
the presence of chronic coronary ar-
tery disease, is unknown. In the 
present study, this topic was ad-
dressed and a consecutive cohort of 
patients was evaluated for viability. 
On a segmental basis, 35% of the 
dysfunctional segments was consid-
ered viable. Applying the cut-off 
value of 2::4 dysfunctional but viable 
segments, 57% of the patients had 
sustained 
improvement 
viable segments; they had an average 
of7.5::!:: 2.9 dysfunctional but viable 
segments. 
FIGURE 2. Prevalence of vioble ond nonviable tissue; 35% of dysfunctional myocar-
dium wos viable, whereas 65% was nonviable myocardium. Twenty-one percent of 
dysfunctional myocardium showed sustained improvement, 5% worsening, and 9"/o a 
biphosic woll motion paffern. 
In the only other study addressing 
the issue of the prevalence of viabil-
ity in patients with ischemic cardio-
myopathy, Auerbach et aJl 6 demon-
strated that 156 of 283 patients had 
:520% had more dysfunctional segments compared 
with patients with a LVEF >20% and :530% (14.3 :!: 
1.9 vs 11.1 :!: 4.1; p <0.005) or a LVEF >30% 
(14.3 :!: 1.9 vs 10.1 :!: 3.8; p <0.005). The number of 
dysfunctional segments was not significantly different 
between patients with a L VEF > 30% and those with 
aLVEF >20%and :530%(10.1::!:: 3.8vs 11.1:!: 4.1; 
p = 0.3). Forty-seven patients (57%) had clinically 
significant viability (an average of 7.5 :!: 2.9 seg-
ments) and 36 patients (43%) had predominantly non-
viable myocardium (an average of 1.6 :!: 1.2 viable 
segments). Clinical features were similar in the pa-
tients with and without viability. Moreover, there was 
no correlation between LVEF and the number of vi-
able dysfunctional segments (r = 0.03, n = 83, p = 
NS; see Figure 3). 
Heart failure is becoming the most comprehensive 
problem in clinical cardiology, in terms of affected 
patients. It has been shown that dysfunctional myo-
cardium does not always represent irreversibly dam-
aged myocardium; some patients improve in LV func-
tion and clinical outcome after revascularization.4 ·5•8 
However, revascularization procedures are associated 
with a higher risk in these patients.4 •5•9 Therefore, a 
careful evaluation is mandatory for optimal patient 
management and risk stratification. To explain the 
postoperative improvement in LV performance and 
prognosis, the concept of viability was proposed.4 •5 
Patients with viable myocardium are likely to benefit 
from revascularization, whereas patients without via-
ble myocardium will not benefit.4 •5 Moreover, preop-
erative viability testing results in improved risk strat-
ification.'o Finally, viable myocardium in patients 
with ischemic cardiomyopathy who were treated med~ 
ically was associated with an extremely high event 
viable myocardium on positron emis-
sion tomography using F18-fluorode-
oxyglucose. Thus, our study and Auerbach et al's 
work demonstrate that 57% and 55%, respectively, of 
the patients with ischemic cardiomyopathy had signif-
icant viable tissue. This does not necessarily mean that 
all of these patients are suitable candidates for revas-
cularization; other factors including comorbidity, in-
adequate target vessels, and severe LV dilation also 
influence the decision as to whether patients should 
undergo revascularization. Moreover, it is unclear 
whether these findings apply to the general popula-
tion, because the patients in this and Auerbach's study 
were evaluated in tertiary referral centers. An impor-
tant observation in the present study, in line with 
Auerbach et al's study,16 is that the clinical character-
istics were similar between patients with and without 
viability; this implies that specific testing for viability 
is mandatory. Finally, the prevalence of viability was 
equally distributed among patients with different de-
grees of LV dysfunction; thus, viability assessment 
should not be reserved for patients with milder (or 
more severe) forms of LV dysfunction. 
In the present study, dobutamine echocardiography 
was used to detect viability. The hallmark of viable 
myocardium on dobutamine stress echocardiography 
is improvement of contractile function during the in-
fusion of low-dose dobutamine (5 to 10 p..g!kg/min) 
(contractile reserve).5 The protocol has been expanded 
to low- to high-dose dobutamine echocardiography, 
using a maximum dosage of 40 p..glkg/min with the 
addition of atropine if necessary.7 The low- to high-
dose dobutamine protocol is safe 17 and has the advan-
tage that it allows assessment of viability and limited 
coronary flow reserve; from a patient standpoint, both 
issues are important for the decision to proceed with 
revascularization. Still, recent studies have indicated 
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that nuclear imaging techniques may be more sensitive 
for the detection of myocardial viability. 18•19 In the 
present study, only 35% of the dysfunctional segments 
were classified as viable. In previous studies with nuclear 
imaging techniques, this percentage was usually high-
er.18 However, in the study by Auerbach et al16 and this 
study, the prevalence of viability on a patient basis was 
comparable. 
In conclusion, dobutamine stress echocardiog-
raphy demonstrated viability in 35% of the dys-
functional segments. When the cut-off value of 2:!4 
dysfunctional but viable segments was applied to 
classify a patient as viable, 57% of the patients 
were considered to have substantial viability. Thus, 
in 57% of the patients with ischemic cardiomy-
opathy and heart failure, a clinically significant 
amount of viable myocardium is present and cor-
onary revascularization may be considered as ther-
apy for these patients. 
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photon emission computed tomography in patients with 
chronic ischaemic left ventricular dysfunction 
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Objective: To assess the prevalence of myocardial viability by lechnetium-99m (Tc-99m)-tetrofosmin/ 
fluorine--18-fluorodeoxyglucose (FDG) single photon emission computed tomography (SPECT) in 
patients with ischoemic cardiomyopathy. 
Design: A retrospective observational study. 
Setting: Thoroxcenler Rotterdam (a tertiary referral centre). 
Patients: 104 patients with chronic coronary artery disease and severely depressed left ventricular 
function presenting with heart failure symptoms. 
See end of orticle for 
outhors' offiliotions 
Main outcome measures: Prevalence of myocardial viability as evaluated by Tc-99m-tetrofosmin/ 
FDG SPECT imaging. Two strategies for assessing viability in dysfunctional myocardium were used: 
perfusion imaging alone, and the combination of perfusion and metabolic imaging. 
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Results: On perfusion imaging alone, 56 patients (54%) hod o signiftcont amount of viable myocar-
dium, whereas 48 patients (46%) did not. Among the 48 patients with no significant viability by per-
fusion imaging alone, seven additional patients (15%) hod significantly viable myocardium on 
combined perfusion and metabolic imaging. Thus with o combination of perfusion and metabolic 
imaging, 63 patients (61 %) hod viable myocardium and 41 (39%) did not. 
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Conclusions: On the basis of the presence of viable dysfunc:tionol myocardium, 61% of patients with 
chronic coronary artery disease and depressed lefl ventricular ejection fraction presenting with heart 
failure symptoms may be considered for coronary revasculorisotion. The combination of perfusion and 
metabolic imaging identified more patients with sign"tficant viability than myocardial perfusion imaging 
alone. 
Chronic coronary anery disease is lhe most important cause of left ventricular dysfunction leading to heart failure. When this occurs it has an extremely poor 
prognosis.' ' In nearly 70% of the patients in 1:, major heart 
failure trials, coronary artery disease was the underlying cause 
of the hean failure.' The management of these patients 
remains difficult, while both the incidence and the prevalence 
of chronic heart failure have been increasing in recent years.' 
Medical treatment is still suboptimal in these patients, 
although significant improvements in survival have been 
achieved with angiotensin convening enzyme (ACE) inhibi-
tion, blockade of aldosterone receptors by spironolactone, and 
~ adrenergic blockade.'-' Other therapeutic options are heart 
transplantation and coronary revascularisarion. The possibili-
ties of heart transplantation arc limited by the availability of 
donor heans, but coronary revascularisation could be an 
effective alternative. In a subset of patients vvith heart failure 
secondary to chronic coronary artery disease, revascularisa-
tion has been shovvn to improve left ventricular ejection frac-
tion (LVEF), hean failure symptoms, and survival.'' However, 
revascularisation in such patients is also associated with 
increased periproccdu.ral morbidity and mortality.' ' 
The concept of myocardial viability was proposed to explain 
the improvement of LVEF and heart failure symptoms after 
revascularisation." ''Dysfunctional but viable myocardium is 
likely to regain contranile function after coronary 
revascularisation." On the other hand, dysfunctional non-
viable myocardium (scar tissue) clearly will not improve. 
Bon ow estimated that between 25---40% of patients with heart 
failure caused by ischaemic heart disease have the potential 
for functional improvement after revascularisation." Quantifi-
cation of myocardial viability in patients with chronic 
coronary artery disease, depressed left ventricular function, 
and heart failure is at present limited, but this information is 
important as such patients may benefit from 
revascularisation.14 " Our aim in this study was therefore to 
evaluate myocardial viability in a consecutive series of 104 
patients with chronic coronary artery disease and depressed 
LVEF presenting with heart failure symptoms. 
METHODS 
Patient population, study protocol 
The study population consisted of 104 consecutive patients 
with ischaemic cardiomyopathy (chronic coronary artery dis-
ease as assessed by angiography and an LVEF of :s: 35%), who 
presented with heart failure as the predominant symptOm and 
were referred for evaluation of myocardial viability. Patients 
with primary cardiomyopathy or concomitant significant val-
var disease were not included. 
All patients underwent resting echocardiography to identify 
dysfunctional myocardial tissue, and dual isotope simultane-
ous acquisition myocardial single photon emission computed 
tomography (SPECT), including Tc-99m tetrofosmin and 
fluorodeoxyglucose (FDG) to assess myocardial perfusion and 
Abbreviations: ACE, ongiotensin conver~ing enzyme; FDG, 
Auorodeoxyglucose; LVEf, left ventriculor eiection froction; PET, pos'1tron 
emission lomogrophy; ROC, receiver opero!ing chorocteristic; SPECT, 
single photon emission computed !omogrophy 
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glucose utilisation, respectively."" LVEF was assessed by 
radionuclide ventriculography. 
The local medical ethics committee approved the protocol 
and all patients gave informed consent. 
Assessment of contractile function 
A Hewlett-Packard Sonos-5500 imaging system (Hewlett-
Packard Inc, Andover. Massachusetts, USA), equipped with a 
1.8 MHz uansducer using second harmonic imaging to 
optimise endocardial border visualisation, was used to record 
cross sectional echocardiograms. Four standard views (apical 
two and four chamber views, and parasternal short and long 
axis views) were stored on tape. 
Off-line interpretation was undertaken using a computer 
>ystem that digitised the taped images and displayed them in 
a cincloop format. Two experienced reviewers blinded to the 
SPECT data scored the digitised echocardiograms visually. In 
case of disagreement. a majority decision was achieved by a 
third reviewer. The left ventricle was divided according to the 
standard 16 segment model described by the American Soci-
ety of Echocardiography (six basal. six distal, and four apical 
segments)." Regional wall motion and systolic wall thicken-
ing were scored using a five point grading scale: L normal 
(normal endocardial excursion and systolic wall thickening); 
2. mildly hypokinetic (mildly reduced excursion and wall 
thickening); 3, severely hypokinetic {severely reduced excur-
sion and thickening); 4, akinetic (absent excursion and wall 
thickening); 5, dyskinetic (paradoxical systolic outward wall 
morion). Myocardial segments were comidered normal if the 
regional wall motion was normal or mildly hypokinetic. Only 
segments with severe hypokinesia, akinesia, or dyskinesia 
were evaluated for myocardial viability. 
SPECT data acquisition 
After a light breakfast, the patients received an intravenous 
injection of Tc-99m-tetrofosmin (600 MBq) to evaluate 
resting perfusion. FDG imaging to evaluate glucose utilisation 
was done after the administration of acipimox (500 mg oral 
dose) in all patients. Acipimox enhances myocardial FOG 
uptake by reducing the plasma concentration of free fatty 
acids. Following acipimox administration, the patiems re-
ceived a low fat, carbohydrate rich meal. This >mall meal fur· 
ther enhances myocardial FDG uptake by stimulating endog· 
cnous insulin release. Several studies have shown excellent 
imaging using acipimox." 
Patients with diabetes mellitus were asked to continue their 
antidiabetic drug regimen. Plasma glucose concentrations 
were measured immediately before the study. In patients with 
a plasma glucose concentration of more than 8 mmol/1, insu-
lin was given intravenously to enhance myocardial FDG 
uptake. The plasma glucose concemration was then measmed 
again and additional intravenous insulin given if necessary. 
Sixty minutes after the meal, FOG { 185 MBq) was injected, 
and after an a further 45 minutes to allow cardiac FOG uptake, 
dual isotope simultaneous acquisition SPECT was performed. 
Perfusion and metabolic imaging were both done at restvv:ith-
out stressors. Patients continued their normal cardiac drug 
treatment during the SPECT study. 
A triple head gamma camera system (Picker Prism 3000XP, 
Cleveland. Ohio. USA) was used. The camera system was 
equipped with high energy 511 keV collimators. The energies 
were centred on the 140 keV phmon peak of technetiillll-99m 
tetrofosmin with a 15% window and on the 511 keV photon 
peak of FDG with a 15% window. Data acquisition was done in 
the supine position. over 360° { 120 sectors of 3"). Total imag-
ing time was 32 minutes. Data were stored in a 64 x 64, 16 bit 
matrix. 
SPECT data reconstruction and analysis 
From the raw scintigraphic data, 6 mm thick ( l pixel) transax-
ial slices were reconstructed by filtered back projeCtion using a 
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IT~ble 1 Clinical characteristic;~ 
'I 104 patients undergoing dual isotope I 
simultaneous acquisition single photon . 
I 
emission computed tomogr:~::.,, of I 
Clinicallealures patients 
LVH ,;;20% 23 [22%] 
LVEF >20'7",, ,;;30% 54 (52'7"o] 
tVEF >30%, .;35% 27[26%) 
Number of s~nosed arteries 2. I {0.8) 
{mean (SD)) 
Previous Ml 
Previous CABG 
Previcu• PTCA 
Diabetes mellitus 
Drug treatment 
ACE inhibiter. 
~ Blocker. 
Calcium ontogonists 
Nitrates 
Diuretics 
Doto ore n [%] unless specified. 
97 {93%) 
16(15%] 
13 [13%] 
15 [14%] 
86 {83%) 
53 {51%) 
29 [28'Yo) 
74 [71%) 
66 [63%] 
ACE, angiotensin converting enzyme; CABG, 
coronary artery bypa» graft surgery; LVEF, leh 
ventricular ejedion fraction; Ml, myocardial 
infarction; PTCA, percutaneous tronsluminal 
coronary ongioplosly. 
Butterworth filter (cut off frequency at 0.17 cycle;pixcl of order 
35). Attenuation correction was nor applied. Further recon-
struction yielded standard short and long axis projections 
perpendicular to the heart axis. The Tc·99m-tetrofosmin and 
the FDG data were reconstructed ~imultaneously. This approach 
permits exact alignment of the perfusion and FOG images. 
The perfusion and FOG short axis slices were adjusted to 
peak myocardial acrivity (100%). The left ventricle was divided 
into 16 segments matching the echocardiographic segments." 
Both Tc-99m-tetrofosmin and FDG uptake defects were graded 
semiquantitatively on a four point scale: 0, normal (;;<. 75%-
100%); J, mildly reduced(;?; 50o/a--75%; 1. moderately reduced 
(;;<. 25%-50%): 3, severely reduced or absent (>S 25% uptake). 
Dysfunctional segments (identified by resting echocardio-
graphy) were subsequently evaluated for viability. 
Viable myocardium was defined using two approaches: per-
fusion criteria alone, and a combination of perfusion and 
metabolic criteria. Using perfusion alone, myocardium ·with a 
To-99m-tetrofosmin uptake score of ,; I was considered 
viable, while myocardium with a >core of;:;. 2 was considered 
non"viable. Using the combination of perfusion and metabo· 
]ism, myocardium with a Tc-99m-tetrofosmin uptake score of 
,; 1 or with a reduction in Tc-99m-tetrofosmin uptake score 
that was more severe than the reduction in FDG activity by 
;:;. 1 point (perfusion-metabolism mismatch pattern) was 
considered viable. Dysfunctional myocardium with a propor-
tionate reduction in both Tc-99m-tetrofosmin and FDG 
uptake (perfusion-metabolism match pattern) was consid-
ered non-viable. 
A patient with fom or more dysfunctional but viable 
segments was considered to have a functionally significant 
amount of viable myocardium. Tills definition is based on previ-
ous work using receiver operating characteristic (ROC) curve 
analysis showing that improvement in LVEF afterrevascularisa-
tion can be anticipated when more rhan 25% of the left ventri-
cle is viable (four or more segments in a 16 segment model)." 
Assessment of LVEF 
To assess LVEF ar the time of the viability testing, we 
performed radionudide ventriculography at rest in all 
patients_ A small field of view gamma can1era system (Orbiter, 
Siemens, Erlangen, Germany) was used, oriented in a 45' left 
anterior oblique position with a 5-10" caudal tilt. After injec-
tion of To-99m (740 MBq), radionuclide ventriculography was 
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Figure 1 Myocardial perfusion in viable and non-viable tissue. In 
viable myocardium, perfusion was normal in 57% of dysfunctional 
segments, mildly reduced in 32%, moderately reduced in 10%, and 
severely reduced or absent in 1 %. Non-viable tissue hod moderately 
reduced perfusion in 42% of dysfunctional segments and severely 
reduced or absent perfusion in 56%. 
done at rest with the patient in the supine position. The LVEF 
was calculated by standard methods (Odyssey VP. Picker, 
Cleveland, Ohio. USA). 
Statistical analysis 
All continuous data are expressed as mean (SD). Percentages 
are rounded. Comparisons were made using the Student t test 
for unpaired samples. A probability value of p < 0.05 was 
considered significant. 
RESULTS 
Patient characteristics 
Clinical characteristics of the 104 patients (87 men, !7 
women; mean (SD) age. 60 (9) yean) are summarised in table 
!. All patients presented with symptoms of heart failure. The 
mean New York Heart Association (l\'YHA) functional class 
was 2.5 (0.9); 67 patients were in NYHA class III or IV. The 
majority (93%) of the patients had suffered a previous 
myocardial infarn (all occurring more than one month before 
viability assessment). LVEF assessed by radionuclideventricu-
lography averaged 25 (7)% (range 9-35%). In 23 patients the 
LVEF was 20% or less, in 54 it was between 21% and 30%, and 
in 27 it was more than 30%. 
Segmental analysis 
Contractile function 
Cross sectional echocardiographic analysis of regional left 
ventricular function was done in 1664 segments, of which 189 
were normal and 297 mild hypokinetic. Of 1178 dysfunctional 
segments (71%), 584 showed severe hypokinesia, 578 aki-
nesia, and 16 dyskinesia. The mean (SD) number of dysfunc-
tional segments per patient was 11.3 (4.2). 
Table 2 Comparison of segment viability in three 
groups divided by left ventricular eiection fraction 
Charccteristics of lVEF ~20% LVEF 21-30% LVEF >30% 
segments (23 patients) (54 patients) (27 pctientsl 
Dysfllnctioncl 14.1 [2.0) 10.9(4.5)! 9.7 {3.9) 
Viable by Tc-99m 6.4 (3.71 4.6 [3.8)* 3.8 [3.2) 
Viable byTc-99m 7.2 {4.0) 5.1 [4.1)* 4.2 [3.2) 
+FDG 
•p-<0.05; tp<0.005 vLVEF ~20%. 
FDG, Auorodeoxyglucose; LVEF, left ventricular ejection fraction 
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Figure 2 (A) Amount of viable myocardium indicated by the 
number of viable segments in 23 patients with o left ventricular 
eiection fraction (LVEf) .;; 20%. Using perfusion as the only criterion 
of viability, 18 patients (78%) hod significant viability (e. 4 viable 
segments) ond live (22%) did not hove signilicontviobility. 
(B) Amount of viable myocardium indicated by the number of viable 
segments in 54 patients with on LVEF > 20% but,:;; 30%. Using 
perfusion as the only criter<on of viability, 27 patients (50%) hod 
significant viability (e. 4 viable segments). ond 27(50%) did not 
hove significant viability. (C) Amount of viable myocardium 
indicated by the number of viable segments in 27 patients with on 
lVEF > 30% but.;; 35%. Using perfusion os the only criterion of 
viability, 11 patients (41 %) had significant viability (;, 4 viable 
segments) and 16 (59%) did not hove significant viability. 
Perfusion imaging alone 
Using myocardial perfusion as the only criterion of viability, 
497 dysfunctional segments ( 42%) were classified as viable. 
Three hundred and sb:teen dysfunctional segments (27%) had 
normal Tc-99m-tetrofosmin uptake, and 181 (15%) had a 
mildly reduced uptake. The remaining 681 dysfunctional seg-
ments (58%) had a Tc-99m tetrofosmin uptake score of 2 or 3 
and were classified as non-viable. 
Combined perfusion ond metabolic imaging 
Using perfusion imaging in conjunction with FDG SPECT, 558 
of the dysfunctional myocardial segments (47%) were 
classified as viable. Of these viable dysfunctional segments, 
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Figure 3 (A) A moun~ of viable myocardium indicated by the 
number of viable segments in 23 patients with a left ventricular 
ejection fraction (LVEF) ,;; 20%. Using perfusion in combination with 
metabolic criteria for viability, 19 patients {83%) hod significant 
viability {"' 4 viable segments) and four {17%) did not. {B) Amount of 
viable myocardium indicated by the number of viable segments in 
54 patients with on LVEF > 20% but eS 30%. Using perfusion in 
combination with metabolic criteria for viability, 30 patients (56%) 
hod significant viability(;, 4 viable segments) and 24 (44%) did not. 
{C) Amount of viable myocardium indicated by the number of viable 
segments in 27 patients on LVEF > 30% but,;; 35%. Using perfusion 
in combination with metabolic criteria for viability, 14 patients (52%) 
hod significant viability(;, 4 viable segments) and 13 {48%) did not. 
497 ( 42%) had normal or mildly reduced perfusion and 61 
additional segments (5%) had a perfusion-metabolism 
mismatch pattern. Conversely, 620 dysfunctional segments 
(53%) were classified as non-viable (with a matching pattern 
of perfusion and metabolism). Figure 1 shows the myocardial 
perlusion in the dysfuncrional segments that were classified 
as viable and non-viable by combined perfusion and metabolic 
imaging. 
Patient analysis 
Contractile function 
Patients with an LVEF of 20% or less had more dysfunctional 
segments than those with an LVEF of 21-30% ( 14.1 (2.0) v 
10.9 {4.5), p < 0.005) or those with an LVEF of more than 30% 
(14.1 (2.0) v 9.7 (3.9), p < 0.0001). The number of dysfunc-
40 
tiona! segments was not significantly different between 
patients with an LVEF of more than 30% and those with an 
LVEF of 21-30% (9.7 (3.9) v 10.9 {4.5); p = 0.2) (table2). 
Perfusion imaging alone 
All patients had on average 4.8 (3.7} (range 0-14) dysfunc-
tional but viable segments. When myocardial perfusion was 
used as the only criterion of viability, 56 patients (54%) had a 
significant amount of viable myocardium (on average 7.5 (2.9) 
segments) and 48 patients { 46%) did not have significant 
viability (1.6 (1.2) segments). Figure 2 shows the number of 
viable segments per patient with perlusion imaging alone for 
the three LVEF groups. 
Combined perfusion and metabolic imaging 
Among the 48 patients with no significant viability by 
perfusion imaging alone. seven additional patients ( 15%) had 
viable myocardium when assessed using a combination of 
perfusion and metabolic imaging. All 56 patients with signifi-
cant viability when assessed by perfusion alone also had 
significant viability with combined perfusion and metabolic 
imaging (on average, 8.2 (3.2) viable segments). Thus 
perfusion imaging in combination with metabolic imaging 
showed that 63 patients (61%) had a significant amount of 
viable tissue (7.8 (3.2) segments). Forty one patients (39%) 
did not have significant residual viable dysfunctional tissue 
(on average, 1.6 (1.2) viable segments). OveralL the patients 
had 5.4 (4.0) viable dysfunctional segments. Figure 3 shows 
the number of viable dysfunctional segments for patients in 
the three different LVEF categories. 
DISCUSSION 
Viable myocardium 
Heart failure is becoming a major problem in clinical cardiol-
ogy. In recent years the incidence of patients with heart failure 
has increased despite progress in prevention and treaunent.' 
Chronic heart failure is predominantly caused by coronary 
artery disease and has a poor prognosis.' In a subset of 
patients with heart failure resulting from coronary artery dis-
ease, coronary revascularisation may improve left ventricular 
function, heart failure symptoms, and survival,'' but the risks 
of revascularisation in such patients are substantial. Also, 
apart from the need to assess clinical variables such as target 
vessels and comorbid factors, it is important to evaluate myo-
cardial viability as part of the complex selection process in 
candidates for revascularisation. 
Previous estimates suggest that between 25-40% of the 
patients with heart failure caused by coronary artery disease 
may show useful functional improvement after 
revascularisation." In our hospital, patients with coronary 
artery disease, a depressed LVEF, and heart failure are always 
referred for assessment of myocardial viability. This approach 
allows improved risk stratification and results in optimal 
treatment for the individual patient. In the present study, we 
examined myocardial viability in a consecutive series of 
patients from our heart failure registry. 
A few previous studies have examined myocardial viability 
on an individual patient basis. Using FDG positron emission 
tomography (PET), Pasquet and colleagues found that among 
66 patients with severe left ventricular dysfunction, 28 (47%) 
had an improvement in LVEF of at least 5% after coronary 
revascularisation, while eight (14%) had an improvement of 
more than 10%.22 Al-Mohammad and colleagues studied the 
prevalence of hibernating myocardiwn in 27 patients using 
FDG PET." Fourteen of these had significant areas of 
hibernating myocardiwn on PET. Auerbach and associates, 
also using FDG PET. studied 283 patients with ischaemic car-
diomyopathy and found rhat 156 (55%) had viable 
myocardium." In the present study; 54% of the patients 
showed significant viability when myocardial perfusion was 
used as the only index, while perfusion imaging in combina-
tion with metabolic imaging identified a further 7%; thus 61% 
of the patients in all had a significant amount of viable tissue. 
These observations are in close agreement with those of 
Al-Mohammad and Auerbach using FDG PET.''" 
In the present study patients with an LVEF of 20% or less 
had more dysfunctional but viable segments than those with 
an LVEF of21-30% or with an LVEF of more than 30%. In line 
with our results, Fath-Ordoubadi and colleagues reported that 
in 47 patients with coronary artery disease and chronic left 
ventricular dysfunction, those with an LVEF of 30% or less had 
more dysfunctional but viable segments than those with an 
LVEF of more than 30%." Moreover. after revascularisation the 
LVEF improved in patients with an initial LVEF of 30% or less, 
whereas it remained unchanged in those with an LVEF of 
more than 30%. It seems that patients with the most severe 
left ventricular dysfunction benefit more from revascularisa-
tion than those with less severe dysfunction. These findings 
may have important clinical implications in relation to revas-
cularisation, as severe left ventricular dysfunction has a very 
poor prognosis when treated medically.' 
How much viable tissue is required to be clinically 
relevant? 
In the present study a patient was considered to have a 
significant amount of viable myocardium if there were at least 
four or more dysfunctional viable segments in a 16 segment 
model. This definition was based on a previous study using 
ROC curve analysis showing that improvement in LVEF after 
revascularisation can be anticipated when 25% or more of the 
left ventricle is viable." Di Carli and colleagues reported that in 
patients with coronary artery disease and left ventricular dys-
function and with more than 5% viable tissue, the survival rate 
of revascularised patients was higher than in those who were 
treated medically (88% v 50%)." These data suggest that 
revascularisation in patients with 5-25% of viable myocardial 
tissue, while being unlikely to result in functional recovery, 
may still improve prognosis. Moreover, five prognostic FDG 
PET studies have reported a high event rate (42%) in patients 
with viable tissue treated medically," though these studies 
were of retrospective design without randornised treatment. 
Nevertheless it appears that for functional improvement to 
occur more viable myocardium is needed than for improve-
ment in prognosis. How much viable myocardium is needed to 
be clinically relevant remains to be establi>hed in randomised 
prospective studies focusing on both functional improvement 
and prognosis. 
Perfusion alone versus perfusion and metabolism 
Detection of reduced myocardial perfusion (without any addi-
tional information about metabolism) has been proposed as a 
method for differentiating viable from non-viable myocar-
dium. Thallium-201 or technetium-99m labelled tracers have 
been used in various studies to assess myocardial viability.'' 
However, it appears that the diagnostic accuracy of perfusion 
imaging for detecting viable tissue is less than that of 
perfusion imaging combined with FDG metabolic imaging. 
Three studies have shovvn that metabolic evidence of viability 
may be present while perfusion is absent. Sawada and 
colleagues studied 20 patients with a previous myocardial inf-
arction and reported that evidence of viability obtained by 
FDG PET was still present in 50% of segments which had 
technetium-99m activity of less than 40%." Soufer and asso-
ciates, in a study of 37 patients with coronary artery disease, 
found that FDG PET accurately predicted functional improve-
ment after revascularisation in segments that were non-viable 
with technetium-99m imaging but viable with FDG metabolic 
imaging." Altchoefer and colleagues studied 111 patients ~vith 
coronary artery disease and showed that 5-11% of segments 
with technetium-99m activity of 30% or less were viable 
according to FDG imaging." 
Our study supports those findings. YVhen only perfusion 
was used to indicate viable myocardium, 56 patiems (54%) 
showed significant viability, while a combination of perfusion 
and FOG imaging identified 63 patients (61%) with signifi-
cantly viable myocardium. Hence, of the 48 patients with no 
significant viability by perfusion imaging alone, seven 
additional patients ( 15%} had significantly viable myocardium 
when the information on metabolic imaging was added. This 
is of clinical relevance, as about one in seven patients initially 
thought not to have a significant amount of viable tissue on 
perfusion imaging were found to be eligible for revascularisa-
tion when the combined lest was used. It thus appears that 
perfusion imaging alone underestimates viability, and the 
combination of perfusion imaging and FDG metabolic 
imaging is a better way of discriminating between viable and 
non-viable myocardium. Furthermore, combined imaging has 
been shown to provide better discrimination between seg-
ments with a relatively high and a relatively low likelihood of 
recovery of function after revascularisation." 
Study limitations 
The centre where this study took place is a tertiary referral 
centre and thus a pre-existing patient selection bias may be 
present. 
The SPECT imaging protocol did not include administration 
of nitrates before tracer injection. Nitrate administration may 
enhance the detection of myocardial viability with To-99m-
tetrofosmin SPECT in patients >vith coronary artery disease 
and left ventricular dysfunction." 
During SPECT data reconstruction, no attenuation correc-
tion was applied and this may have influenced the accuracy of 
the results. Matsunari and colleagues reported that the use of 
attenuation corrected Tc-99m-tetrofosmin SPECT improved 
the detection of viable myocardium, mainly by decreasing the 
underestimation of viability in the inferior septal region." 
The findings in our study did not include the results of 
recovery of function after revascularisation. However, that was 
not a goal of the study. Our aim was specifically to quantify the 
presence of significant myocardial viability in patients with 
chronic coronary artery disease, depressed LVEF, and heart 
failure symptoms. 
Conclusions 
On the basis of the presence of viable dysfunctional 
myocardium, 61% of patients with chronic coronary artery 
disease and a depressed left ventricular ejection fraction 
presenting with heart failure symptoms may be considered for 
coronary rcvascularisation. The combination of perfusion and 
metabolic imaging identified more patients with viable 
myocardium than perfusion imaging alone. 
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Abstract 
Background: Q waves on the ECG are often considered to be reflective of 
irreversibly scarred myocardium, as a result of antecedent transmural myocardial infarction. 
However, there are some indications that residual viable tissue may be present in Q wave 
infarcted regions. It is clinically relevant to know how many Q wave regions contain viable 
tissue, since these patients may benefit from revascularization in terms of improvement of 
function and long-term survival. 
Methods: Patients (n=l50) with chronic electrocardiographic Q wave infarction, heart 
failure symptoms and chronic coronary artery disease underwent dobutamine-atropine stress 
echocardiography to assess myocardial viability. Residual viability in regions with Q wave 
infarction was considered present when the end-diastolic wall thickness (EDWT) was >6 mm 
and the response during dobutamine infusion indicated viable tissue. 
Results: Baseline echocardiography revealed 517 dysfunctional myocardial regions, 
202 of the dysfunctional regions were related to Q waves on the ECG, the other 315 
dysfunctional regions were not. EDWT was $6 mm in 13 regions with a Q wave on the ECG, 
with only 1 region exhibiting viable tissue during dobutamine stress echocardiography. 
EDWT was >6 mm in 189 regions with a Q wave with 118 (62%) having viable tissue on 
dobutamine stress echocardiography. In 6 dysfunctional regions without a Q wave EDWT 
was ::;6 mm with all being nonviable on dobutamine stress echocardiography; of the 309 
regions without a Q wave and EDWT >6 mm, 204 (66%) exhibited viability on dobutamine 
stress echocardiography. 
Conclusions: 58% of dysfunctional regions related to chronic Q waves was viable 
according to the combined information of EDWT and dobutamine stress echocardiography. 
EDWT :>6 mm virtually excludes viability; regions with EDWT >6 mm need additional 
testing to detect/exclude viability. 
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Introduction 
Left ventricular dysfunction in patients with chronic coronary artery disease most 
often results from either scarring, as a consequence of myocardial necrosis, or from 
hibernating myocardium (1). In the case of hibernating myocardium, coronary 
revascularization may reduce heart failure symptoms, and improve left ventricular function 
and survival (2,3). Q waves on ECG are often considered to be reflective of irreversibly 
scarred tissue, as a result of antecedent transmural myocardial infarction. There is, however, 
some evidence that viable tissue may be present in regions with Q waves on the ECG. 
Autopsy studies in patients with myocardial infarction revealed that substantial amounts of 
viable tissue were present in regions with Q waves ( 4,5). Moreover, chronic Q waves have 
disappeared and associated abnormal regional wall motion has improved after coronary 
revascularization (6,7). However, it is currently unclear how many regions with Q waves 
contain viable tissue. To evaluate myocardial viability in Q wave regions, 150 consecutive 
patients with a previous Q wave infarction were studied with dobutamine-atropine stress 
echocardiography. 
Material and methods 
Patient population, study protocol: The study included 150 consecutive patients 
with chronic electrocardiographic Q wave infarction, heart failure symptoms and chronic 
coronary artery disease. Initially 195 patients were considered for inclusion, however patients 
with electrocardiographic evidence of intraventricular conduction abnormalities (5 patients 
with left bundle branch block, 8 with right bundle branch block), primary cardiomyopathy (4), 
significant valvular heart disease (17), or an unacceptable acoustic window (11) were not 
included. In all patients, ECGs were obtained > 1 year after onset of acute myocardial 
infarction. Patients with previous coronary bypass surgery or coronary angioplasty were 
studied > 1 year after coronary revascularization. Echocardiography at rest to identify regional 
dysfunction and assess end-diastolic wall thickness (EDWT) in the infarct region was 
followed by low-high-dose dobutamine stress to detect residual viability in these regions. 
Resting radionuclide ventriculography was used to determine the left ventricular ejection 
fraction. The local medical ethics committee approved the protocol and all patients gave 
informed consent. 
Electrocardiography: The surface ECGs were read by two experienced observers 
without knowledge of the dobutamine-atropine stress echocardiographic results. Q waves 
were considered pathologic if they met the following criteria: (1) Q wave of2:30 ms in aVF, 
(2) Q wave of240 ms in I and aVL, (3) Q wave of240 ms in 22 ofV4 through V6, (4) R 
wave of240 ms in Vl, (5) any Q wave in V2, and (6) R wave o;O,l mV and 10 ms in lead V2; 
according to the Selvester QRS screening criteria for Q wave myocardial infarction (8,9). 
Echocardiography: All echocardiograms were recorded with an HP Sonos-5500 
system (Andover, Massachusetts) with a 1.8 MHz transducer using second harmonic imaging 
to optimize endocardial border visualization. After baseline echocardiography, dobutamine 
was administered, starting at a dose of 5 f.Lglkg body weight per minute for 5 minutes, 
followed by a l 0 ~g/kg/min dose for 5 minutes, Then, incremental dobutamine doses of l 0 
~g/kg/min were given at 3-minute intervals up to a maximum dose of 40 ~g/kg/min. If the test 
end-point was not reached at a dobutamine dose of 40 f.Lglkg/min, atropine (up to 2 mg) was 
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given intravenously. Test end-points were: achievement of target heart rate, extensive new 
wall motion abnormalities, ST -segment depression (2:2mm compared with baseline), severe 
angina, systolic blood pressure fall >40 uuu Hg, blood pressure >2401\20 mm Hg, significant 
arrhythmia. 
Echocardiographic analysis: Two experienced reviewers unaware of the electro-
cardiographic data scored the echocardiograms using a standard 16-segment model (10). To 
relate the echocardiographic data to the Q waves on ECG, the left ventricle was divided into 
four major regions: anterior, septal, lateral, and inferoposterior. Measurement of EDWT and 
the scoring of regional function and response to dobutamine infusion were performed by two 
observers, blinded to the ECG data. 
1. End-diastolic wall thickness: The resting echocardiographic images were analyzed 
off-line using standard parasternal and apical views. EDWT was assessed as previously 
described (ll, 12). The frames that provided best possible visualization of the endocardial and 
epicardial borders were selected. The EDWT was assessed at the center of each myocardial 
region from the leading endocardial edge to the leading epicardial edge and calculated as the 
mean value of three measurements. According to the EDWT, viability was considered absent 
when EDWT was s6 mm, and present when EDWT was >6 uuu (11,12). 
2. Regional function and response to dobutamine: Regional wall motion and 
systolic wall thickening were scored on a 5-point scale: (l) normal, (2) mild hypokinetic, (3) 
severe hypokinetic, (4) akinetic and (5) dyskinetic. Myocardial segments were considered 
normal if the regional wall motion was normal or mild hypokinetic. Only dysfunctional 
segments (segments with severe hypokinesia, akinesia or dyskinesia at resting 
echocardiography) were evaluated for myocardial viability. Segments with improvement, 
worsening or a biphasic wall motion response during dobutamine stress echocardiography 
were considered viable (13). Segments with unchanged wall motion were considered 
nonviable (\3). For each patient a wall motion index score (WMSI) was calculated (total wall 
motion score divided by the number of analyzed segments) at rest, at low-dose, and at peak 
stress. 
Assessment of the ejection fraction: The left ventricular ejection fraction was 
assessed by radionuclide ventriculography at rest in all patients. A small field-of-view gamma 
camera system (Orbiter, Siemens, Erlangen, Germany) was used, oriented in a 45° left 
anterior oblique position with a 5 to 10° caudal tilt. After injection of Tc-99m (740 MBq), 
radionuclide ventriculography was performed at rest with the patient in supine position. The 
left ventricular ejection fraction was calculated using standard methods (Odyssey VP, Picker, 
Cleveland, Ohio) (13). 
Statistical analysis: All continuous data are expressed as mean ± SD, percentages are 
rounded. Continuous variables were compared using the student t-test for unpaired samples. 
Differences between proportions were compared using the chi-square test. A value of p<0.05 
was considered statistically significant. 
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Results 
Patient population, electrocardiographic results: All patients presented with heart 
failure symptoms, New York Heart Association (NYHA) functional class was on average 2.8 
± 0.7, while 72% of the patients was in NYHA functional class Ill or IV. The left ventricular 
function was severely impaired in all patients, the ejection fraction averaged 31% ± 12%. 
Importantly, 40 patients (27%) had a left ventricular ejection fraction <25%. The clinical 
characteristics of the study population are presented in Table 1. 
All 150 patients had a previous Q wave myocardial infarction at least one year before 
the study (mean 7.2 ± 5.9 years before). Pathological Q waves on the echocardiogram were 
present in 220 myocardial regions: 101 anterior, 30 septal, 30 lateral, and 59 infero-posterior 
regions exhibited Q waves. On average patients had 1.5 ± 0.6 regions with a Q wave pattern. 
Table 1. Demographics of 150 patients undergoing dobutamine stress echocardiography 
Age (yrs) 
Male 
Previous CABG > 1 year 
Previous PTCA > 1 year 
Previous cerebrovascular disease 
Diabetes mellitus 
Family history 
Smoking previous/current 
Multivessel disease 
NYHA functional class 
LVEF (%) 
59± 10 
125 (83%) 
22 (15%) 
22 (15%) 
2 (1%) 
23 (15%) 
91 (61%) 
58 (39%) I 55 (35%) 
137 (91 %) 
2.8 ± 0.7 
31 ± 12 
Data are presented as mean± SD or number(%) of patients; CABG =coronary artery bypass 
graft surgery; LVEF ~left ventricular ejection fraction; MI ~myocardial infarction; NYHA = 
New York Heart Association; PTCA =percutaneous transluminal coronary angioplasty. 
Resting echocardiography: Echocardiography at rest revealed 517 dysfunctional 
myocardial regions, 202 of the dysfunctional regions were related to Q waves on the ECG, the 
other 315 dysfunctional regions were not. Thus, 202 out of 220 regions (92%) with Q waves 
were dysfunctional at resting echocardiography. In addition, 315 regions not related to Q 
waves on the ECG revealed abnormal resting wall motion. 
The EDWT was preserved (>6 mm) in 498 of 517 (96%) dysfunctional regions. 
Figures 1A and lB demonstrate the obtained data in regions without and with chronic Q 
waves, respectively. An EDWT ::::;6 mm was more frequently observed in Q wave regions than 
in dysfunctional regions without Q waves (13 of202 versus 6 of315, p<0.05). 
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315 dysfunctional regions 
without Q waves 
DSE viable 
204 
Figure lA. Diagram showing the data obtained for the 315 dysfunctional regions without Q 
waves. The end-diastolic wall thickness (EDWT} was preserved (>6 mm) in 309 (98%) and 
reduced (~6 mm) in 6 (2%) of the dysfunctional regions. Based on the combined information 
of EDWT and dobutamine stress echocardiography (DSE), 65% (204 of 315) of the 
dysfunctional regions without Q waves exhibited viable tissue. 
Figure lB. Diagram showing the data obtained for the 202 dysfimctional regions with 
chronic electrocardiographic Q waves. The end-diastolic wall thickness (EDWT) was 
preserved (>6 mm) in 189 (94%) and reduced (:>6 mm) in 13 (6%) of the dysfimctional 
regions. Based on the combined information of ED WT and dobutamine stress 
echocardiography (DSE), 58% (118 of 202) of the dysfimctional regions with a Q wave 
infarction exhibited viable tissue. 
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Dobutamine stress echocardiography: Table 2 shows the hemodynamic and wall 
motion changes during dobutamine stress. There was a significant increase in heart rate at 
baseline compared to the heart rate at peak stress (74 ± 16 vs. 130 ± 18 beats/min, p<O.OOO 1 ). 
Overall, diastolic blood pressure decreased (75 ± 14 to 72 ± 15 mm Hg, p<0.05) and systolic 
blood pressure did not significantly change during dobutamine infusion. During low-dose 
dobutamine infusion, wall motion improved significantly, (baseline WMSI 2.81 ± 0.71 vs. 
low-dose WMSI 2.50 ± 0.66, p<O.OOOl). At peak stress, WMSI worsened compared to the 
WMSI at the low-dose stage (2.74 ± 0.69 vs. 2.50 ± 0.66, p<0.005). Regions with EDWT :06 
mm virtually never exhibited viability on dobutamine stress echocardiography, as indicated in 
Figures lA and lB. In regions with EDWT >6 mm, the response to dobutamine varied. In 
regions with a Q wave infarction, 62% exhibited viability on stress echocardiography, 
whereas 38% of the regions demonstrated scar tissue. In regions without a Q wave, 66% 
exhibited viable tissue and 34% scar tissue on dobutamine stress echocardiography. 
Table 2. Dobutamine stress echocardiographic data. 
Heart rate (beats/min) 
Systolic BP (mm Hg) 
Diastolic BP (mm Hg) 
WMSI 
Baseline 
74 ± 16 
126 ± 26 
75 ± 14 
2.81 ± 0.71 
Low-dose 
76 ± 18 
125 ± 28 
74 ± 15 
2.50 ± 0.66 
Peak 
130 ± 18 
126 ± 28 
72 ± 15 
2.74 ± 0.69 
Data are presented as mean± SD or number (%) of patients. BP =blood pressure; WMSI = 
wall motion score index. 
Qwave 
n=202 
0 Viable II Nonviable 
No Qwave 
n=315 
Figure 2. Pie chart showing the incidence of viable myocardium in 517 dysfunctional 
regions; combined information of end-diastolic wall thickness and dobutamine stress 
echocardiography demonstrated residual viability in 58% (118 of 202) of the dysfunctional 
regions with a Q wave pattern, and in 65% (204 of 315) dysfunctional regions without Q 
waves on the ECG (p~0.2). 
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Based on the combination of the EDWT and the response to dobutamine, 58% ( 118 of 
202) of the regions with a Q wave infarction exhibited viable tissue. In addition, in 65% (204 
of 315) of the dysfunctional regions not related to Q waves on the ECG, viable tissue was 
present. The incidence of viable tissue in dysfunctional regions with a Q wave infarction was 
not different from the incidence of dysfunctional regions without a Q wave infarction (Figure 
2). 
Discussion 
The findings in the present study demonstrate that chronic Q waves on the ECG do not 
exclude the presence of viable myocardial tissue in patients with severely depressed left 
ventricular function. An EDWT 56 rnm, indicating scar tissue, was more frequently observed 
in Q wave regions than in dysfunctional regions without Q waves. In general, regions with an 
EDWT o£6 mm were scarce. Only 19 of 517 regions had an EDWT o£6 mm. La Canna et al 
(12), comparably showed that only 13% of dysfunctional regions in patients with severely 
depressed left ventricular function had an EDWT <5 mm. In line with these previous studies, 
regions with an EDWT :56 mm virtually never exhibited viable tissue on dobutamine 
echocardiography. Cwajg et al (11) showed that only 19% of the regions with an EDWT o£6 
mm was viable during dobutamine stimulation. Baer et al (14) used magnetic resonance 
imaging and demonstrated that regions with EDWT <5 mm never improved in contractile 
function after revascularization, indicating that regions with very thin walls do not contain 
viable tissue and do not improve in function after revascularization. In regions with an EDWT 
>5.5 mm however, the response to dobutamine varied significantly. In our study, only 62% of 
the Q wave regions with an EDWT >6 rnm was viable on dobutamine stress 
echocardiography, whereas 38% of these regions exhibited scar tissue on dobutamine 
echocardiography. Similarly, La Canna et al (12) demonstrated that 42% of the dysnmctional 
segments with a preserved EDWT (>5 mm) was nonviable on dobutamine stress 
echocardiography. Moreover, Baer et al. (14) demonstrated that 38% of the segments with an 
EDWT >5.5 mm did not improve in function post-revascularization. Based on these results it 
can be concluded that assessment of EDWT can be used as an initial screening technique for 
assessment of viability. It can safely be concluded that regions with an EDWT :56 rnm do not 
contain viable myocardium and do not improve in function after revascularization. However, 
in segments with an EDWT >6 mm, additional testing is needed, since approximately 40% of 
these regions do not contain viable myocardium and will not improve in function post-
revascularization. 
The aim of the current study was to evaluate the incidence of viable tissue in regions 
with Q wave infarctions. Previous studies in small subsets of patients have already indicated 
that some patients with Q wave infarctions have viable myocardium. Brunken et al (15) 
showed in 20 patients that positron emission tomography using Fl8-fluorodeoxyglucose 
revealed residual glucose metabolism in 21 of 31 ( 68%) Q wave regions. Similarly, Tillisch et 
al (16) evaluated 17 patients with positron emission tomography in combination with F18-
fluorodeoxyglucose and showed that 16 of 28 (57%) regions with Q waves on the ECG 
improved in contractile function after revascularization. Besides these 2 studies, no studies 
have focused on the incidence of viable myocardium in patients with Q wave infarctions. In 
the present study, a combination of resting echocardiography (to assess EDWT) and 
dobutamine stress echocardiography was used to assess viability, in a large cohort of patients. 
These echocardiographic techniques are more widely available than positron emission 
tomography. Based on the combined information of EDWT and the findings during 
dobutamine infusion, the incidence of viable myocardium in 150 patients with Q wave 
infarctions was 58%, in line with the previous studies. Hence, electrocardiographic evidence 
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of "transmural" infarction (Q waves) together with regional dysfunction at rest does not 
exclude the presence of viable myocardium. In particular, the incidence of viable myocardium 
in regions with Q wave infarction was comparable to the incidence of viable myocardium in 
regions without a Q wave (Figure 2). This finding is of clinical importance, since many 
patients present with Q wave infarctions, depressed LV function and heart failure symptoms. 
In the presence of viable myocardium, these patients may benefit from revascularization in 
terms of improvement of left ventricular function and longevity (17-20). As evidenced by the 
high incidence of viable myocardium in regions with Q wave infarctions in this large cohort 
of patients, viability testing should be performed and Q waves in combination with contractile 
dysfunction per se does not rule out the presence of viable myocardium. 
Limitations: In the current study myocardial viability was assessed by dobutamine-
atropine stress echocardiography. This is a safe and widely available imaging method, with a 
good sensitivity and specificity for the evaluation of myocardial viability (17). Still, 
functional improvement of contractile dysfunction after coronary revascularization is 
considered the final proof of myocardial viability. In this study functional improvement after 
coronary revascularization was not assessed. 
Patients who underwent previous coronary revascularization were included in the 
study. Coronary revascularization might have influenced the presence and the number of Q 
waves as well as the presence of viable myocardium. However, the time-interval between 
revascularization and the current study was > 1 year in all patients. 
Conclusions: Chronic Q waves on electrocardiography do not exclude the presence of 
viable myocardium; in 58% of the Q wave regions in 150 patients, viable tissue was present. 
Thus, patients presenting with a previous Q wave infarction, severely depressed left 
ventricular function and heart failure should be referred for viability testing. Initial evaluation 
by resting echocardiography may already exclude the presence of viable tissue when EDWT 
is 6 mm or less. However, in regions with Q waves and an EDWT >6 rnrn, additional testing 
is needed since 38% of these regions did not show viability during dobutamine stress 
echocardiography 
References 
1. Beller GA. Noninvasive assessment of myocardial viability. N Eng J Med 2000;343: 1488-
90. 
2. Rahimtoola SH. From coronary artery disease to heart failure: role of the hibemating 
myocardium. Am J Cardioll995;75:16E-22E. 
3. Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Eng J Med 1998;339:173-
81. 
4. Savage Rlv1, Wagner GS, Ideker RE, et al. Correlation of postmortem anatomic findings 
with electrocardiographic changes in patients with myocardial infarction: retrospective 
study of patients with typical anterior and posterior infarcts. Circulation 1977;55:279-85. 
5. Sullivan W, Vlodaver Z, Tuna N, et al. Correlations of echocardiographic and pathologic 
findings in healed myocardial infarction. Am J Cardioll978;42:724-32. 
6. Zeft HJ, Friedberg HD, King JF, et al. Reappearance of anterior QRS forces after 
coronary bypass surgery. An Electrovectorcardiographic study. Am J Cardiel 
1975;36:163-8. 
7. Conde CA, Meller J, Espinoza J, et al. Disappearance of abnonnal Q waves after 
aortocoronary bypass surgery. Am J Cardioll975;36 :889-93. 
51 
8. Anderson WD, Wagner NB, Lee KL, et al. Evaluation of a QRS scoring system for 
estimating myocardial infarct size, VI: identification of screening criteria for non-acute 
myocardial infarcts. Am J Cardio\1988;61:729-33. 
9. Sevilla D, Wagner N, Anderson WD, et al. Sensitivity of a set of myocardial infarction 
screening criteria in patients with anatomically documented single and multiple infarcts. 
Am J Cardio\1990;66:792-5. 
10. Bourdillon PD, Broderik TM, Sawada SG, et al. Regional wall motion index for infarct 
and non-infarct region after reperfusion in acute myocardial infarction: comparison with 
global wall motion index. JAm Soc Echo !989;2:398-407. 
11. Cwajg JM, Cwajg E, Nagueh SF, et al. End-diastolic wall thickness as a predictor of 
recovery of function in myocardial hibernation: relation to rest-redistribution Tl-201 
tomography and dobutamine stress echocardiography. J Am Col! Cardia! 2000;35: !152-
61. 
12. La Canna G, Rahimtoola SH, Visioli 0, et al. Sensitivity, specificity, and predictive 
accuracies of non-invasive tests, singly and in combination, for diagnosis of hibernating 
myocardium. Eur Heart J 2000;21: !358-67. 
13. Bax JJ, Polderrnans D, Elhendy A, et al. Improvement ofleft ventricular ejection fraction, 
heart failure symptoms and prognosis after revascularization in patients with chronic 
coronary artery disease and viable myocardium detected by dobutamine stress 
echocardiography. JAm Col! Cardioll999;34:163-9. 
14. Baer FM, Theissen P, Schneider CA, et al. Dobutamine magnetic resonance imaging 
predicts contractile recovery of chronically dysfunctional myocardium after successful 
revascularization. J Am Col! Cardia! !998;3!: 1040-8. 
15. Brunken R, Tillisch J, Schwaiger M, et al. Regional perfusion, glucose metabolism, and 
wall motion in patients with chronic electrocardiographic Q wave infarctions: evidence for 
persistence of viable tissue in some infarct regions by positron emission tomography. 
Circulation !986;73:95!-63. 
!6. Tillisch J, Brunken R, Marshall R, et a!. Reversibility of cardiac wall-motion 
abnormalities predicted by positron tomography. New Eng! J Med 1986;314:884-8. 
!7. Bax JJ, Wijns W, Cornel JH, et a!. Accuracy of currently available techniques for 
prediction of functional recovery after revascularization in patients with left ventricular 
dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll 
Cardiol1997;30:!45!-60. 
18. Pasquet A, Robert A, D'Hondt Al\11, et al. Prognostic value of myocardial ischemia and 
viability in patients with chronic left ventricular ischemic dysfunction. Circulation 
!999; 100: !4!-8. 
19. Cigarroa CG, deFilippi CR, Brickner E, et al. Dobutamine stress echocardiography 
identifies hibernating myocardium and predicts recovery of left ventricular function after 
coronary revascularization. Circulation 1993;88:430-6. 
20. La Canna G, Alfieri 0, Guibbini R, et a!. Echocardiography during infusion of 
dobutamine for identification of reversible dysfunction in patients with coronary artery 
disease. JAm Col! Cardio\1994;23:617-26. 
52 
Chapter 5 
Assessment of viable tissue in Q-wave 
regions by metabolic imaging using single-
photon emission computed tomography in 
ischemic cardiomyopathy 
Schinkel AFL, Bax JJ, Elhendy A, Boersma E, Vourvouri EC, 
Sozzi FB, Valkema R, Roelandt JRTC, Poldermans D 
Am J Cardiol2002;89:ll7l-ll75 
53 

Assessment of Viable Tissue in Q-Wave 
Regions !by MetalboUe Imaging Using 
Single-Photon Emission Computed 
Tomography illn Ischemic Cardiomyopathy 
Arend F.L. Schinkel, MD, Jeroen J. Box, MD, Abdou Elhendy, MD, Eric Boersma, PhD, 
Eleni C. Vourvouri, MD, Fa biola B. Sozzi, MD, Roelf Valkema, MD, 
Jos R.T.C. Roelandt, MD, and Don Poldermans, MD 
Chronic electrocardiographic Q waves ore often be-
lieved to reflect irreversibly scarred, transmurally in-
farcted myocardium. The aim of this study was to eval-
uate whether residual viable tissue persists in 
dysfunctional myocardial regions related to chronic Q 
waves on the surface electrocardiogram. A total of 148 
patients with healed myocardial infarction and impaired 
left ventricular (LV) function with heart failure symptoms 
undetwent electrocardiography and metabolic imaging 
using technetium {Tc-99m) tetrofosmin/F 18-fluorode-
oxyglucose (FDG) single-photon emission computed to-
mography {SPECn. The left ventricle was divided into 4 
major regions to compare myocardial viability in re-o 
gions with and without chronic Q waves on surface 
electrocardiography. According to FOG SPECT metabolic 
t raditionally, left ventricular (LV) dysfunction due to chronic coronary artery disease was considered 
irreversible and amenable only to medical therapy. 1 
However, it has become clear that chronic LV dys-
function in patients with chronic coronary artery dis-
ease is not always irreversible.2 '3 If jeopardized but 
viable myocardium is present, coronary revasculariza-
tion may lead to improved regional and global func-
tion.4-7 Moreover, improvement of functional status 
and better survival may be expected if patients with a 
substantial amount of dysfunctional but -viable myo-
cardium are revascularized.4-7 Chronic electrocardio-
graphic Q waves are often believed to reflect irre-vers-
ibly scarred, transmurally infarcted myocardium. 
There is, however, some evidence that residual viable 
myocardium may be present in dysfunctional regions 
with chronic Q waves on electrocardiography. Patho-
logic studies in patients with myocardial infarction 
suggested that substantial amounts of hibernating tis-
sue may persist in regions with Q waves. 8' 9 In addi-
tion, disappearance of chronic Q waves and improve~ 
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imaging, residual viable tissue persisted in a high pro-
portion (61%) of dysfunctional myocardial regions with 
chronic Q waves. Regions with chronic Q waves were 
more often dysfunctional than regions without Q waves. 
Moreover, dysfunctional regions with chronic Q waves 
were less frequently viable compared with dysfunctional 
regions without Q waves on the electrocardiogram. This 
study demonstrates that chronic Q waves on eiectrocar· 
diography do not necessarily imply irreversib-ly scarred 
myocardium. Residual viable tissue persists in a hig~ 
proportion of dysfunctional ventricular regions accord-
ing to FDG SPECT metabolic imaging. ©2002 by Ex-
cerpta Medica, Inc. 
(Am J Card;ol 2002;89:1171-1175) 
ment of LV function and contractility have been ob-
served after coronary revascularization. 10·11 It is 
currently not clear in how many ventricular regions 
with Q waves viable myocardium persists. Accord-
ingly, this study evaluates myocardial viability in Q-
wave regions in a consecutive series of patients with 
depressed LV ejection fraction (EF) and heart failure. 
METHODS 
Patient popukltion and study protocol: The study 
population consisted of 148 consecutive patients with 
chronic coronary artery disease and an impaired LV 
function, who had heart failure as the predominant 
symptom. All patients had a previous myocardial in-
farction >6 months before viability assessment Pa-
tients with left bundle branch block, primary cardio-
myopathy, or concomitant significant valvular disease 
were not included. Patients with previous coronary 
revascularization were studied > 1 year after the re-
vascularization procedure. All patients underwent 
echocardiography at rest to identify dysfunctional 
myocardial tissue and dual-isotope simultaneous ac-
quisition myocardial single-photon emission com-
puted tomography (SPECT), including technetium 
(Tc-99m) tetrofosmin and Fl8-ftuorodeoxyglucose 
(FDG) to assess myocardial perfusion and glucose 
utilization, respectively. The L VEF was assessed by 
radionuclide ventriculography. Systemic hypertension 
was defined as a blood pressure 2::140/90 mrn Hg, ot 
treatment with antihypertensive medication. Hyper-
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cholesterolemia was defined as a total cholesterol 
~6.4 mmol!L, or treatment with lipid-lowering med-
ication. The hospital medical ethics committee ap-
proved the protocol and all patients gave informed 
consent. 
Electrocardiographic analysis: Two experienced ob-
servers, illlaware of any other data, read the surface elec-
trocardiograms. According to the Selvester QRS screening 
criteria for Q-wave myocardial infarction, Q waves were 
classified as pathologic if there was: (1) a Q wave of ~30 
ms in lead a VF; (2) a Q wave of ~40 ms in leads I and 
aVL; (3) a Q wave of~40 ms in ~2 of leads V 4 to V6 ; (4) a R wave of ~40 ms in lead V 1; (5) any Q wave 
in lead V2; and (6) R wave ::S0.1 mV and ~10 ms in lead 
V 2. 12•
13 Accordingly, pathologic Q waves were assigned to 
4 LV regions: anterior (preserved R wave in lead V1 and 
pathologic Q wave in ~1 ofleads V2 to V5), septal (patho-
logic Q waves in leads V1, V2, and/or V3), lateral (patho-
logic Q wave in > 1 of leads I, a VL, or V 6), or inferopos-
terior (pathologic Q wave in > 1 of leads II, lli, or a VF).14 
Assessment of wall motion abnormalities: A Hewlett 
Packard Sonos-5500 imaging system (Andover, Mas-
sachusetts), equipped with a 1.8-MHz transducer us-
ing second harmonic imaging to optimize endocardial 
border visualization, was used to record 2-dimen-
sional echocardiograms. Four standard views were 
recorded, and 2 experienced reviewers blinded to the 
SPECT data visually scored the digitized echocardio-
grams. Regional wall motion and systolic wall thick-
ening were scored using a 16-segment model (Figure 
1) and a 5-point grading scale: 1 = normal, 2 = mildly 
hypokinetic, 3 = severely hypokinetic, 4 = akinetic, 
and 5 = dyskinetic. 15 
SPECT data acquisition: Patients received, after a 
light breakfast, an intravenous injection of Tc-99m-
tetrofosmin ( 600 MBq) to evaluate perfusion at rest. 
FDG imaging, to evaluate glucose utilization, was 
performed following administration of Acipimox 
(Byk, Zwanenburg, The Netherlands; 500 mg, oral 
dose) in aU patients. Acipimox enhances myocardial 
FDG uptake by reducing the plasma level of free-fatty 
acids. Following Acipimox administration, the pa-
tients received a low-fat, carbohydrate-rich meal. This 
small meal further enhances myocardial FDG uptake, 
by stimulating endogenous insulin release. Several 
studies have demonstrated very good image quality 
using Acipimox. 16 - 18 Sixty minutes after the meal, 
FDG (185 MBq) was injected, and after an additional 
45 minutes to allow cardiac FDG uptake, dual-isotope 
simultaneous acquisition SPECT was performed. Per-
fusion and metabolic imaging were performed at rest 
without stressors. A triple-head gamma camera sys-
tem (Picker Prism 3000XP, Cleveland, Ohio) was 
used. The camera system was equipped with commer-
cially available high-energy 511-keV collimators. 19 
The energies were centered on the 140-ke V photon 
peak of Tc-99m-tetrofosmin with a 15% window and 
on the 511-keV photon peak of FDG with a 15% 
window. Data acquisition was performed in the supine 
position, over 360° (120 sectors of3°). Total imaging 
time was 32 minutes. Data were stored in a 64 X 64, 
16-bit matrix. 
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FIGURE I. LV wall segments in the 16-segmenl model. Four ma· 
ior regions were considered: the anterior region comprised seg-
ments 2, 7, and 12.; the septal region consisted of segmenis 1, 
5, 6, 10, and 11; the lateral region comprised segments 3, 8, 
and 13; and the inferoposterior region consisted of segmenis 4, 
9, 14, 15, and 16. AO =aorta; AP2CH = apical2-chamber 
view; AP4CH = apical4-chamber view; lA = left atrium; LV= 
left ventricle; PSLAX = poraslernallong·oxis view; PSSAX = 
poraslemal short-oxis view; RA = right atrium; RV = right ven· 
tride. 
SPECT data reconstruction and analysis: From the 
raw scintigraphic data, 6-mm-thick (1 pixel) transaxial 
slices were reconstructed by filtered backprojection 
using a Butterworth filter (cut-off frequency at 0.17 
cycle/pixel of order 3.5). Attenuation correction was 
not applied. Further reconstruction yielded standard 
short- and long-axis projections perpendicular to the 
heart axis. The Tc-99m-tetrofosmin and the FDG data 
were reconstructed simultaneously, to obtain an exact 
alignment of the perfusion and metabolic images. The 
perfusion and FDG studies were adjusted to peak 
myocardial activity (100%). A similar 16-segment 
model as for the echo data was used (Figure 1). Only 
segments with severe hypokinesia, akinesia, or dyski-
nesia were evaluated for myocardial viability. Both 
T c-99m-tetrofosmin and FDG uptake defects were 
semiquantitatively graded on a 4-point scale: 0 = 
normal, 1 = mildly reduced, 2 = moderately reduced, 
and 3 = severely reduced or absent. Myocardium with 
a Tc-99m-tetrofosmin uptake score ::s1 or a reduction 
in Tc-99m-tetrofosmin uptake score more severe than 
the reduction in FDG activity by ~1 point (mismatch 
pattern) was considered viable. Dysfunctional myo-
cardium with concordantly reduced Tc-99m-tetrofos-
min and FDG uptake (match pattern) was considered 
nonviable. 
TABlE 1 Clinical Chorocteristics of the 148 Study Patients 
Men/women 125(84%)/23 {16%) 
Age (yrs) 60 :':: 9 
Systemic hypertension 20 {14%) 
Diabetes mellitus 24 {16%) 
Hypercholesterolemia 67 {45%) 
Smoking history 
Previous 58 {39%) 
Current 54 {36%) 
family history of coronary artery disease 90 {61%) 
Previous cerebrovascular disease 2 {1%) 
Previous coronary revascularization 39 {26%) 
Multivessel coronary disease 134(91%) 
LVEF {%) 31:!: 11, range 10-43 
Dolo ere presented os number [%1 of patients or mean value :t SD 
See Method, far definition of hyperlen•ion and hyperchobterolemio 
Comparison of electrocardiography, echocardiogra-
phy, and SPECT: Q waves were ascribed to 4 regions: 
anterior, septal, lateral, and inferoposterior. Accord-
ingly, the corresponding SPECT and echo segments 
(both using the same 16-segment model, Figure I) 
were grouped according to these 4 regions. A region 
was considered dysfunctional if ~ 1 segment in the 
region was severely hypokinetic, akinetic, or dyski-
netic on echocardiography. A region was considered 
viable when ~ 1 segment in the region was viable on 
SPECT (see the previously mentioned criteria). 
Assessment of the left ventricular ejection fraction: To 
assess the L VEF at the time of the viability testing, 
radionuclide ventriculography at rest was performed 
in all patients. A small field-of-view gamma camera 
system (Orbiter, Siemens, Erlangen, Germany) was 
used, oriented in a 45° left anterior oblique position 
with a 5° to 10° caudal tilt. After injection of Tc-99m 
(740 MBq), radionuclide ventriculography was per-
formed at rest with the patient in a supine position. 
The LVEF was calculated by standard methods (Od-
yssey VP, Picker, Cleveland, Ohio).20 
Statistical analysis: All continuous data are ex-
pressed as mean ::±:: SD, percentages are rounded. 
Continuous variables were compared using the Stu-
dent's t test for unpaired samples. Differences be-
tween proportions were compared using the chi-
square test. A p value of <0.05 was considered sta-
tistically significant. 
RESULTS 
The clinical characteristics of the patients are listed 
in Table l. 
Electrocardiographic results: An abnonnal Q-wave 
pattern was present in 216 myocardial regions (101 
anterior, 29 septal, 28 lateral, and 58 inferoposterior). 
The patients had on average 1.5 :±: 0.6 regions asso-
ciated with a Q-wave pattern on the electrocardio-
gram. 
Wall motion: Of a total of216 Q-wave regions, 200 
(93%) had an abnormal wall motion pattern. Most of 
the regions without Q waves also exhibited an abnor-
mal wall motion pattern (326 of 376 regions, 87%). 
Hence, most of the regions had an abnormal wall 
motion pattern, but regions with Q waves were more 
often dysfunctional compared with regions without Q 
waves (p <0.05). Regions with abnonnal wall motion 
had an average of2.7 :±: 1.1 dysfunctional segments: 
1.5 ::±:: 0.8 severely hypokinetic, 1.2 .::':: 1.0 akinetic, 
and 0.03 :±: 0.21 dyskinetic segments. Overall, there 
were 526 dysfunctional regions, with 200 related to 
chronic Q waves on the electrocardiogram. 
FOG SPECT: According to metabolic imaging with 
FDG SPECT, 365 of the 526 dysfunctional myocar-
dial regions (69%) were classified as viable. There 
was a significant difference between the proportion of 
dysfunctional but viable regions between regions with 
and without Q waves. However, in a high proportion 
of regions with an abnormal wall motion and patho-
logic Q waves on the electrocardiogram, persistent 
viable myocardium was identified. FDG SPECT met-
abolic imaging demonstrated persistent viable myo-
cardial tissue in 122 of the 200 dysfunctional regions 
(61%) with a Q-wave pattern, and in 243 of 326 
dysfunctional regions (75%) without Q waves on the 
electrocardiogram (p <0.005). There were on average 
1.4 .::':: 1.0 viable segments in a region. Figure 2 shows 
the incidence of viable myocardium in dysfunctional 
regions with and without chronic Q waves. 
DISCUSSION 
Chronic electrocardiographic Q waves are often 
believed to reflect scarred tissue. However, there is 
evidence that viable tissue may be present in dysfunc-
tional myocardium related to chronic Q waves on the 
electrocardiogram. 8 - 11 The present study demon-
strates that chronic Q waves on electrocardiography 
do not necessarily imply irreversible myocardial dam-
age. According to FDG SPECT metabolic imaging, 
viable tissue persisted in a high proportion (61%) of 
dysfunctional myocardial regions with chronic Q 
waves. The persistence of viable tissue in Q-wave 
infarcted regions has important implications for clin-
ical decision making, because multiple studies4 - 720 
have demonstrated that residual myocardial viability 
is an important dctcnninant of outcome after coronary 
revascularization. In the presence of persistent viable 
myocardium, revascularization can improve LV func-
tion, reduce heart failure symptoms, and improve 
perioperative and late surviva\.4 - 7 "20 Moreover, pa-
tients with LV dysfunction as a result of jeopardized 
but viable myocardium have a better prognosis fol-
lowing coronary revascularization than after medical 
therapy.21 The current findings suggest that, in pa-
tients with LV dysfunction as a result of Q-wave 
infarcted myocardium, viability testing should not be 
omitted simply because chronic Q waves are present 
on the electrocardiogram. FDG SPECT can be a use-
ful noninvasive tool that enables physicians to identify 
those patients who will benefit most from coronary 
revascularization. 
In the present study, residual viable tissue was 
present in a large proportion of dysfunctional regions 
with Q waves. Thus far, data on myocardial viability 
in Q-wave infarction are limited. Hashimoto et af2 
studied 22 patients with FDG and positron emission 
57 
Qwave 
n=200 
No Q wave 
n=326 
FDG imaging using SPECT cameras 
equipped with high-energy collima-
tors was developed. Several studies 
have compared FDG SPECT to FDG 
positron emission tomography, 
showing excellent agreement be-
tween the 2 techniques, whereas 
D Viable 1111 Nonviable 
243 
(75%) 
other studies have shown the accu-
racy of FDG SPECT to predict func-
tional recovery.25- 29 The availability 
of FOG SPECT may contribute to a 
more widespread use of FDG for the 
assessment of viability in patients 
with LV dysfunction. 
Study limitations: This study has 
several limitations. The first limitation 
is the lack of quantitative information 
on myocardial perfusion and metabo-
lism. Second, the correlation between 
FIGURE 2. The proportion of viable myooordium in 526 dysfunctional ventricular re-
gions according to FDG SPECT imaging. Viable tissue persisted in 122 of the 200 
dysfunctional regions (61%) with chronic electrocarcliogrophic Q waves, ond in 243 
of 326 dysfunctional regions (75%) without a Q-wave pattern (p <0.005). 
electrocardiographic Q waves and the 
infarct location may not be exact. 
Third, coronary revascularization may 
have influenced the presence and num-
ber of Q waves as well as the detection 
tomography. Myocardial viability in the infarcted re-
gion was observed in 36% of the patients with a 
Q-wave infarction. Tillisch et af3 studied 15 patients 
with LV dysfunction and Q waves using FDG positron 
emission tomography. In 54% of dysfunctional re-
gions with a Q wave on the electrocardiogram, meta-
bolic imaging demonstrated viable myocardium. 
Brunken et al14 studied 20 patients with FDG positron 
emission tomography and showed viable myocardium 
in 68% of the Q-wave regions. The present findings 
using FDG SPECT imaging are consistent with the 
previous observations with FDG positron emission 
tomography and revealed viable myocardium in 61% 
of the regions with a Q-wave infarction. 
Assessment of viability by FOG SPECT: Since the 
introduction of the concept of myocardial viability, 2•3 
several noninvasive methods have been developed to 
identify jeopardized but viable myocardium. Various 
nuclear imaging techniques can be used to assess 
whether characteristics of viable myocardium, cell 
membrane integrity, or residual metabolic activity, are 
present in dysfunctional myocardium. Many studies 
have reported on the high diagnostic accuracy of FDG 
imaging with positron emission tomography to assess 
myocardial viability. Preserved myocardial uptake of 
FDG in combination with reduced myocardial perfu-
sion (flow-metabolism mismatch) is indicative of vi-
able myocardium. Matched defects are considered 
nonviable scar tissue. In patients with severe LV dys-
function, preoperative viability assessment using FDG 
positron emission tomography is a well-established 
method to predict functional recovery after coronary 
revascularization?4 However, positron emission to-
mography is not widely available, and the number of 
patients with LV dysfunction who require viability 
testing is growing. Therefore, as a widely available 
alternative to positron emission tomographic imaging, 
58 
of viable myocardium. Finally, func-
tional outcome after coronary revascularization was not 
studied. 
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Abstract 
Background: Due to chronic exhaustion of cardiomyocytes and damage of the 
contractile apparatus, contractile reserve may be observed less frequent in hibernating than in 
stunned myocardium. The aim of this study was to assess the presence of contractile reserve 
in response to dobutarnine infusion in a large group of patients with stunned and hibernating 
myocardium. 
Methods: A total of 198 consecutive patients with ischemic cardiomyopathy 
(L VEF:540%), underwent resting 2D echo to assess regional contractile dysfunction. Based on 
assessment of perfusion (with Tc-99m-tetrofosmin SPECT) and glucose utilization (with Fl8-
fluorodeoxyglucose SPECT), dysfunctional segments were classified as stunned, hibernating 
or scar tissue (divided into transmural and nontransmural scars). Contractile reserve was 
evaluated by dobutamine stress echocardiography. 
Results: Dobutamine-induced contractile reserve was more frequently found in 
stunned than in hibernating myocardium (61% versus 51%, respectively, p<O.Ol). Only 14% 
of the scarred segments improved in wall motion during dobutamine infusion, significantly 
less than stunned or hibernating myocardium (p<O.OOI). Nontransmural scars exhibited 
contractile reserve more frequently as compared to transmural scars. 
Conclusion: The progressive reduction of contractile reserve in stunned, hibernating, 
and scar tissue, supports the hypothesis that stunning, hibernation, and scar are not 
circumscript pathophysiological entities but represent gradual ultrastructural damage on the 
myocyte level. 
62 
Introduction 
In patients with ischemic cardiomyopathy, distinguishing between hibernating, 
stunned and scarred myocardium may have important implications for clinical management 
and outcome. If hibernating and/or stunned myocardium is present, coronary revascularization 
may not only reverse regional wall motion abnormalities but also improve global function, 
heart failure symptoms, and survival (1-3). Hibernating myocardium was defined as a chronic 
state of contractile dysfunction with reduced blood flow at rest (4,5). Frequently however, 
regional perfusion in chronic dysfunctional myocardium was (near-)normal and has been 
referred to as (repetitive) stunning ( 6). Instead of two different entities, it is likely that 
stunning and hibernation form a continuum and that a gradual reduction of flow is 
accompanied with more ultrastructural damage on the myocyte leveL Due to chronic 
exhaustion of the myocytes and damage of the contractile apparatus, contractile reserve may 
be observed less frequent in hibernating myocardium as compared to stunned myocardium. 
However, the presence/absence of contractile reserve in these different entities has not been 
studied extensively. Therefore, aim of this study was to assess the presence/absence of 
contractile reserve in response to dobutamine infusion in a large group of patients with 
stunned and hibernating myocardium. 
Material and methods 
Study population: A total of 198 consecutive patients in clinically cardiac stable 
condition, with angiographically proven chronic coronary artery disease, a depressed left 
ventricular ejection fraction (LVEFS.40%), and heart failure symptoms were studied at least 
six months fl-om previous myocardial infarction. Patients with primary cardiomyopathy, 
significant valvular heart disease, or an inadequate acoustic window were not included in the 
study protocol. 
The study protocol was as follows. First, L VEF was assessed by radionuclide ventri-
culography. Next, dysfunctional myocardium was identified by resting 2D echo-cardiography; 
the dysfunctional myocardium was then evaluated for the presence of stunning or hibernation 
by assessing perfusion and glucose metabolism using single-photon emission computed 
tomography (SPECT) imaging. Finally, the presence of contractile reserve was evaluated by 
dobutamine stress echocardiography. All patients gave their informed consent; the local 
Ethics Committee approved the study protocol. 
Radionuclide ventriculography, assessment of LVEF: After injection of Tc-99m 
(740 MBq), radionuclide ventriculography was performed at rest with the patient in supine 
position. A small field-of-view gamma camera system (Orbiter, Siemens, Erlangen, Germany) 
was used, oriented in a 45° left anterior oblique position with a 5 to 10° caudal tilt. The LVEF 
was calculated by standard methods (3). 
2D echocardiography, assessment of regional dysfunction and contractile reserve: 
A commercially available imaging system (Hewlett Packard Sonos 5500, Andover, Mass.) 
and a 1. 8 MHz transducer using second harmonic imaging to optimize endocardial border 
visualization were used (9). Two-dimensional imaging was performed with the patient in the 
left lateral position; standard views were recorded on optical disk (cine loops). 
To assess the contractile reserve in dysfunctional myocardium, dobutamine stress 
echocardiography was performed as described previously (9). Beta-blocker therapy was not 
routinely discontinued during dobutamine stress echocardiography. Two patients were in 
atrial fibrillation. After the resting echocardiographic study, dobutamine was administered 
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intravenously, starting at a dose of 5 ~glkg body weight per minute for 5 minutes, followed by 
a 10 ~g/kg/min dose for 5 minutes (low-dose). Incremental doses of 10 ~g/kg/min 
dobutamine were given at 3-minute intervals up to a dose of 40 ~g/kg/min, and atropine was 
added if necessary. 
Echocardiographic analysis: Two experienced observers, unaware of the clinical 
data (and the presence/absence of the SPECT results), scored the digitized echocardiograms 
offline. In case of disagreement, a majority decision was achieved by a third observer. The 
left ventricle was divided into 16 segments according to the American Society of 
Echocardiography (1 0). Regional wall motion and systolic wall thickening were scored using 
a 5-point grading scale: !=normal, 2o=mildly hypokinetic, 3~severely hypokinetic, 4~akinetic, 
5=dyskinetic. Segments with hypokinesia, akinesia or dyskinesia were considered abnormal; 
segments with mild hypokinesia were considered as normal. Contractile reserve was defined 
as an improvement of segmental wall motion score by ;:::I grade following infusion of low-
dose dobutamine. Wall motion score index was determined as the sum of the segmental scores 
of the 16 segments, divided by 16. 
SPECT imaging, assessment of stunning/hibernation: All patients underwent dual-
isotope simultaneous acquisition SPECT. Resting Tc-99m-tetrofosmin SPECT ( 600 MBq) 
was used to assess regional perfusion. Myocardial glucose utilization was evaluated by F 18-
fluorodeoxyglucose (FDG) SPECT (185 MBq). To optimize and standardize the metabolic 
conditions during FDG SPECT, Acipimox (500 mg orally, Byk, The Netherlands) was 
administered in all patients (11,12). Patients with diabetes mellitus were instructed to continue 
antidiabetic medication. Plasma glucose levels were measured immediately before the study. 
In patients with a plasma glucose level >8 mmoVL, insulin was administered intravenously to 
enhance myocardial FDG uptake. The plasma glucose level was measured again, and 
additional insulin was given if necessary. With this regimen, the image quality was good in all 
patients studied. A triple-head gamma camera system (Picker Prism 3000XP, Cleveland, 
Ohio) was used. The camera system was equipped with commercially available high-energy 
511 keV collimators (13). The energies were centered on the 140 keV photon peak ofTc-
99m-tetrofosmin with a 15% window and on the 511 keV photon peak of FDG with a 15% 
window. Data acquisition was performed over 360° (120 sectors of 3°), with the patient in the 
supine position. Total imaging time was 32 minutes. Data were stored in a 64 X 64, 16-bit 
matrix. The image data were reconstructed by filtered backprojection using a Butterworth 
filter (cutoff frequency 0.17 cycles/pixel); 6 mm thick (1 pixel) transaxial slices were 
obtained. Subsequently, standard short- and long-axis projections perpendicular to the heart 
axis were reconstructed. 
Scintigraphic analysis: The left ventricle was divided into 16 segments identical to 
the echocardiographic segmentation (10). Both Tc-99m-tetrofosmin and FDG studies were 
analyzed quantitatively (segments normalized to maximum tracer uptake). Dysfunctional 
segments (identified by resting echocardiography) were evaluated for viability (14-16). 
Dysfunctional segments with normal perfusion (according to the normalized Tc-99m 
tetrofosmin uptake being >80%) were classified as stunned. Dysfunctional segments with a 
perfusion defect (normalized Tc-99m-tetrofosmin uptake <80%) were classified as 
hibernating when a perfusion-FDG mismatch was present (FDG uptake ;:::IO% increased as 
compared to Tc-99m-tetrofosmin uptake). Dysfunctional segments with a perfusion defect 
were classified as scar tissue when a perfusion-FDG match was present (<10% difference in 
tracer activities); these segments were subdivided into nontransmural and transmural scars. 
Segments with Tc-99m tetrofosmin and FDG uptake :2:50%, but without mismatch were 
64 
classified as nontransmural scars, whereas segments with tracer activities <50% were 
classified as transmural scars (14-16). 
Statistical Analysis: Values are expressed as mean ± SD, when appropriate, 
percentages are rounded. Continuous variables were compared using the Student t-test for 
unpaired samples. Differences between proportions were compared using the Chi-square test. 
A value ofp<0.05 was considered statistically significant. 
Results 
Patient characteristics: The clinical characteristics of the 198 patients are 
summarized in Table 1. All patients had heart failure symptoms, New York Heart Association 
(NYHA) functional class was on average 2.5 ± 0.9 and the majority of the patients (120, 61%) 
was in NYHA class III or IV. Ventricular function was severely impaired in all patients; the 
LVEF averaged 30 ± 12%. 
Table 1. Clinical characteristics of the 198 study patients 
Male/Female 
Age (years) 
Previous MI 
Previous CABG 
Previous PTCA 
Previous CV A 
Hypertension 
Hypercholesterolemia 
Diabetes mellitus 
Smoking history/present 
Number of coronary arteries narrowed >50% 
Angina 
Medication 
Aspirin/oral anticoagulants 
ACE inhibitors 
Diuretics 
Nitrates 
Beta blockers 
Calcium antagonists 
Digoxin 
167 (84%) I 31(16%) 
60 ± 9 
182 (92%) 
37 (19%) 
30 (15%) 
2 (1%) 
25 (13%) 
98 (49%) 
31 (16%) 
74 (37%) I 65 (33%) 
2.5 ± 0.7 
129 (65%) 
175 (88%) 
144 (73%) 
103 (52%) 
151 (76%) 
114(58%) 
73 (37%) 
41 (21 %) 
Data presented are number(%) of patients. ACE= angiotensin-converting enzyme; CABG = 
coronary artery bypass graft surgery; CV A = cerebrovascular accident; MI = myocardial 
infarction; PTCA =percutaneous transluminal coronary angioplasty. 
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2D echocardiography, assessment of regional dysfunction: Echocardiography at 
rest was performed in 3168 segments, 1016 (32%) segments were normal or mildly 
hypokinetic and not considered for myocardial viability. Of the 2152 dysfunctional segments, 
1119 were severely hypokinetic, 1014 were akinetic, and 19 dyskinetic. 
SPECT, tissue characterization: Dual isotope SPECT imaging demonstrated that 
666 (31 %) of the 2152 dysfunctional segments had a normal perfusion and glucose utilization, 
these segments were considered stunned. A reduced perfusion and relatively preserved 
glucose utilization (hibernating myocardium) was seen in 221 (10%) of the dysfunctional 
segments. The majority of the dysfunctional segments (1265, 59%) had concordantly reduced 
perfusion and metabolism and were considered scar tissue. There were 248 (20%) 
nontransmural and 1017 (80%) transmural scars. The prevalence of stunned myocardium was 
higher in patients with mild heart failure symptoms (NYHA I/11) than in patients with severe 
heart failure symptoms (NYHA III/IV), 255 of 715 segments (36%) versus 411 of 1437 
segments (29%), P=O.OOl. Stunned myocardium was more frequently present in patients with 
angina, 450 of 1349 segments (33%) than in patients without angina, 216 of 803 segments 
(27%), P<0.005. 
Dobutamine echocardiography, assessment of contractile reserve, hemodynamic 
changes during dobutamine stimulation: The hemodynamic variables at baseline and 
during low-dose dobutamine infusion (5 11glkg/min and 10 11g/kg/min stages) are shown in 
Table 2. During low-dose dobutamine infusion both heart rate and the systolic heart rate-
systolic blood pressure product increased significantly. The administration of dobutamine was 
well tolerated in all patients; the protocol was completed in all patients and no serious side-
effects occurred. 
Table 2. Hemodynamic Changes during Dobutamine Infusion 
Baseline 5 11gikg/min 
Heart rate (beats/min) 74 ± 15 77 ± 16 
Systolic BP (mmHg) 125 ± 23 126 ± 22 
Diastolic BP (mmHg) 75 ± 12 74 ± 12 
Rate pressure product 9243 ± 2479 9721 ± 2728 
Wall motion score index 2.8 ± 0.7 2.5 ± 0.7 * 
10 1-lg/kg/min 
85±19*t 
127 ± 22 
70 ± 12 * t 
10810 ± 3220 * t 
2.5 ± 0.7 * 
* p<0.05 versus baseline. t p<0.05 versus 5 Jlg/kg/min dobutamine infusion dose. Data 
presented are mean value± SD. BP =blood pressure. 
Contractile reserve: Generally, wall motion score increased significantly in response 
to low-dose dobutamine (see Table 2). Overall, 696 (32%) ofall2152 dysfunctional segments 
exhibited contractile reserve during low-dose dobutamine stimulation. The prevalence of 
contractile reserve was higher in patients with mild heart failure symptoms (NYHA I/II) 
compared to patients with severe heart failure symptoms (NYHA III/IV), 269 of 715 
segments (38%) versus 427 of 1437 segments (30%), respectively, P<O.OO!. In patients with 
and without angina, contractile reserve was present in 469 of 1349 (35%) and in 227 of 803 
segments (28%), respectively, P<0.005. 
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Figure 1. Contractile reserve according to baseline wall motion (3= severely hypokinetic, 4= 
akinetic, 5 = dyskinetic) in all dysfunctional segments. 
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Figure 2. The presence of contractile reserve according to resting Tc-99m-tetrofosmin 
perfusion (O~normal (100% 2: uptake> 80%), I~mildly reduced (80% 2: uptake> 50%), 
]=moderately reduced (50%;;::: uptake > 25%), ]=severely reduced or absent (25%;;::: uptake 
2: 0%). 
Contractile reserve and baseline wall motion: Contractile reserve in relation to 
severity of wall motion abnormalities is demonstrated in Figure 1. Severely hypokinetic 
segments more often exhibited contractile reserve compared to akinetic segments (582 of 
1119 (52%) versus 114 of 1014 (11%) respectively, p<O.OOl). In contrast, dobutamine-
induced contractile reserve was absent in all 19 segments that were dyskinetic at baseline 
echocardiography. 
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Contractile reserve versus myocardial perfusion: Figure 2 demonstrates the relation 
behveen myocardial perfusion as measured by Tc-99m-tetrofosmin and the presence of 
contractile reserve. Contractile reserve was present in the majority (73%) of the segments 
with normal perfusion whereas it was virtually absent in segments with severely reduced or 
absent perfusion. 
Contractile reserve in stunned, hibernating and scar tissue: Dobutamine-induced 
contractile reserve was observed in 519 out of 887 (59%) of the dysfunctional segments that 
were viable (either stunned or hibernating) according to FDG metabolic imaging. However, 
contractile reserve more frequently found in stunned than in hibernating myocardium ( 407 of 
666, 61% versus 112 of 221, 51%, respectively, p<O.O!). Only 177 of the 1265 scarred 
segments (14%) improved in wall motion during dobutamine infusion, this was considerably 
less often compared to the contractile reserve seen in stunned or hibernating myocardium 
(p<O.OO!, see Figure 3). 
Contractile reserve versus the extent of scar: Residual contractile reserve was 
related to the extent of scar tissue. Figure 4 shows that a contractile response to dobutamine 
was more frequently observed in non transmural than in transmural scar tissue. 
100% 
75% 
50% 
61% 
25% 51% 
0% 
Stunned Hibernating Scar 
Figure 3: Segments with (open portions) and without (solid portions) contractile reserve in 
response to dobutamine infusion in stunned, hibernating, and scarred myocardium. 
Contractile reserve was more frequently found in stunned than in hibernating myocardium 
(407 of 666, 61% versus 112 of 221. 51%, respectively, p<O.OJ). Only 177 of the 1,265 
scarred segments (14%) exhibited contractile reserve, this was considerably less than in 
stunned or hibernating myocardium (p<O.OOJ). 
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Figure 4. Contractile reserve in nontransmural and transmural scar tissue. Contractile 
reserve was morefj-equently observed in nontransmural than in transmural scar (p<O.OOJ) 
Dobutamine echocardiography, assessment of ischemia: During low-high-dose 
dobutamine echocardiography, 345 (16%) segments showed sustained improvement, 351 
(16%) a biphasic response, 131 (6%) worsening, and 345 (16%) no change of wall motion 
pattern. Hence, myocardial ischemia was present in 482 (22%) of the 2152 dysfunctional 
segments. Table 3 demonstrates the patterns of functional response to low-high- dose 
dobutamine infusion in stunned and hibernating myocardium. The prevalence of the biphasic 
response and worsening (patterns indicating myocardial ischemia) were similar between 
stunned and hibernating segments. A sustained improvement of wall motion during 
dobutamine echocardiography was more frequently observed in stunned than in hibernating 
myocardium, 217 (33%) versus 52 (24%) segments, P<0.005. Hibernating segments more 
often showed no change during dobutamine infusion compared to stunned segments, 94 
(43%) versus 206 (31%) segments, P<0.05. 
Table 3. Functional response during low-high-dose dobutamine infusion 
Sustained improvement 
Biphasic response 
Worsening 
No change 
Stunned segments 
(n~666) 
217 (33%) 
190 (29%) 
53 (8%) 
206 (31%) 
Data presented are number of segments(%). 
P-value 
<0.05 
NS 
NS 
<0.005 
Hibernating segments 
(n~221) 
52 (24%) 
60 (27%) 
15 (7%) 
94 (43%) 
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Discussion 
In the present study, in 198 patients with ischemic cardiomyopathy, dobutamine-
induced contractile reserve was observed in 32% of all dysfunctional segments. It was more 
frequently observed in stunned myocardium than in hibernating myocardium ( 61% versus 
51%, P<O.Ol). Moreover, patients with more severe heart failure less frequently showed 
contractile reserve, as compared to patients with mild heart failure. Contractile reserve was 
absent in the majority of scar segments; only 14% of the scar segments exhibited contractile 
reserve. Moreover, residual contractile reserve was also related to the extent of scar tissue; 
nontransmural scar tissue more often exhibited a dobutamine-induced contractile response 
than transmural scars. 
Contractile reserve in chronic dysfunctional myocardium: In the current study, 
32% of all dysfunctional segments exhibited contractile reserve. This percentage is in line 
with previous studies: in a recent meta-analysis (17) of 16 studies involving 448 patients with 
chronic ischemic LV dysfunction, 1128 of 2268 (50%) of dysfunctional segments had 
contractile reserve. The presence or absence of contractile reserve was related to the baseline 
wall motion abnormalities: contractile reserve occurred more frequently in severely 
hypokinetic segments as compared to akinetic segments, and in dyskinetic segments 
contractile reserve was never observed (Figure 1). Thus, the more severe the wall motion 
abnormalities, the lower the incidence of contractile reserve. The presence/absence of 
contractile reserve was also related to resting perfusion: the majority of segments with normal 
perfusion exhibited contractile reserve, whereas the incidence of contractile reserve was 
inversely related to the severity of the reduction in resting perfusion (Figure 2). Similar 
findings were reported by Panza et al, showing less contractile reserve in segments with more 
severely reduced perfusion evaluated by positron emission tomography (18). These 
observations suggest that more damaged segments (with more severe wall motion 
abnonnalities and lower levels of perfusion) less frequently exhibited contractile reserve. 
Contractile reserve in stunning and hibernation: In the current study, segments 
were divided into stunned and hibernating, based on the combined assessment of perfusion 
and glucose utilization (3, 5-8). According to recent studies, stunned myocardium is thought 
to have normal resting perfusion, whereas hibernating myocardium may have reduced resting 
perfusion (5-8). Therefore, in the current study and in other recent studies (3, 5-8), chronic 
dysfunctional myocardium with normal resting perfusion is considered stunned, whereas 
segments with a reduced resting perfusion (but with preserved FDG uptake) are considered 
hibernating. More recently, Fallavolita and Canty (7,8) have shown in a pig model of chronic 
hibernation, that in dysfunctional myocardium blood flow was normal at 1-2 months (indicative 
of chronic stunning), but was reduced at 3-4 months (hibernation). These observations suggest a 
temporal progression of chronic stunning, (characterized by normal flow), to hibernation (with a 
reduced resting flow). It is conceivable that longer duration of myocardial dysfunction in 
combination with more severe reductions in myocardial blood flow lead to more extensive 
myocyte damage. Studies in patients with ischemic cardiomyopathy have shown structural 
dedifferentiation of cardiac myocytes in biopsy samples obtained at the time of coronary 
revascularization (6,19,20). Hibernating myocardium showed a loss of contractile filaments 
(sarcomeres), an accumulation of glycogen in the spaces previously occupied by the 
myofilaments, nuclei with uniformly distributed chromatin, small mitochondria, and a nearly 
absent sarcoplasmatic reticulum (6,19,20). For these reasons, it is anticipated that contractile 
reserve may be less frequently present in hibernating myocardium as compared to stunned 
myocardium. Indeed, studies in small groups of patients have indicated that contractile 
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reserve was less frequently preserved in hibernating myocardium as compared to stunned 
myocardium (21,22). In the current study, with a large group of patients, contractile reserve 
was present in 61% of the stunned segments as compared to 51% of the hibernating segments. 
Moreover, patients with severe heart failure less frequently exhibited contractile reserve as 
compared to patients with mild heart failure. These observations provide further evidence that 
more severe damage results in loss of contractile reserve. In these segments, viability may still 
be maintained (as evidenced by the preserved glucose utilization in some of these segments). 
Clinical relevance and future studies: From a clinical point-of-view the most 
important question is the potential of improvement of contractile function in segments with 
hibernation but without contractile reserve (the segments that are thought to be more severely 
damaged). These segments are indeed damaged more severely as demonstrated by Pagano et 
al. recently (23). These authors studied 22 patients with ischemic cardiomyopathy with FDG 
PET and low-dose dobutamine echocardiography. Transmural biopsies were obtained during 
bypass surgery and the histological findings were related to the FDG PET and dobutamine 
echocardiographic data. Segments with preserved FDG uptake but without contractile reserve 
appeared more damaged (higher extent of myofibrillar loss) as compared to segments with 
preserved FDG uptake and contractile reserve. Segments with hibernation but without 
contractile reserve are frequently observed in patients with ischemic cardiomyopathy (up to 
30-40%) (24,25). Currently, there are no data available on the recovery of function of these 
segments. However, we have recently demonstrated that recovery of function of hibernating 
myocardium may take longer time as compared to stunned myocardium (26). Thus, more 
severely damaged myocardium is likely to take longer time to recover in function. If there is a 
point-of-no-return (when damage is too much) needs further study. It is important to realize 
however that more severely damaged myocardium less frequently exhibits contractile reserve, 
but that recovery of function should not be excluded and therefore these patients may be still 
candidates for revascularization. 
Contractile reserve in scar tissue: In the current study, the presence of contractile 
reserve was also evaluated in scar tissue. In all segments with scar tissue (as defined by 
combined perfusion-FDG imaging), contractile reserve was only present in 14%. In segments 
with transmural scars it was virtually never observed, while a substantial percentage of the 
segments with nontransmural scars did exhibit contractile reserve. This finding is not 
surprising, since segments with non transmural scar contain a substantial amount of normal, 
viable tissue (located epicardially). This tissue responds well to dobutamine infusion and 
explains the observed improved contraction. The resolution of echocardiography does not 
allow discrimination of these endocardial and epicardial layers, but recent studies with 
magnetic resonance imaging have demonstrated the superior resolution of this technique (27), 
enabling the detection of the "epicardial" contractile reserve in subendocardial scars (28). 
Although these segments are not likely to improve in contractile function post-
revascularization, they may be important in the prevention of remodeling, and thus long-term 
prognosis. 
Conclusions: LV dysfunction in patlents with ischemic cardiomyopathy is often 
caused by myocardial stunning, hibernation, and scar tissue. The results of this study show 
that dobutamine-induced contractile reserve was more often found in stunned than in 
hibernating myocardium. In contrast, contractile reserve was virtually absent in scarred 
myocardium. Nontransmural scar more often exhibited contractile reserve than transmural 
scar tissue. This progressive reduction of contractile reserve in stunned, hibernating, 
nontransmural and transmural scar tissue, supports the hypothesis that stunning, hibernation, 
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and scar are not circumscript pathophysiological entities but represent gradual ultrastructural 
damage on the myocyte leveL Further studies are needed to determine the clinical relevance 
(in terms of effect on long-term prognosis) of these different segments. 
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Abstract 
Background: During the noninvasive assessment of myocardial viability with 18F-
fluorodeoxyglucose (FDG) metabolic imaging, adequate regulation of metabolic conditions is 
needed to ensure optimal image quality. Preliminary data suggest a good image quality of 
FDG imaging following nicotinic acid derivatives (Acipimox) administration. However, the 
image quality of this protocol in patients with diabetes is unclear. 
Methods: Seventy patients with ischemic cardiomyopathy undenvent FDG single-
photon emission computed tomography (SPECT) using Acipimox for the assessment of 
myocardial viability, followed by resting 2D echocardiography to identifY dysfunctional 
myocardial tissue. The image quality was scored visually and quantitatively; the myocardium 
to background (M/B) ratio was determined by region-of-interest analysis. The plasma 
concentrations of glucose and free fatty acids were determined to evaluate the metabolic 
conditions before and during FDG imaging. 
Results: A total of 34 patients had diabetes mellitus; of these 34 patients, 12 had 
insulin-dependent diabetes mellitus and 22 had non-insulin dependent diabetes mellitus. The 
remaining 36 patients had no diabetes. During FDG SPECT no severe side effects occmTed. 
Acipimox significantly lowered plasma levels of free fatty acids in both groups. Fifteen of 34 
patients with diabetes had a plasma glucose level >9 mmol/L, which was lowered successfully 
in all patients with additional insulin. Visual evaluation of the FDG images showed a good, 
moderate, and poor image quality in 27, 5, and 2 patients with diabetes mellitus respectively, 
and in 32, 4, and 0 patients without diabetes respectively (P~NS). The M/B ratio of FDG 
SPECT images was comparable in patients with and without diabetes mellitus (3.1 ± 1.0 
versus 3.5 ± 0.9, P~NS). The type of diabetes had no influence on FDG image quality 
Conclusion: FDG SPECT metabolic imaging following Acipimox is safe and 
practical for routine assessment of viability in patients with ischemic cardiomyopathy. Image 
quality is good, even in patients with diabetes, although additional insulin is sometimes 
needed. 
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Introduction 
Diabetes mellitus is an independent predictor of morbidity and mortality in patients 
with chronic left ventricular (LV) dysfunction (1 ,2). Patients with dysfunctional but viable 
myocardium may considerably benefit from coronary revascularization in terms of functional 
outcome and survival, but revascularization procedures in patients with diabetes mellitus are 
associated with a higher morbidity and mortality than in nondiabetic patients (3). Therefore, 
the assessment of myocardial viability is particularly relevant in these patients, in order to 
select the appropriate management strategy. Metabolic imaging with fluorine-18 
fluorodeoxyglucose (FDG) is an accepted technique for the assessment of myocardial 
viability ( 4-7). However, adequate regulation of metabolic conditions is needed to ensure 
optimal image quality. Hyperinsulinemic euglycemic clamping guarantees excellent image 
quality, but is impractical. The use of nicotinic acid derivatives (Acipimox, Byk, The 
Netherlands) is a practical alternative that increases patient throughput in busy nuclear 
cardiology laboratories. Preliminary data suggest a good image quality of FDG imaging 
following Acipimox administration (8,9). However, the image quality of this protocol in 
patients with diabetes is unclear and remains to be evaluated. In the present study, we have 
evaluated the feasibility and image quality of cardiac FDG SPECT imaging using Acipimox 
in patients with diabetes; results were compared to patients without diabetes. In addition, 
subsets of patients with insulin-dependent diabetes mellitus (IDDM) and with non-insulin 
dependent diabetes mellitus (NIDDM) were studied. 
Material and methods 
Patient population, study protocol: The study population consisted of 70 patients 
with chronic coronary artery disease and an impaired left ventricular function, who were 
referred to our imaging laboratory for the evaluation of myocardial viability. A total of 34 
patients had diabetes mellitus; of these 34 patients, 12 had IDDM and 22 had NIDDM. The 
remaining 36 patients had no diabetes. Patients with primary cardiomyopathy or concomitant 
significant valvular disease were not included. All patients unden.vent dual-isotope SPECT 
including Tc-99m tetrofosmin to evaluate perfusion and FDG imaging to glucose utilization, 
followed by resting 2D echocardiography to identify dysfunctional myocardial tissue. The 
precise L VEF was assessed by radionuclide ventriculography. The local Ethics committee 
approved the protocol and all patients gave informed consent. 
Assessment of regional contractile dysfunction, 2D echocardiography: For echo-
cardiography, a Hewlett Packard Sonos-5500 imaging system (Andover, Mass.) was used, 
equipped with a 1.8 MHz transducer using second harmonic imaging to optimize endocardial 
border visualization. Cine loops in four standard views were digitized (parasternal long- and 
short-axes, apical 2- and 4-chamber views), and two experienced reviewers scored the 
regional contractile function. The left ventricle was divided according to the standard 16-
segment model suggested by the American Society ofEchocardiography (10). Regional wall 
motion and systolic wall thickening were scored using a 5-point grading scale: 1 =normal, 
2=mild hypokinetic, 3=severe hypokinetic, 4=akinetic, 5=dyskinetic. Segments with severe 
hypokinesia, akinesia or dyskinesia were evaluated for myocardial viability. 
Assessment of LVEF, radionuclide ventriculography: The LV ejection fraction was 
assessed by radionuclide ventriculography. A small field-of-view gamma camera system 
(Orbiter, Siemens, Erlangen, Germany) was used, oriented in a 45° left anterior oblique 
position with a 5 to 1 0' caudal tilt. After injection of Tc-99m (740 MBq), radionuclide 
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ventriculography was performed at rest with the patient in supine position. The L VEF was 
calculated by standard methods (Odyssey VP, Picker, Cleveland, Ohio). 
SPECT data acquisition: Patients received, after a light breakfast, an intravenous 
injection of Tc-99m-tetrofosmin (600 MBq) to evaluate resting perfusion. Patients with 
diabetes mellitus were instructed to continue their antidiabetic medication. To detennine the 
plasma concentration of glucose and free fatty acids, venous blood samples ware taken at 
baseline and once immediately before the FDG injection. In patients with a plasma glucose 
level >9 mmol/L at baseline, 6 units of insulin was administered subcutaneously. When 
plasma glucose levels remained >9 mrnol!L, additional insulin was administered. FDG 
imaging, to evaluate myocardial glucose utilization, was performed following Acipimox 
administration (500 mg, oral dose) in all patients. Acipimox enhances myocardial FDG 
uptake by reducing the plasma level of free fatty acids (11-13). After the Acipimox 
administration, the patients received a low-fat, carbohydrate-rich meaL This small meal 
further enhances myocardial FDG uptake, by stimulating endogenous insulin release. Sixty 
minutes after the meal, FDG (185 MBq) was injected, and after an additional45 minutes to 
allow cardiac FDG uptake, dual-isotope simultaneous acquisition SPECT was performed. 
Perfusion and metabolic imaging were performed at rest without stressors. 
A triple-head gamma camera system (Picker Prism 3000XP, Cleveland, Ohio) was 
used. The camera system was equipped with commercially available high-energy 511 ke V 
collimators (14). The energies were centered on the 140 keV photon peak oftechnetium-99m 
tetrofosmin with a 15% window and on the 511 ke V photon peak of FDG with a 15% 
window. Data acquisition was performed in the supine position, over 360° (120 sectors of3°). 
Total imaging time was 32 minutes. Data were stored in a 64x64, 16-bit matrix. 
SPECT data reconstruction and analysis: From the raw scintigraphic data, 6 mm 
thick (1 pixel) transaxial slices were reconstructed by filtered backprojection using a 
Butterworth filter (cutoff frequency at 0.17 cycle/pixel of order 3.5). Attenuation correction 
was not applied. Further reconstruction yielded standard short- and long-axis projections 
perpendicular to the heart axis. The Tc-99m-tetrofosmin and the FDG data were reconstructed 
simultaneously, in order to obtain an exact alignment of the perfusion and metabolic images. 
The perfusion and FDG short-axis slices were plotted in polar maps, which were 
normalized to maximum activity (set at 100%); the polar maps were divided into 16 segments 
matching the echocardiographic segments (15). The segments were divided into four groups, 
based on the tracer activities: O=normal tracer uptake (activity >75%), l=mildly reduced 
tracer uptake (activity ::;;75% and >50%), 2=moderately reduced tracer uptake (activity ::;so% 
and >25%), 3=severely reduced or absent tracer uptake (activity ::;;25%). Dysfunctional 
segments (identified by resting echocardiography) were subsequently evaluated for viability. 
Segments with normal perfusion (Tc-99m-tetrofosmin score :::;1) and segments with a 
perfusion defect (score <:2) but relatively increased FDG uptake (FDG score higher than 
perfusion score, mismatch pattern) were considered viable. Segments with a perfusion defect 
and concordantly reduced FDG uptake (match pattern) were considered nonviable. 
Assessment of image quality: The image quality was scored visually using a 3-point 
grading scale: 1 =good (high target-to-background ratio), 2=moderate but interpretable 
(moderate target-to-background ratio), 3=uninterpretable (poor target-to-background ratio). 
To quantitatively assess the image quality of the FDG images, the myocardium to background 
(M/B) ratio was measured in the midventricular short axis plane. A 2x2 pixel region-of-
interest (ROI) was drawn over the myocardium with the highest activity and a similar ROI 
was placed in the center of the LV cavity. From these activities the MIB ratio was calculated. 
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Plasma samples and analytical techniques: Venous blood samples were obtained at 
baseline and immediately before FDG injection to measure plasma levels of glucose and free 
fatty acids. Plasma glucose was determined with the glucose oxidase method (YSI glucose 
analyzer, Yellow Springs, Ohio, USA). The free fatty acid levels were assessed by enzymatic 
colourimetric methods (NEFAC, Wako Chemicals, Neuss, Germany). 
Statistical analysis: All continuous data are expressed as mean ±SD, percentages are 
rounded. Continuous variables were compared using the Student t-test. Differences between 
proportions were compared using the Chi-square test. A value of P<0.05 was considered 
statistically significant. 
Results 
Patient characteristics: Clinical characteristics were comparable between the group 
of patients with diabetes mellitus and the group without diabetes mellitus (see Table 1). All 
patients presented with symptoms of heart failure, and had severely impaired LV function due 
to chronic coronary artery disease. 
Table 1. Clinical characteristics of the 70 study patients 
Men /women 
Age (yrs) 
Hypertension 
Hypercholesterolemia 
Smoking history 
Previous 
Current 
Patients with diabetes 
(n ~ 34) 
30 (88%) /4 (12%) 
59± 8 
5 (15%) 
17 (50%) 
12 (35%) 
10 (29%) 
Family history of CAD 22 (65%) 
Previous MI 31 (91%) 
Multivessel disease 30 (88%) 
LVEF (%) 32 ± 13 
P-value 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
Patients without diabetes 
(n ~ 36) 
31 (86%) /5 (14%) 
60 ± 11 
7 (19%) 
13 (36%) 
10 (28%) 
19 (53%) 
16 (44%) 
35 (97%) 
33 (92%) 
34 ± 10 
Data presented are mean value ± SD or number (%) of patients. CAD = coronary artery 
disease; L VEF =left ventricular ejection fraction; MI =myocardial infarction. 
Plasma substrate levels, glucose: Figure 1 demonstrates the plasma glucose levels 
measured at baseline and immediately before FDG injection. At baseline, the patients with 
diabetes had higher plasma glucose levels than the patients without diabetes. After 
subcutaneous administration of insulin, the differences in glucose levels in patients with and 
without diabetes mellitus were smaller (Figure 1 ). Fifteen of 34 patients with diabetes (7 
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IDDM, 8 NIDDM) had a plasma glucose level >9 mmol/L, which was lowered successfully in 
all patients with additional insulin. 
Free fatty acids: At baseline, the patients witb diabetes had similar plasma levels of 
free fatty acids as the nondiabetic patients, at the time of FDG injection plasma levels of free 
fatty acids had declined significantly in both groups (Figure 2). 
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Figure 1. Bar graft demonstrating the plasma glucose levels measured at baseline (white 
bars) and immediately before FDG injection (black bars). * P<O.OOOJ versus no diabetes;** 
P<0.005 versus no diabetes; t P<O.OOJ versus immediately before FDG injection. Values are 
expressed as mean ± SD. 
500 
405 ± 247' 
....J 400 350 ± 283' E 
-0 300 
E 
c 200 
<( 
L!.. 
L!.. 100 82 ± 123 
0 
Diabetes No diabetes 
Figure 2. Plasma concentration of free fatty acids (FF A) in patients with diabetes mellitus 
and those without diabetes, at baseline (white bars) and after oral administration of Acipimox 
(black bars).* P<O.OOOJ versus after Acipimox. 
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Safety of FDG SPECT using Acipimox: No serious side effects (evaluated by direct 
questioning/physical examination) occurred during FDG SPECT imaging. Nineteen patients 
had a mild and transient skin flush after Acipimox administration. Mild skin flushing occurred 
in 5 of 34 (15%) patients with diabetes and in 14 of 36 (39%) patients without diabetes 
(P<0.05). 
FDG SPECT image quality: Visual evaluation of the FDG images showed a good, 
moderate, and poor image quality in 27, 5, and 2 patients with diabetes mellitus respectively, 
and in 32, 4, and 0 patients without diabetes respectively (NS). The M/B ratio ofFDG SPECT 
images was comparable in patients with and without diabetes mellitus (see Figure 3). 
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Figure 3. The image quality (MIB ratio) of FDG SPECT images was comparable in patients 
with and without diabetes mellitus. 
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Figure 4. Region-of-interest analysis demonstrated that the type of diabetes, insulin 
dependent diabetes mellitus (IDDM) versus non-insulin dependent diabetes mellitus 
(NIDDM), had no influence on FDG image quality. 
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Myocardial Viability: The 2 patients with poor FDG image quality were excluded 
from the analysis of myocardial viability. The number of dysfunctional segments was 
comparable in patients with and without diabetes mellitus (10.2±5.4 versus 8.3±4.1, NS). 
According to metabolic imaging with FDG SPECT, patients with diabetes had more 
dysfunctional but viable myocardial tissue than patients without diabetes. Patients with 
diabetes had on average 5.3±4.4 dysfunctional but viable segments, whereas those without 
diabetes had 3.3±3.3 viable segments (P<0.05). 
Results in patients with NIDDM versus IDDM: Patients with IDDM had similar 
clinical characteristics compared to patients with NIDDM (see Table 2). Glucose levels were 
comparable in patients with IDDM and NIDDM (10.1±4.8 mmo!JL versus 7.6±2.6 mmol/L at 
baseline, NS, and 8.6±3.2 mmol/L versus 7.8±3.0 mmol/L at the time ofFDG injection, NS). 
At baseline, free fatty acids levels were comparable in patients with IDDM and NIDDM 
(242±189 nmollmL versus 404±305 nmollmL, P~NS). However, after the administration of 
Acipimox, at the time of FDG injection, free fatty acid levels were lower in patients with 
IDDM than in those with NIDDM (27±17 nmollmL versus 102±116 nmollmL, P<0.05). 
Region-of-interest analysis demonstrated that the type of diabetes (IDDM versus NIDDM) 
had no influence on FDG image quality (Figure 4). Also patients with IDDM and NIDDM 
had a comparable amount of dysfunctional segments (10.4±5.8 versus 10.1±5.1, NS). Patients 
with IDDM and NIDDM had a comparable number of dysfunctional but viable segments 
(6.5±4.8 versus 4.6±3.9, NS). 
Table 2. Clinical characteristics ofthe 34 patients with diabetes mellitus 
Men /women 
Age (yrs) 
Hypertension 
Hypercholesterolemia 
Smoking history 
Previous 
Current 
Family history of CAD 
Previous MI 
Multivessel disease 
LVEF (%) 
Format similar to Table 1. 
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Patients with NIDDM 
(n ~ 22) 
19 (86%) /3 (14%) 
60 ± 8 
4 (18%) 
12 (55%) 
7 (32%) 
8 (36%) 
13 (59%) 
19 (86%) 
19 (86%) 
34± 14 
P-value 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
Patients with IDDM 
(n ~ 12) 
11 (92%) /I (8%) 
57± 9 
I (8%) 
5 (42%) 
5 (42%) 
2 (17%) 
9 (75%) 
12 (100%) 
II (92%) 
30 ± 14 
Discussion 
Noninvasive assessment of myocardial viability in patients with ischemic cardio-
myopathy has major implications for clinical decision making. \Vhen a substantial amount of 
dysfunctional but viable myocardium is present, coronary revascularization may improve LV 
function and long-term survival. Currently, both the number of patients with heart failure due 
to coronary artery disease and the prevalence of diabetes mellitus are increasing rapidly 
(16,17). Diabetes mellitus is a well-knovm risk factor for coronary artery disease. Patients 
with diabetes have a four-fold increased risk for developing heart failure after myocardial 
infarction (18). The assessment of myocardial viability is particularly relevant in these 
patients, since coronary revascularization in patients with diabetes mellitus is associated with 
a high morbidity and mortality (3). Currently, FDG PET is considered the gold standard 
technique for the assessment of myocardial viability (4-7). Recently, FDG metabolic imaging 
has become widely available with the introduction of FDG SPECT using dedicated 
collimators (19-24). The image quality of FDG imaging is influenced by the metabolic 
conditions (8,9). Several protocols were introduced to lower free fatty acid levels, which 
appears the main determinant of image quality during FDG imaging (8). FDG imaging 
following oral glucose loading is practical, but the image quality varies substantially, with 20-
30% of the images being uninterpretable (in particular in patients with diabetes). The 
hyperinsulinemic euglycemic clamp ensures excellent image quality, but is labor-intensive 
and time consuming. Recently, FDG SPECT following oral administration of nicotinic acid 
derivatives (Acipimox) has been suggested as a clinically useful protocol that increases the 
patient throughput in busy nuclear cardiology laboratories (8,9). Acipimox is a nicotinic acid 
derivative, which inhibits lipolysis and decreases plasma concentrations of free fatty acids 
(11-13). Two preliminary studies showed good image quality of FDG imaging using 
Acipimox (8,9). However, the image quality with this protocol in patients with diabetes is 
unclear, while this is the most challenging patient subset to obtain a good image quality. 
The present study assessed the feasibility and image quality of FDG SPECT following 
oral administration of Acipimox for the assessment of myocardial viability in patients with 
diabetes mellitus. Metabolic conditions (plasma substrate levels) were monitored. As 
anticipated baseline glucose levels were higher in patients with diabetes. In patients with 
plasma glucose levels >9 mmol/L additional insulin was added. An oral dose of Acipimox 
effectively lowered the free fatty acids concentrations in both patient groups. No serious side 
effects of Acipimox were observed. The image quality was comparable in patients with and 
without diabetes mellitus and the type of diabetes mellitus (IDDM, NIDDM) did not influence 
FDG image quality. These findings demonstrate that FDG SPECT following oral 
administration of Acipimox is a safe and clinically useful method for the assessment of 
myocardial viability that offers a good image quality, even in patients with diabetes mellitus. 
It should be stated that Acipimox is currently not available in the United States. 
Recently, Vitale et aL (25) studied 10 patients with ischemic LV dysfunction and NIDDM 
using FDG PET. In that study, FDG imaging was performed following administration of 
Niacin (a nicotinic acid), yielding suboptimal results. However, nicotinic acid derivatives (e.g. 
Acipimox), are known to be 20 times as potent as nicotinic acids, which may explain the 
lesser results in the study by Vitale et al. using Niacin. 
Of interest, patients with diabetes had more dysfunctional but viable myocardial tissue 
than patients without diabetes. This observation is in line with our previous work (26). The 
reason for this finding is currently unclear and awaits further research. 
In conclusion, FDG SPECT metabolic imaging following Acipimox is safe and 
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practical for routine assessment of viability in patients with ischemic cardiomyopathy. Image 
quality is good, even in patients with diabetes, although additional insulin is sometimes 
needed. 
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Perfusion and Contractile Reserve in Chronic Dysfunctional 
Myocardium: Relation to Functional Outcome After 
Surgical Revascularization 
Jeroen J. Bax, MD; Don Poldermans, MD; Arend F.L. Schinkel, :MD; Eric Boersma, MSc; 
Abdou Elhendy, MD; Alexander Maat, MD; Roelf Valkema, MD; 
Eric P. Krenning, :MD; Jos R.T.C. Roelandt, MD 
Background--Chrorric dysfunctional but viable myocardium may exhibit contractile reserve and/or intact perfusion. 
Segments with intact perfusion without contractile reserve are frequently observed inpatients with ischemic cardiomy-
opathy. The clinical relevance of this observation is unclear; in particular, the functional outcome after revascularization 
is unknown. Thus, contractile reserve (using low-dose dobutamine echocardiography) and perfusion (using resting ~'lmTc 
tetrofosmin) were evaluated in 114 patients with ischemic cardiomyopathy and the findings were related to functional 
outcome (9 to 12 months after revascularization). 
Methods and Results-Patients (n=114) with ischemic cardiomyopathy undergoing surgical revascularization were 
evaluated for perfusion (using 99mTc tetrofosmin) and contractile reserve (using low-dose dobutamine echocardiogra-
phy). Contractile function (two-dimensional echocardiography) was assessed before and 9 to 12 months after 
revascularization. In the 1 336 dysfunctional segments, perfusion was preserved in 51% of the segments and contractile 
reserve in 31% (P<.05); 47% of the segments v.rith perfusion did not exhibit contractile reserve. The majority (66%) 
of segments v.rith recovery of function postrevascularization had intact perfusion and contractile reserve; the majority 
(58%) of segments v.rithout functional recovery lacked both perfusion and contractile reserve. Interestingly, 22% of 
segments v.rith functional recovery and 25% of segments v.rithout functional recovery showed intact perfusion without 
contractile reserve. 
Conclusion-Segments v.rith intact perfusion/contractile reserve have a high likelihood of recovery of function 
postrevascularization; segments v.rithout contractile reserve/perfusion have a low likelihood of recovery and segments 
v.rith intact perfusion v.rithout contractile reserve have an intermediate likelihood of recovery. (Circulation. 2002; 
106fsuppllj:I-14-I-18.) 
Key Words: myocardial viability 11 hibernating myocardium a heart failure 11 perfusion 11 contractile reserve 
I n patients with chronic ischemic left ventricular (LV) dysfunction, improvement of contractile function and fa-
vorable long-term prognosis after surgical revascularization 
have been demonstrated in those patients with dysfunctional 
but viable myocardium.'- 6 Different techniques are available 
for the assessment of viable myocardium, based on the 
detection of different characteristics of viable myocardi-
um.'-6 These characteristics include preserved glucose me-
tabolism, intact cell membrane and mitochondria, preserved 
perfusion, and the presence of contractile reserve.'- 6 The first 
4 characteristics can be evaluated by nuclear imaging tech-
niques: Glucose metabolism can be evaluated by Fl8-
fluorodeoxyglucose (FOG) imaging,7•8 intact cell membranes 
can be evaluated by 201Tl imaging,9 intact mitochondria can 
be assessed by 99mTc sestamibi imaging, 10 and preserved 
perfusion can be evaluated by either imaging with thallium-
201 or 99mTc-labeled tracersY·10 The presence of contractile 
reserve can be assessed during the infusion of low-dose 
dobutamine using two-dimensional (20) echocardiography or 
magnetic resonance imaging.'-6 However, dysfunctional but 
viable myocardium does not always eiliibit all characteris-
tics. In particular, in a substantial percentage (approximately 
25%) of the patients contractile reserve appeared absent, 
although other markers of viability (glucose metabolism, 
intact cell membrane, perfusion) were still present.'l.l 2 The 
precise clinical relevance of this observation is thus far 
unclear and remains a matter of debate;n in particular, the 
functional outcome after revascularization of these patients is 
uncertain. To further evaluate this phenomenon, we assessed 
contractile reserve (using low-dose dobutamine echocardiog-
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TABLE 1. Patient Characteristics (n=114) 
Age {years) 61±7 
Sex (M/F) 106/fl 
Previous Ml 109 (96%) 
MVD 104(91%} 
Number stenosed coronary 2.7±.6 
arteries 
LVEF (%} 34±10 
Previous CABG i4 (12%) 
Previous PTCA 16(14%) 
Diabetes 19(17%) 
Renal failure 25 (22%) 
COPD 19(17%} 
Peripheral vascular diseese 18(16%) 
CABG: coronary artery bypass grafting; COPD: chronic obstructive pulmOflary 
diSease; LVEF: left venlril:ular ejection fraction; Ml: myocanlial infarction; MVD: 
multi-vessel disease; PTCA: percutaneous transluminat coronary angioplasty. 
raphy) and perfusion (using resting \>9mTc tetrofosmin) in a 
large group of patients with ischemic cardiomyopathy; the 
findings were subsequently related to functional outcome, 
assessed 9 to 12 months after revascularization. 
Methods 
Patients 
The study population existed of 114 patients with ischemic cardio-
myopathy who were already scheduled for surgical revasculariza-
tion. All patients presented with symptoms of heart failure whereas 
38% of the patients had accompanying angina pectoris. Indications 
for surgery were heart failure in all (New York Heart Association 
[NYHA) score 3.2±0.8), together with angina in 38% (Canadian 
Cardiovascular Society [CCS] score 2.7±0.4). The decision for revas-
cularization was based on clinical grounds (symptoms, presencefabsence of 
ischemia, angiographic findings). 
Additional characteristics are presented in Table I. All patients 
were stable during the study. Patients with severe mitral regurgita-
tion were not included. Each patient gave informed consent to the 
study protocol that was approved by the local Ethics Committee. 
Study Protocol 
At the entrance of the study, the patients underwent radionuclide 
ventriculography (RNV) to assess LV ejection fraction (L VEF), 
resting 2D echocardiography to identifY regional contractile dysfunc-
tion, low-dose dobutaminc echocardiography to assess contractile 
reserve in dysfunctional myocardium, and resting -Tc tetrofosmin 
single-photon emission computed tomography (SPECT) to assess 
perfusion in dysfunctional myocardium. Late (9 to 12 months) after 
revascularization, resting segmental contractile function was re-
assessed using resting 2D echocardiography and global LV function 
(LVEF) by RNV. 
Assessment of LVEF 
LVEF was assessed before and 9 to 12 months after surgical 
revascularization by using equilibrium RNV. 14 RNV was performed 
at rest with the patient in the supine position after the administration 
of 740 MBq of ""mTc. Images were acquired with a small field-of-
view gamma camera (Orbiter, Siemens Corp, Iselin, NJ), oriented in 
the 45-degree left anterior oblique position with a 5- to 10-degree 
caudal tilt. The L VEF was calculated from the 45-degree left anterior 
oblique view by an automated technique. An improvement in L VEF 
by 5% or more was considered sit,>nificant. 15 
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Assessment of Resting Contractile Function 
Before/After Revascularization 
Resting contractile function was assessed by 2D echocardiography 
before and 9 to 12 months after revascularization. Four standard 
views of the LV were recorded (videotape and digitized in cine-loop 
format): parasternal long- and short-axis views and apical two- and 
four-chamber views. The prerevascularization and the postrevascu-
larization images were reviewed (random order) off-line and con-
sensus was achieved by 2 observers unaware of the other tests 
(low-dose dobutamine echocardiography, perfusion imaging). For 
analysis, a 16-segment model was used as suggested by American 
Society of Echocardiography. '" Both inward wall motion and wall 
thickening were analyzed. Each segment was assigned a wall motion 
score of 1 to 4: normal or mildly hypokinetic=l, severely hypoki-
netic=2 (decreased endocardial excursion and systolic wall thicken-
ing), akinetic=3 (absence of endocardial excursion and systolic wall 
thickening), and dyskinetic=4 (paradolliC outward movement in 
systole). Segments were considered dysfunctional when the wall 
motion score was 2 or more. Improvement of segmental wall motion 
score after revascularization by I grade or more was considered 
significant with the exception of improvement from dyskinesia to 
akinesia postrevascularization. 
Assessment of Contractile Reserve 
Contractile reserve was assessed using low-dose dobutamine echo-
cardiography. Dobutamine was infused at 5 and 10 J.tgfkg/min. 5 
minutes per stage. Images were acquired at the end of both stages 
(parasternal long- and short·axis views and apical two- and four-
chamber views) and analyzed by 2 observers (blinded to the 
postrevascularization echocardiograms and unaware of the perfusion 
data) using the 16-segment model and the 4-point scoring system as 
described above. Dysfunctional segments (resting wall motion score 
2 or more) were evaluated for the presence of contractile reserve, 
defined as improvement of wall motion score by I grade or more, 
with the exception of improvement from dyskinesia to akinesia. 
Assessment of Perfusion 
Perfusion was assessed at rest using ""'Tc tetrofosmin (600 MBq) 
SPECT. Data acquisition was performed with a triple-head gamma 
camera system (Picker Prism 3000 XP, Cleveland, OH); the energy 
was centered on the 140 keY photon peak of ""'Tc with a 15% 
window. Imaging was performed over 360 degrees (120 sectors of3 
degrees) with a total imaging time of 32 minutes. Data were stored 
in 64X64, 16-bit matrix. The raw scintigraphic data were recon-
structed by filtered back projection using a Butterworth filter (cut-off 
frequency at 0.17 cycle/pixel, of order 3.5). No attenuation correc-
tion was used. Further reconstruction yielded standard long- and 
short-axis projections perpendicular to the heart axis. Reconstructed 
slices were 8 rnm in all projections. The short-axis slices were 
displayed in polar map format, adjusted for peak myocardial activity 
(100%). The myocardium was divided into 16 segments, matching 
the echocardiographic segments (4 apical segments, 6 distal seg-
ments [anterior, anterolateral, inferolateral, inferior, inferoseptal, and 
anteroseptal], and 6 basal segments, comparable with the distal 
segments). Segments were divided into 4 categories: I =normal 
tracer uptake(> 75%), 2=moderatcly reduced tracer uptake (50% to 
75%), 3=severely reduced tracer uptake (30% to 50%), and 4=ab-
sent tracer uptake ( <30%). In dysfunctional segments, perfusion was 
considered preserved when activity was 50% or more (score 1 or 2). 
Statistical Analysis 
Descriptive results are expressed as mean±SD. Patient data were 
compared using the Student's t test for paired and unpaired data 
when appropriate. Comparison of proportions was performed using 
chi-square analysis. McNemar testing was used to evaluate differ-
ences in positivity for contractile reserve (as assessed by low-dose 
dobutamine echocardio~o'Taphy) and perfusion (assessed by """'Tc 
tetrofosmin SPECT). P<.05 was considered significant. 
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Hypokinesia Akinesia Dyskinesia 
Figure 1. Relation between severity of contractife dysfunction at 
rest and the presence of contractile reserve; of the 412 seg-
ments wflh =ntractile reserve, 68% were hypokinetic, 31% aki-
netic, and 1% dyskinetic. 
Results 
Contractile Function, Pre-
and Postrevascularization 
Six patients died during the study period (2 within 30 days 
after surgery (heart failure), 4 during the follow-up period (3 
heart failure, I noncardiac death); 5 of these patients had 
absent perfusion and absent contractile reserve in all dysfunc-
tional segments; 1 patient had 2 dysfunctional segments 
without perfusion/contractile reserve and 3 dysfunctional 
segments with preserved perfusion but without contractile 
reserve. In the remaining 108 patients, the symptoms im-
proved significantly (mean CCS score reduced to 1.2::!::0.3. 
mean NYHA score reduced to 1.9:!:0.7, both P<.05 versus 
scores before revascularization). 
Regional contractile function, as assessed by resting 20 
echocardiography, demonstrated normal contraction in 392 
(23%) segments and abnormal contraction in 1336 (77%) 
segments. Of the I 336 dysfunctional segments, 646 were 
severely hypokinetic, 629 akinetic, and 61 dyskinetic. Im-
provement of function postrevascularization occurred in 357 
(27%) segments (63% severely hypokinetic, 37% akinetic 
and 0% dyskinetic segments), whereas 979 (73%) segments 
did not improve (or even deteriorate in contractile function). 
Recovery of function was not observed more frequently in 
the 41 patients with angina as compared with the 67 patients 
without angina (153 versus 204 dysfunctional segments). 
LVEF was 34:::':::10% before revascularization and did not 
significantly improve after revascularization (36::!:: II%). 
However, an improvement in L VEF of 5% or more was 
observed in 38 patients (from 28::!:8% before to 36::!::4% after 
revascularization). 
Presence of Contractile Reserve in 
Dysfunctional Myocardium 
In the 1 336 dysfunctional segments, low-dose dobutamine 
echocardiography demonstrated improvement of function 
(contractile reserve) in 412 (31%) segments. Of these 412 
segments with contractile reserve, approximately two-third 
were hypo kinetic 68% and one-third were akinetic (Figure l ). 
In the remaining 924 dysfunctional segments, no improve-
%segments 
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Hypokinesia Akinesia Dyskinesia 
Figure 2. Relation between severity of contractile dysfunction at 
rest and the presence of intact perfusion; of the 683 segments 
with intact perfusion, 70% were hypokinetic, 28% akinetic. and 
2% dyskinetic. 
ment of contraction occurred during infusion of low-dose 
dobutamine. 
Preserved Perfusion in Dysfunctional Myocardium 
In the I 336 dysfunctional segments, 09"'Tc tetrofosmin dem-
onstrated preserved perfusion in 683 (51%) segments; 57% of 
the segments had perfusion score 1, and43% of the segments 
had perfusion score 2. Of the segments with preserved 
perfusion, the majority was hypokinetic (Figure 2). In the 
remaining 653 dysfunctional segments perfusion was not 
preserved (72% of the segments with perfusion score 3 and 
28% of the segments with perfusion score 4). 
Intact Perfusion Versus Preserved Contractile 
Reserve in Dysfunctional Myocardium 
In the 1 336 dysfunctional segments, perfusion was more 
frequently preserved as compared with contractile reserve 
(31% versus 51%, P<.05). The exact distribution of seg-
ments according to the presence/absence of petfusion/con-
tractile reserve is shown in Table 2. In the 683 segments with 
preserved perfusion, contractile reserve was present in 360 
(53%) and absent in 323 (47%) segments. Conversely, in the 
653 segments without preserved perfusion, contractile reserve 
was present in 52 (8%) segments and absent in 601 (92%) 
segments (Figure 3). Disagreement between the 2 techniques 
was 28%, with 86% being related to segments with preserved 
perfusion without contractile reserve. 
The distribution of segments according to the presence/ 
absence of perfusion/contractile reserve in relation to the 
absence/presence of angina is shown in Table 3. 
TABLE 2. Characteristics of All1336 Dysfunctional Segments 
category n (%) 
P+ 683 
CR+ 360 (53%) 
CR- 323 (47%) 
P- 653 
CR+ 52 (8%) 
CR- 601 (92%) 
P: periusion; GR: contractile reserve; -.: present; : absent 
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Perfusion intact Perfusion absent 
Figure 3. Relation between contractile reserve and perfusion in 
chronic dysfunctional myocardium. Segments without intact 
perfusion virtually never have preserved contractile reserve 
(right); 47% of the segments with preserved perfusion do not 
exhibit contractile reserve. 
Perfusion and Contractile Reserve Versus 
Functional Outcome 
The absence/presence of perfusion and absence/presence of 
contractile reserve in segments with and without improve~ 
ment of contractile function after revascularization is shown 
in Figure 4. Of the 357 segments with recovery of function, 
the majority (66%) had both preserved perfusion and con-
tractile reserve, whereas only 13% of the 979 segments 
without improvement of contractile function exhibited pre-
served perfusion and contractile reserve (P<.05 versus seg~ 
ments with improvement of function postrevascularization). 
The majority (58%) of the segments without improvement of 
contractile function postrevascularization exhibited neither 
intact perfusion nor preserved contractile reserve. In contrast, 
only 9% of the segments with improvement of contractile 
function postrevascularization lacked both perfusion and 
contractile reserve (P<.OS versus segments without improve-
ment of function postrevascularization). Of interest, 22% of 
the segments with improvement of contractile function and 
25% of the segments without improvement of contractile 
function postrevascularization showed intact perfusion with-
out contractile reserve. Finally, small percentages of seg-
ments with and without improvement of function (3% and 
4%, respectively) showed preserved contractile reserve with-
out intact perfusion. 
Of the 360 segments with preserved perfusion/contractile 
reserve, 66% exhibited recovery of function. Of the 601 
segments without preserved perfusion/contractile reserve, 
95% did not improve in function. Of the 323 segments with 
preserved perfusion without contractile reserve, 24% im-
proved in function. Of the 52 segments with contractile 
reserve without perfusion, 79% did not improve in function. 
Finally, the segments with higher levels of preserved 
perfusion demonstrated a higher likelihood of recovery; 225 
of 389 segments with tracer uptake >75% improved in 
TABLE 3, Dysfunctional Segments in Patients With and 
Without Angina 
P+ICR+ P+ICR P-/CR+ 
Angina+ (n-41 pts) 114 105 28 
Angina - (n=67 pts) 246 218 
" P: periusion; CR: contractile reserve; +: present; : allsent 
92 
ICR 
229 
372 
Recovery .. Rscovary-
Figure 4. Distribution (according to presence/absence of con-
tractile reserve/periusion) of segments with and without recov-
ery postrevascularization. CR: contractile reserve; P: perfusion; 
+: present; - : absent. 
function postrevascularization as compared with 132 of 294 
segments with tracer uptake 50% to 75%. 
Discussion 
In patients with ischemic cardiomyopathy, the assessment of 
residual viability in areas with chronic contractile dysfunction 
is important for prediction of improvement of function 
postrevascularization and prediction of long-term progno· 
sis.'-" Different techniques are available that rely on different 
characteristics of viable myocardium. 1- 6 Perfusion imaging 
(using 99"'Tc-labeled tracers or 201Tl) and assessment of 
contractile reserve (using low-dose dobutamine echocardiog-
raphy) are widely used in the clinical setting for the assess-
ment of viable myocardium. However, frequently chronic 
dysfunctional myocardium has preserved perfusion whereas 
contractile reserve is lacking. 11 ,12 Data on the functional 
outcome of these segments are scarce.l1 In the present study, 
perfusion imaging was compared with assessment of contrac-
tile reserve in a large number of patients with ischemic 
cardiomyopathy who were already scheduled for surgical 
revascularization. Both intact perfusion and the presence of 
contractile reserve were related to the severity of contractile 
dysfunction. Both perfusion and contractile reserve were 
more frequently observed in segments with severe hypokine-
sia as compared with akinetic segments, whereas dyskinetic 
virtually never exhibited intact perfusion of contractile re-
serve. Thus, the presence of these characteristics appears 
related to the severity of damage. 
Moreover, perfusion was significantly more often pre-
served as compared with contractile reserve: 51% of the 
chronic dysfunctional segments showed intact perfusion and 
31% showed contractile reserve. Head-to-head comparison of 
the individual segments revealed that the disagreement be-
tween the 2 imaging modalities was 28%, with 86% of these 
segments showing preserved perfusion without contractile 
reserve. Similar results have been reported by Panza et a!, 12 
who compared 20 'Tl imaging with dobutamine echocardiog-
raphy and demonstrated that a large number of segments 
demonstrated 20'Tl uptake but lacked contractile reserve. 
Studies comparing metabolic imaging with FDG to assess-
ment of contractile reserve by dobutamine echocardiography 
have shown comparable results: A substantial percentage of 
the segments with FDG uptake did not exhibit contractile 
reserve. 18•19 Pagano and colleagues20 demonstrated that seg-
ments with FDG uptake without contractile reserve had more 
ultrastructural damage and a higher percentage of fibrosis as 
compared with segments with preserved FDG uptake and 
intact contractile reserve. Nagueh and coworkers17 studied 20 
patients with 201TI imaging and dobutamine echocardiography 
before surgical revascularization, and transmural biopsies 
were taken during surgery. The authors demonstrated a 
gradual increase of percentage fibrosis in different segments: 
1% fibrosis in segments with both preserved 201Tl uptake and 
contractile reserve, 9% fibrosis in segments with either 
preserved 2n1Tl uptake or contractile reserve, and 28% fibrosis 
in segments without 20 'Tl uptake and without contractile 
reserve. These findings further substantiate the suggestion the 
severity of ultrastructural damage and fibrosis is related to the 
presence/absence of perfusion and contractile reserve. Seg-
ments with both characteristics have the least damage and 
fibrosis, segments with perfusion without contractile reserve 
have more damage/fibrosis and segments without perfusion/ 
contractile reserve have the most severe damage!fibrosis. 
An important issue is how these findings affect improve-
ment of function postrevascularization. In the present smdy, 
the majority of the segments with improvement of contractile 
function postrevascularization showed both preserved perfu-
sion and contractile reserve. Segments with both characteris-
tics presents may thus have a high likelihood of recovery of 
function post-revascularization (66% of the segments with 
both characteristics improved in function). In contrast, the 
majority of segments without recovery of function postrevas-
cularization lacked both perfusion and contractile reserve. 
Segments without intact perfusion and contractile reserve 
may thus be considered to have a low likelihood of recovery 
of function postrevascularization (95% of the segments with-
out perfusion/contractile reserve did not improve in function). 
The segments with intact perfusion without contractile 
reserve pose a problem; 22% of the segments with recovery 
of function exhibited this pattern, but 25% of the segments 
without recovery of function also exhibited this pattern. Thus, 
segments with preserved perfusion without contractile re-
serve have an intermediate likelihood of recovery postrevas-
cularization. However, from a clinical standpoint, it is impor-
tant to emphasize that patients with preserved perfusion with 
contractile reserve may recover in function postrevascular-
ization and should not routinely be denied surgical revascu-
larization. Future studies are needed to identify which pa-
tients with this pattern are likely to improve and which 
patients will not improve in function postrevascularization. 
Limitations 
Functional follow-up was performed at 9 to 12 months. 
whereas longer follow-up may be needed for complete 
recovery of function. This may be of particular importance in 
patients with severely damaged myocardium. In addition, 
long-term survival may be a superior end-point than improve-
ment of function. 
Graft patency was not assessed; thus, graft occlusion may 
have prevented some viable segments from recovery of 
function. 
Finally, although a similar 16-segment model was used for 
echo and SPECT data, misalignment may have influenced the 
results. 
Conclusions 
In chronic dysfunctional myocardium, perfusion is preserved 
more frequently than contractile reserve. Segments with both 
preserved perfusion and contractile reserve have a high 
likelihood of recovery of function postrevascularization; seg-
ments without preserved perfusion/contractile reserve have a 
low likelihood of recovery. Segments with preserved perfu-
sion without contractile reserve have an intermediate likeli-
hood of recovery after revascularization. Additional testing 
needs to be developed to predict which ofthese segments will 
improve and which segments will not improve in function. 
References 
1. Wijns W, Vainer SF, Camici PG. Hibernating myocardium. N Eng/ 
J Med. 1998;339:173-181. 
2. Marwick TH. The viable myocardium: epidemiology, detection, and 
clinical implications. Lancer. 1998;351:815-819. 
3. Beller GA. Selecting patients with ischemic cardiomyopathy for medical 
treaonent, revascularization, or heart transplantation. J Nucl Cardia/. 
1997;4:Sl52-Sl57. 
4. Bonow RO. Identification ofviabk myocardium. Circulmian. 1996;94: 
2674-2678. 
5. Udelson JE. Testing our tests: surrogate end points versus driving patient 
management and outcomes. JAm Call Cardia/. 2001 ;37:89-92. 
6. Bax JJ, Poldennans D, Elhendy A, et al. Sensitivity, specificity, and 
predictive accuracies of various noninasive techniques for detecting 
hibernating myocardium. Curr Probl Cordia/_ 2001:26:141-186. 
Schclbcrt HR. Measurements of myocardial metabolism in patients with 
iochemic heart disease. Am J C@diol. l998;82(5A):61K-67K. 
Schwaiger M. Melin I_ Cardiological applications of nuclear medicine. 
Lancet. 1999;354:661-666. 
Bell .or GA, Ragosta ?\.f_ Extent of myocardial viability in regions of left 
ventricular dysfunction by rest·redistribution thallium·201 imaging: a 
p<>werful predictor of outcome. J Nucl Cardiol. 1998;5:445-448. 
10. Gibbons RJ. Myocardial perfusion imaging. Hearl. 2001;83:555-560 
11. Dilsizian V. Myocardial viability: contrnctile reserve or cell membrane 
integrity? JAm Coli Cardia/. 1996;28:443-446. 
12. Panza JA, Di!sizian V, Laurienzo JM, et al. Relation between thallium 
uptake and contractile response to dobutamine: implication> regarding 
myocardial viability in patients with chronic coronary artery disease and 
left ventricular dysfunction. Circulation. 1995:91:990-998 
13 Vanovcrschelde JLJ, Melin JA. Metabolic imaging and contrnctilc 
re'!<:rve for assessment of myocardial viability: friends or foes? J N~c/ 
CardioL 1999;6:458-461. 
14 Wackers FJT, Berger HJ, Johnstone DE, et al. Multiple gated cardiac 
blood pool imaging for left ventricular ejection ffaction: validation of the 
technique and assessment of variability. Am J Cardia/. 1979;43· 
1159-1165. 
15. Bm: JJ, Visser FC, Poldermans D, et al. Relationship between preop-
erative viability and postoperative improvement in LVEF and heart 
failure symptoms. J Nuc/ Med_ 2001 ;42:79-86. 
16. Schill~r NB, Shah PM, Cra;vford M, ct al. Recommendation for quanti-
fication of the left ventricle by two·dirnensional echocardiob>raphy. JAm 
Sco Echocardiogr. 1989;2:358-367. 
17. Naguch SF, Mikati 1, Weilbaecher D, et al. Relation of contrnetilc reserve 
of hibernating myocardium in relation to myocardial structure in humans 
Circulation. 1999;100:490-496. 
18. Sawada S, Elsner G, Segar DS, et al. Evaluation of patterns of perfusion 
and metabolism in dobutamine·rcsponsive myocardium_ J Am Coli 
CardioL 1997:29:55-61. 
19 Sun KT, Czemin J, Krivokapich J, et al. Effects of dobutamine stimu-
lation on myocardial blood flow, glucose metabolism, and wall motion in 
normal and dysfunctional myocardium. Circu/aiion. 1996:94:3146-3154 
20 Pagano D, Tom1end JN, Parums DV, et al_ Hibernating myocardium 
morphological correlates of inotropic stimulation and glucose uptake. 
Hear/_ 2000;83:456-461 
93 

Chapter 9 
Long-term prognostic value of dobutamine 
stress technetium-99m-sestamibi SPECT: 
A single-center experience 
with 8-year follow-up 
Schinkel AFL, Elhendy A, van Domburg RT, 
Bax JJ, Valkema R, Roelandt JRTC, Poldermans D 
Radiology, in press 
95 
Abstract 
Purpose: To determine the long-tenn prognostic value of dobutamine 99mTc-sestamibi 
SPECT in patients with limited exercise capacity. 
Material and methods: Clinical data and SPECT results were analyzed in 531 
consecutive patients. Follow-up was successful in 528 (99.4%) patients, 55 underwent early 
revascularization and were excluded. A normal/abnormal study was considered in the 
absence/presence of fixed and/or reversible perfusion defects. A summed stress score (SSS) 
was obtained to estimate the extent and severity of perfusion defects. Univariate and 
multivariate Cox proportional hazard regression models were used to identify independent 
predictors of late cardiac events. The incremental value of myocardial perfusion scintigraphy 
over the clinical variables in the prediction of events was performed according to two models. 
In model I, the only scan variable entered was the presence of an abnormal scan. In model II, 
scan variables including the SSS, and the presence of a fixed or reversible defect were 
entered. The probability of survival was calculated using the Kaplan-Meier method. 
Results: An abnormal scan was detected in 312 patients. During the 8 ± 1.5 year 
follow-up (4.5-10.6), cardiac death occurred in 67 patients (total death 165), nonfatal 
infarction in 34, and late revascularization in 49. The annual event rates for cardiac death, 
cardiac death or infarction, and all events were 0.9%, 1.2%, and 1.5% respectively after a 
normal scan, and 2.7%, 3.4%, and 4.4% after an abnormal scan (P<0.05). In a multivariable 
Cox proportional-hazards model, not merely the presence of an abnormal scan but also the 
SSS provided incremental prognostic information over clinical data (P<O.OOOI). The hazard 
ratio for cardiac death was 1.09 (95% CI 1.01 to 1.18) per 1 unit increment of the SSS. 
Conclusion: The incremental prognostic value of dobutamine stress 99mTc-sestamibi 
SPECT over clinical data is maintained over an 8-year follow-up period in patients with 
limited exercise capacity. 
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Introduction 
The primary goal of risk stratification in patients with suspected or known coronary 
artery disease is to distinguish high-risk patients who may benefit from further invasive 
strategies, from low-risk patients who do not require further invasive evaluation. Stress 99mT c-
sestamibi myocardial perfusion imaging provides useful information for risk stratification and 
determination of optimal clinical management (1-3). Multiple studies have reported the 
prognostic value of 99mTc-sestamibi myocardial perfusion imaging in various patient-subsets 
at short- to intermediate-term follow-up (4-7). To overcome a reduced exercise capacity and 
therefore an insufficient test, various types of non-exercise dependent pharmacological 
stressors, such as adenosine or dobutamine, were developed in conjunction with myocardial 
perfusion imaging. 
However, it is important to note that currently no long-term prognostic studies using 
99
mTc-sestamibi myocardial perfusion imaging are available (1-7). The purpose of our study 
was to determine the long-term prognostic value of dobutamine 99mTc-sestamibi SPECT in 
patients with limited exercise capacity. 
Material and methods 
Study population: The study population comprised 531 consecutive patients with 
limited exercise capacity referred for dobutamine stress 99mTc-sestamibi SPECT imaging for 
the evaluation of suspected or known coronary artery disease, between 1990 and 1995. 
Follow-up was successful in 528 of 531 patients (99.4%). Fifty-five patients underwent early 
coronary revascularization (35 CABG, and 20 PTCA) within 60 days of the scintigraphy and 
were excluded from analysis. In these patients the decision to revascularize was already made 
and the test was performed as part of a research protocoL As a result, the prognostic data 
reported are based on 473 patients. All patients gave informed consent before testing. The 
local Medical Ethics Committee approved the study protocoL 
In all patients a structured interview and clinical history were obtained, including 
assessment of cardiac risk factors, prior to the dobutamine stress test. Hypertension was 
defined as a blood pressure :?140/90 mm Hg, or treatment with antihypertensive medication. 
Diabetes mellitus was defined as a fasting glucose level :?7.8 mmol/L or the need for insulin 
or oral hypoglycemic agents. Hypercholesterolemia was defined as a total cholesterol :?6.4 
mmol!L, or treatment with lipid-lowering medication. 
Dobutamine stress protocol: Dobutamine stress testing was performed as described 
previously (8). Dobutamine was injected intravenously, first at a dose of 10 ~-tg/kg/min for 3 
minutes, increasing by 10 ~-tg/kg/min every 3 minutes up to a maximum dose of 40 ~-tg/kg/min. 
If the test end-point was not reached at a dobutamine dose of 40 flg/kg/min, atropine (up to 1 
mg) was given intravenously. Blood pressure, heart rate, and electrocardiography were 
continuously monitored. Test end-points were: achievement of target heart rate (85% of 
maximum age and gender predicted heart rate), horizontal or downs loping ST -segment 
depression >2 mm at an interval of 80 ms after the J-point compared with baseline, ST-
segment elevation > 1 mm in patients without previous MI, severe angina, systolic blood 
pressure fall >40 mm Hg compared to baseline, blood pressure >240/120 mm Hg, or 
significant cardiac arrhythmias. Metoprolol was available to reverse the (side) effects of 
dobutamine/atropine if these did not revert spontaneously after termination of dobutamine 
infusion. Side effects were registered, and the relation between the occurrence of cardiac 
arrhythmias during the test and subsequent cardiac events was evaluated. 
97 
SPECT acquisition and interpretation: An intravenous dose of370 MBq of99mTc-
sestamibi was administered approximately 1 minute prior to the termination of the stress test. 
For resting studies 370 MBq of sestamibi were injected at least 24 hours after the stress study. 
Image acquisition was achieved with a Siemens Gammasonics single-head Rota camera 
(Orbiter, Siemens, Iselin, NJ) without attenuation or scatter correction, using a low-energy all-
purpose collimator. Thirty-two projections were obtained over a 180° arc, from left posterior 
oblique to right anterior oblique, with an acquisition time of 45 seconds per projection. Data 
were collected in a 64x64 matrix (word mode), and images were reconstructed using a filtered 
back projection algorithm and a ramp reconstruction filter. Transaxial tomograms were 
reconstructed using the SPETS software package (Nuclear Diagnostics AB, Ha.gersten, 
Sweden). From the three-dimensional data, oblique (short-axis) and sagittal (vertical long-
axis), perpendicular and parallel to the long-axis, respectively, were reconstructed. For each 
study 6 oblique (short axis) slices from the apex to the base, and 3 sagittal (vertical long axis) 
slices were defined. Each of the 6 short axis slices was divided into 8 equal segments. The 
septal part of the 2 basal slices was excluded from analysis because this region corresponds to 
the fibrous portion of the interventricular septum and normally exhibits reduced uptake. 
Therefore, a total of 47 segments were identified (3 long axis and 44 short axis). The 
interpretation of the scan was semiquantitatively performed by visual analysis assisted by the 
circumferential profiles analysis. Profile curves 2.5 SDs below normal perfusion were 
considered abnormal. Stress and rest tomographic views were reviewed side-by-side on a 
computer display in consensus reading by two experienced observers who were unaware of 
the patients1 clinical data. In case of disagreement a majority decision was achieved by a third 
observer. In this study the original interpretations of the images were used. A reversible 
perfusion defect was defined as a perfusion defect on stress images that partially or 
completely resolved at rest in ;:::2 contiguous segments or slices in the 47-segment modeL A 
fixed perfusion defect was defined as a perfusion defect on stress images in 2 or more 
contiguous segments or slices, which persists on rest images in the 47-segment model. An 
abnormal study was considered in the presence of a fixed and/or reversible perfusion defect. 
To assess the severity of perfusion abnormalities, the left ventricular myocardium was divided 
into 6 segments: anterior, inferior, septal anterior, septal posterior, posterolateral and apical. 
Each of the 6 major left ventricular segments was scored using a 4-point scoring system; 0 = 
normal (100%;:, tracer activity> 75%); l ~slightly reduced (75%;:, tracer activity> 50%); 2 
= moderately reduced (50% '2': tracer activity> 25%); 3 = severely reduced or absent uptake 
(25%;::: tracer activity;::: 0%). A summed stress score (SSS) was obtained by adding the scores 
of the 6 myocardial segments at stress. The SSS incorporates the extent and severity of a 
perfusion defect. 
Follow-up: The follow-up data were collected in the year 2001. One author (A.S.) 
contacted the patient's general practitioner and/or reviewed hospital records. This author was 
blinded to the scan results. The date of the last examination or consultation was used to 
determine follow-up time. The mean follow-up period was 8 ± 1.4 years (range 4.5 to 10.6). 
End points were overall death, cardiac death, nonfatal Ml, and late (>60 days) coronary 
revascularization. Cardiac death was defined as a death caused by acute MI, significant 
cardiac arrhythmias, or refractory congestive heart failure, together with ECG and autopsy 
results when available. Sudden death occurring without another explanation was included as 
cardiac death. Cardiac enzyme levels and ECG-changes defined nonfatal MI. Patients were 
censored at the time of late coronary revascularization. 
Statistical analysis: Values were expressed as mean value ±SD or number, and 
compared using the Student t test or Chi-square test. Univariate and multivariate Cox 
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proportional hazard regression models (BMDP statistical software) were used to identify 
independent predictors of late cardiac events (9). Variables were selected in a stepwise 
forward selection manner with entry and retention set at a significance level of 0.05. The risk 
of a variable was expressed as a hazard ratio with a corresponding 95% confidence interval. 
The incremental value of myocardial perfusion scintigraphy over the clinical variables in the 
prediction of events was performed according to two models. In model I, the only scan 
variable entered was the presence of an abnormal scan. In model II, scan variables including 
the SSS, and the presence of a fixed or reversible defect were entered. The probability of 
survival was calculated using the Kaplan-Meier method, and survival curves were compared 
using the log-rank test. P value <0.05 was considered statistically significant. 
Results 
Demographics and stress test results: The characteristics of the 473 patients (273 
men, age 61 ± 12 years) are presented in Table 1. 
Table 1. Study population (n=173) 
Age (years) 
Male gender 
Hypertension 
Diabetes mellitus 
Smoking 
Hypercholesterolemia 
Congestive heart failure 
Beta-blocker use 
Prior myocardial infarction 
Prior surgical revascularization 
Prior percutaneous revascularization 
61 ± 12 
273 (58) 
214 (45) 
69 (15) 
122 (26) 
116 (25) 
84(18) 
185 (39) 
210 (44) 
92 (19) 
75 (16) 
There was a significant increase of heart rate (70 ± 14 to 136 ± 17 bpm, P<O.OOOl), 
and systolic blood pressure (140 ± 23 to 146 ± 31 mm Hg, P<O.OOl) observed during the 
dobutamine stress test. The highest dobutamine dose was 10 !J-g · kg-1 min-1 in 3 (1%) 
patients, 20 ~g · kg·1 · min-1 in 15 (3%), 30 ~g · kg·1 • min·1 in 66 (14%), and 40 ~g · kg·1 • 
min- 1 in 389 (82%). In 196 (41%) patients atropine was added. Patients who were using beta-
blockers (120 of 185, 65%) more frequently received atropine than those without beta-blocker 
therapy (76 of 288, 26%, P<O.OOl). The test was inconclusive (failure to achieve target heart 
rate in the absence of perfusion abnormalities) in 43 (9%) patients. The prognostic data 
reported were based on 473 patients, including the 43 patients who did not achieve target 
heart rate. No patient experienced a MI or ventricular fibrillation. Side effects were atrial 
fibrillation in 5 patients (I%), short ventricular tachycardia (<10 complexes) in 19 patients 
(4%), severe hypotension (decrease in systolic blood pressure >40 mm Hg) in 3 (0.6%), and 
severe hypertension (blood pressure >2401130 mm Hg) in 3 (0.6%). Minor side effects 
included nausea in 18 (4%), chills in 22 (5%), and headache in 29 (6%). No relation was 
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observed between the occurrence of cardiac arrhythmias during the test and subsequent 
cardiac events; the hazard ratio was 1.3 (range 0.8 to 2.0). 
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Figure 1. Kaplan-Meier survival curves for cardiac death according to the results of 
dobutamine stress 99mTc-sestamibi SPECT. The survival curves indicate that patients with 
normal stress sestamibi images maintained a low event rate up to 8 years after the stress test. 
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Figure 2. Kaplan-Meier survival curves for cardiac events (cardiac death/nonfatal infarction! 
revascularization) according to the results of dobutamine stress 99mTc-sestamibi SPECT. The 
annual cardiac event rate was significantly lower in patients with a normal perfitsion. 
100 
Table 2. Predictors of cardiac death. 
Multivariate analysis 
Univariate Clinical data Modell Model II 
Clinical characteristics 
Age* 1.03 (l.Ol-1.06) 1.03 (1.01-1.05) 1.02( 1.01-1.04) 1.03 (1.01-1.05) 
Male gender 2.4 (1.4-4.1) 2.5 (1.6-3.9) 2.1 (1.3-3.3) 2.3 (1.4-3.6) 
Prior MI 2.0 (1.2-3.3) NS NS NS 
Diabetes mellitus 2.3 (1.3-4.0) 1.8 (1.1-2.8) 1.7 (1.1-2.7) 1.7 (1.1-2.8) 
Hypertension 0.7 (0.4-1.2) NS NS NS 
Hypercholesterolemia 0.9 (0.5-1.5) NS NS NS 
Typical angina 1.1 (0.6-1.9) NS NS NS 
Smoking 1.6 (0.9-2.6) NS NS NS 
Congestive heart failure 4.7 (2.9-7.6) 2.1 (1.4-3.2) 1.9 (1.2-2.8) 1.7 (1.1-2.7) 
Stress test results 
Typical angina 1.0 (0.6-1.7) NS NS 
ST -segment changes 1.5 (0.9-2.5) NS NS 
Scan parameters 
Abnormal scan 3.4 (1.7-6.8) 2.1 (1.2-3.7) 
SSS* 1.22 (1.13-1.32) 1.09 (1.01-1.18) 
Fixed defect 1.8 (1.1-2.9) NS 
Reversible defect 1.2 (0.8-2.0) NS 
*Per 1 unit increment.- indicates variable excluded. Values are expressed as Cox proportional hazard ratio and 
95% confidence interval. In model I, the only scan variable entered was the presence of an abnormal scan. In 
model II, the SSS, and presence of a fixed defect or reversible defect were included. MI = myocardial infarction; 
NS = not statistically significant. 
Table 3. Predictors of cardiac events (cardiac death, myocardial infarction, late coronary 
revascularization). 
Clinical characteristics 
Age* 
Male gender 
Prior MI 
Diabetes mellitus 
Hypertension 
Hypercholesterolemia 
Typical angina 
Smoking 
Congestive heart failure 
Stress test results 
Typical angina 
ST -segment changes 
Scan parameters 
Abnormal scan 
SSS* 
Fixed defect 
Reversible defect 
Format similar to Table 2. 
Univariate 
1.02 (1.00-1.04) 
2.5 (1.6-3.8) 
2.2 (1.5-3.2) 
1.9 (1.2-3.0) 
0.7 (0.5-1.1) 
1.1 (0.7-1.7) 
1.1 (0.7-1.7) 
1.2 (0.8-1.9) 
2.7 (1.8-4.1) 
1.1 (0.7-1.6) 
1.6 (0.8-1.8) 
3.2 (1.9-5.4) 
1.17 (1.10-1.25) 
1.4 (1.0-2.1) 
1.4 (1.0-2.1) 
Clinical data 
1.03 (1.01-1.05) 
2.5 (1.6-3.9) 
NS 
1.8 (1.1-2.8) 
NS 
NS 
NS 
NS 
2.1 (1.4-3.2) 
Multivariate analysis 
Model I 
1.02 (1.01-1.04) 
2.1 (1.3-3.3) 
NS 
1.7 (1.1-2.7) 
NS 
NS 
NS 
NS 
1.9 (1.2-2.8) 
NS 
NS 
2.1 (1.2-3.7) 
Model II 
1.03 (1.01-1.05) 
2.3 (1.4-3.6) 
NS 
1.7 (1.1-2.8) 
NS 
NS 
NS 
NS 
1.7 (1.1-2.7) 
NS 
NS 
1.09 (1.01-1.18) 
NS 
NS 
101 
Predictive value of clinical data and test results: Univariate and multivariate 
predictors of cardiac events are presented in Table 2 and 3. The annual event rates for cardiac 
death, cardiac death or nonfatal MI, and all events were 0.9%, 1.2%, and 1.5% respectively 
for patients with a normal scan, and 2. 7%, 3.4%, and 4.4% for those with an abnormal scan. 
Kaplan-Meier survival curves and cumulative event rates are presented in Figure 1, 2, and 3. 
The survival curves indicate that patients with normal stress sestamibi images maintained a 
low event rate up to 8 years after the stress test. Figure 4 demonstrates the incremental 
prognostic value of dobutamine stress 99mTc-sestamibi SPECT over clinical data. Not merely 
the presence of an abnormal perfusion pattern, but the summed stress score (SSS) provided 
incremental prognostic information as well. The hazard ratio for cardiac death was 1.09 
(range 1.01 to 1.18) per 1 unit increment of the SSS. There was no further increase of the 
hazard ratio ifSSS > 9. 
X2 = 54.6 
Clinical data Scintigraphy 
Figure 3. Incremental prognostic value of dobutamine stress 99mTc-sestamibi SPECT over 
clinical data. Dobutamine stress 99mTc-sestamibi SPECT provided significant additional 
prognostic information on top of clinical data alone. 
1 2 3 4 5 6 7 8 
Years 
Figure 4. Cumulative cardiac event rates per year (cardiac death/nonfatal infarction/ 
revascularization) according to the summed stress score (SSS). Not merely the presence of an 
abnormal perfusion pattern, but the summed stress score (SSS) provided incremental 
prognostic iriformation as well. 
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Discussion 
Risk stratification in patients with suspected or known coronary artery disease is 
essential for optimal clinical decision making (10). The prognostic value of stress technetium 
imaging bas been reported in various patient-subsets at short- to intermediate-term follow-up 
(2-7). The mean follow up of this study is 8 ± 1.4 years as compared to an average follow up 
of 0.8-3.6 years after exercise and 0.8-2.3 years after pharmacological stress sestamibi 
myocardial perfusion imaging among previous studies (2-7). The main finding from this study 
is that the prognostic value of dobutamine stress 99mTc-sestamibi SPECT was maintained at 
long-term fo1low-u~. Univariate and multivariate Cox proportional regression analysis 
demonstrated that 9 mTc-sestamibi SPECT provided incremental prognostic information in 
addition to clinical and stress test parameters all through a nearly complete 8-year follow-up 
period. Patients with a normal scan had a good long-term prognosis, and in contrast, patients 
with an abnonnal test had an elevated risk of future cardiac events. Not merely the presence 
of an abnormal perfusion pattern, but the extent and severity of the perfusion defect provided 
incremental prognostic information as well 
Long-term prognostic significance: Although long-term prognostic studies are 
currently not available, the medium-term prognostic value of dobutamine stress 99mTc-
sestamibi SPECT has been reported in several studies (4-7). Geleijnse eta!. (4) studied 392 
patients with a median follow-up period of 22 ± 13 months. There were 27 (7%) cardiac 
deaths during follow up, nonfatal Ml occurred in 17 (4%) patients, and 34 (9%) patients 
underwent late coronary revascularization (10%). The hard cardiac event rate (cardiac death 
or nonfatal MI) was 0.8% for patients with a normal scan, and 9.2% per year in subjects an 
abnormal dobutamine stress 99mTc-sestamibi SPECT scintigraphy. The medium-term 
prognosis of women with chest pain and normal dobutamine stress 99mTc-sestamibi SPECT 
images is excellent (5). None of the study population of 80 women died or had a nonfatal MI 
during the follow-up period of 23 ± 13 months. Senior et a!. (6) followed up 61 patients 
undergoing coronary angiography and dobutamine stress 99mTc-sestamibi SPECT for 19 ± 11 
months. There were 2 (3%) deaths, 2 (3%) nonfatal Ml, 13 (21 %) patients with unstable 
angina, and 3 (5%) subjects with congestive heart failure during the follow-up period. The 
event rate was 3% in patients with normal and 44% in patients with abnormal results. 
Recently, Calnon et a!. (7) studied 308 high-risk patients who underwent dobutamine stress 
99mTc-sestamibi SPECT. During an average follow-up of 1.9 ± 1.1 years, there were 15 
cardiac deaths and 18 Mis. Event rates were 10.0% in patients with an abnormal SPECT 
images and 2.3% in those with normal results. 
The findings from the present study extend the conclusions drawn from these four 
medium-term prognostic studies (4-7). In the current study population of 473 patients, the 
prognostic value of dobutamine sestamibi SPECT imaging was maintained over an 8-year 
period. The event rates for cardiac death, cardiac death or nonfatal MI, and all events were 
respectively, 0.9%, 1.2%, and 1.5% per year for patients with a normal scan, and 2.7%, 3.4%, 
and 4.4% per year for those with an abnormal scan. Moreover, Kaplan-Meier survival curves 
continued to diverge over time, whereas the curve of patients with a normal SPECT study 
showed a very favorable event-free survival, indicating that the prognostic value was 
maintained during the entire follow-up period. This is particularly relevant since recently 
some investigators have suggested that the "warranty" period for normal stress sestamibi 
scans appeared to be 2 years (2). In contrast, the findings from the present study indicate that 
patients with normal stress sestamibi images have a durable good prognosis up to 8 years after 
the index stress test. The annual event rate for cardiac death or nonfatal MI in patients with 
normal scintigraphy results was comparable to the event rate in the general population. 
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Hence, patients with normal SPECT images can be spared further invasive evaluation of their 
coronary anatomy. However, the clinical value and optimal time intervals of periodic stress 
testing in these patients deserve further investigation. 
Incremental prognostic value: In this study a multivariate Cox regression model 
demonstrated that dobutarnine stress 99rncrc-sestamibi SPECT imaging had an incremental 
prognostic value in addition to prognostic information from the clinical data and stress test 
results. This is in line with the findings obtained by long-term follow-up studies using 
thallium-201 SPECT imaging to stratify patients (10-14). Independent clinical predictors of 
cardiac events were age, male gender, diabetes mellitus, and congestive heart failure. Typical 
angina was not independently predictive of events, perhaps due to diminished physical 
activity in a population with limited exercise capacity. The incremental value of myocardial 
perfusion scintigraphy over the clinical variables in the prediction of events was performed 
according to two models. In the first model, the presence of an abnormal scan was a powerful 
independent scintigraphic predictor of future cardiac events. The second model demonstrated 
that the SSS was additive to clinical parameters, hemodynamic, and electrocardiographic 
parameters. This indicates that the long-term prognosis is not only related to the presence but 
also to the extent and severity of perfusion defects on dobutamine stress 99mTc-sestamibi 
SPECT scans. 
Limitations: The diagnostic value of dobutamine stress 99mTc-sestamibi SPECT was 
high, however 9% of the patients had an inconclusive test (failure to achieve the target heart 
rate or to demonstrate a perfusion abnormality). Therefore, the diagnostic value and perhaps 
the prognostic value could have been even higher if beta-blocker medication was routinely 
withheld before stress testing. 
Conclusions: The incremental prognostic value of dobutamine stress 99mTc-sestamibi 
SPECT over clinical data is maintained at long-term follow-up. Patients with normal test 
results have a good long-term prognosis, and thus may not require further invasive evaluation. 
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Prognostic Value of Dobutamine-Atropine Stress 
99mTc-Tetrofosmin Myocardial Perfusion SPECT 
in Patients with Known or Suspected Coronary 
Artery Disease 
Arend F.L. Schinkel, :MD; Abdou Elhendy, MD, PhD; Ron T. van Domburg, PhD; Jeroen J. Bax, MD, PhD; 
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Department of Cardiology, Thoraxcenter. Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands 
~smrc-Tetrofosmin is a recently introduced radioactive isotope 
for the assessment of myocardial perfusion. Data regarding the 
prognostic value of stress imaging using this isotope are scarce. 
The aim of this study was to assess the prognostic value of 
dobutamine-atropine ~~"'Tc-tetrofosmin SPECT for the predic-
tion of late cardiac events in patients with known or suspected 
coronary artery disease. Methods: A total of 72i consecutive 
patients with limited exercise capacity underwent dobutamine-
atropine stress 99mTc-tetrofosmin SPECT. Follow-up was suc-
cessful in 719 of 721 patients (99.7%). Twenty-eight patients 
who underwent early revascularization were excluded. Results: 
Myocardial perfusion abnormalities were detected in 381 pa-
tients (55%) and included fixed defects in 190 patients (27%) 
and reversible defects 191 patients (28%). During a mean fol-
low-up period of 37 :':. 17 mo, there were 150 deaths (22%), of 
which 62 (41%) were attributed to cardiac causes. Nonfatal 
myocardial infarction occurred in 23 patients {3%), and late (>3 
mo) coronary revascularization was performed on 21 patients 
(3%). The cardiac death rate was 1 %/yin patients with a normal 
scan and 5.1 %/y in patients with an abnormal scan (P < 
0.0001). In a multivariable Cox proportional-hazards model, the 
presence of abnormal perfusion was independently associated 
with an increased risk of cardiac death, after adjusting for 
clinical and stress test data (hazard ratio, 8.2; 95% confidence 
interval, 3.2-21). Conclusion: Dobutamine-atropine stress 
g9"'Tc-tetrofosmin SPECT is a useful imaging method for distin-
guishing patients at high and low risk of future cardiac events. 
The presence of perfusion abnormalities provides incremental 
prognostic information to clinical, stress electrocardiographic, 
and hemodynamic data. 
Key Words: tetrofosmin: coronary artery disease; SPECT 
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Rannacologic stress myocardial perfusion imaging is a 
useful alternative to exercise stress in patients with limited 
exercise capacity (1-3). For many years, 201Tl was the most 
widely used radioactive isotope in conjunction with phar-
macologic stress testing for the diagnosis and risk stratifi-
cation of coronary artery disease (CAD) (I). The use of 
99
"'Tc-labeled agents provides the advantages of improved 
image quality, increased consistency of image analysis, and 
a larger injectable dose because of a shorter half-life com-
pared with 201 Tl (2-4). 99mTc-Labeled agents (sestamibi and 
tetrofosmin) share similar phannacokinetic properties. 
These radiopharmaceuticals are distributed "Within the myo-
cardium in proportion to the regional cardiac blood flow. 
After intravenous injection, a relatively rapid clearance of 
the tracer from the blood and extracardiac structures occurs 
with minimal redistribution from the myocardium. Al-
though several studies have revealed the diagnostic value of 
99
"'Tc-tetrofosmin SPECT (5-JJ), the data to define the 
prognostic value of stress imaging with 99mTc-tetrofosmin 
are limited. In a recent study ( 12), the extent of reversible 
perfusion abnormalities during dipyridamole infusion was 
lower with tetrofosmin than with sestamibi. It was con-
cluded that the data relating to the prognostic value of 
99mTc-sestamibi in the literature should not be empirically 
extrapolated to 99mTc-tetrofosmin imaging because of these 
differences. In addition, few studies have shown a reduced 
sensitivity oftetrofosmin imaging in patients with interme-
diate stenotic lesions due to a low extraction fraction and 
early plateau phase (13). These findings may have important 
prognostic implications in patients with normal tetrofosmin 
perfusion studies. In these cases CAD may be missed. Recent 
stuclies have shown that hyperemia induced by a dobutamine-
atropine stress test is of a magnitude at least equal to hyperemia 
induced by vasodilator stress agents such as dipyridamole (14). 
The aim of this study was to assess the prognostic value of 
dobutamine-atropine 99"'Tc-tetrofosmin SPECT in patients 
v.':ith known or suspected CAD. 
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MATERIALS AND METHODS 
Patient Selection 
Between 1994 and 2000, 721 consecutive patients with limited 
exercise capacity were referred for dobutamine-atropine stress 
9
'hnTc-tetrofosmin SPECT for evaluation of suspected or known 
CAD. Follow-up was successful in 719 of 721 patients (99.7%). 
Twenty-eight patients who underwent coronary revascularization 
within 3 mo of scintigraphy were excluded from analysis. In these 
patients, the decision to revascularize may be influenced by test 
results. Consequently. the prognostic data reported are based on 
693 patients. All patients gave infonned consent before testing. 
The Hospital Ethics Committee approved the protocol. 
Clinical Data 
Before the dobutamine stress test. a structured interview and 
clinical history, including assessment of cardiac risk factors, were 
obtained. Hypertension was defined as a blood pressure of 
2::!40/90 mm Hg or treatment with antihypertensive medication. 
Diabetes mellitus was defined as a fasting glucose level of 2::7.8 
mmol'L or the need for insulin or oral hypoglycemic agents. 
Hypercholesterolemia was defined as a total cholesterol of 2::6.4 
mmol/L or treatment with lipid-lowering medication. 
Dobutamine Stress Test 
The dobutamine-atropine stress test was performed as described 
(7). Dobutamine was administered intravenously, starting at a dose 
of 5 !J,g/kglmin for 3 min, then 10 fig/kg/min for 3 min, increasing 
by 10 j.!.g/kg/min every 3 min up to a maximum dose of 40 
j.!.g/kg/min. If the test endpoint was not reached at a dobutamine 
dose of 40 fLgfkglmin, atropine (up to 2 mg) was given intrave-
nously. Blood pressure, heart rate, and electrocardiography were 
monitored continuously. Test endpoints were achievement of tar-
get heart rate (85% of maximum age-predicted heart rate), hori-
zontal or dO\.vnsloping ST-segment depression of >2 mm, ST-
segment elevation of > 1 mm in patients without previous 
myocardial infarction, severe angina, systolic blood pressure fall 
of >40 mm Hg, blood pressure of >240/120 mm Hg, or signifi-
cant arrhythmia. Metoprolol was available to reverse the (side) 
effects of dobutamine or atropine if these did not revert spontane-
ously after tennination of dobutamine infusion. 
SPECT 
Approximately 1 min before the termination of the stress test, an 
intravenous dose of370 MBq 99mTc-tetrofosmin was administered. 
For resting studies, 370 MBq tetrofosmin were injected at least 
24 h after the stress study. Image acquisition was performed with 
a triple-head gamma-camera system (Prism 3000 XP; Picker In-
ternational, Cleveland, OH). For each study, 6 oblique (short axis) 
slices from the apex to the base and 3 sagittal (vertical long axis) 
slices were defined. Each of the 6 short-axis slices was divided into 
8 equal segments. The septal part of the 2 basal slices was 
excluded from analysis because this region corresponds to the 
fibrous portion of the interventricular septum and normally exhib-
its reduced uptake. Therefore, 47 segments were identified (3 long 
axis and 44 short axis). The interpretation of the scan was per-
formed semiquantitatively by visual analysis assisted by analysis 
of the circumferential profiles. Stress and rest tomographic views 
were reviewed side by side by an experienced observer who was 
unaware of each patient's clinical data. A reversible perfusion 
defect was defined as a perfusion defect on stress images that 
partially or completely resolved at rest in ~2 contiguous segments 
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or slices in the 47-segment model. A fixed perfusion defect was 
defined as a perfusion defect on stress images in ~2 contiguous 
segments or slices, which persists on rest images in the 47-segment 
model. An abnormal study was considered in the presence of a 
fixed or reversible perfusion defect (or both). To assess the severity 
of perfusion abnormalities, the left ventricular myocardium was 
divided into 6 segments: anterior, inferior, septal anterior, septal 
posterior, posterolateral, and apical. Each of the 6 major left 
ventricular segments was scored using a 4-grade scoring method 
(0 = normal, I "' slightly reduced, 2 = moderately reduced, 3 = 
severely reduced or absent uptake). The perfusion defect score was 
derived by the summation of the score of the 6-myocardial seg-
ments at stress (SSS) and at rest (SRS). The difference was 
expressed as the summed difference score (SDS). 
Patient Follow-Up 
Follow-up data were obtained in 2000. The mean follow-up 
period was 37 ± 17 mo. The present status was determined by 
contacting the patient's general practitioner or by review of hos-
pital records. The date of the last review or consultation was used 
to calculate the follow-up time. Outcome events were overall 
death, cardiac death, nonfatal myocardial infarction, and late (> 3 
mo) coronary revascularization. Cardiac death was defined as 
death caused by acute myocardial infarction, significant cardiac 
arrhythmias, or refractory congestive heart failure. Sudden death 
occurring without another explanation was included as cardiac 
death. Nonfatal myocardial infarction was defined by cardiac en-
zyme levels and electrocardiographic changes. 
Statistical Analysis 
Data were expressed as mean value ± SD or number and 
compared using the Student t test or x2 test. Univariate and 
multivariate Cox proportional-hazards regression models were 
used to identify independent predictors of late cardiac events. 
Variables were selected in a stepwise forward selection marmer 
with entry and retention set at a significance level of0.05. The risk 
of a variable was expressed as a hazard ratio with a corresponding 
95% confidence interval. The incremental value of myocardial 
perfusion scintigraphy over the clinical variables in the prediction 
of events was performed according to 2 models. In model 1, the 
only scan variable entered was the presence of an abnormal scan. 
In model 2, the presence of a fixed defect or reversible defect was 
included separately. The probability of survival was calculated 
using the Kaplan-Meier method, and survival curves were com-
pared using the log·rank test. P < 0.05 was considered statistically 
significant. 
RESULTS 
Demographics and Stress Test Results 
Clinical characteristics are presented in Table 1. During 
the dobutamine-atropine stress test, there was a significant 
increase of heart rate (from 77 ± 17 to 133 ± 17 beats per 
minute; P < 0.0001) and systolic blood pressure (from 
144 ± 23 to 155 ± 32 mm Hg; P < 0.0001). The highest 
dobutamine dose was I 0 p.g.'kg/min in 1% of the patients, 
20 f.Lg/kg!min in 16%, 30 f.Lgfkg/min in 17%, and 40 f.Lg/ 
kg/min in 66%. Atropine was added in testing 258 patients 
(37%); it was administered more frequently in testing pa-
tients who received (3-blocker therapy (150/253 [59%]) than 
in patients who did not (108/440 [25%]; P < 0.001). The 
TABLE 1 
Baseline Characteristics 
Characteristic 
Patients (n) 
Age (y) 
Moo 
Women 
Hypertension 
Diabetes mellitus 
Smoking 
Hypercholesterolemia 
Congestive heart failure 
13-Biocker use 
History 
Myocardial infarction 
Coronary angioplasty 
Coronary artery bypass surgery 
Value(%) 
693 
60 ;!: 10 
419 (60) 
274 (40} 
327 (47} 
125 (18} 
169 (24) 
248 (36) 
121 (17} 
253 (37) 
194 (28} 
111 (16) 
100 (14) 
test was inconclusive (failure to achieve the target heart rate 
in the absence of perfusion abnormalities) in 7% of the 
patients. The cardiac event rate in patients who did not 
achieve the target heart rate did not differ from the event 
rate in patients with a complete test (P = 0.48). No rela-
tionship was found between the achieved final stage of 
dobutamine infusion and subsequent cardiac death or in-
farction. 
Side effects during dobutamine-atropine stress were short 
ventricular tachycardia (<10 complexes) in 23 patients 
(3.3%), atrial fibrillation in 7 patients (1.0%), severe hypo-
tension (decrease in systolic blood pressure of >40 mm Hg) 
in 7 patients (1.0%), and severe hypertension (blood pres-
sure of >240/130 mm Hg) in 5 patients (0.7%). Minor side 
effects were chills in 52 patients (7.5%), headache in 46 
patients (6.6%), and nausea in 38 patients (5.5%). No pa-
tient experienced a myocardial infarction or ventricular fi-
brillation. 
SPECT and Follow-Up Results 
Myocardial perfusion abnormalities were present in 381 
of the 693 patients (55%) and included fixed defects alone 
in 190 patients (27%) and reversible defects in 191 patients 
(28%). These defects were completely reversible in 61 
patients (9%) and partially reversible in 130 patients (19%). 
There were 150 deaths (22%) during follow-up, of which 
62 were attributed to cardiac causes. Nonfatal myocar-
dial infarction occurred in 23 patients (3%), and late coro-
nary revascularization (>3 mo) was performed on 21 pa-
tients (3%). 
Univariate Analysis 
The cardiac death rate (adjusted for number of patients at 
risk) was I %/yin patients with normal scans versus 5.1%/y 
in patients with abnormal scans during the 5-y follow-up 
period (P < 0.0001) (Fig. 1). Patients with a normal 99mTc-
tetrofosmin SPECT scan had a hard~event rate (cardiac 
death or myocardial infarction) of 1.5%/y compared with 
5.5%/y in those with abnormal scans (P < 0.0001). Uni-
variate predictors of endpoints of interest are shown in 
Table 2. The most powerful predictor for cardiac death. 
cardiac death or (re)infarction, coronary revascularization, 
and all events was abnormal perfusion. Moreover, the extent 
and severity of the defect (expressed by the SSS, SRS, and 
SDS) were related to cardiac death or nonfatal myocardial 
infarction. 
Multivariate Analysis 
A stepwise logistic regression model showed that an 
abnormal scan was the strongest independent predictor of 
cardiac death. Multivariate predictors of cardiac death are 
presented in Table 3. The addition of the perfusion param-
eters to the clinical variables was performed according to 2 
models. In the first model (Table 3, model!) the presence of 
an abnormal scan was added to the clinical characteristics, 
Normal scan 
1.0 
" 
0.8 
> 
-~ 
, 
"' 0.6 
0.4 
0 
P<0.0001 
Abnormal scan 
2 3 4 
Follow-up (y) 
5 FIGURE 1. Kaplan-Meier curves for car-
diac death during follow-up in patients 
with normal and abnormal 99mTc-tetrofos-
min SPECT scans. 
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TABLE 2 
Univariate Predictors of Late Cardiac Events 
Hazard ratio (95% Cl) 
Cardiac death All cardiac 
Predictor Cardiac death orMI Revascularization events• 
Clinical characteristics 
Age (per year) 1.03 (1.01-1.05) 1.01 (1.01-1.05) 0.99 (0.98-1.00) 1.01 (1.00-1.03) 
Age >70 y 1.4(0.8-2.7) 1.4 (0.8-2.5) 0.8 (0.4-1.7) 1.2(0.7-1.9) 
Male gender 1.5 (0.9-2.7) 2.0 (1.6-3.4) 2.7 (1.4-5.4) 2.3 (1.5-3.6) 
Previous Ml 1.6 (0.9-2.7) 1.8 (1.1-2.8) 2.4 (1.4-4.2} 2.1 (1.4-3.2) 
Diabetes mellitus 2.2 (1.2-3.9) 2.0 (1.2-3.3) 1.2 (0.6-2.4} 1.7(1.1-2.7) 
Hypertension 1.3 (0.8-2.2) 1.3 (0.8-2.1) 0.8 (0.4-1.3) u (0.8-1.7) 
Hypercholesterolemia 0.7 (0.4-1.2) 0.6 (0.4-1.0) 1.4 (0.8-2.4) 1.0(0.6-1.4) 
Smoking 2.0 (1.1-3.4} 1.8 (1.1-3.0) 2.1 (1.2-3.8) 2.2 (1.4-3.3) 
Congestive heart failure 4.4 (2.5-7.9) 3.7 (2.2-6.3) 0.6 (0.3-1.5) 2.4 (1 .5-3.8) 
Stress test results 
Angina pectoris 0.7(0.4-1.5) 1.0 (0.5-1.7) 2.1 (1.1-3.8) 1.2 (0.8-2.0) 
ST-segment changes 1.0 (0.6-1.8) 0.9 (0.6-1 .6) 0.8 (0.4-1.6) 0.8 (0.5-1.3) 
Scan parameters 
AbnollT!al scan 8.2 (3.5-19.4) 5.4 (2.8-10.1) 4.0 (1 .9-8.4) 5.6 (3.3-9.5) 
Rxed defect 2.7 (1.7-4.4) 2.1 (1.4-3.1) 1.2 (0.7-2.1) 1.4(1.1-1.8) 
Reversible defect 2.0 (1.3-3.3) 1.8 (1.2-2.7) 3.0 (1.8-5.1) 1.5 (1.2-1.8) 
sss 1.18 (1.09-1.27) i .19 (1.11-1.27) 1.13 (1.04-1.23} 1.17(1.11-1.24) 
SRS 1.16 (1.08-1.26) i .17 (1.09-1.25) 1.05 (0.95-1.16) 1.13 (1.06-1.19} 
SDS 1.13 (0.95-1.33) 1.14 (0.99-1.32) 1.34 (1.17-1.57) 1.26 (1.13-1.41} 
'Cardiac death, Ml, revascularization. 
Cl =confidence interval; Ml = myocardial infarction. 
stress electrocardiographic data, and hemodynamic data. In 
model 2 the presence of a fixed or reversible perfusion 
defect was added separately. The presence of an abnormal 
scan (model!) provided incremental prognostic value over 
clinical, stress electrocardiographic, and hemodynamic data 
(log-likelihood, -324 to -305; P < 0.0001). Model2 also 
offered incremental prognostic information compared with 
the clinical, stress electrocardiographic, and hemodynamic 
parameters (log-likelihood, -324 to -313; P < 0.0001). 
Predictor 
Clinical characteristics 
Age (per year) 
Diabetes mellitus 
Smoking 
Congestive heart failure 
Stress test results 
Typical angina 
ST-segment changes 
Scan parameters 
Abnormal scan 
DISCUSSION 
99mT c-Tetrofosmin is currently used in many nuclear lab-
oratories in the United States and in Europe. Because of 
TABLE 3 
Multivariate Predictors of Cardiac Death 
Clinical data 
1.05 (1.02-1.08) 
2.0 (1.1-3.4) 
2.1 (1.2-3.6) 
4.2 (2.5-7.0) 
Hazard ratio (95% Cl) 
Model1 
1.05 (1.02-1.06) 
1.9 (1.1-3.2) 
1.9 (1.1-3.2) 
3.9 (2.3-{':;.6) 
NS 
NS 
8.2 (3.2-21) 
Model2 
1.04 (1.01-1.07) 
NS 
1.6 (1.0-3.0) 
3.7 (2.2-6.2) 
NS 
NS 
Reversible defect 2.1 (1.2-3.5) 
Fixed defect 2.2 (1.2-4.0) 
Cl =confidence interval; NS = not significant;-= variable excluded. 
In model 1, presence of abnormal scan was only scan variable entered. In model 2, presence of fixed defect or reversible defect was 
included separately. 
112 
considerations of sensitivity in moderately stenotic lesions 
and the possibility of underestimating perfusion abnormal-
ities, studies of the prognostic information obtained by 
imaging with this tracer are important to clarify-whether 
the physician can rely on the results of the test in planning 
further management of patients-particularly in deferring 
further diagnostic evaluation or interventions in patients 
with a negative study. 
To our lmowledge, this is the first study to assess the 
prognostic value of dobutamine 99mTc-tetrofosmin imaging. 
This study showed that dobutamine-atropine 99mTc-tetrofos-
min SPECT provided incremental prognostic value over 
clinical data, for distinguishing patients with high and low 
risk of future cardiac events. A normal perfusion scan was 
related to a good prognosis and identified the patient subset 
at low risk for cardiac death (cardiac death rate, 1%/y). This 
event rate is comparable with that in the general population 
(15). Conversely, the cardiac death rate was 5.1 %/y in 
patients with abnormal scan results (P < 0.0001). 
The most important predictor of late cardiac events was 
an abnormal perfusion scan, which increased the risk for 
cardiac death by 8-fold. Fixed and reversible perfusion 
abnormalities provided incremental independent prognostic 
information. Survival curves continued to diverge over 
time, indicating that the prognostic value of 99mTc-tetrofos-
min SPECT was maintained during the entire follow-up 
period. 
In contrast to the limited experience with prognostic 
applications of 99mT c-tetrofosmin myocardial perfusion im-
aging, multiple studies (16-21) have reported the prognos-
tic value of imaging with 99mTc-sestamibi, the perfusion 
agent that was introduced earlier. Most of these studies, 
with patient populations that were comparable with our 
study, showed that normal perfusion scintigraphy was re-
lated to a very low probability of future cardiac events. 
Nevertheless, most of these studies showed that the event 
rate was relatively higher in patients with normal pharma-
cologic stress compared with normal exercise stress perfu-
sion imaging, probably attributed to the referral of patients 
with a higher risk status to pharmacologic stress testing 
(22). Stratmann et al. (10 reported the prognostic value of 
exercise 99mTc-sestamibi SPECT in 521 patients with a 
median follow-up period of 13 mo. Patients with normal 
sestam.ibi images had a hard-event rate (cardiac death or 
myocardial infarction) of 0.5%/y compared with 7%/y for 
those with abnormal sestamibi scans. Heller et a!. (17) 
reported hard-event rates of 1.4% and 7.4% during a 
12.8-mo follow-up period for subjects with normal and 
abnormal dipyridamole 99mTc-sestamibi scintigraphy, re-
spectively. Berman eta!. (18) reported a hard-event rate of 
0.2% in patients with normal or equivocal exercise 99mTc-
sestam.ibi studies and 7.5% in patients with abnormal results 
over a follow-up period of 20 mo. Geleijnse et al. (19) 
reported that, in 392 patients, hard cardiac-event rates were 
0.8%/y and 6.8%/y in subjects with normal and abnormal 
dobutamine 99mTc-sestamibi SPECT scintigraphy, respec-
tively. A recent study ofHachamovitch eta!. (20) applied a 
dual-isotope protocol (rest thallium and exercise sestarnibi) 
in 2,113 patients. The event rates were 0.3%, 4.7%, and 
10% over the 19-mo follow-up period for subjects with a 
normal study, mildly abnormal study, and severely abnor-
mal study, respectively. 
Our study implies that dobutamine tetrofosmin scintigra-
phy can differentiate patients into low-risk and high-risk 
categories, with event rates after a normal study comparable 
with that reported in patients undergoing sestamibi imaging. 
The observed limitations of tetrofosmin with regard to the 
low extraction fraction and estimation of the extent of 
hypoperfusion were reported with vasodilator stress and, 
therefore, similar findings may not apply with exercise or 
exercise simulating stress modalities such as dobutamine. In 
a recent study by Galassi et al. (23), 459 patients underwent 
exercise tetrofosmin SPECT. During follow-up perfusion, 
15 cardiac deaths occurred, compared with 62 in our study, 
probably reflecting the higher risk status in patients who 
were unable to perform exercise stress test. 
Several studies have shown a relationship between the 
extent and severity of99mTc-sestamibi perfusion defects and 
the prognosis. In our study, this issue was addressed, and the 
extent and severity of 99mTc-tetrofosmin perfusion defects 
were expressed by the SSS and SRS and evaluated as a 
continuous variable. The univariate analysis showed that 
SSS and SRS were predictors of cardiac death, cardiac death 
or (re)infarction, and all cardiac events. Furthermore, the 
SSS was a predictor for late coronary revascularization. A 
recent study by Hachamovitch et a!. (20) reported that the 
extent and severity of reversible defects present on dual-
isotope SPECT scans (as measured by the SDS) provided 
important prognostic information. In line with this, our 
study shows that the SDS, which represents the amount of 
stress-induced ischemia, is a strong predictor of the need for 
coronary revascularization and all future cardiac events. 
Nevertheless, in univariate and in multivariate analyses, the 
most powerful predictor of cardiac events was an abnormal 
scan (Tables 2 and 3). 
Previous studies have revealed the safety and feasibility 
of high-dose dobutamine-atropine stress testing (24-28). 
Consistently, dobutamine-atropine stress testing was ac-
complished in this study without serious side effects: No 
sustained ventricular tachycardia, ventricular fibrillation, 
myocardial infarction, or death occurred. Side effects were 
generally well tolerated and rarely required termination of 
the study (24-28). 
Although the feasibility of the test was high, 7% of 
patients had an inconclusive test (failure to achieve the 
target heart rate or to show a perfusion abnormality). The 
feasibility and perhaps the prognostic value could have been 
even higher if !)-blocker therapy was routinely discontinued 
before the stress test. 
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CONCLUSION 
Dobutamine-atropine stress 99mTc-tetrofosmin SPECT is 
a useful imaging method for distinguishing patients at high 
and low risk of future cardiac events. The presence of 
perfusion abnormalities provides incremental prognostic in-
formation in addition to clinical, stress electrocardiographic, 
and hemodynamic data. Patients with normal perfusion 
studies have a low rate of cardiac death (1 %). The presence 
of abnormal perfusion was associated with an 8-fold in-
crease in the risk of cardiac events. 
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Prognostic value of dobutamine-atropine 
stress myocardial perfusion imaging in 
patients with diabetes mellitus 
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OBJECTIVE- Exercise tolerance in pmients 'Wlth d1abetes IS frequently impmrcd due to 
noncardiac dis~asc such as claudication and polyneuropathy_ This study assesses th~ prognostic 
value of dobutamine stress myocardial perfusion imaging in paliem.s with diabetes 
RESEARCH DESIGN AND METHODS- A total of 107 consecuuve d1abetic patients 
who were unable w undergo exc1nsc stress testing underwent dobutaminc-atropine stress 
myocardial perfuswn 1maging. Follow-up was successful in 206 of2.07 (99_5%) pauents. A total 
of 12 patients underwent enr!y (<60 days) revasculanzatwn and were excluded from the 
onolysis End points during follow-up were hard cardiac events, defined as cardiac demh and 
nonfatal myocardial infarctwn. 
RESULTS- Abnormal myocardial perfuston was detected ill 125 (64%) paucnts. During 
4.1 ± 2_4 years of follow-up, 73 (_)8%) deaths occurred. 36 ( '1-9%) of which were due to cardiac 
causes. Nonfatal myocardial infarction occurred in 7 (4%) patients, and '1-5 (23%) patients 
underwcm late coronMy rcvascularization. Cardiat death occurred in 2 o[ 69 (3%) patients with 
normal myocardml perfusion and in 34 of 125 (27%) patients with perfuswn abnormalities (P < 
0_0001)_ A muhivariable Cox proportional hazard made! demonstrated that. m addition \0 
clinical and stress test data, arr abnormal scm had an incremental prognostic vallle for predicnon 
of cardiac death (hazard rat10 7.2, 95% Cl l.7-30)_ The summed "tre"s score ;vas an imponant 
predictor of cardiac death: 1 he hazard rauo was 1.2 (95% Cl l 07-l .34) p~r one-unit mcrement 
CONCLUSIONS- Dobuwmme-atropine stress myocardial perfusion imaging provides ad-
ditional prognosuc mformation incremental to clinical daw in pauents with diobnes who are 
unable to undngo exercise stress testing 
D iabetes is considered a major risk factor for cardiovascular disease (l-4). Coronary artery d1sease 1s a ma-
jor cause of morbidity and mortality in 
patients with diabetes_ When clinical cor-
onary hean disease develops in patients 
with diabetes, the clinical outcome is 
worse than in patients with coronary 
Diabetes Care 25:1637-1643, 2002 
heart disease without diabetes (5,6)_ Dia-
betic pauents have higher cardiac event 
rates. more silem ischemia, and a higher 
morbidity after acute myocardial infarc-
tion than nondiabetic patients (7-10) 
Myocardial revasculari::ation procedures 
in diabeuc patients are associated with 
higher morbidity and mortality rates than 
eeeeooeeeeeee oo oe ee eooeoeoeo ee eooooeeeoeoooeee eo • 
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Address correspcmdence :Jncl rcpTir.t requests to Don Poldermans. MD. PC. D. Thc>raxcemcr Room Bil 300, 
Dcpa:tmcnt o[ Cardiology, [rosmus :..kdtud C~ntcc. Dr. ~-lolcwJLCrpldn 40, 3015 GD Rot<crdam. the 
Nctherl.mcls. E-ma,]: poldcnmns®hlkd ozr.nl 
Rccei\'Cd [c,, public~1.on 12 \brcil 2002 o~d accepted m rc,•i:;cd form lB ).by 2002 
Abbrevi~tions: '1'''"Tc. lcchnwum-99m, SPECT, sir>gle-rhoton cmLSS1on cnm?utccltamc>graphy: SSS. 
summed strcso score 
A t;Jbk cbc.,.h~rc in th<> tssuc ,;hows con,;en;ional nnd Systcme lm~rnnuonol (SI) umts JnJ cconvcr>wn 
bcwrs for m~ny subsumc·cs 
nondiabetic patients However, coronary 
artery bypass grafting may substantially 
improve long"term outcome m selected 
diabetic patients (ll.l2.). Therefore, tlts 
clinically important to determine the risk 
of cardiac events in patients wtth diabetes 
in order to select the appropriate manage-
ment strategy 
Several techniques have been pro~ 
posed for the prognostic stratification of 
diabetic patients, such as exercise stress 
testing, in conjunction with thallium 
scintigraphy or echocardiography (13-
17). However. many dtabetic patients are 
unable to undergo an exercise stress test 
due to the higher prevalence of stroke, 
peripheral vascular disease, and neurop-
athy (18-20). Such patients generally 
represent a higher risk population than 
patients who are able to undergo exercise 
stress testing, and therefore, pharmaco-
logic stress testing may predict a greater 
number of cardiac events in these pa" 
tients_ Dobutamine-atropine stress myo-
cardial perfusion tmaging may be a useful 
alternative in these htgh-risk patients 
(21,22). However, the value of dobu-
tamine-atropine stress myocardtal perfu-
sion imaging in the prognostic 
strallftcation of diabetic patients has not 
been prevwusly studied_ The aim of this 
study was to assess the incremental prog-
nostic value of dobutamine"atropine 
stress myocardial perfusion imaging rela-
tive to clinical data in diabetic pallents 
who are unable to undergo an exercise 
test. 
RESEARCH DESIGN AND 
METHODS 
Patient population 
The study population comisted o[ 207 
consec:uuve patients with diabetes who 
were unable to undergo an exercise test 
and underwent dobutamine-atropine 
stress myocardial perfuston imaging 
These patients were included in an elec-
tronic registry that accumulated in the 
course of daily clinical care. The Lest was 
requested for evaluation o[ myocardial 
ischemia in all patients; 91 pauents had 
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Table 1-Ba.seline chamcteristics 
N 
Age (years) 
Male sex 
Hypenenslorr 
Smokirrg 
Hypercholesterolemia 
Heart failure 
History of myocardial 
mfarction 
History of myocardial 
revasculati2ation 
f)-blockers 
Calcium channel blockers 
Type I diabetes 
Duration of diabetes (years) 
Complications of diabetes 
Nephropathy 
-:\europathy 
Retinopathy 
Peripheral atherosclerosis 
Stroke 
D~ta are means ± SE or n (%). 
194 
61 ± 10 
116 (60) 
110 (57) 
48 (25) 
64 (33) 
51 (26) 
82 (42) 
52 (27) 
66 (34) 
102 (53) 
58 (30) 
9 ± 10 
37 (19) 
31 (16) 
37 (19) 
34 {18) 
17 (9) 
knovm or suspected coronary artery dis-
ease, 63 had atypical angina, and 53 had 
typical angina_ Diabetes was defined as a 
fasting blood glucose level > 140 mgfdl or 
the need for insulin or oral hypoglycemic 
agents. Follow-up was successful in 206 
o£207 patients (99.5%)_ A total of 12 pa-
tients who unden.vent coronary revascu-
larization within 60 days of the test were 
excluded from the analysis. This exclu-
sion was based on previously published 
data indicating that referral to coronary 
revascularization in the first 60 days after 
nuclear testing tends to be based on the 
results of the scan and that referral to re-
vascularization >60 days after nuclear 
testing tends to be based on worsening of 
the patient's clinical status (23). Data 
from the remaining 194 patients are re-
ported_ All patients gave informed con-
sent before testing. The medical ethics 
committee of the hospital approved the 
study protocoL 
Clinical data 
Before the test, a structured interview was 
performed and a clinical history -was ob-
tained, including assessment of cardiac 
nsk factors. Hypertension was defined as 
blood pressure ~ 140/90 mmHg or need 
for antihypertensive medication. Hyper-
cholesterolemia -was defined as total cho-
lesterol level ~6.4 mmolll or need for 
lipid-lowering medication 
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The type and duration of diabetes. as 
well as the presence of diabetic complica-
tions at baseline, including nephropathy, 
neuropathy, stroke, retinopathy, and pe-
ripheral atherosclerosis, were assessed by 
review of hospital records or contacting 
the patient's treating physician. Nephrop-
athy was defined as a serum creatinine 
concentration >250 jJIDOlll, urinary al-
bumin excretion rate in an overnight 
specimen > 200 fi-g/min on more than 
one consecutive occasion, or the need for 
dialysis or renal transplantation. Stroke 
was defined as a sudden neurologic deficit 
that persisted for >24 hand was evi-
denced by a leswn in the expected site of 
injury by computed tomography or mag-
netic resonance imaging when available 
Diabetic retinopathy was assessed by ex-
perienced ophthalmologists via ophthal-
moscopy with pupil dilatation and/or 
retinal photography. Peripheral athero-
sclerosis was defined as the need for pe-
ripheral by"Pass surgery or amputation of 
at least one digit. 
Dobutamine stress protocol 
Dobutamine-atropine stress testing was 
performed according to a standard proto-
col as previously reported (24)_ Dobut-
amine was administered intravenously, 
starting at a dose of lO fi-g· kg-1 • min-1 for 
3 min, increasing by 10 fi-g· kg-1 • min-1 
every 3 min, up tO a maximum dose of 40 
f'.g · kg-1 • min-1. If the test end point was 
not reached at a dobutamine dose of 40 
f'.g · kg-1 • min-1, atropine (:s:;l mg) was 
administered intravenously. Blood pres-
sure and heart rate were monitored and 
electrocardiography was performed con-
stantly_ Test end points included the fol-
lowing: achievement of target heart rate 
(85% of maximum age- and sex-predicted 
heart rate), horizontal or dovmsloping 
ST-segment depression >2 mm at an in-
terval of 80 ms after thej-point compared 
with baseline, ST -segment elevation > 1 
mm in patients without previous myocar-
dial infarction, severe angina, decrease in 
systolic blood pressure >40 mmHg, 
blood pressure > 2401120 mmHg, or sig-
nificant cardiac arrhythmia. Metoprolol 
was available for administration to reverse 
the adverse effects of dobutamine/ 
atropine. 
Myocardial perfusion imaging 
Approximately l min before the termina-
tion of the dobutamine-atropine stress 
test, an intravenous dose of 370 MBq of 
technetium-99m (99mTc)-sestamibi (in 
69 patients) or 99mTc-tetrofosmin (in 125 
patients) was injected. For resting studies, 
370 MBq of the same tracer was injected 
at least 24 h after the stress test. Image 
acquisition was performed with a com-
mercially available single-photon emis-
sion computed tomography (SPECT) 
camera system (Orbiter camera; Siemens, 
Iselin, NJ; or Picker Prism 3000XP cam-
era; Picker, Cleveland, OH). For each 
study, six oblique (short axJs) slices from 
the apex to the base and three sagittal 
(venical long axis) slices were defined 
Each of the six short-axis slices was divid-
ed into eight equal segments. The septal 
part of the two basal slices was excluded 
from analysis because this region corre-
sponds to the fibrous ponion of the inter-
ventricular septum and normally exhibits 
reduced uptake. Therefore, a total of 4 7 
segments were identified (3 long-axis and 
44 short-axis). The interpretation of the 
scan was semiquantitatively performed 
by visual analysis assisted by the clrcum-
ferential profiles analysis_ Stress and rest 
tomographic views were reviewed s!de-
by-side by two experienced observers 
who were unaware of the patients' clinical 
data. In case of disagreement, a majority 
decision was achieved by a third observer. 
A reversible perfusion defect was defined 
as a perfusion defect on stress images that 
partially or completely resolved at rest in 
~2 contiguous segments or slices in the 
47 -segment modeL A fixed perfusion de-
fect -was defined as a perfusion defect on 
stress images in two or more contiguous 
segments or slices that persisted on rest 
images in the 4 7 -segment model. An ab-
normal study was considered in the pres-
ence of a fixed and! or reversible perfusion 
defect. To assess the severity of perfusion 
abnormalities, the left ventricular myo-
cardium -was divided into six segments: 
anterior, inferior, septal anterior, septal 
posterior, posterolateral, and apicaL Each 
of the six major left vemricular segments 
was scored using a four-point scoringsys-
tem (0 = normal, I = slightly reduced, 
2 = moderately reduced, and 3 = severe-
ly reduced or absent uptake). The perfu-
sion defect score was derived by the 
summation of the score of the six myocar-
dial segments at stress (summed stress 
score [SSS]). 
Data collection and end points 
Follow-up data were obtained by review-
ing hospital records and/or by contacting 
Table 2-Pre:dictors of cardiac de:ath 
Multivariate analysis 
Univariate Clinical data Modell Modell\ 
Clinical characteristics 
Age* 1.07 (1.03-1.12) 1.08 (l.03-Ll2) 1.08 (1.03-1.13) 1.08 (1.04-1.13) 
Male sex 0.8 (0.4-1.6) NS NS NS 
Previous myocardial infarction 1.8 (0.9-3.5) NS NS NS 
Hypenension 0.6 (0.3-1.2) NS NS NS 
Hypercholesterolemia 1.1 (0.6-2.2) :\!S NS NS 
Smoking 1.2 (0.6-2.5) NS NS NS 
Heart failure 3.8 (2.0-7.-t) 3.1 (1.6-6.0) 2.5 (1.3-4.9) 2.2 (l.l-4.4) 
Type l diabetes 1.8 (0.8-3.9) NS NS NS 
Durauon of diabetes (years)" 1.05 (1.01-1.08) NS NS NS 
Diabetic complications 
Nephropathy 1.9 (0.8-4.3) :--:!5 NS NS 
Neuropathy 0.8 (0.3-2.3) NS NS NS 
Retinopathy l.3 (0.5-3.1) NS NS N$ 
Peripheral atherosclerosis 3.7 (1.6--8.4) 3.2 (1.6-6.5) 3.1 (1.5-6.2) 3.4(1.7--6.9} 
Stroke 2.7 (0.9-7.8) NS 
" 
NS 
Stress test results 
Typical angina 0.8 (0.3-1.7) NS NS 
ST-segment changes l.l (0.5-2.2) NS NS 
Scan parameters 
Abnormal scan 9.7(2.3-40) 7.2 (1.7-30) 
sss• 1.21 (l.l0-1.34) 1.20 (1.07-1.34) 
Data are Cox propomonal hazard ratio (95% CI). ln model l. the varlabk entered was the presence of an abnormal scan; m modelll, the SSS was includec 'Per 
one"unit increment;-, varil!ble excluded: NS, not statlstically significant. 
the patient's general practitioner. The 
date of the last review or consultation was 
used to determine follow-up time. The 
mean follow-up period was 4.1 :.t 2.4 
years (range 6 months to 10 years). End 
points comprised overall death, cardiac 
death, nonfatal myocardial infarction, 
and late (>60 days) coronary revascular-
ization. Cardiac death was defined as a 
death caused by acute myocardial infarc-
tion, sigmficant cardiac arrhythmias, or 
refractory congestive heart failure. Sud-
den death occurring without another ex-
planation was included as cardiac death 
Nonfatal myocardial infarction was de-
fined by elevated cardiac enzyme levels 
and typical changes on electrocardiogra-
phy. 
Statistical analysis 
Values were expressed as mean value :.t 
SD or number and were compared using 
the Student's t test or x2 test. Univariate 
and multivariate Cox proportional hazard 
regression models (BMDP statistical soft-
ware, Los Angeles, Cll,.) were used to iden-
tify independent predictors of late cardiac 
events (25). Variables were selected in a 
stepwise forw11rd-selection manner with 
entry and retention set at a significance 
level of 0.05. The risk of a variable was 
expressed as a hazard ratio with corre-
sponding 95% CI. The incremental value 
of myocardial perfusion scintigraphy over 
the clinical variables in the prediction of 
events was determined according to two 
models. In model I, the variable entered 
was the presence of an abnormal scan; in 
model II, the SSS was entered. The prob-
ability of survival was calculated using the 
Kaplan-Meier method, and survival 
curves were compared using the log-rank 
test. P < 0.05 was considered statistically 
significant. 
RESULTS 
Patient characteristics and 
dobutamine stress test 
Baseline data from the 194 patients (116 
men and 78 women aged 61 :.t 10 years) 
are summarized in Table l. During the 
dobutamine-atropine stress test, heart 
rate increased from 77 :.t 17 to 136 :.t 17 
bpm (P < 0_0001), and systolic blood 
pressure increased from 144 ::'::: 26 to 
158 :.t 33 mmHg (P < 0.001). The peak 
dobutamine dose was 10 ~J-g· kg-t ·min-J 
in 5 patients (3%), 20 ~J-g · kg-1 ·min-' in 
2+ patients (12%), 30 ~J-g · kg-1 ·min-1 m 
35 patients (18%), and 40 ~J-g · kg-1 • 
min-1 in 130 patients (67%). In 78 pa~ 
tients (40%), atropine was added. Atro-
pine was more frequently administered in 
patients using 13-blocker therapy ( 41 of 
66 patients, 62 %) than in those not taking 
13-blockers (37 of 128,29%. P < 0.0001) 
Adverse effects during the test were ven-
tricular tachycardia (> 10 beats) in 1 
patient (0.5%), short ventricular tachy-
cardia (<10 beats) in 7 patients (3.6%), 
atrial fibrillation in 2 patients (1.0%), se-
vere hypotension (decrease in systolic 
blood pressure >40 mmHg) in 3 patients 
(1.5%), nausea in ll patients (5.7%), and 
headache in 12 patients (6.2%). No pa-
tient experienced a myocardial infarction 
or fatal complication_ Typical angina oc-
curred in 53 patients (27%), whereas 54 
patients (28%) exhibited ST-segment 
changes. 
Myocardial perfusion images and 
follow-up 
Abnormal myocardial perfusion was de-
tected in 125 patients (64%). A total of 17 
patients (9%) had reversible perfusion de-
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Table 3-Predictors of hard cardiac events (cardiac death or myocardial infarction) 
Multivariate analysis 
Univariate Clinical data Modell Model II 
Chn'tcal characteristics 
Age~ 1.06 (1.03--1.12) 1.06 (1.03--l.ll) 1.07 (L03~Lll) 1.06 (1.03-l.lO) 
Male sex 0_7 (0.4---1.3) NS NS 0.5 (0.3-0.9) 
Previous myocardial infarction 1.6 (0.9-2.9) NS NS NS 
Hypertension 0.9 (0_5~1.6) N$ NS NS 
Hypercholesterolemia 1.0 (0.5-1.9) NS NS NS 
Smoking 1.4 (0.7~2.6) NS NS NS 
Heart failure 3.2 (1.7-5.9) 2.7 (1.5-5.0) 2.5 (1.4-4.7) 2.1 (1.1~4.0) 
Type l diabetes 2.0 (0.9-4.2) NS NS NS 
Duration of diabetes (years)* 1.04 (LOI-1.08) 1.04 (l.Ol-l.07) 1.04 (l.Oi-1.07) 1.04 (l .01-1_07) 
Diabetic complications 
Nephropathy 1.7 (0.7-3.7) NS NS NS 
Neuropathy 0.8 (0.3~2.1) NS NS NS 
Retmopathy 1.2 (0_7~1.4) NS NS NS 
Peripheral atherosclerosis 3.2 (1.4-7.0) 3.0 (1.6~5.8) 3.3 0.6--5.9) 3.1 (1.6--6.0) 
Stroke NS NS NS 
Stress test results 
Typical angina 0.8 (0.4---1.7) NS NS 
ST-segment changes Ll (0.6--2.0) NS NS 
Scan parameters 
Abnormal scan 3.4 (1_4--S.l) 2.8 (1.2~6.8) 
sss~ U6 (1.06--U?) Ll3 (1.02-1.25) 
Data are Cox proponional hazard ratio (95% (j)_ In model!, the variable entered was the presence of an abnormal scan: in rnodellL the SSS was include( •Per 
one-unit increment;-, variable ""eluded 
fects, 61 patients (31 %) had fixed defects, 
and 47 patients (24%) had fixed plus re-
versible defects. During the follow-up pe-
riod of 4.1 ::: 2.4years, 73 patients {38%) 
died; 36 of these patients {19%) died of 
cardiac causes. Nonfatal myocardial in-
farction occurred in 15 patients (8%), and 
18 patients (9%) unden.vent late coronary 
revascularization (coronary artery bypass 
grafting in 6 patients and percutaneous 
transluminal coronary angiography in l2 
patients)_ Of the remaining 46 patients 
with reversible perfusion defects or fixed 
and reversible perfusion defects, most { 43 
patients) had limited perfusion defects 
and received medical treatment; one pa-
tient was accepted for coronary revascu-
larization but died of noncardiac cause 
before coronary revascularization, one 
patient refused coronary revasculariza-
tion and received medical treatment, and 
one patient had normal results of coro-
nary angiography. 
Predictive value of clinical data and 
test results 
During a follow-up period of 4.1 :!: 2.4 
years, cardiac death occurred in2 (3%) of 
69 patients with normal myocardial per-
120 
fusion and 34 (27%) of 125 patients with 
abnormal perfusion {P < 0.0001). Uni-
variate and multivariate predictors of car-
diac events are shown in Tables 2 and 3. 
Among clinical variables, age, heart fail-
ure, and peripheral atherosclerosis were 
independent predictors of cardiac death 
and hard cardiac events (cardiac death! 
nonfatal infarction). The duration of dia-
betes was a clinical predictor of hard 
cardiac events as well. An abnormal scan 
provided incremental prognostic infor-
mation over these clinical variables. 
Kaplan-Meier survival curves for the end 
points cardiac death and cardiac death! 
nonfatal infarction are presented in Figs 
l and 2, respectively. Event-free survival 
was significantly better for patients with 
normal perfusion than for those with ab-
normal perfusion. In patients with a nor-
mal scan, there was no cardiac mortality 
$2.5 years after the myocardial perfusion 
study. The SSS provided incremental 
prognostic information as well (see Tables 
2 and 3). Cumulative event rates accord-
ing to the SSS are depicted in Fig. 3. Cu-
mulative event rates increased as a 
function of defect extent and severity. 
CONCLUSIONS- This study as-
sessed the incremental value of dobu-
tamine-atropine stress myocardial 
perfusion imaging in the prediction of 
cardiac events in diabetic patients vvith 
limited exercise capacity. Follow-up end 
points were cardiac death and nonfatal 
myocardial infarction_ During the fol-
low-up period of 4_1:!: 2.4 years, 73 pa-
tients (38%) died; 36 of these patients 
(27%) died of cardiac causes. Nonfatal 
myocardial infarction occurred in 15 pa-
tients (8%), and 18 patients (9%) under-
went late coronary revascularization 
Clinical predictors of cardiac death alone 
and hard cardiac events (cardiac death 
and myocardial infarction) were age, 
heart failure, and peripheral atherosclero-
sis. The duration of diabetes (years) was a 
clinical predictor of hard cardiac events as 
well. Dobutamine-atropine stress myo-
cardial perlusion imaging provided incre-
mental prognostic information for the 
prediction of cardiac death and hard car-
diac events relative to clinical and stress 
Lest data. Cardiac death occurred in 3% of 
the patiems with normal myocardial per-
fusion and in 27% of the patients with 
abnormal perfusion (P < 0.0001)_ The 
100% normal scan 
.. 
> 90% -~ 
, 
• 80% 0 
p=0.0002 
abnormal scan 
~ 70% 
:;; 
• 60% .c 
~ 
50% 
0 2 3 4 5 6 
Follow-up (years) 
period of 2.5 ± 1.5 years, 39 deaths and 
41 nonfatal infarctions occurred. The 
presence and the extent of abnormal 
stress myocardial perfusion imaging inde-
pendently predicted subsequent cardiac 
events. Although exercise is the most 
physiological stress method and provides 
useful prognostic information by study-
ing hemodynamic response and exercise 
tolerance, many diabetic patients are un-
able to exercise adequately due to periph-
eral vascular disease, neuropathy, and 
degenerative joint disease (18-20). 
Therefore, studies of the prognostic value 
of pharmacological stress testing are im-
portant in these patients. Cardiac death 
rate in this study is much higher (4.5%) 
than in previous studies of diabetic pa-
tients, in which cardiac death rate ranged 
between 1.8 and 2. 7%. This demonstrates 
the importance of noninvasive imaging in 
this high-risk population with limited ex-
ercise capacity. Previous studies of the 
general population showed that dobu-
tamine-atropine stress myocardial perfu-
sion imaging is an alternative in patients 
who are unable to undergo exercise stress 
testing (21 ,22,26), particularly in patients 
with relative contraindications to vasodi-
lator stress agents (patients with obstruc-
tive airway disease) or in those who have 
ingested caffeine or aminophylline 
shortly before stress myocardial perfusion 
imaging. The present study is the first to 
demonstrate that dobutamine-atropine 
stress myocardial perfusion imaging 
forms a safe and useful substitute to exer-
Figure !-Kaplan-Meier survival curves for cardiac death as a function of dobutamine stress 
99mTc-sestamibi SPECT results. Event-free survival is much better in patients with normal test 
results compared with those with abnormal test results 
SSS also provided powerful prognostic in-
formation on both end points. These find-
ings demonstrate that the evaluation of 
severity of functional abnormalities as a 
consequence of coronary artery disease by 
dobutamine-atropine stress myocardial 
perfusion imaging provides clinically use-
ful information in diabetic patients. 
Pre\ious studies 
Currently, there are no clinical outcome 
data to define the role o[ dobutamine-
atropine stress myocardial perfusion im-
aging as a prognostic tool in patients with 
diabetes (26). Data on the prognostic 
value of myocardial perfusion imaging in 
diabetic patients are limited. Felsher et al. 
(13) demonstrated that exercise planar 
thallium imaging was useful for the risk 
stratification of 123 diabetic patients. 
Four cardiac deaths and eight nonfatal in-
farctions occurred during the follow-up 
period of 1.8 ± 0.9 years. Vanzetto et al. 
(14) evaluated the prognostic value of ex-
ercise thallium imaging in 158 diabetic 
patients. During the follow-up period of 
1. 9 ± l. 4 years, cardiac death occurred in 
8 patients and nonfatal infarction oc-
curred in 14 patients. The authors con-
cluded that inability to exercise was 
associated with a high risk of events and 
suggested that, for the assessment of 
prognosis in these patients, pharmaco-
logic stress myocardial perfusion imaging 
be performed. Cohen et al. (15) demon-
strated that abnormal dipyridamole stress 
thallium images were important adverse 
indictors of long-term prognosis in 101 
diabetic patients undergoing peripheral 
vascular surgery. Kang et al. (16) evalu-
ated the ~rognostic value of rest thallium/ 
stress 9 rnTc-sestamibi myocardial 
perfusion imaging in diabetic patients. 
During the follow-up period of 2.0 ± 0.6 
years, 50 cardiac deaths and 42 nonfatal 
infarctions occurred in 1,080 patients 
with diabetes. Most o[ these patients had 
undergone exercise stress testing, 
whereas the others had undergone aden-
osine stress testing. As in the present 
study, an abnormal scan and the SSS pro-
vided incremental prognostic informa-
tion over clinical data. Recently, Giri et al. 
(27) studied 929 diabetic patients after 
exercise or vasodilator stress myocardial 
perfusion imaging. During a follow-up 
100% 
.. 
> 90% i: , 
• 0 
80% 
~ 70% 
:;; 
• 60% .c 
e 
0. 
50% 
0 2 
p=0.002 
3 
Follow-up (years) 
normal scan 
abnormal scan 
4 5 6 
Figure l-Kaplan-Meier survival curves for hard cardiac events (cardiac death/nonfatal infarc-
tion) as a function of dobutamine stress 99"'T c-sestamibi SPECT results. A significant difference in 
event -:free survival exists between patients with normal test results and those in whom test results 
are abnormal. 
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4 
Years 
Figure 3-Cumutativc cardiac event rates (cardiac deaihlnonjatal infarctionlnvaswlarizatlon) 
according to 555. 
cise stress imaging in patients vvith diabe-
tes as welL 
In summary, dobutamine-atropine 
stress myocardial perfusion imaging is a 
clinically useful method for the prognos-
tic stratification of patients with diabetes 
who were unable to undergo exercise 
stress testing. The lest provides incremen-
tal prognostic information relative to clin-
ical parameters. Patients with normal 
perfusion have a good prognosis, whereas 
patients with an abnormal test are at a 
high risk for cardiac events. Both an ab-
normal myocardial perfusion and the SSS 
are imponant determinants of prognosis. 
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Incremental value of exercise 99mTc-
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single-photon emission computed 
tomography for the prediction 
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Abstract 
Background: 99mTc-tetrofosmin single-photon emission computed tomography 
(SPECT) is a useful alternative to 201Tl scintigraphy for the assessment of myocardial 
perfusion. Currently, information on the prognostic value of exercise 99mTc-tetrofosmin 
SPECT is limited. This study assessed the incremental value of exercise 99mTc-tetrofosmin 
SPECT for the prediction of cardiac events in patients with known or suspected coronary 
artery disease. 
Methods: Exercise 99mTc-tetrofosmin SPECT imaging was performed in 655 
consecutive patients. Follow-up was successful in 648 (98.9%) patients. Ten patients 
undenvent early coronary revascularization and were excluded. End points were cardiac 
death, nonfatal infarction, and late (>60 days) coronary revascularization. An abnormal study 
was defined as the presence of fixed and/or reversible perfusion defects. A summed stress 
score (SSS) was derived to estimate the extent and severity of perfusion defects. 
Results: An abnormal scan was detected in 344 (54%) patients. During a mean 
follow-up period of 4 ± 1.3 years, 56 (9%) patients died (22 cardiac deaths). Nonfatal 
myocardial infarction occurred in 19 (3%) patients, and 89 (14%) patients underwent late 
coronary revascularization. An abnormal scan was an independent predictor of cardiac death 
(hazard ratio 3.5, CI 1.1-12.2), and provided incremental information over clinical and 
exercise test data (Loglikelihood -133 to -125, P<0.05). The SSS provided incremental 
prognostic information over clinical data as well (Loglikelihood -133 to -127, P<O.OS) (hazard 
ratio 1.23 (CJ l.I0-1.38). An abnormal scan (hazard ratio 3.3 (CJ 1.1-12.2)) and the SSS 
(hazard ratio 1.25 (CI 1.07-1.45)) were powerful independent predictors of the combined end 
point of any cardiac event. 
Conclusion: Exercise 99mTc-tetrofosmin myocardial perfusion SPECT provides 
information incremental to clinical data, in the prediction of cardiac events in patients with 
known or suspected coronary artery disease. 
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Introduction 
Exercise thallium-201 e01 Tl) myocardial perfusion imaging has been used for the 
grediction of cardiac events over the last two decades (1-3). Previous studies have shown that 
01 Tl myocardial perfusion variables have incremental value for the prediction of cardiac 
events over clinical and exercise test information alone (1-3). The new technetium-99m 
C9mTc) labeled perfusion tracers provide an improved image quality, and have a much shorter 
half-life compared to 201 Tl (4-6). Several studies have confirmed the diagnostic accuracy of 
exercise 99mTc-tetrofosmin SPECT imaging (7-10). However, information on the prognostic 
value of exercise 99mTc-tetrofosmin myocardial perfusion imaging is scarce (11,12). 
Additionally, the value of exercise 99mTc-tetrofosmin SPECT for the prediction of cardiac 
death as an individual end-point has not yet been demonstrated. From a clinical point of view 
this is important to know, since the prevention of cardiac death differs from the prevention of 
other cardiac events (13-16). The aim of this study was to assess the value of exercise 99mTc-
tetrofosmin SPECT for the prediction of cardiac events in patients with known or suspected 
coronary artery disease. 
Material and methods 
Patient Selection: The study population consisted of 655 consecutive patients referred 
for exercise 99mTc-tetrofosmin SPECT imaging for the evaluation of suspected or known 
coronary artery disease. Follow-up was successful in 648 patients (98.9%). Ten patients 
undef'Nent coronary revascularization in the first 60 days after the nuclear testing. These 
patients were excluded from the analysis, because referral to coronary revascularization in the 
first 60 days after nuclear testing tends to be based on the results of the scan, and referral to 
revascularization >60 days after testing tends to be based on worsening of the patient's 
clinical status (17). The data from the remaining 638 patients are reported. All patients gave 
informed consent before the test The protocol was approved by the Hospital Ethics 
Committee. 
Clinical data: Before nuclear testing, a stmctured interview and clinical history were 
acquired and cardiac risk factors were assessed. Hypertension was defined as a blood pressure 
2':140/90 mmHg, or treatment with antihypertensive medication. Diabetes mellitus was 
defined as a fasting glucose level 2':7.8 mmol/L or the need for insulin or oral hypoglycemic 
agents. Hypercholesterolemia was defined as a total cholesterol 2':6.4 mmoVL, or treatment 
with lipid-lowering medication. 
Exercise protocol: All patients performed a symptom-limited upright bicycle 
ergometry test with stepwise increment of 20 W every minute. Three electrocardiographic 
leads were continuously monitored. Cuff blood pressure measurements and tvvelve-lead 
electrocardiography were recorded at rest and every minute during exercise and recovery. 
Computer averaging of the electrocardiographic complexes was perfonned by the Schiller 
system Cardiovit CSG/12. Significant ST-segment depression was defined as a >1 mm 
horizontal or downsloping St-segment depression occurring at 80 ms after the J point. 
99mTc-Tetrofosmin SPECT imaging: An intravenous dose of 370 MBq of 99mTc-
tetrofosmin (Myoview, Amersham, Buckinghamshire, United Kingdom) was administered 
approximately 1 minute before the termination of the exercise test For resting studies 370 
MBq of tetrofosmin were injected at least 24 hours after the exercise study. Image acquisition 
was performed with a triple head gamma camera system (Picker Prism 3000 XP, Cleveland, 
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Ohio, USA). For each study six oblique (short axis) slices from the apex to the base, three 
sagittal (vertical long axis) slices were defined. Each of the 6 short axis slices was divided 
into 8 equal segments. The septal part of the 2 basal slices was excluded from analysis 
because this region corresponds to the fibrous portion of the interventricular septum and 
normally exhibits reduced uptake. Consequently, a total of 47 segments were identified (3 
long axis and 44 short axis). The interpretation of the scan was semiquantitatively performed 
by visual analysis assisted by the circumferential profiles analysis. Exercise and rest 
tomographic views were reviewed side by side by an experienced observer who was unaware 
of the patients' clinical data. A reversible perfusion defect was defined as a perfusion defect 
on the exercise images that partially or completely resolved at rest in ~ contiguous segments 
or slices in the 47-segment model. A fixed perfusion defect was defined as a perfusion defect 
on exercise images in 2 or more contiguous segments or slices, which persists on rest images 
in the 47-segment modeL An abnormal study was considered in the presence of fixed/and or 
reversible perfusion defect. To assess the severity of perfusion abnormalities, the left 
ventricular myocardium was divided into 6 segments: anterior, inferior, septal anterior, septal 
posterior, posterolateral and apical. Each of the 6 major left ventricular segments was scored 
using a 4-point scoring method (0 ~ normal, 1 ~ slightly reduced, 2 ~moderately reduced, 3 ~ 
severely reduced or absent uptake). The summed stress score was calculated to estimate the 
extent and severity of perfusion defects. 
Follow-up: Follow-up data collection was performed by contacting the patient's 
general practitioner and by review of hospital records. The date of the last review or 
consultation was used to calculate follow-up time. Outcome events were: overall death, 
cardiac death, nonfatal myocardial infarction, and late (>60 days) coronary revascularization. 
Cardiac death was defined as a death caused by acute myocardial infarction, significant 
cardiac arrhythmias, or refractory congestive heart failure. Sudden death occurring without 
another explanation was included as cardiac death. Nonfatal myocardial infarction was 
defined by cardiac enzyme levels and ECG-changes. 
Statistical analysis: Continuous data were expressed as mean value ± SD. The 
Student's t test was used to analyze continuous data. Differences behveen proportions were 
compared using the Chi-square test. Univariate and multivariate Cox proportional hazard 
regression models (BMDP Statistical Software Inc., Los Angeles, California, USA) were used 
to identify independent predictors of late cardiac events (18). Variables were selected in a 
stepwise forward selection manner with entry and retention set at a significance level of 0.05. 
The risk of a variable was expressed as a hazard ratio with a corresponding 95% confidence 
interval. The incremental value of myocardial perfusion scintigraphy over the clinical 
variables in the prediction of events was performed according to hvo models. In model I, the 
presence of an abnormal scan was included, and in model II, the SSS was included. The 
probability of survival was calculated using the Kaplan-Meier method, and survival curves 
were compared using the log-rank test. A p value <0.05 was considered statistically 
significant. 
Results 
Patient characteristics and exercise test results: The clinical characteristics of the 
638 patients are presented in Table l.There was a significant increase of heart rate (76 ± 18 to 
140 ± 24 beats/min, P<O.OOOl), and systolic blood pressure (140 ± 21 to 180 ± 30 mm Hg, 
P<O.OOOl) from rest to peak exercise. The mean work load was 152 ± 39 W. During the 
exercise test, 106 patients had typical angina, and 124 had significant ST-segment depression. 
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Side effects were short ventricular tachycardia (<10 complexes) in 7 patients (1%), and atrial 
fibrillation in 8 patients (1 %). Minor side effects were dizziness in 40 patients (6%), headache 
in 18 (3%), and nausea in 12 (2%). No patient experienced a myocardial infarction or 
ventricular fibrillation. 
Table 1. Baseline Characteristics 
Age (y) 
Man 
Women 
Congestive heart failure 
Diabetes mellitus 
Hypercholesterolemia 
Hypertension 
Previous myocardial infarction 
Smoking 
Beta blockers 
Calcium channel blockers 
Number(%) 
56±11 
428 (67) 
210 (33) 
70 (11) 
58 (9) 
268 (42) 
275 (43) 
171 (27) 
153 (24) 
261 (41) 
269 (42) 
SPECT and follow-up results: An abnormal scan was detected in 344 (54%) 
patients. Myocardial perfusion abnormalities included fixed defects alone in 186 (29% ), and 
reversible defects in 158 (25%). These defects were completely reversible in 56 (9%) patients 
and partially reversible in 102 (16%) patients. During a mean follow-up period of 4 ± 1.3 
years, 56 (9%) patients died, of these patients 22 (39%) died due to cardiac causes. Nonfatal 
myocardial infarction occurred in 19 (3%) patients, and 89 (14%) patients underwent late 
coronary revascularization. 
100% Normal scan 
iii 
> -~ 90% P<0.001 
"' 
Abnormal scan 
(J) 
80% 
0 2 3 4 
Follow-up (y) 
Figure 1. Kaplan-Meier survival curves(end point of cardiac death) in patients with normal 
and abnormal exercise 99mTc-tetrofosmin SPECT. 
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Predictive value of clinical data and SPECT results: There was a significant 
difference in event-free survival between patients with a normal and patients with an 
abnormal 99mTc-tetrofosmin myocardial perfusion scan (Figure 1 and 2). Kaplan Meier 
survival analysis revealed that a normal perfusion scan was associated with a very low risk for 
cardiac death (annual cardiac death rate <0.3%). Predictors of cardiac death by Cox analysis 
are shown in Table 2. Univariate predictors were age, male gender, a history of congestive 
heart failure, peak heart rate, systolic blood pressure, rate pressure product, an abnormal 
perfusion scan, and the SSS. A multivariate model demonstrated that an abnormal scan was 
the most powerful independent predictor of cardiac death (Table 2). The addition of the 
perfusion parameters to the clinical variables was performed using two models. In model I, 
the presence of an abnormal scan was added to clinical and exercise test data. In model II, the 
SSS was added. An abnormal scan (model I) was an independent predictor of cardiac death 
(hazard ratio ~ 3.5, Cl 1.1-12.2), and provided incremental information over clinical and 
exercise test data (Loglikelihood -133 to -125, P<0.05). Model ll provided incremental 
prognostic information over clinical data as well (Loglikelihood -133 to -127, P<0.05). 
P<0.0001 
80% 
0 2 3 4 
Follow-up (y) 
Figure 2. Kaplan-Meier curves (end points of cardiac death, nonfatal infarction, and 
coronary revascularization) in patients with normal and abnormal exercise 99mTc-tetrofosmin 
SPECT myocardial perfusion images. 
Univariate predictors of all cardiac events (cardiac death, non-fatal myocardial 
infarction and late revascularization) were age, male gender, previous myocardial infarction, 
peak heart rate, systolic blood pressure, rate pressure product, typical angina, ST -segment 
changes, an abnormal scan, and the SSS (Table 3). A multivariate model demonstrated that an 
abnormal scan (hazard ratio 3.3 (Cl 1.1-12.2)) and the SSS (hazard ratio 1.25 (Cll.07-1.45)) 
were powerful independent predictors of all cardiac events (Table 3). 
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Table 2. Predictors of cardiac death 
Univariate 
Multivariate 
(HR. CI) HR(CI) Model I Model II 
Age* 1.04 (1.00-1.09) 1.04 (1.00-1.09) NS NS 
Male gender 3.4 (1.0-11.6) 3.4(1.0-11.5) NS NS 
Congestive heart 2.7 (1.0-7.3) NS NS NS failure 
Diabetes mellitus 0.5 (0.1-3.8) NS NS NS 
History of angina 0.5 (0.2-1.6) NS NS NS 
Hypercholesterolemia 0.5 (0.2-1.4) NS NS NS 
Hypertension 1.0 (0.4-2.4) NS NS NS 
Previous MI 1.9 (0.8-4.4) NS NS NS 
Smoking 0.9 (0.3-2.5) NS NS NS 
Exercise test results 
Peak heart rate 0.97 (0.96-0.99) NS NS 
Peak systolic BP 0.98 (0.97-0.99) NS NS 
Peak RPP 0.88 (0.82-0.95) 0.90 (0.83--D.97) NS 
Typical angina 1.1 (0.4-3.3) NS NS 
ST -segment changes 0.8 (0.3-2.1) NS NS 
Scan parameters 
Abnormal scan 3.4 (1.3-11.7) 3.5 (1.1-12.2) 
SSS* 1.23 (1.10-1.39) 1.23 (1.1 0-1.38) 
Values are expressed as Cox proportional hazard ratio and 95% confidence intervaL In model!, the presence of 
an abnormal scan was entered. In model II, the SSS was included. MI = myocardial infarction; BP= blood 
pressure; RPP =rate pressure product; NS =not statistically significant;*Per 1 unit increment;- indicates 
Table 3. Predictors of cardiac events (cardiac death, myocardial infarction, late coronary 
revascularization) 
Univariate Multivariate 
HR (CI) HR(CI) Modell Model II 
Age* 1.02 (1.01-1.04) 1.02 (1.01-1.04) NS 1.02 (1.00-1.04) 
Male gender 1.9 (1.3-2.9) 1.9 (1.2-2.8) NS NS 
Congestive heart failure 1.5 (0.9-2.4) NS NS NS 
Diabetes mellitus 1.5 (0.9-2.5) NS NS NS 
History of angina 1.3 (0.9-1.9) NS NS NS 
H ypercholes tero lemi a 0.9 (0.7-1.3) NS NS NS 
Hypertension 0.9 (0.6-1.3) NS NS NS 
Previous MI 1.6 (1.1-2.3) NS NS NS 
Smoking 1.3 (0.9-1.8) NS NS NS 
Exercise test results 
Peak heart rate 0.98 (0.97-0.99) 0.98 (0.97-0.99) 0.98 (0.97-0.99) 
Peak systolic BP 0.98 (0.97-0.99) NS NS 
Peak RPP 0.91 (0.86-0.96) NS NS 
Typical angina 2.0 (1.3-2.9) 1.6 (1.1-2.4) NS 
ST -segment changes 1.4 (1.0-2.0) NS NS 
Scan parameters 
Abnormal scan 3.1 (2.1-4.6) 3.3 (1.1-12.2) 
SSS* 1.16 (1.10-1.22) 1.25 (1.07-1.45) 
Fonnat similar to Table 2. 
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Discussion 
The main finding of this study is that exercise 99mTc-tetrofosmin SPECT myocardial 
perfusion imaging provides prognostic information incremental to clinical data and exercise 
test results, in the prediction of cardiac events. A normal perfusion scan was associated with a 
very low risk for cardiac death (annual cardiac death rate <0.3%). The cardiac death rate was 
significantly increased in patients with an abnormal 99mTc-tetrofosmin SPECT study. The 
survival curves continued to diverge during the follow-up period, which indicates a sustained 
prognostic value of 99mTc-tetrofosmin SPECT over the 4 years of follow up. Multivariate Cox 
analysis showed that after adjusting for clinical and exercise stress data, the SPECT results 
had significant incremental prognostic value. An abnormal scan and a larger SSS were related 
to a significant increase of the risk of cardiac death and all cardiac events. 
Comparison to previous studies: To date, information on the prognostic value of 
exercise 99mTc-tetrofosmin SPECT myocardial perfusion imaging is limited (11,12). Groutars 
et al. (11) reported a very favorable outcome in 246 patients with a normal exercise dual-
isotope 201 TV99mTc-tetrofosmin test during the follow-up period of 2.1 ± 0.3 years. Recently, 
Galassi et al. (12) studied 459 patients with exercise 99mTc-tetrofosmin SPECT. During 
follow-up 25 hard cardiac events (cardiac death and nonfatal infarction) occurred. 
Multivariate analysis showed that exercise 99mTc-tetrofosmin SPECT provided incremental 
information over clinical and exercise data for the prediction of hard cardiac events. However, 
nuclear data had no incremental value over clinical and exercise information when the 
combined endpoint of all cardiac events (cardiac death, infarction, and coronary 
revascularization). 
Hence, the currently available studies on the prognostic value of exercise 99mTc-
tetrofosmin SPECT have only evaluated patients with a normal scan, or used a combined 
study endpoint (11,12). Compared to the previous studies, our study included a large number 
of patients, with a nearly complete follow-up, and there was a larger number of cardiac 
events. In this setting, exercise 99mTc-tetrofosmin SPECT information predicted cardiac death 
as a single endpoint, as well as all cardiac events. 
Clinical implications: 99mTc-tetrofosmin provides an imrrroved image quality, and has 
a much shorter half-life compared to 201Tl (4-6). Nevertheless, 9 mTc-tetrofosmin has a lower 
extraction fraction and a less parallel relationship between myocardial blood flow and 
myocardial tracer uptake during vasodilator stress compared to 99mTc-sestamibi (19,20). It is 
not known whether these findings are reproducible with other forms of stress. Furthermore, 
the prognostic implications of these findings are uncertain. 
The present study demonstrated that exercise 99mTc-tetrofosmin imaging provides 
important ~rognostic information in patients with known or suspected coronary artery disease 
(1-3,21). 9 mTc-tetrofosmin effectively identified patients at high and low risk for cardiac 
death. Patients with a normal scan have very favorable prognosis, and a cardiac death rate 
comparable to that in the general population (22). Therefore, these patients can be excluded 
from further invasive procedures. Conversely, high-risk patients with an abnormal myocardial 
perfusion scan, particularly those with a large perfusion abnormality, may benefit from 
coronary revascularization. The clinical management of these patients should be 
individualized and further studies are needed to demonstrate the value of revascularization in 
that subset of patients. 
Limitations: No attenuation correction or scatter correction was used during 99mTc-
tetrofosmin SPECT myocardial perfusion imaging. Application of attenuation and scatter 
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correction may have further improved the accuracy of the 99mTc-tetrofosmin myocardial 
perfusion images. 
Conclusion: Exercise 99mTc-tetrofosmin SPECT myocardial perfusion imaging 
effectively identifies patients at low and high risk of cardiac death. Perfusion variables are 
strong predictors of cardiac death and all cardiac events. 99mTc-tetrofosmin SPECT data are 
incremental to both clinical and exercise stress parameters in the prediction of cardiac events. 
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Abstract 
Background: Patients with a normal stress 99m-technetiurn sestamibi study were 
shown to have a favorable outcome at intermediate term follow up. However, long-term 
survival has not been studied. Aim of this study was to evaluate the incidence and predictors 
of mortality and cardiac events at long term follow up after a normal exercise stress sestamibi 
study. 
Methods and results: We studied 218 patients (age 53± 10 years, 108 men) who had 
normal myocardial perfusion assessed by 99m-technetium sestamibi SPECT at rest and during 
symptom-limited bicycle exercise stress test. End points during a follow up period of 7.4 ± 
1.8 years were hard cardiac events (cardiac death and non-fatal myocardial infarction) and all 
causes of mortality. During follow up, 13 patients died of various causes (cardiac death in one 
patient). Ten patients had non-fatal myocardial infarction (a total of 11 hard cardiac events). 
By multivariate analysis, independent predictors of cardiac events were history of coronary 
artery disease (CAD) (c2 ~s, p ~ 0.03) and lower exercise heart rate (c2 ~ 12, p ~ 0.001). 
Independent predictors of all causes of mortality were age (c2 = 4, p = 0.05) and exercise 
heart rate (c2 ~ 5, p ~ 0.03). The annual mortality rate was 0.6% in the first 5 years and 1.8% 
betvveen the sixth and eighth years. The annual hard cardiac event rate was 0.7% in the first 5 
years and 1.5% bet\veen the sixth and eighth years. ROC curves identified an exercise heart 
rate <130/min as the cut off value that separated patients with regards to their risk for 
mortality and hard cardiac events. 
Conclusion: It is concluded that the annual mortality and cardiac event rate is less 
than 1% during 5 year follow up after a normal exercise sestamibi study. Therefore, it is not 
required to repeat the test during that period. Follow up should be closer in patients with a 
history of CAD and in those who fail to achieve an exercise heart rate 2::130/min. 
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Introduction 
The management of patients with suspected coronary artery disease (CAD) should be 
based on proper evaluation of the risk of mortality and cardiac events in an individual patient, 
based on clinical data and the results of non-invasive stress testing techniques whenever these 
are indicated. Identification of patients at low risk of cardiac events has an important impact 
on patients' management by avoiding the risk and the cost related to further diagnostic and 
therapeutic approaches, which are unlikely to improve the outcome in low risk patients (1-3). 
Stress 99m-technetium sestamibi SPECT imaging is a useful technique for the diagnosis and 
prognostic stratification of patients with known or suspected coronary artery disease (4-23). 
Patients with a normal stress sestamibi myocardial perfusion study were reported to have a 
low event rate at short and intermediate term follow up (9, 19). However, the long-term 
outcome after a normal study is unknown. The mean duration of follow in previous reports 
ranged between 13 and 28 months. Therefore, it is not known whether the low risk warrantee 
of a normal study can be maintained at longer-term follow up. Due to the lack of long tenn 
follow up data, it is not known whether patients with a normal study may require repeated 
testing, and if so what would be the time interval at which the low risk status is no longer 
guaranteed in a patient with a previously normal study. Additionally, data regarding overall 
survival after a normal stress sestamibi study are scarce. 
The aim of this study was to evaluate the incidence and predictors of mortality and 
cardiac events at long term follow up after a normal exercise stress 99m-technetium sestamibi 
SPECT imaging. 
Methods 
Patient selection: Study population comprised consecutive patients referred for 
exercise stress testing in conjunction with 99m technetium sestamibi SPECT imaging for 
evaluation of suspected CAD between 1988-1995, who had normal myocardial perfusion at 
rest and during exercise stress. Exclusion criteria were the presence of significant valvular 
heart disease and unstable chest pain. Mean age was 53 ± 10 years. Inclusion criteria were 
fulfilled in 218 patients (108 men and 110 women). Follow-up data was collected in the year 
2000 and could be completed in all patients. Mean follow up duration in was 7.4 ± 1.8 
(maximal= 11.7 years). The minimum follow up duration (in patients without events) was 5.2 
years. 
Exercise stress test: All patients undenvent a symptom limited upright bicycle 
ergometry test with stepwise increment of 20 Watts each minute. 3 electrocardiographic leads 
were continuously monitored. 12-lead electrocardiogram was recorded at rest and every 
minute until the end of recovery phase. The level of ST -segment was calculated by averaging 
the signals using a computerised system (Cardiovet, CSG/12, Schiller, Baar, Switzerland). An 
ischemic response was defined as 2:1-mm horizontal or downsloping ST-segment depression 
persisting 80 ms after the J point. 
SPECT imaging: Approximately 1 minute before the termination of the exercise 
stress test, an intravenous dose of 3 70 MBq of 99m-technetium sestamibi was administered. 
Stress images were acquired 1 hour after termination of the exercise test. For resting studies, 
370 MBq of sestamibi were injected 24 hours after the stress study. Image acquisition was 
performed with a Siemens Gammasonics single-head Rota Camera (Orbiter; Siemens Corp., 
Iselin, NJ). Thirty-two projections were obtained, from the left posterior oblique to the right 
anterior oblique over 180 degrees. For each study six oblique (short axis) slices from the apex 
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to the base and three sagittal (vertical long axis) slices from the septum to the lateral wall 
were defined. Each of the 6 short axis slices was divided into 8 equal segments. The 
interpretation of the scan was semiquantitatively performed by visual analysis assisted by the 
circumferential profiles analysis. Images were reviewed side by side by an experienced 
observer who was unaware of the patients' clinical or electrocardiographic data. A reversible 
perfusion defect was defined as a perfusion defect on stress images that partially or 
completely resolved at rest in 2:2 contiguous segments or slices. A fixed perfusion defect was 
defined as a perfusion defect on stress images in 2 or more contiguous segments or slices, 
which persists on rest image. A normal study was defined as absence of perfusion 
abnormalities. 
Follow-up: Follow-up was obtained by mailed questionnaires and scripted telephone 
interviews. Events were verified by contacting the patients' primary physician and reviewing 
medical records and death certificates. The end points considered were all causes of mortality 
and hard cardiac events defined as nonfatal myocardial infarction and cardiac death. Sudden 
death occurring without another explanation was included as cardiac death. Myocardial 
infarction was defined according to usual clinical, electrocardiographic and enzymatic 
criteria. Patients who had coronary revascularization (angioplasty or coronary artery bypass 
surgery) prior to other events were censored at the time ofrevascularization. 
Statistical analysis: Unless specified, data are presented as mean values ± SD. The 
Chi square test was used to compare differences between proportions. The Student t test was 
used for analysis of continuous data. P value <0.05 was considered statistically significant. 
Logistic regression models were used to identify independent predictors of follow up events. 
P value <0.05 was considered statistically significant. Parameters included in the multivariate 
analysis model were those found to be significant (or of borderline significance, p=O.l) in the 
univariate analysis. 
Results 
Clinical features: Mean age was 53 ± 10 years. There were 108 men and 110 women. 
Forty-seven patients (22%) had a history of coronary artery disease (previous coronary 
angioplasty in 33 patients and previous non-Q myocardial infarction in 14 patients). In the 
remaining patients, the pretest probability of CAD based on Diamond and Forrester (24) 
classification was low in 57 patients and intermediate or high in 114 patients. Medications at 
the day of the test included beta-blockers in 68 (31 %) patients, calcium channel blockers in 59 
(27%) patients and angiotensin converting enzyme inhibitors in 27 (12%) patients. Chest pain 
was the main complaint in 158 (72%) patients. This was classified as atypical in 114 patients 
and typical of angina in 44 patients. Risk factors for CAD were diabetes mellitus in 14 (6%), 
cigarette smoking in 58 (27%), hypercholesterolemia in 53 (24%) and hypertension in 71 
(33%) patients. 
Hemodynamic response: There was a significant increase of the heart rate (78 ± 15 
vs 148 ± 24 beats/minute, p<O.OOOl); systolic blood pressure (137 ± 21 vs 188 ± 25 mm Hg, 
p<O.OOOl) and rate pressure product (10691 ± 2584 vs 28703 ± 9964, p<O.OOOOl) from rest to 
peak exercise respectively. The target heart rate (85% of the maximal predicted heart rate) 
was reached in 161 patients (74%). The mean working capacity was 144 ± 42 Watts. Nine 
(4%) patients had ST segment depression and 25 (11 %) patients had angina induced by 
exerctse. 
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Follow up: During follow up, 13 patients died of various causes (cardiac death in one 
patient). Ten patients had non-fatal myocardial infarction (a total of 11 hard cardiac events). 
Revascularization procedures were performed in 15 patients (5 underwent coronary artery 
bypass surgery and 10 underwent coronary angioplasty). Clinical and exercise stress test 
variables associated with hard cardiac events in Cox regression model are presented in table 1. 
Univariate predictors were exercise heart rate, ST segment depression, a history of 
hypertension and a history of CAD. Variables considered for multivariate analysis were those 
found to be significant or had borderline significance in the univariate analysis (p<0.1, tables). 
Independent predictors in the multivariate analysis were a history of CAD and lower exercise 
heart rate. Predictors of all cause mortality are presented in table 2. Univariate predictors were 
older age, history of CAD, lower exercise heart rate, and inability to achieve the target heart 
rate. By multivariate analysis, age and exercise heart rate were independent predictors of 
mortality. The annual mortality rate was 0.6% in the first 5 years and 1.8% between the sixth 
and eighth years. The annual hard cardiac event rate was 0.7% in the first 5 years and 1.5% 
between the sixth and eighth years. 
Table 1. Predictors of hard cardiac events (cardiac death and non-fatal myocardial infarction) 
in a Cox regression analysis 
2 p Hazard ratio 95%CI 
Univariate analysis 
Hypertension 5 0.03 3.8 1.1-13.9 
History of CAD 6 0.009 4.6 1.3-15.7 
Exercise heart rate 8 0.003 0.96 0.94-0.99 
ST depression 9 0.002 15 1.5-32 
Multivariate analysis 
History of CAD 5 0.03 4.8 1.2-19.8 
Exercise heart rate 12 0.001 0.95 0.92-0.98 
CAD ~ Coronary artery disease 
Table 2. Predictors of all causes of mortality in a Cox regression analysis 
2 p Hazard ratio 95% Cl 
Univariate analysis 
Age 14 0.0001 1.13 1.05-1.21 
History of CAD 7 0.005 4.5 1.4-14.2 
Exercise heart rate 16 0.0001 0.96 0.94-0.98 
Target HR achieved 6 0.01 4.1 1.2-13 
ST depression 2 0.1 4.6 0.6-41 
Multivariate analysis 
Age 4 0.05 1.08 1.00-1.17 
Exercise heart rate 5 0.03 0.97 0.95-1.00 
CAD = coronary artery disease 
HR ~ heart rate 
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ROC curves identified an exercise heart rate <130/min as the cut off value that 
separated patients with regards to their risk for mortality and hard cardiac events. Kaplan 
Meier survival curves based on ability to achieve an exercise heart rate ;:::130/ minute are 
shown in figure 1 (hard cardiac events) and figure 2 (all cause mortality). 
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Figure 1. Kaplan Meier event free survival (for the endpoint of cardiac death and non-fatal 
myocardial infarction) according to the ability to achieve an exercise heart rate 2 130 beats 
/minute. 
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Figure 2. Kaplan Meier survival (for the endpoint of all causes of mortality) according to the 
ability to achieve an exercise heart rate 2 130 beats /minute. 
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Discussion 
In this study we assessed the long-term outcome of 218 patients with suspected CAD 
who were followed up for a mean of 7.4 years after a normal exercise stress 99-rn technetium 
sestamibi study. The annual mortality rate was 0.6% in the first 5 years and 1.8% between the 
sixth and eighth years. The hard cardiac event rate was 0. 7% in the first 5 years and 1.5% 
between the sixth and eighth years. Therefore, the study demonstrated that the low risk 
warrantee of a normal exercise sestamibi study is sustained during the 7 years following the 
test with a particularly very low event rate in the first 5 years. In a multivariate analysis of 
clinical and exercise stress test data, independent predictors of mortality were age and 
exercise heart rate. Independent predictors of hard cardiac events were history CAD (previous 
myocardial infarction or coronary angioplasty) and exercise heart rate. Failure to achieve a 
maximal exercise heart rate ;:::130 identified patients with a higher risk of death and hard 
cardiac events. 
Impairment of heart rate response to exercise has been associated with increased risk 
of mortality and incident coronary artery disease. The associated risk was reported to be 
persistent after adjustment to the qualitative presence of perfusion abnormalities (25). One 
possible explanation of the association between lower heart rate response and events in our 
study is the reduced sensitivity of exercise stress myocardial perfusion imaging at a lower 
heart rate, reflecting inability to induce myocardial ischemia with exercise. Therefore, patients 
who fail to achieve a heart rate ;:::130 should be subjected to another stress testing preferably 
after 2 years, as event free survival curves showed significant diversion (figure 1) after 2 
years. Perhaps, a pharmacological stress study may overcome the potential limitation of 
reduced sensitivity of exercise myocardial perfusion imaging in patients with lower exercise 
heart rate response during an earlier stress study. 
There were 11 hard cardiac events among the 218 patients of this study during the 
median follow up of 7.4 years. These consisted mainly of none fatal myocardial infarction (1 0 
patients); whereas only one patient had cardiac death. A history of CAD was an independent 
predictor of hard events. The occurrence of none fatal myocardial infarction in these patients 
does not necessarily indicate failure of the technique to predict a functionally significant 
CAD. This may be explained by the fact that the majority of myocardial infarctions occur in 
myocardial territories subtended with mildly stenotic coronary arteries, in which the stenosis 
may not be of sufficient severity to induce flow heterogeneity at the time of exercise testing. 
Another explanation is the occurrence of late restenosis after angioplasty in coronary arteries 
that had no significant restenosis at the time of the stress study. 
Comparison with previous studies: Previous studies have reported a low cardiac 
event rate at short and intermediate term follow up after exercise or pharmacologic stress 
myocardial perfusion imaging. To our knowledge, this study provided the longest-term follow 
up after stress sestamibi study, with a mean follow up of 7.4 years as compared to the mean 
follow up in previous studies which ranged between 13 and 28 months. Stratmann et al (7) 
found that the annualized rate of nonfatal myocardial infarction or cardiac death in 521 
patients after exercise MIBI SPECT was 0.5% with a normal, and 7% with an abnormal 
study. Brown et al (9) reported a 0.5% annual event rate in 234 patients with normal exercise 
or dipyridamole planar MIBI imaging followed up for 10 ± 2 months. In another study of 207 
patients with normal exercise planar or SPECT MIBI studies, none died during a follow-up 
period of 13.5 ± 2 months, while 1 patient (0.5%) had a nonfatal myocardial infarction (8). 
Berman et al (6) used a dual-isotope imaging in 1,702 patients with known or suspected CAD. 
Only 2 of 1,131 patients with normal or equivocal studies (0.1%) had a nonfatal myocardial 
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infarction or cardiac death during a follow-up of 20 ± 5 months, compared with 43 of 571 
patients with an abnonnal study (8%). In 2,200 patients without documented CAD followed 
up after exercise testing with dual-isotope SPECT (5), Hachamovitch et al reported an event 
rate of0.3% in 1,623 patients with normal SPECT studies. 
In 412 patients with intermediate pretest probability of CAD followed up for 17 ± 13 
months, Nallamouthu et al (13) reported only one event in 295 patients with normal studies 
(0.3%; p < 0.0001). Travin et al (21) studied 1,226 men and 1,151 women who underwent 
MIBI SPECT with either exercise or dipyridamole testing, a normal rest-stress MIBI study 
was associated with an annual rate of cardiac death or nonfatal myocardial infarction of 1. 7% 
in men and 0.8% in women. 
Studies that evaluated the prognostic value of pharmacological stress sestarnibi 
SPECT have reported a low risk of cardiac events in patients with a normal study. However, 
event rate tended to be higher after a normal pharmacologic as compared to exercise stress 
studies, reflecting the higher risk status of a population unable to perform an exercise stress 
test (26). 
Evaluation of all cause of mortality. Recently, the evaluation of all causes of mortality 
as a separate follow up endpoint in patients with known or suspected CAD has gained an 
increasing interest. This is due to the difficulties encountered in determining the actual cause 
of death in some patients (27) and the fact that CAD is associated with other conditions which 
are independently associated with increased risk of death such as diabetes mellitus, 
hypertension, smoking and peripheral vascular disease. This is the first study that evaluates 
long-term mortality rate after stress sestamibi studies. We found that patients with normal 
sestamibi studies have a very low annual mortality rate during a mean of 7.4 years of follow 
up. 
Limitations: Although this study reports the longest term follow up after a sestamibi 
study, the number of patients was relatively low as well as the number of events. Further 
studies from other centers are needed to confirm these findings. 
Summary and clinical implications: The optimal use of stress imaging techniques in 
the risk stratification of patients with known or suspected CAD requires adequate knowledge 
of the outcome of patients relative to the results obtained by these techniques. Although it is 
well established that a normal stress sestamibi study identifies patients at low risk of cardiac 
events at intermediate term follow up, it is not known whether the physician can rely upon 
these results in predicting longer term outcome. Performing the test at regular intervals in 
individuals with a normal study may not be cost effective. On the other hand deferring these 
individuals from future non-invasive testing may result in failure to predict events at longer 
term follow up. This study showed that the annual mortality and cardiac event rate is less than 
1% during 5 year follow up after a normal exercise sestamibi study and therefore, it is not 
required to repeat the test during that period, particularly in those patients who have no 
history of CAD and who were able to achieve an exercise heart rate ;:::130/min. Follow up 
should be closer in patients with a history of CAD and in those who fail to achieve an exercise 
heart rate ;:::130/min. 
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Prognostic significance of silent ischemia 
assessed by dobutamine stress 
99-m technetium sestamibi SPECT imaging 
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Abstract 
Rationale: The aim of this study was to assess the prognostic significance of 
reversible perfusion abnormalities in patients without angina during dobutamine stress 99m-
technetium sestamibi SPECT. 
Method: The study comprised 224 patients (age~ 60 ± 11 year, 144 men) with 
completely or partially reversible perfusion abnormality during dobutamine stress sestamibi 
SPECT. Follow up end points were hard cardiac events (cardiac death and non-fatal 
myocardial infarction). 
Results: Angina occurred in 93 (42%) patients during dobutamine stress test 
(symptomatic ischemia group). The 131 patients without angina represented the silent 
ischemia group. There was no significant difference between patients with and without angina 
with regards to summed stress perfusion score (5.3 ± 2.5 vs 5.2 ± 2.2, p ~ 0.9), or summed 
ischemic score (3.1 ± 1.7 vs 3.2 ± 1.4, p ~ 0.7). During a median follow up of 7.2 years, 
cardiac death occurred in 14 (15%) patients with and in 21 (16%) patients without angina. 
Non-fatal myocardial infarction occurred in 8 (9%) patients with and in 13 (10%) patients 
without angina. In a multivariate analysis model of clinical and perfusion data, independent 
predictors of cardiac events were age (hazard ratio= 1.02, CI 1.01-1.05 per year increment), 
diabetes mellitus (HR ~ 1.9, Cll.2-3.4) and ischemic perfusion score (HR 2.1, Cll.3-3.8). 
Conclusion: Patients with silent ischemia defined as reversible perfi.rsion 
abnormalities without associated angina during dobutamine stress sestamibi SPECT imaging 
have similar extent of ischemia and similar cardiac event rate compared to patients with 
symptomatic ischemia. Therefore, the absence of angina in association with reversible 
perfusion abnormalities should not be interpreted as a sign of more benign prognosis. 
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Introduction 
Dobutamine stress 99m technetium sestamibi SPECT myocardial perfusion imaging is 
a sensitive technique for eliciting myocardial ischemia in patients with coronary artery disease 
(CAD) (!). The technique was additionally shown to provide incremental data for risk 
stratification in patients with known or suspected CAD (2,3). Reversible perfusion 
abnormalities are the wholemark of myocardial ischemia in patients undergoing stress 
myocardial perfusion imaging (4). In many patients with CAD, reversible perfusion 
abnormalities may occur during stress without symptoms (5-17). It is not known whether the 
absence of angina in patients with reversible perfusion abnormalities during dobutamine stress 
test implies a better outcome as compared to patients with symptomatic ischemia. There is a 
controversy in the literature regarding the extent of ischemic burden in silent versus 
symptomatic ischemia during exercise or dipyridamole stress myocardial perfusion imaging 
with some reports indicating similar extent (8,12) and others indicating less severe ischemia 
in patients without angina (5,6,17). However, data regarding the prognosis of silent versus 
symptomatic ischemia during stress myocardial perfusion imaging are scarce. Furthermore, 
the prognostic significance of silent ischemia on dobutamine perfusion imaging has not been 
previously investigated. The aim of this study is to compare the outcome of patients with 
reversible perfusion abnormalities on dobutamine stress 99m-technetium sestamibi SPECT in 
the presence and in absence of angina during the test. 
Methods 
Study population: The study included 224 consecutive patients with limited exercise 
capacity referred for dobutamine-atropine stress 99mTc-sestamibi SPECT imaging for the 
evaluation of suspected or known CAD, between 1990 and 1995 in our institute, who 
demonstrated completely or partially reversible perfusion abnonnalities. All patients gave 
informed consent before testing. The medical ethics commission approved the protocol of the 
study. A structured interview and clinical history were obtained, including assessment of 
cardiac risk factors, and the symptoms prior to the dobutamine stress test. 
Dobutamine stress protocol: Dobutamine-atropine stress test was performed as 
described previously (16). Dobutamine was injected intravenously, first at a dose of 10 
mg/kg/min for 3 minutes, increasing by 10 mg/kg/min every 3 minutes up to a maximum dose 
of 40 mg/kg/min. Test end-points were: achievement of target heart rate (85% of maximum 
age and gender predicted heart rate), horizontal or downsloping ST -segment depression >2 
mrn at an interval of 80 ms after the J-point compared with baseline, ST -segment elevation > 1 
mrn in patients without previous myocardial infarction, severe angina, systolic blood pressure 
fall >40 mm Hg, blood pressure >2401120 mm Hg, or significant cardiac arrhythmia. If the 
test end-point was not reached at a dobutamine dose of 40 mgikg/min, atropine (up to I mg) 
was given intravenously. Blood pressure, heart rate, and electrocardiography were 
continuously monitored. Metoprolol was available to reverse the side effects of 
dobutamine/atropine if these did not revert spontaneously after termination of dobutamine 
infusion. 
SPECT acquisition and interpretation: An intravenous dose of370 MBq of99mTc-
sestamibi was administered approximately 1 minute prior to the termination of the stress test. 
For resting studies 370 MBq of sestamibi were injected at least 24 hours after the stress study. 
Image acquisition was performed with a Siemens Gammasonics single-head Roter camera 
(Orbiter, Siemens, Iselin, New Jersey). For each study 6 oblique (short axis) slices from the 
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apex to the base, and 3 sagittal (vertical long axis) slices were defined. Each of the 6 short 
axis slices was divided into 8 equal segments. The septal part of the 2 basal slices was 
excluded from analysis because this region corresponds to the fibrous portion of the 
interventricular septum and normally exhibits reduced uptake. Therefore, a total of 4 7 
segments were identified (3 long axis and 44 short axis). The interpretation of the scan was 
semiquantitatively performed by visual analysis assisted by the circumferential profile 
analysis. Stress and rest tomographic views were reviewed side-by-side by two experienced 
observers who were unaware of the patients' clinical data. In case of disagreement a majority 
decision was achieved by a third observer. A reversible perfusion defect was defined as a 
perfusion defect on stress images that partially or completely resolved at rest in 2::::2 contiguous 
segments or slices in the 4 7 -segment model. A fixed perfusion defect was defined as a 
perfusion defect on stress images in 2 or more contiguous segments or slices, which persists 
on rest images in the 47-segment modeL By inclusion criteria, only patients with partially or 
completely reversible perfusion abnormalities were enrolled. To assess the severity of 
perfusion abnormalities, the left ventricular myocardium was divided into 6 segments: 
anterior, inferior, septal anterior, septal posterior, posterolateral and apical. Each of the 6 
major left ventricular segments was scored using a 4-point scoring system (0 = normal, 1 = 
slightly reduced, 2 ~ moderately reduced, 3 ~ severely reduced or absent uptake). Perfusion 
defect score was derived by the summation of the score of the 6-myocardial segments at stress 
(SSS) and at rest (SRS). The difference between stress and rest scores was considered 
representative of the severity of myocardial ischemia (SDS). 
Follow-up: The follow-up data were collected by contacting the patient's general 
practitioner and/or by review of hospital records. The date of the last examination or 
consultation was used to determine follow-up time. The mean follow-up period was 7.4 ± 3 
years. End points were all cause mortality, cardiac death, and nonfatal myocardial infarction. 
Myocardial revascularization procedures were classified as early (<60 days), and late (>60 
days) after the stress study. Patients who underwent early revascularization were censored at 
the time of revascularization. Cardiac death was defined as a death caused by acute 
myocardial infarction, significant cardiac arrhythmias, or congestive heart failure. Sudden 
death occurring without another explanation was included as cardiac death. Nonfatal 
myocardial infarction was defined by standard criteria of chest pain, cardiac enzyme levels 
and ECG-changes. Hard cardiac events were defined as cardiac death and non-fatal 
myocardial infarction. 
Statistical analysis: Values were expressed as mean value ±SD or number, and 
compared using the Student t test or Chi-square test. Univariate and multivariate Cox 
proportional hazard regression models (BMDP statistical software) were used to identify 
independent predictors of hard cardiac events among clinical stress test and perfusion data. 
Variables were selected in a stepwise forward selection manner with entry and retention set at 
a significance level of 0.05. The risk of a variable was expressed as a hazard ratio with a 
corresponding 95% confidence interval. The probability of survival was calculated using the 
Kaplan-Meier method, and survival curves were compared in patients with and without 
angina during dobutamine stress test using the log-rank test. P value <0.05 was considered 
statistically significant. 
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Results 
Clinical characteristics and hemodynamic data: There were 144 men and 80 
women. Mean age was 60 ± 12 years. A history of previous myocardial infarction was 
obtained in 113 (50%) patients. Ninety-two (41 %) patients had typical anginal complaints 
before the test. There was a significant increase of heart rate (68 ± 13 to 133 ± 17 bpm, 
P<O.OOO!), and systolic blood pressure (139 ± 22 to 148 ± 24 mm Hg, P<O.Ol) from rest to 
peak dobutamine-atropine stress test respectively. No patient experienced a myocardial 
infarction or ventricular fibrillation during the test. Ninety-three (42%) patients had angina 
during dobutamine stress test. The remaining 131 patients were considered to have silent 
ischemia. Side effects were atrial fibrillation in 2 patients (1 %), short ventricular tachycardia 
(<10 complexes) in 9 patients (5%), and symptomatic hypertension in 2 (1 %) patients. Minor 
side effects were nausea in 13 (6%), chills in 13 (6%), and headache in 15 (7%) patients. The 
test was terminated due to achievement of the target heart rate in 166 patients (74%), angina 
in 30 (13%), maximal dobutamine and atropine dose in 17 (8%), ST segment changes in 4 
(2%), arrhythmias in 5 (2%) and hypotension in 2 (1%) patients. 
Table 1. Clinical characteristics in patients with and without angina during dobutamine stress 
myocardial perfusion imaging 
Angina during dobutamine stress 
Yes No P value 
N~93 N~ 131 
Age 60 ±10 60 ±12 0.9 
Men 66 (71 %) 78 (60%) 0.5 
History of myocardial infarction 53 (57%) 60 (46%) 0.6 
Diabetes Mellitus 15 (16%) 20 (15%) 0.9 
Hypertension 48 (52%) 51 (39%) 0.8 
Hypercholesterolemia 25 (27%) 36 (27%) 0.9 
Smoking 20 (22%) 39 (30%) 0.7 
History of anglna 47 (51%) 35 (27%) 0.01 
Atypical chest pain 38 (41 %) 51 (45%) 
ACE inhibitors 27 (29%) 33 (25%) 0.8 
Beta blockers 40 (43%) 48 (37%) 0.7 
Calcium channel blockers 42 (45%) 47 (36%) 0.5 
ACE - angiotensin converting enzyme 
Clinical characteristics of patients with and those without angina during dobutamine 
stress test are presented in table 1. Dobutamine stress data are presented in table 2. No 
significant difference was detected between the 2 groups with regards to age, gender, 
prevalence of previous myocardial infarction, risk factors for CAD, dobutamine systolic blood 
pressure, dobutamine dose and frequency of administration of atropine. Patients with angina 
during dobutamine stress more often had a history of angina prior to the test and had 
significantly lower stress heart rate compared to patients without angina. 
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SPECT results: Table 2 demonstrates perfusion parameters in patients with and 
without angina during dobutamine stress. No significant difference was found between the 2 
groups regarding SSS, SRS, and SDS, 
Table 2. Dobutamine stress test and perfusion data in patients with and without angina during 
the test 
Angina during dobutamine stress 
Yes No P value 
N~93 N~ 131 
Stress heart rate 127 ± 18 137 ± 17 0,0001 
Stress systolic blood pressure 141 ± 22 138 ± 17 0.3 
Dobutamine dose 37.6 ± 6 38.5 ± 4 0.9 
Atropine use 39 (42%) 63 (48%) 0.8 
ST -segment depression 32 (34%) 35 (27%) 0.7 
Abnormal resting perfusion 60 (65%) 73 (56%) 0.5 
Summed rest score 2.2 ± 1.5 2 ± 1.5 0.4 
Summed stress score 5.3 ± 2.5 5.2 ± 2.2 0.9 
Summed difference score 3.1+1.7 3.2 + 1.4 0.5 
Follow up data: During follow-up, 78 (35%) deaths occurred of which 35 (45%) were 
due to cardiac causes. Nonfatal myocardial infarction occurred in 21 (9%) patients. A total of 
53 patients (24%) underwent revascularization, which was early (<60 days) in 11 patents and 
late (>60 days) in 42 patients. Patients with angina during dobutamine stress had a higher 
incidence of unstable angina during follow up. Survival curves in patients with and without 
angina during dobutamine stress test are presented in figure 1. No significant difference was 
found regarding incidence of mortality and cardiac events during the follow up in the 2 groups 
(table 3). 
Table 3. Follow up events in patients with and without angina during dobutamine stress 
myocardial perfusion imaging 
Death 
Cardiac death 
Non-fatal Ml 
Unstable angina 
Early revascularization 
Late revascularization 
PC! 
CABG 
Angina during dobutamine stress 
Yes No 
N~93 N~ 131 
35 (38%) 
14 (15%) 
8 (9%) 
23 (25%) 
6 (6%) 
18 (19%) 
8 (9%) 
10(11%) 
43 (33%) 
21 (16%) 
13 (10%) 
14(11%) 
5 (4%) 
24 (18%) 
ll (8%) 
13 (10%) 
PCI =percutaneous intervention; CABG = coronary artery bypass grafting 
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P value 
0.7 
0.9 
0.9 
0.01 
0.5 
0.9 
ST-segment depression: ST segment depression occurred in 66 patients during stress. 
No significant difference was found between patients with and without ST-segment 
depression with regards to sunnned stress score 5 ± 2.1 vs 5.3 ± 2.4 (p ~ 0.4), summed rest 
score 2 ± !.6 vs 2.1 ± 1.9 (p ~ 0.8) and summed difference score 3.1 ± !.7 vs 3.2 ± 1.7 (p ~ 
0.7). 
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Figure 1. Event free sun;ival cun;es in patients with reversible perfusion abnormalities on 
dobutamine sestamibi SPECT in the presence and in the absence of angina during the 
dobutamine stress test. End points are A) all cause mortality, B) hard cardiac events (cardiac 
death and nonfatal myocardial infarction); C) all cardiac events (hard cardiac events and 
revascularization). 
151 
Predictors of cardiac events: In a multivariate analysis model of clinical and 
perfusion data, independent predictors of cardiac events were age (hazard ratio = 1.02, CI 
1.01-1.05 per year increment), diabetes mellitus (HR ~ 1.9, CI L2-3A) and ischemic 
perfusion score (HR 2.1, CI 1.3-3.8). 
Discussion 
Identification of stress test variables associated with adverse cardiovascular outcome is 
important in clinical decision-making (4). In this study, we assessed the outcome of patients 
with reversible perfusion abnormalities in the absence of angina during dobutamine stress 
99m sestamibi SPECT, as compared to patients who experienced angina during the test. 
Among 224 patients with reversible abnormalities, 93 (42%) patients had angina. There was 
no significant difference between patients with and without angina with regards to extent and 
severity of reversible or fixed perfusion abnormalities. Patients with angina during 
dobutamine stress were more likely to have a history of angina prior to the stress test and had 
a lower peak stress heart rate, which may be explained by earlier termination of the test due to 
angina. During a median follow up period of 7.4 years, there was no difference between 
patients with and without angina during dobutamine stress with regards to cumulative total 
mortality (38% vs 33%), cardiac death and non-fatal myocardial infarction (24% vs 26%) 
rates, and the composite endpoint of all cardiac events (cardiac death, myocardial infarction 
and late revascularization) (43% vs 44%). The incidence of unstable angina during follow up 
was higher in patients with angina during dobutamine stress test (25% vs 11 %). In a 
multivariate analysis model, independent predictors of cardiac events were age, diabetes 
mellitus and ischemic perfusion defect score, while angina was not predictive. The incidence 
of ST segment depression was similar in patients with and without angina during stress. The 
extent of perfusion abnormalities was not different in patients with and without ST -segment 
depression. 
Comparison with previous studies: Although many previous studies have assessed 
the extent of ischemia in presence and in absence of angina during stress myocardial 
perfusion imaging, prognostic studies are scarce, particularly with 99m technetium labeled 
agents. Additionally, our study provided the longest term follow up as well as the largest 
number of hard cardiac events during follow up, when compared to previous reports (11 ,13 ). 
Some investigators have reported a greater extent and severity of ischemia in symptomatic 
patients than in those with silent ischemia. Travin et al (6) reported that patients with 
exercise-induced thallium redistribution without angina had less ischemia than patients with 
angina. Klein et al (5) reported that the induction of chest pain is associated with more 
extensive thallium perfusion abnormalities when analyzed in a broad-spectrum population 
with CAD. The analysis of chest pain tended to lose its value when it was restricted to a CAD 
population with a greater prior likelihood of inducible ischemia. Marcassa et al (17) studied 
300 patients with ischemic heart disease and reversible hypoperfusion on exercise sestamibi 
tomography. Patients with painful ischemia had more reversible hypoperfusion, and higher 
incidence of ST segment depression than did patients with silent ischemia. In contrast, 
numerous studies have failed to find a difference in the amount of ischemic myocardium 
between patients with silent and symptomatic ischemia during exercise or pharmacologic 
stress testing. Mahmarian et al (12) studied 356 low risk patients with treadmill exercise 
thallium-201 SPECT. There were no differences in the extent, severity of reversible perfusion 
abnormalities, or distribution of coronary stenoses in patients with silent or symptomatic 
ischemia. Gasperetti et al (8) studied 103 consecutive patients undergoing symptom-limited 
exercise thallium-201 scintigraphy. Fifty-nine patients (57%) had no angina on exercise 
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testing. There was no difference between the two groups with respect to extent of reversible 
perfusion abnormalities or extent of angiographic CAD. We have recently shown that in 85 
patients with CAD and reversible perfusion abnormalities on dobutamine sestamibi SPECT, 
the extent of reversible abnormalities was similar in patients with and without angina. 
Some previous studies suggested a common pathway for both the electrical and 
painful response to ischemic stimulus (7). In contrast with previous studies on exercise stress 
test which reported a higher prevalence of ST -segment depression with symptomatic 
ischemia ( 6-8), the prevalence of ST segment depression was not different in patients with 
and without angina in this study. This may be explained by the lower sensitivity of the 
electrocardiogram with dobutamine as compared with exercise stress. In this study, only 29% 
of patients with ischemia on SPECT demonstrated ST segment depression. This low 
sensitivity of dobutamine ECG was attributed to lower rate pressure product achieved by 
dobutamine as compared to exercise stress test ( 1). 
Prognostic studies: The presence of silent ischemia on exercise thallium imaging was 
shown to be associated with adverse prognosis in asymptomatic population (14,15). Travin et 
a! (6) studied 134 patients with redistribution on a thallium-201 exercise test who did not 
experience angina and 134 patients also having redistribution who had angina during the test. 
Patients without angina had less ischemic thallium-201 images and were less likely to 
undergo early revascularization, but the occurrence of adverse cardiac events was similar 
(21% vs 29%). Heller eta!. (13) reported follow up events in 146 patients with reversible 
perfusion defects on 201- thallium scans (82 patients with and 74 patients without angina). 
There was no difference between both groups with regards to mortality and cardiac event rate 
during a mean follow up period of mean 5.2 years. Pancholy eta!. (II) studied 521 patients 
with coronary artery disease. Symptomatic ischemia (ST depression or reversible defects) was 
detected in 210 patients, whereas 311 patients had silent ischemia. During a mean follow-up 
of24 months, there were 30 cardiac events. There was no significant difference in the event-
free survival in patients with symptomatic or silent ischemia. 
Study limitations: Most patients were receiving anti-anginal medication, which may 
have decreased the prevalence of angina or ST -segment depression and influenced the extent 
and severity of ischemia. Nevertheless, the percentage of patients with or without angina who 
received medication was not different, and the effect of medications in both groups can be 
expected to be similar. 
Clinical implications: The outcome of patients after a positive dobutamine stress 
sestamibi study is predicted by the extent of reversible hypoperfusion, but not by symptoms of 
angina during the test. Patients with silent ischemia defined as reversible perfusion 
abnormalities without associated angina during dobutamine stress sestamibi SPECT imaging 
have similar mortality and hard cardiac event rate compared to patients with symptomatic 
ischemia, but are less likely to have unstable angina during follow up. Therefore, the absence 
of angina in association with perfusion abnonnalities should not be interpreted as a sign of 
more benign prognosis. 
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Abstract 
Background: Left ventricular (LV) dysfunction is correlated with elevated natriuretic 
peptides, however the presence of myocardial contractile reserve may inversely influence 
natriuretic peptide levels in patients with reduced LV function. 
Methods: Plasma atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) 
were determined in 66 consecutive patients referred to dobutamine stress echocardiography 
for the evaluation of myocardial viability. ANP and BNP were measured using 
immunoradiometric assays. Left ventricular ejection fraction (L VEF) was assessed by 
echocardiography at rest. Echocardiograms were analyzed using a 16-segment 5-point model. 
Contractile reserve was defined as an improvement of segmental wall motion score by ::::1 
grade following infusion of low-dose dobutamine (10 !lg/kg/min) in 2:2 severely dyssynergic 
segments. 
Results: ANP and BNP plasma concentrations were higher in patients with a 
LVEF,;35% compared to patients with a LVEF>35% (ANP: 11.1 ± 9.7 versus 34.4 ± 37.0, 
p<0.0005, BNP: 62.4 ± 79.0 versus 11.6 ± 14.0 pmoVL, p<0.0005, respectively). The 
presence of contractile reserve influenced the ANP and BNP levels in patients with wall 
motion abnormalities. Patients with a preserved myocardial contractile reserve had lower 
ANP and BNP levels than patients without contractile reserve (ANP: 15.7 ± 8.0 versus 44.8 ± 
41.9, p<0.05, BNP: 17.9 ± 12.0 versus 78.3 ± 89.4 pmoi/L, p<0.05, respectively). 
Cardiovascular medical therapy, including beta-blockers and ACE-inhibitors, was comparable 
between the patient groups. 
Conclusions: Plasma natriuretic peptide levels are elevated in patients with LV 
dysfunction. However, in the presence of preserved myocardial contractile reserve, relatively 
low ANP and BNP levels are present. 
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Introduction 
Ischemic left ventricular (LV) dysfunction is the principal cause of congestive heart 
failure, which is associated with a poor prognosis (1-3). The management of these patients is 
challenging, whereas the prevalence of congestive heart failure is increasing over the last 
decade (2). Substantial reductions of morbidity and mortality can be achieved with medical 
therapy, additionally coronary revascularization may improve outcome in patients with severe 
ischemic LV dysfunction with a preserved myocardial contractile reserve ( 4-6). 
Recently, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) have 
been proposed for the detection and management of patients with LV dysfunction (7 -11 ). 
ANP is a cardiac hormone that is synthesized and secreted primarily in atrium, whereas BNP 
is produced in the ventricles in response to changes in wall stretch. Plasma natriuretic peptide 
concentrations may be elevated in patients with LV dysfunction, and elevated ANP and BNP 
levels are related to an adverse outcome (7 -11 ). Previous studies demonstrated that a 
preserved myocardial contractile reserve is related to a favorable outcome in patients with LV 
dysfunction. Currently, the relation between the presence of myocardial contractile reserve 
and plasma natriuretic peptides is not clear. In this study, we investigated the effect of 
myocardial contractile reserve on plasma ANP and BNP levels in patients referred to 
dobutamine stress echocardiography with a varying degree of heart failure. 
Methods 
Patient population, study protocol: The study population consisted of 66 
consecutive patients referred to dobutamine stress echocardiography for the evaluation of 
known or suspected coronary artery disease. Patients with primary cardiomyopathy, 
concomitant significant valvular disease, or left ventricular hypertrophy were not included. 
Plasma ANP and BNP concentrations were determined using immunoradiometric assays. All 
patients underwent resting echocardiography to assess the LV ejection fraction (LVEF) and to 
identify dysfunctional myocardial tissue. Left ventricular myocardial contractile reserve was 
assessed during low-dose dobutamine stress echocardiography. The local medical ethics 
committee approved the study protocol and all patients gave informed consent. 
Cardiac peptide measurements: Before stress echocardiography a blood sample was 
drawn from a peripheral vein, after the patient had rested for at least 30 minutes in a supine 
position. The blood sample was dra\¥!1 into a pre-chilled tube containing edetic acid (EDTA, 
1.9 mg/ml) and the protease inhibitor aprotonin (Trasylol, 100 kiU/ml) to prevent breakdown 
of the cardiac peptides. The sample was placed on ice and promptly centrifuged at 3000 rpm 
(4°C) for 10 minutes. The plasma was separated and stored at -80°C. Plasma concentrations 
of ANP and BNP were determined using standard commercially available immunoradiometric 
assay kits (Shionoria ANP and BNP kits, Shionogi, Osaka, Japan). 
Echocardiography: A commercially available imaging system (Hewlett Packard 
Sonos 5500, Andover, Mass.) and a 1.8 MHz transducer using second harmonic imaging to 
optimize endocardial border visualization were used. Two-dimensional imaging was 
performed with the patient in the left lateral position; standard views were recorded on optical 
disk (cine loops). 
After the venous blood samples were drawn, dobutamine stress echocardiography was 
performed to assess the contractile reserve in dysfunctional myocardium. Following the 
resting echocardiographic study, dobutamine was administered intravenously, starting at a 
dose of 5 ~g/kg body weight per minute for 5 minutes, followed by a 10 ~g/kg/min dose for 5 
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minutes (low-dose). Incremental doses of 10 !J-g/kg/min dobutamine were given at 3-minute 
intervals up to a dose of 40 !J-glkg/min, and atropine was added if target heart rate was not 
achieved. 
Global LV function, assessment of LVEF: The LVEF was determined off-line by 
the 2-dimensional biplane disk method. using the modified Simpson's rule (13). The 
endocardial borders of the 2- and 4-chamber apical views were digitally traced at end-diastole 
and end-systole. Subsequently, the LV end-diastolic and end-systolic volumes ejection 
fraction were measured and the LVEF was calculated. A L VEF $35% was considered 
abnormal. 
Regional LV function, segmental analysis: Two experienced observers, unaware of 
the clinical data, scored the digitized echocardiograms offline. In case of disagreement, a 
majority decision was achieved by a third observer. The left ventricle was divided into 16 
segments according to the American Society ofEchocardiography (12). Regional wall motion 
and systolic wall thickening were scored using a 5-point grading scale: 1 =normal, 2=mildly 
hypokinetic, 3=severely hypokinetic, 4=akinetic, 5=dyskinetic. Segments with severe 
hypokinesia, akinesia or dyskinesia were considered abnormaL The wall motion score index 
(WMSI) was calculated as the sum of the segmental scores divided by the number of analyzed 
segments. Contractile reserve was defined as an improvement of segmental wall motion score 
by 21 grade following infusion of low-dose dobutamine (10 )lg/kg/min) in 22 severely 
dyssynergic segments. Ischemia was defined as new or worsened wall motion abnormalities 
during high-dose dobutamine stress indicated by a deterioration of segmental wall motion 
score by ~1 grade. 
Statistical analysis: Values are expressed as mean ± SD, when appropriate, 
percentages are rounded. Continuous variables were compared using the Student t-test for 
unpaired samples. Differences bet\.veen proportions were compared using the Chi-square test. 
A value ofp<0.05 was considered statistically significant. 
Results 
Patient characteristics: The clinical characteristics of the 66 patients are presented in 
Table 1. A total of 44 patients were in New York Heart Association (NYHA) functional class 
Jill, 22 in class III/IV. 
Global function, LVEF: The L VEF at rest was on average 47±15%, 21 patients had a 
L VEF$35%. Dobutamine-stress echocardiography was performed in all patients without side 
effects. The hemodynamic changes in response to low-dose dobutamine infusion are 
presented in Table 2. 
Wall motion analysis: Segmental wall motion abnormalities were present in 27 
patients. Of these patients, 13 patients had a preserved myocardial contractile reserve, the 
remaining 14 patients had no contractile reserve. The clinical characteristics were comparable 
in patients with and in patients without contractile reserve (see Table 3). Patients with a 
preserved contractile reserve less often had a history of myocardial infarction compared with 
patients without contractile reserve. 
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Table 1. Baseline characteristics 
Men/Women 
Age (years) 
NYHA functional class 
LVEF (%) 
Ischemia 
Diabetes mellitus 
Hypercholesterolemia 
Smoking 
History 
Myocardial infarction 
Coronary angioplasty 
Coronary bypass surgery 
Medical therapy 
Beta-blockers 
Calcium channel blockers 
Nitrates 
ACE-inhibitors 
Diuretics 
Digoxin 
Aspirin 
Cholesterol lowering drugs 
Data are presented as number(%). 
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p < 0.0005 
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a_ 20 z 11.1 
<1: 
10 
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LVEF>35% 
41 (62) /25 (38) 
63 ± 13 
1.8 ± 1.0 
47 ± 15 
18 (27) 
2 (3) 
20 (30) 
8 (12) 
19 (29) 
3 (5) 
10(15) 
20 (30) 
I 0 (15) 
8 (12) 
13 (20) 
8 (12) 
5 (8) 
26 (39) 
20 (30) 
34.4 
LVEF_:::35% 
Figure 1. Plasma ANP concentrations in patients with a LVEF > 35% and in patients with a 
LVEF-535%. 
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Table 2. Hemodynamic data during dobutamine infusion 
Baseline 5 11g/kg/min 1 0 !lglkg/min 
Heart rate (bpm) 74 ± 15 81 ± 22* 90±26* t 
Systolic BP (mmHg) 131 ± 22 132 ± 25 131±23 
Diastolic BP (mmHg) 76± 12 75 ± 13 72±11* 
Rate pressure product 9595 ± 2446 10554 ± 3039 11693 ± 3862 t 
Data presented are mean value± SD. * p<0.05 versus baseline. t p<0.05 versus 5 ~g/kg/min 
dobutamine infusion stage. BP = blood pressure. 
Natriuretic peptide concentrations versus LVEF: The plasma levels of each 
natriuretic peptide were significantly elevated in patients with an abnormal LV function. 
Figure 1 demonstrates that the plasma ANP concentrations were significantly higher in the 
patients with a LVEE35% compared to patients with a LVEF>35% (34.4 ± 37.0 versus 11.1 
± 9.7 versus, p<0.0005). In line with this, plasma BNP concentrations were higher in patients 
with a LVEF:>35% than in those with an LVEF>35% (62.4 ± 79.0 versus 11.6 ± 14.0 pmoVL, 
p<0.0005, see Figure 2). 
100 
p < 0.0005 
75 62.4 
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LVEF>35% LVEF$35% 
Figure 2. Plasma BNP concentrations in patients with a LVEF > 35 %and in patients with a 
LVEF0:35%. 
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Natriuretic peptide concentrations versus contractile reserve: The presence of 
contractile reserve influenced the natriuretic peptide concentrations in patients with wall 
motion abnormalities. The patients with a preserved myocardial contractile reserve had a 
lower ANP concentration than the patients without contractile reserve (15.7 ± 8.0 versus 44.8 
± 41.9, p<O.OS, see Figure 3). Also, plasma BNP levels were lower in patients with a 
preserved myocardial contractile reserve than in patients without contractile reserve (17.9 ± 
12.0 versus 78.3 ± 89.4 pmol/L, p<O.OS, respectively, Figure 4). 
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Figure 3. Plasma ANP concentrations in patients with wall motion abnormalities with and 
without a preserved left ventricular myocardial contractile reserve. 
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Figure 4. Plasma BNP concentrations in patients with wall motion abnonnalities with and 
without a preserved left ventricular myocardial contractile reserve. 
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Discussion 
Previous studies have demonstrated that plasma natriuretic peptide concentrations are 
elevated in patients congestive heart failure (7 -II). Although the number of patient with 
congestive heart failure due to ischemic heart disease is increasing rapidly (2), there are no 
data available on the relation between myocardial contractile reserve and plasma natriuretic 
peptide concentrations. In this study, ANP and BNP levels were determined in a patient 
cohort with known or suspected coronary artery disease and a varying degree of heart failure. 
The main finding from the present study is that the presence of myocardial contractile reserve 
during low-dose dobutamine stress echocardiography influences plasma levels of both 
natriuretic peptides in patients with an impaired LV function. Plasma ANP and BNP levels 
were markedly elevated in patients without contractile reserve, compared to patients with a 
preserved contractile reserve. Cardiovascular medical therapy, including beta-blockers and 
ACE inhibitors, was comparable between the patient groups. 
Pathophysiological role of ANP and BNP: The natriuretic peptides have a major role 
in the protection of the heart from volume overload (14). The cardiac hormones ANP and 
BNP are produced in the atria and ventricles, respectively, in response to an increase in wall 
stretch, or pressure. Elevated plasma ANP and BNP concentrations have a natriuretic and 
diuretic effect. In addition, high plasma BNP levels cause a fluid-shift from the capillary bed 
to the interstitium, decreasing preload and blood pressure. Hence, ANP and BNP are 
functional counterparts of the renin-angiotensin aldosterone system. Therefore there may be a 
future for these natriuretic peptides in screening and guiding management in patients with LV 
dysfunction. In the present study, the ANP and BNP plasma concentrations were significantly 
elevated in the patients with LV dysfunction, whereas the patients with a normal function had 
normal natriuretic peptide levels. These findings indicate that an increased wall tension or 
stretch in abnonnally contracting myocardial tissue may lead to elevated plasma natriuretic 
peptide levels, and confirm the "volume overload" hypothesis for the production and secretion 
of these peptides. This is in line with the study of Sumida et al. (15) showing that the 
secretion of natriuretic peptides increases in proportion to the severity of LV dysfunction, and 
is elevated in infarct regions. 
Contractile reserve in patients with LV dysfunction: Since the introduction of the 
concepts of myocardial viability, hibernation, and stunning, it has become clear that ischemic 
LV dysfunction is not an irreversible process (16,17). In more than 50% of the patients with 
ischemic cardiomyopathy and heart failure, a clinically significant amount of viable 
myocardium is present and coronary revascularization may be considered (18). The 
evaluation of myocardial contractile reserve may have important clinical implications in 
patients with ischemic LV dysfunction. Recently, Chaudry et al. (19) evaluated contractile 
reserve during low-dose dobutamine stress echocardiography in 80 patients with ischemic LV 
dysfunction. Contractile reserve was a significant predictor of survival in these patients. 
Moreover, the presence of contractile reserve is related to the extent of interstitial fibrosis and 
predicts the recovery of systolic function after coronary revascularization (20). Several studies 
have reported that plasma natriuretic peptides are predictive of long-term survival after 
myocardial infarction, although the mechanism for this is not clear (21 ,22). In the current 
study myocardial contractile reserve influenced plasma natriuretic peptide levels. Plasma 
ANP and BNP levels were high in patients without contractile reserve, and relatively low in 
patients with a preserved contractile reserve. Hence, natriuretic peptides are correlated with 
myocardial viability in dysfunctional myocardium. This may partially explain why natriuretic 
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peptides predict survival in patients who had a myocardial infarction. Further research is 
needed to fully elucidate this issue. 
Conclusions: The presence of myocardial contractile reserve influences the plasma 
natriuretic peptide concentrations in patients with LV dysfunction. Plasma ANP and BNP 
levels were markedly elevated in patients with LV dysfunction without contractile reserve, 
compared with patients with a preserved contractile reserve. These findings may give further 
insights into the role of these natriuretic peptides in patients with LV dysfunction. 
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Left ventricular hypertrophy screening using a 
hand-held ultrasound device 
E. C. Vourvouri, D. Poldermans, A. F. L. Schinkel, L. Y. Koroleva, F. B. Sozzi, 
G. E. Parharidis, J. J. Bax and J. R. T. C. Roeland! 
Department of Cardiology, Thoraxcentre, Erasmus Medical Centre Rotterdam, Rotterdam, The Netherlands 
Aims To test the diagnostic potential of a hand-held 
ultrasound device for screening for left ventricular hyper-
trophy in a hypertensive population using a standard 
echocardiographic system as a reference. 
Methods One hundred consecutive hypertensive patients 
were enrolled. An experienced investigator performed 
measurements of the thickness of the anterior septum and 
posterior wall using the parasternal 2D-long axis view and 
the end-diastolic dimension of the left ventricle with both 
imaging devices. Left ventricular hypertrophy was defined 
as an increase in left ventricular mass ~ 134 g. m - 2 for 
men and ~ 110 g . m- z for women, when indexed for body 
surface area and ~ 143 g. m- 1 for men and ~ 102 g. m- 1 
for women, when indexed for height. 
Results Sixty+five men and 35 women were studied (age 
60 ± 11 years); mean duration of hypertension: 13 ± 11 
years; mean blood pressures: systolic !50± 20 mmHg and 
diastolic 89 ± 11 mrnHg. The anterior septum and posterior 
wall were visualized in all patients ;vith both imaging 
devices. The standard echocardiographic system identified 
Introduction 
Left ventricle hypertrophy which expresses end-organ 
damage from hypertension, is an independent potent 
marker of cardiovascular risk in arterial hyperten-
sion[l-31. lt is considered as an asymptomatic pre-clinical 
stage of the cardiovascular disease, that may lead to 
cardiac eventsf4l. Also, reversal of left ventricular hyper-
trophy can improve the patient's outcome[51. Early iden-
tification of left ventricular hypertrophy and treatment 
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2002. 
Correspondence: Don Poldermans, MD, PhD, Thoraxcentre, 
Room Ba 300. Erasmus Medical Centre Rotterdam, Dr. 
Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. 
left ventricular hypertrophy by body surface area in 18 
(18%) patients and by height in 26 (26%) patients. 
The agreement between the standard echocardiographic 
system and the hand-held device for the assessment of left 
ventricular hypertrophy was 93%, kappa: 0·77 (left ven-
tricular mass/body surface area) and 90%, kappa: 0·76 (left 
ventricular mass/height). 
Conclusions We conclude that hand-held devices can 
be effectively applied for screening for left ventricular 
hypertrophy in hypertensive patients. 
(Eur Heart J, 2002; 23: 1516-1521, doi:10.1053/euhj.2002. 
3162) 
© 2002 Published by Elsevier Science Ltd on behalf of 
The European Society of Cardiology. 
Key Words: Left ventricular hypertrophy, left ventricular 
mass, hand-held ultrasound device. 
See doi: 10.1053/euhj.2002.3292 for the Editorial comment 
on this article 
is therefore the cornerstone of appropriate management. 
The electrocardiogram (ECG), although commonly 
available and inexpensive has proven insensitive in 
detecting the presence of left ventricular hyper-
trophy[6-SJ_ Echocardiography is a sensitive means for 
measurement of left ventricular thickness and has com-
parable accuracy to the magnetic resonance imaging 
(MRI) especially in patients with normal left ventricular 
geometry[~-loJ_ New and small echocardiographic de-
vices are now becoming available which could be used as 
screening tools for various pathomorphologies of the 
heart. 
The aim of the present study was to evaluate the 
potential and diagnostic accuracy of a recently 
developed portable hand-held ultrasound system for 
screening for left ventricular hypertrophy in hyper-
tensive patients using a standard two-dimensional 
echocardiographic system as a reference. 
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Table 1 Patients characteristics 
Age (years) 
Male, n (%) 
Years ofHT 
Heart rate (beats , min~ 1) 
SBP (rnrnHg) 
DBP(=Hg) 
BMI(kg.m~ 2) 
60 ± 11 
65 (65%) 
13 ± 11 
71 ± 11 
150 ± 20 
89 ± ll 
27±4 
HT=hypertension: SBP=systolic blood pressure; DBP-diastolic 
blood pressure; BMI =Body Mass Index. 
Study patients and methods 
Study population 
One hundred consecutive hypertensive patients visiting 
the outpatient clinic (65 men, mean age 60 ± 11 years) 
were enrolled in the study. Patient characteristics are 
presented in Table I. 
Study design 
The study protocol consisted of an echocardiographic 
examination by means of a standard echocardiographic 
system, Hewlett Packard (Sones 5500; Andover, Mass, 
U.S.A) or Vingmed (System V; Harten, Norway), and an 
echocardiographic examination by means of a hand-held 
device. Both studies were performed within 10 days 
(range 2-7 days) by the same investigator with experience 
in echocardiography. The order of the second visit was 
arranged by a study coordinator unaware of the results. 
For the evaluation of the intra-observer variability the 
same observer performed the same test in 30 patients 
within a week after the last examination, provided they 
had unchanged characteristics. For the evaluation of 
inter-observer variability, a second observer, who was 
blinded to the results of the other investigator, performed 
the echo study with the hand-held device in 30 patients. 
All patients had a baseline electrocardiogram per-
formed. The ECGs were examined for evidence of left 
ventricular hypertrophy using the Sokolow-Lyon (the 
sum of the amplitudes of the S wave in V1 and the R 
wave in V5 or V6, 35 mm) and the sex-specific Cornell 
criteria (the sum of the amplitudes of the S wave in V3 
and the R wave in aVL, >20 mm in women and >24 mm 
in men)llll_ 
All patients were known hypertensives. Blood press-
ure was measured in the supine position. For the study, 
we took the average of 12 measurements over 60 min 
with a 5 min interval using a semi-automatic device 
(Accutor 2, Datascope, Datascope Corp. CA, U.S.A.). 
Echocardiographic methods 
Linear measurements of the thickness of the anterior 
septum and posterior wall and the left ventricular 
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end-diastolic dimension were obtained at the para-
sternal, two dimensional long axis view with both 
devices on-line, according to American Society of 
Echocardiography recommendations[l 2l. The measure-
ments reported are the mean of five cycles. 
Left ventricular mass was calculated from the 
Devereux-modi:fied American Society ofEchocardiogra-
phy (ASE)-cube equationP01: 0·80 (1·04 [(IVST+ 
PWT+ L VED)3 - L VED3]+0·6g. The left ventricular 
mass index (g. m - 2) was calculated by dividing the left 
ventricular mass by body surface area. Since this index 
can fail in identifying left ventricular hypertrophy in 
obese individuaJsll 3l a second index was calculated by 
dividing the left ventricular mass by height (g. m- 1). 
Body surface area (m2) was derived from the Du 
Bois formulaP 4l: 0·007184 x (weight [kg] o-425 " (height 
[cm])0 ' 725 . Body mass index (kg. m2) was derived from 
the average weight and height. 
Left ventricular hypertrophy was defined as an in-
crease in the left ventricular mass index ;::>: 134 g. m - 2 
for men and ;::.: 110 g. m- 2 for women, when indexed 
for body surface areaU 5 -- 17l, or ;::.: 143 g. m -t for men 
and ;::.: 102 g . m- 1 for women, when indexed for 
height[l 3"161. 
The inter- and intra-observer variability was 96% and 
98%, respectively. 
The ultrasound stethoscope 
The SonoHeart® (SonoSite Inc., Bothell, Washington, 
U.S.A.) hand-held ultrasound system (weight 2·4 kg, 
Fig. 1) was used in this study.lt is equipped with a small 
2-4 MHz phased array broadband transducer and oper-
ates on a rechargeable lithium ion battery or AC power. 
The two-dimensional control settings are comparable 
to a standard echocardiographic device and a caliper 
is integrated in the unit for linear measurements. 
SonoHeart® has a storage memory of 50 images and can 
be connected to a video-recorder, a printer or an exter-
nal monitor. Colour power Doppler flow mapping is 
also integrated into the system. 
Statistics 
Descriptive statistics were reported as mean± SD or by 
frequency percentages. The difference between the 
measurements of the left ventricular mass indexed for 
body surface area and the height of those two devices 
can be appreciated from Fig. 2 (a) and (b) with the 
Bland-Altman[18l plot graphic. 
The agreement for the measurements between the two 
examination techniques was assessed from 2 x 2 tables 
using weighted kappa statistics. Kappa values <0·4, 
between 0·4 and 0·75, and >0·75 were considered to 
represent poor, fair to good and excellent agreement, 
respectively, based on Fleiss's classification[191. 
Figure 1 Photograph of the SonoHeartS device, a hand-
held ultrasound imager, used in this study. 
Results 
Clinical characteristics 
The mean systolic blood pressure was 150 ± 20 mmHg 
and the diastolic blood pressure 89 ± 11 mmHg. The 
mean heart rate was 71 ± 11 beats . min- 1• 
Electrocardiography 
Four patients were found to have left ventricular hyper-
trophy according to the Sokolov~Lyon criteria and 13 
according to the Cornell criteria. The sensitivity of the 
ECG for the detection of left ventricular hypertrophy 
was, respectively, 5% and 16% and the specificity was, 
respectively, 96% and 87%. 
Measurements and agreement 
Visualization was feasible in all patients with both 
imaging devices. The results of the measurements of 
the thickness of the anterior septum and the posterior 
wall and the dimension of the left ventricle with both 
examination techniques are summarized in Table 2. 
The mean left ventricular mass indexed by body 
surface area was 96·2 ± 36 g. m - 2 with the standard 
echocardiographic system and 103 ± 33 g. m- 2 with the 
hand-held device. Using the threshold of ;;::: 134 g. m- 2 
for men and ;;::: 110 g. m- 2 for women the standard 
echocardiographic system identified left ventricular 
hypertrophy in 18 (18%) patients (nine women and nine 
men). The agreement between the two methods was 
93%, kappa 0·77 (Fig. 3(a)). 
The mean left ventricular mass indexed by height was 
Ill· 5 ± 43 g . m- 1 with the standard echocardiographic 
system and 120 ± 40 g. m -I with the hand-held device. 
Using the threshold of ;;:: 143 g. m- 1 for men and 
;;::: 102 g. m- 1 for women the standard echocardio-
graphic system identified left ventricular hypertrophy in 
26 patients (13 women and 13 men). The agreement 
between the two methods was 90%, kappa=0·76 (Fig. 
3(b)). 
Discussion 
The presence of left ventricular hypertrophy, calculated 
as an absolute left ventricular mass has an independent 
prognostic value on top of age and blood press-
ure[3·20·21l. Recent studies have reported good reliability 
for echocardiographic measurements of left ventricular 
massl22.2JJ_ 
Our study showed that this new, hand-held device 
could be effectively used for screening for left ventricular 
hypertrophy in office practice. Recently, we demon-
strated in a previous study the efficacy and high accuracy 
of this small imaging device in assessing the patho-
morphology and function of the heart enhancing and 
extending the physical examination to allow goal-
oriented examination, such as screeningl24l. 
Although echocardiography can assess left ventricular 
hypertrophy accurately compared to the 'gold standard' 
MRI, the World Health Organisation~Intemational 
Society of Hypertension (WHO~ISH)i25l and the Joint 
National Committee on prevention, detection, evalu-
ation and treatment of high blood pressurel26l do not 
recommend routine echocardiography in all hyperten-
sive patients. Thus, in patients categorized as high risk 
patients (having cardiovascular risk factors or an end-
organ damage), treatment is already indicated and 
echocardiography results will not change their manage-
mentl27J. However, echocardiography is recommended 
in patients with concomitant heart diseasel27·28l and in 
patients with 'stage one' hypertension (patients with 
high~normal blood pressure who do not have clinical 
cardiovascular disease, target organ damage or other 
risk factors). This is recommended in order to avoid 
misclassi:fication as 'mild' hypertension in patients that 
have an end-organ damage as left ventricular hypertro-
phyl25·26·28·29l. Both, Black and Shepsl30·31l support this 
view introducing limited echocardiographic protocols. 
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Figure 2 Bland-Altman plot, demonstrating the magnitude of the difference between the measurements with the two 
techniques (differences plotted against their mean average) of (a) left ventricular mass indexed for body surface area 
(BSA) and (b) left ventricular mass indexed for height. SD=2 standard deviations of the mean difference in the 
measurements of the two devices. Using standard echocardiographic system as the gold standard, the sensitivity and 
specificity of the band-held device for screening of the presence of left l'entricular hypertrophy were calculated as was 
the positive predicthe value (PPV), negative predictive value (NPV) and accuracy. 
Table 2 Measurements (in em) of the anterior septum (AS), the posterior wall 
(PW) and the left ventricular end-diastolic dimension (LVED) with both imaging 
devices 
Type of 
examination 
Standard echo 
Hand-held device 
SE-hand-held 
AS 
1·18 
1·21 
-0·03 
so 
PW LVEO AS PW LVED 
4·85 
... 
0·05 
0·29 0·20 
0·26 0·16 
0·03 0·04 
SD=standard deviation; Number of patients: 100. 
However, the indication of echocardiography in 
hypertensive patients may be broadened, as this new and 
inexpensive (...., 1/lOth of the price of a standard echo-
cardiographic system) hand-held ultrasound device 
becomes widely available. In our view, such small hand-
held imaging devices, reducing the cost and being ultra-
portable and easy to use, will allow routinely echocar-
diographic examination in all hypertensive patients. 
Performing as an extension to physical examination they 
will provide the clinician with immediate, valuable infor-
mation about prognosis and risk classification, assisting 
him in his decision of therapy. Of course, the initiation 
of aggressive therapy is dependent on not only the 
presence of left ventricular hypertrophy but also on 
other parameters such as cardiovascular risk factors and 
end-organ damage. Furthermore, it is becoming increas-
ingly clear that we should aim for aggressive treatment 
in most hypertensive patients. 
The efficacy of the selected therapy could be followed 
with the hand-held device by serial estimation of left 
ventricular mass with every visit at the outpatient clinic. 
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AS 
Range of 
measurements 
PW LVED 
0·5-2·2 0·4--1·3 3-4--6·8 
0·7-2·3 0·6-1·4 3·5--6·6 
However, the reliability ofleft ventricular mass measure-
ments depends on many factors, such as the experience 
of the operator, the age of the patient, the body habitus 
or the presence of an abnormal left ventricular geometry 
or emphysema. Furthermore the amount of regression 
with therapy also plays a significant role in the 
likelihood of true changes[23l. 
By analysing the left ventricular geometric pattern, 
risk stratification can be carried out: patients "With 
normal left ventricular architecture have the best prog-
nosis, those with concentric remodelling or eccentric 
hypertrophy have intermediate, and those with concen-
tric left ventricular hypertrophy have the worst prog-
nosis[3·25·32l. Furthermore, echocardiography provides 
us not only with left ventricular mass determination, 
but with additional valuable information such as left 
ventricular systolic function or valvular abnormalities. 
The method used most frequently for the diagnosis of 
left ventricular hypertrophy is still standard electrocar-
diography. Although the ECG has low sensitivity and 
specificity in recognising left ventricular hypertrophy, it 
(a) 
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Figure 3 Agreement of the left ventricular mass (LVM) indexed by body surface area (BSA) (a) and by 
height {b), measured by the band-held device and the standard echocardiographic system. 
should not be abandoned in patients with known 
or suspected coronary artery disease as it pro-
vides additional information on ischaemia, previous 
myocardial infarction and rhythm abnormalities. 
Left ventricular mass determination, especially with 
theM-mode based methodology, can be unreliable in an 
asymmetric heart. In the presence of such an anatomy, 
the 3D echocardiogram and the ECG-gated magnetic 
resonance imaging have a higher accuracy and reliabil-
ity. However, albeit they are superior compared to 
conventional echocardiographic methods, they have a 
higher cost and a varied availabilityt33l_ 
The study was perfonned by a cardiologist with 
experience in echocardiography. We believe that phys-
icians can be trained to use this hand-held device and to 
recognize and distinguish nonnal from abnonnal find-
ings. In case of an abnormal finding or in case of doubt 
an echocardiographic study with a standard echocardio-
graphic system perfonned by an experienced investi-
gator should follow. However, training and licensing for 
use of these devices by non-cardiologists will become an 
important issue in the future. 
Recently, Goodkin et af.134l studied the use of the 
hand-held device at the point-of-care and compared it to 
the physical examination. They reported that the use of 
this device by cardiologists improved the detection of 
important cardiovascular findings. However, they 
pointed out that such a hand-held device cannot be a 
substitute for the final diagnosis, in case of abnormal 
findings. This is in concordance with the study per-
formed by Spencer et af.13 5J in critically ill patients. 
Moreover, Schiller[36l comments that further evaluation 
of these devices will improve their practical use. 
Limitations 
In this study, we calculated the left ventricular mass by 
the Devereux modified (ASE)-cube equation. Due to the 
absence of the M-mode feature of the hand-held device 
the measurements were performed with the use of cal-
lipers on the two-dimensional parasternal long axis view 
according to the American Society ofEchocardiography 
recommendations[11 l. The same measuring technique 
was used for both devices for perfonnance comparison. 
The hand-held device used in this study had colour 
power Doppler flow mapping instead of the traditional 
colour Doppler. Furthermore, it had no Doppler 
modalities with which to obtain haemodynamic data. By 
now, spectral Doppler and colour Doppler are inte-
grated in the new generation of personal ultrasound 
imagers. 
Conclusion 
The hand-held ultrasound device, being ultra-portable, 
and inexpensive could become part of the clinical exami-
nation in high-risk patient groups, performing like an 
excellent screening tool. 
We are grateful to Eric Boersma, PhD, for expert statistical 
advise. 
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Abstract 
Background: Background: A hand-carried cardiac ultrasound (HCU) device is a 
recently introduced imaging device which may be potential useful in the primary care setting. 
Aim: To test the screening potential of a HCU for the detection of LV dysfunction by 
evaluating LV ejection fraction (LVEF) and inferior vena cava (IVC) collapse. A standard 
echocardiographic system (SE) and plasma brain natriuretic peptide (BNP) measurements 
were used as a reference. 
Methods: Eighty-eight (88) consecutive patients (56 male, age 59±12 years) with 
suspected LV dysfunction were emolled in the study. The HCU-LVEF was visually estimated 
and the SE-LVEF derived by the Simpson's biplane method. A LVEF ,;35% represented LV 
dysfunction. An IVC collapse of <50% and BNP levels :2:15 pmol!L were considered 
abnormaL The correlation of the HCU-LVEF, the HCU-IVC and BNP to the SE-LVEF and 
SE-IVC were analysed independently using two-by-two tables. 
Results: Six patients were excluded because of poor echo images. 17/82 patients had 
LV dysfunction. Both, the HCU and BNP could identifY 16 out of these 17 patients. The 
agreement for L VEF and IVC collapse between SE and HCU was 98% and 96% respectively. 
The sensitivity of IVC collapse, HCU-LVEF and BNP in identifYing patients with LV 
dysfunction were respectively 30%, 94% and 94%. 
Conclusion: A HCU device can reliably be used as a screening tool for LV 
dysfunction. 
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Introduction 
Congestive heart failure is a disease associated with high morbidity, mortality and cost 
(1-4). One of the main precursor forms of heart failure is left ventricular (LV) dysfunction, 
which at early stages is asymptomatic. Appropriate and early treatment can delay if not 
prevent the development of chronic heart failure (5-7) which makes screening for this disorder 
worthwhile (8). However, clinical diagnosis of LV dysfunction with the existing conventional 
criteria is often difficult and inaccurate (9-11). 
Brain natriuretic peptide (BNP) is a cardiac neurohormone secreted in the ventricles as 
a response to volume and pressure overload (12,13) and may be elevated in patients with LV 
dysfunction (14, 15). Studies have suggested measurements of plasma BNP levels as a 
potential new screening method for the diagnosis of patients with impaired LV dysfunction 
(14-17). Echocardiography on the other hand, is known to be the screening method of choice 
for LV dysfunction assessment (3,18-19) but is considered to be unpractical and costly 
(15,16,20). Furthermore, the inspiratory changes in diameter of the IVC collapse as an 
indicator of right-sided filling pressure can be measured by echocardiography (21-22). 
However, the utility of this parameter as a screening parameter for LV dysfunction has not 
been studied yet. Hand-carried cardiac ultrasound (HCU) devices aim to bring 
echocardiography into the community setting allowing screening programmes for various 
cardiac pathologies (23-25). 
The purpose of the current study was to test the diagnostic potential of a HCU device 
(SonoHeartTM, SonoSite Inc and OptiGoTM, Philips Medical Systems) in screening for LV 
dysfunction by evaluating LV ejection fraction (LVEF) and the IVC collapse. A standard 
echocardiographic system (SE) evaluating LV function and IVC collapse and BNP 
concentration measurements were used as a reference. 
Methods 
Study patients: The study was approved by the Institutional Medical Ethical 
Committee and informed consent for the study was obtained from all patients. Eighty-eight 
(88) consecutive patients referred from the outpatient cardiology clinic to the echo lab with 
suspected LV dysfunction were included in the study. All patients were clinically stable and 
cardiac medication was unchanged during the study period. Patients characteristics are listed 
in table I. 
The HCU device: Two HCU devices were used: the OptiGoTM (Philips Medical 
Systems) and the SonoHeartTM Plus (SonoSite Inc) (Figure 1 ). Both devices operate on a 
rechargeable battery or AC current and allow quantitative assessment of the heart with 
inclusive linear callipers. SonoHeartTM has a storage memory of 50 images which can be 
downloaded into a PC and has also connection to a VCR, a printer or an external monitor. The 
OptiGo TM uses a Compactflash card to archive images which also can be downloaded into a 
PC. Colour flow Power Doppler and Colour flow Doppler is integrated to the SonoHeartTM 
and OptiGoTM respectively. SonoHeartTM Plus has in addition M-Mode and pulsed Doppler. 
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Figure 1. Photograph of the two ultrasound stethoscopes used in this study. (A) The 
OptiGoTM and (B) the SonoHeartTMplus. 
Echocardiographic data: The study protocol consisted of t\vo consecutive 
echocardiographic examinations: one examination by means of a standard echocardiographic 
system (Sonos 5500, Andover, Mass) and the other by means of a HCU device 
(SonoHeartTM, SonoSite Inc or OptiGoTM, Philips Medical Systems). All images were 
stored in the memory of the portable devices and as digital loops onto optical discs for the SE. 
Both studies were performed on the same day by tvvo independent cardiologists blinded to 
each other's results and to medical history or clinical status of the patient. 
L VEF evaluation using SE: Images were acquired with the SE at standard cardiac 
views. We used LVEF, derived with the previously validated modified Simpson's biplane 
discs method (26), as our gold standard for classification of LV function. The analysis was 
performed on a computerised off-line station by an independent third observer blinded to the 
HCU device and BNP results. The cinematic frames corresponding to end-diastole and end-
systole were selected from 2-chamber and 4-chamber views. 
LVEF evaluation using a HCU device: Global LV systolic function was estimated 
visually from the same with the SE cardiac views in all patients. Normal LV systolic function 
was defined by normal LV end-diastolic ($5.5 em) and end-systolic ($3.5 em) dimensions and 
no major wall motion abnormalities (27) whereas EF ::::.;35% was considered to represent a 
severely reduced LV function. 
IVC measurements: The expiratory and inspiratory IVC diameter and percent 
collapse were measured with SE and HCU devices from the subcostal view with the patient in 
supine position. The diameter was measured within 2 em of the right atrium origin of IV C. In 
case of quiet respiration and minimal IVC variation the patient was asked to suddenly inhale 
("sniff') and the subsequent IVC was measured (Figure 2). The collapse index (IVC-CI) was 
calculated by taking the difference of the two dimensions and dividing it by end-expiratory 
IVC dimensions. An IV C-CI < 50% represented an elevated right atrium (RA) pressure (>I 0 
mmHg) (22). 
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Measurement of plasma BNP: Before the echocardiographic assessments, blood 
samples were obtained from the antecubital vein of all patients after they had rested for at 
least 15 minutes. Blood was collected into chilled tubes containing edetic acid (EDTA) and 
aprotinin (!.9 mg and 100 klU/ml blood, respectively). Plasma samples were centrifuged 
promptly (for 10 minutes) and stored at -SO"C until final analysis. BNP was measured using a 
standard commercially available imrnunoradiometric assay kit (Shionoria BNP kit, Shionogi, 
Osaka, Japan). Results of BNP concentration were received within 1 month from the 
echocardiographic examination. A BNP level of ?15 pmol!L was considered to represent 
severe LV dysfunction and derived from a large study population of more than one thousand 
patients in our centre. 
Invasive hemodynamic data: Right-sided heart catheterisation was performed in a 
subgroup of 20 patients to compare invasively obtained RA pressure measurements to the RA 
pressure estimated echocardiographically by the IVC collapse. The hemodynamic data were 
acquired with fluid-filled Swan-Ganz catheters (Baxter Healthcare Corp., Edwards Critical 
Care Division, Irvine, California) immediately after the echocardiographic study with the 
HCU device and before any invasive interventions. Normal RA pressure was considered 
<10mmHg. Medication remained unchanged during the study period. Blood samples for BNP 
were obtained from all the patients prior to invasive interventions and results were compared 
to invasive data. 
Statistical analysis: Descriptive statistics were reported as mean ± SD for continuous 
variables and as percentages for categorical variables. The agreement for the two examination 
techniques in evaluating L VEF and IV C-CI measurements were assessed from 2X2 tables 
using weighted kappa statistics. The same statistical method was used for the agreement 
between BNP measurements versus L VEF and between RA pressure measured invasively 
versus the echocardiographically estimated RA pressure. Kappa values <0.4, between 0.4 and 
0.75, and >0.75 were considered to represent poor, fair to good and excellent agreement 
respectively, based on Fleiss's classification (28). Differences between propmiions were 
compared using the Chi-square test. The Student's t test was used to compare continuous 
variables. A value ofp<0.05 was considered statistically significant. 
Figure 2. Imaging of the inferior vena cava during expiration (A) and inspiration (B). A 
collapse of less than 50% is present, indicating and elevated right-sided filling pressure 
(OptiGoTM). 
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Results 
Patients characteristics: Eighty-eight (88) patients (52 male, age 59±12) referred for 
echocardiography with suspected LV dysfunction were included in the study. Out of the 
initial 88 patients, 6 were excluded from the study due to poor visualisation of the LV (2 
patients), and IVC (4 patients) leaving 82 patients for analysis. Sixty-four out of 82 patients 
were classified according to the New York Heart Association functional class I or II, 14 were 
class III and 4 patients were class IV. The classification was performed by an investigator 
blinded to the results of the echocardiographic examinations. 
Table 1. Baseline characteristics of the 88 patients with suspected LV dysfunction 
Age (years) 
Male, n 
History of myocardial infarction 
Hypertension, knuwn 
Diabetes mellitus, treated 
No history of cardiovascular disease 
Beta-blockers 
Nitrates 
Calcium-antagonists 
Diuretics 
Aspirin/anticoagulants 
Lipid-lowering agents 
52±12 
57 (59%) 
34 (39%) 
15 (17%) 
9 (10%) 
32 (36%) 
36 (41%) 
15 (17%) 
15 (17%) 
12 (14%) 
40 (45%) 
37 (42%) 
Echocardiographic data: Out of the 82 patients to analyse, 17 had an EF 535% as 
assessed by theSE Simpson's biplane discs method. The HCU examination detected 16/17 
patients showing a sensitivity of 94% and specificity of 100% in the diagnosis of LV 
dysfunction (table 2A). The agreement between the two imaging techniques for the IVC-CI 
was very good (96%, kappa~0,87) (table 3A). However, there was no correlation between 
IVC-CI and LVEF assessed by SE (agreement:76%,kappa~0.19) (table 3B). 
BNP data: Results of BNP were available for all 82 patients. BNP levels were 
elevated in 16 out of the 17 patients with LV dysfunction. However, in 8 patients with normal 
L VEF the BNP levels were also elevated resulting in a sensitivity of BNP in diagnosing 
patients with LV dysfunction of94% and a specificity of 88% (table 2B). 
Subgroup analysis: 20 patients underwent a right-sided heart catheterisation as part 
of diagnostic procedure. The characteristic data of the patients are listed in table 4. The mean 
RA pressure measured invasively was 8±9 mmHg. The agreement for the measurement of the 
RA pressure between the two techniques was 95%, kappa 0.9 (table 5). The correlation 
between BNP and invasively measured RA pressure was poor (60%, kappa~0.29). 
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Table 2. Agreement between (A) a HCU device and (B) BNP measurements and a standard 
echo in the assessment ofLVEF. 
No of patients: 82. The numbers inside the tables express the absolute number of patients. 
Abnormal LVEF: o;35%. Abnormal BNP: <15 pmol!L 
abnormal 
normal 
abnormal 
normal 
LVEF (SE) 
abnormal normal 
16 0 
1 65 
" Agreement -99 Yo, kappa 0.96. 
Sensitivity=94% (95%CI:0.77-0.77) 
Specificity""lOO% (95%CI:0.95-0.95) 
PPV=IOO% (95%CI:0.82-0.82) 
NPV=98% (95%CI:0.94-0.94) 
LVEF (SE) 
abnormal normal 
16 8 
57 
Agreement =89%, kappa -0.71. 
Sensitivity=94% (95%CI:0.73-0.99) 
Specificity=87% (95%CI:0.82-0.89) 
PPV=67% (95%CI:0.51-0.70) 
NPV=98% (95%CI:0.92-l.O) 
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Table 3. (A) Agreement between a HCU device and a standard echo in the assessment ofJVC 
collapse and (B) correlation between IVC collapse and LVEF 
No of patients: 82. The numbers inside the tables express the absolute number of patients. 
LVEF=left ventricular ejection fraction. IVC-CI=inferior vena cava collapse index. Abnormal 
LVEF: S35%; Abnomal IV C-CI: <50%. 
abnormal 
normal 
abnormal 
normal 
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IVC(SE) 
abnormal normal 
12 1 
2 67 
-
0 
-Agreement 96 Yo, kappa 0.87. 
Sensitivity=86% (95%CI:0.64-0.92) 
Specificity=98% (95%CI:0.94-l.O) 
PPV=92% (95%Cl:0.68-I.O) 
NPV=97% (95%CI:0.93-0.98) 
LVEF (SE) 
abnormal normal 
5 8 
12 57 
0 Agreement -76 Yo, kappa -0.19. 
Sensitivity=30% (95%CI:0.12-0.49) 
Specificity=88% (95%Cl:0.83-0.93) 
PPV=38% (95%CI:0.16-0.64) 
NPV=83% (95%CI:0.78-0.87) 
Discussion 
Heart failure and LV systolic dysfunction occur frequently, especially in the elderly 
population and are related to poor prognosis and considerable health-care cost (3). Early 
recognition and initiation of appropriate treatment can improve survival (6). However, 
diagnosis of LV dysfunction, especially in asymptomatic patients, may be difficult to assess 
by physical examination only, even when routine lab values, electrocardiograms and chest X-
rays are added (29). 
BNP is a 32 amino acid polypeptide containing a 17 amino acid ring structure 
common to all natriuretic peptides. The source of BNP is the cardiac ventricles and its release 
is directly proportional to ventricular volume expansion and pressure overload (12,13). BNP 
levels are elevated in patients with heart failure and LV dysfunction. Also the effect of 
treatment in these patients can be monitored with repeated BNP measurements, as suggested 
by Troughton et al (30). Furthermore BNP levels seem to be an independent predictor of long-
tenn survival after myocardial infarction (31) and all cause mortality for patients with LV 
dysfunction (32,33). BNP measurements have therefore been proposed as a new simple and 
inexpensive screening tool for LV dysfunction (14-17, 34,35). Furthermore the European 
Society of Cardiology has recently incorporated the BNP measurements into the diagnosis of 
heart failure (18). BNP levels are useful in "ruling out" this disorder due to very high negative 
predictive values, especially in untreated patients. In accordance with previous studies we 
demonstrated that BNP measurements show high sensitivity in detecting patients with LV 
dysfunction. However, we have to take into account that BNP, as an indicator of raised 
intracardiac pressure, can be elevated in various forms of heart disease besides LV systolic 
dysfunction including atrial fibrillation, LV diastolic dysfunction, LV hypertrophy and 
significant valve disease (36-37). This may explain our results regarding BNP measurements. 
Echocardiogaphy as a screening tool for LV dysfunction: According to the 
guidelines of the European Society of Cardiology, objective evidence of LV dysfunction must 
be added to clinical symptoms to establish the diagnosis of heart failure. Echocardiography 
has been proposed to be the screening method of choice to demonstrate cardiac dysfunction 
(18,19). However, echocardiography is considered not cost-effective as a screening tool, 
especially for patients with low probability of cardiac dysfunction, and its availability is often 
limited in the different clinical settings. Newly developed HCU devices offer high image 
quality, ultra-portability and significantly lower capital cost (!/lOth of the cost of a SE). The 
value of such devices for screening for various cardiac pathologies has been shown in 
previous studies (23-25, 27, 38-39). The main finding of the current study was that a HCU 
device, estimating LVEF, is a sensitive tool for screening for LV dysfunction as assessed by 
SE. 
We tested furthermore the hypothesis of diagnosing LV dysfunction by assessing the 
percentage collapse of IV C. However, this parameter appeared to be oflow sensitivity (30%) 
and positive predictive value (38%) for the detection of LV dysfunction with both devices, SE 
and HCU echocardiography. To our knowledge, this is the first study that evaluated the 
parameter of the percentage collapse of IVC as a potential screening parameter for LV 
dysfunction. In the contrary and as previously shown (22), the correlation of the 
echocardiogaphically estimated RA pressure, assessed by the JVC collapse, compared to the 
invasively assessed RA pressure (agreement 95%). 
Echocardiography, can provide non-invasively, additional valuable information about 
other significant abnormalities beyond LV function. Thus, LV hypertrophy, valvular 
abnormalities or mass lesions can be diagnosed instantly with echocardiography but could be 
missed by physical examination or a blood test. Furthermore, the addition of the Doppler 
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feature in some of these devices enables the differentiation between systolic and diastolic 
dysfunction. 
Use of ultrasound stethoscopes: The American Society of Cardiology recommends 
Level I of training as an absolute minimal level required for the use of HCU devices ( 40). 
Studies have shown that minimal echo training may enable physicians to use HCU for 
interpreting simple abnormalities with high efficacy and accuracy (41-42). 
Limitations: The HCU devices used in this study were SonoHeart plusTM and 
OptiGoTM. Although the former has two additional modalities (pulsed Doppler and the M-
Mode ), we used only the 2D feature for the L VEF and the IVC collapse evaluation to avoid 
bias between the two devices. There are therefore no data about the diastolic LV function of 
the heart or flow data. Furthermore no additional data about other cardiac abnormalities were 
reported since the purpose of the study was to test the potential of a HCU device as a 
screening tool for LV dysfunction. 
Conclusion: Echocardiography is a most practical tool to demonstrate cardiac 
dysfunction. The HCU devices lead to incorporation of echocardiography into the physical 
examination and can broaden the availability of echocardiography allowing screening 
programmes for the identification of patients with LV dysfunction. 
References 
l. McKee PA, Castelli WP, McNamara PM, Kannel! WB. The natural history of heart 
failure: the Framingham Study. N Engl J Med 1971;285: 1441-46. 
2. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, Grobbee 
DE. The epidemiology of heart failure. Eur Heart J 1997;18:208-25. 
3. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A, Grobbee DE. 
Prevalence of heart failure and left ventricular dysfunction in the general population. The 
Rotterdam Study. Eur Heart J 1999;20:447-55. 
4. Macintyre K, Capewell S, Stewart S, Chalmers JWT, Boyd J, Finlayson A, Redpath A, 
Pell JP, McMmray JN. Evidence of improving prognosis in heart failure. Trends in case 
fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 
2000; 102:1126-31. 
5. The CONSENSUS Trial Study Group. Effects of Enalapril on mortality in severe 
congestive heart failure. N Eng! J Med 1987;316: 1429-35. 
6. The SOL VD investigators. Effect of Enalapril on mortality and the development of heart 
failure in asymptomatic patients with reduced left ventricular ejection fractions. N Eng J 
Med 1992;327:685-91. 
7. The MERIT-HF Study Group. Effect of metoprolol CRIXL in chronic heart failure: 
Metoprolol CRIXL Randomised Intervention Trial in Congestive Heart Failure (MERIT-
HF). Lancet 1999;353:2001-07. 
8. Grimes DA, Shulz KF. Uses and abuses of screening tests. Lancet 2002;359:881-84. 
9. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart 
failure in primary health care. Eur Hear J 1991; 12:315-21. 
10. Stevenson LW. The limited availability of physical signs for estimating hemodynamics in 
chronic heart failure. JAMA 1989;261;884-8. 
11. Hobbs FDR, Jones MI, Allan TF, WilsonS, Tobias R. European survey of primary care 
physician perceptions on heart failure diagnosis and management (EURO-HF). Eur Heart 
J 2000;2!:1877-87. 
182 
12. Yandle TG. Biochemistry of natriuretic peptides. J Intern Med 1994;235:561-76. 
13. Daggubati S, Parks JR, Overton RM, Cintron G, Schocken DD, Vesely DL. 
Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohonnone 
peptides compared as early heart failure indicators. Cardiovasc Res 1997;36:246-55. 
14. Cowie MR, Struthers AD, Wood DA, Coats AJS, Thompson SG, Poole-Wilson PA. Value 
of natriuretic peptide in assessment of patients with possible new heart failure in primary 
care. Lancet 1997;350: 1349-53. 
15. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstali-Pedoe 
H, McMurray JN, Dargie HJ. Biochemical detection of left-ventricular systolic 
dysfunction. Lancet 1998;351 :9-13. 
16. Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, Morrisey R, 
Garcia A, Chiu A, De Maria A. Utility of B-natriuretic peptide as a rapid, point-of-care 
test for screening patients undergoing echocardiography to determine left ventricular 
dysfunction. Am Heart J 2001 ;141 :367-74. 
17. Morrison KL, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of 
a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung 
disease in patients presenting with dyspnea. JAm Coli Cardiol2002;39:202-9. 
18. Remme WJ, Swedberg K, (co-chairmen). Guidelines for the diagnosis and treatment of 
chronic heart failure. Task Force for the diagnosis and treatment of chronic heart failure, 
European Society of Cardiology. Eur Heart J 2001 ;22: 1527-60. 
19. Guidelines for the evaluation and management of heart failure. Report of the ACC/AHA 
task force on practice guidelines. JAm Coli Cardioll995;26:1376-98. 
20. Talreja D, Gruver C, Sklenar J, Dent J, Kaul S. Efficient utilisation of echocardiography 
for the assessment ofleft ventricular systolic function. Am Heart J 2000;139:394-8. 
21. Sorrell VL, Reeves WC. Noninvasive right and left heart catheterization: taking the echo 
lab beyond an image-only laboratory. Echocardiography 2001; 18:31-41. 
22. Stein JH, Neumann A, Marcus RH. Comparison of estimates of right atrial pressure by 
physical examination and echocardiography in patients with congestive heart failure and 
reasons for discrepancies. Am J Cardioll997;80:1615-18. 
23. Vourvouri EC, Poldermans D, Schinkel AFL, Koroleva L, Sozzi FB, Bax JJ, Roeland! 
JRTC. Left ventricular hypertrophy screening using a hand-held ultrasound device. Eur 
Heart J 2002,26:1516-21. 
24. Vourvouri EC, Poldermans D, Schinkel AFL, Sozzi FB, Bax JJ, van Urk H, Roeland! 
JRTC. Abdominal aortic aneurysm screening using a hand-held ultrasound device. A pilot 
study. Eur J Vase Endovasc Surg 2001;22:352-4. 
25. Bruce CJ, Spitteli PC, Montgomery SC, Bailey KR, Tajik AJ, Seward JB: Personal 
Ultrasound Imager: Abdominal aortic aneurysm screening. J Am Soc Echoc. 
2000;13:674-79. 
26. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell 
H, Reichek N, Sahn D, Schnittger I, et al. Recommendations for quantitation of the left 
ventricle by two dimensional echocardiography: American Society of Echocardiography 
Committee on Standards Subcommittee. JAm Soc Echocardiogr 1989;2:358-367. 
27. Vourvouri EC, Poldermans D, de Sutter J, Sozzi FB, Izzo P, Roeland! JRTC. Experience 
with an ultrasound stethoscope. JAm Soc Echocardiogr 2002;15:80-5. 
28. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York, 
NY:Wiley,l981. 
29. Davie AP, Francis CM, Love MP, Caruana L, Starkey IR, Shaw TR. Value of the 
electrocardiogram in identifYing heart failure due to left ventricular systolic dysfunction. 
BMJ 1996;312:222. 
183 
30. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. 
Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-
BNP) concentrations. Lancet. 2000;355:1126-30. 
31. Arakawa N, Nakmura M, Aoki H, Hiramori K. Plasma brain natriuretic peptide 
concentrations predict survival after acute myocardial infarction. J Am Call Cardiel 
1996;27: 1656-61. 
32. McDonagh TA, Cunningham AD, Morrison CE, McMurray JN, Ford E, Morton JJ, 
Dargie HJ. Left ventricular dysfunction, natriuretic peptides and mortality in an urban 
population. Heart 2001;86:21-26. 
33. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R. B-type 
natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 
2002;105:2392-97. 
34. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, Due P, 
Westheim A, Omland T, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, 
Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS. B-type natriuretic peptide 
and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing 
Not Properly (BNP) Multinational Study. Circulation 2002;106:416-22 
35. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Due P, Omland T, 
Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, 
Perez A, Kazanegra R, Herrmann HC, McCullough PA. Rapid measurement of B-type 
natriuretic peptide in the emergency diagnosis of heart failure. N Eng J Med 
2002;347:161-7. 
36. Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, Hiramori K. Value of plasma B 
type natriuretic peptide measurement for heart disease screening in a Japanese population. 
Heart 2002;87: 131-135. 
37. Struthers AD. Introducing a new role for BNP: as a general indicator of cardiac structural 
disease rather than a specific indicator of systolic dysfunction only. Heart 2002;87:97-98. 
38. Roelandt JRTC. A personal ultrasound imager (ultrasound stethoscope). A revolution in 
the physical cardiac diagnosis' Eur Heart J 2002;23: 523-27. 
39. Spencer KT, Anderson AS, Bhargava A, Bales AC, Sorrentino M, Furlong K, Lang RM. 
Physician-performed point-of-care echocardiography using a laptop platform compared 
with physical examination in the cardiovascular patient. JAm Col! Cardiol2001;37:2013-
8.0. 
40. Seward JB, Douglas PS, Erbel R, Kerber RE, Kronzon I, Rakowski H, Sahn DJ, Sisk EF, 
Tajik AJ, Wann S. Hand-carried cardiac ultrasound (HCU) device: recommendations 
regarding new technology. A report from the echocardiography task force on new 
technology of the nomenclature and standards committee of the American Society of 
Echocardiography. JAm Soc Echocardiogr 2002;15:369-73. 
41. Alexander JH, Peterson ED, Chen AY, Harding TM, Adams DB, Kisslo J. Training and 
accuracy of non-cardiologists in simple use of point-of-care echo: A preliminary report 
from the Duke Limited Echo Assessment Project (LEAP). Thoraxcenter Journal 
2001;13:105-110. 
42. Kimura BJ, Bocchicchio M, Willis CL, DeMaria AN. Screening cardiac ultrasonographic 
examination in patients with suspected cardiac disease in the emergency department. Am 
Heart J. 2001;142:324-30. 
184 
Summary and conclusions 
In this thesis, the use of myocardial stress imaging, both nuclear imaging and 
dobutamine stress echocardiography, for the evaluation of coronary artery disease is 
described. 
Part 1: Myocardial viability 
In chapter 1 a systematic review is provided evaluating the value of nuclear imaging 
and dobutamine stress echocardiography in the detection of coronary artery disease, 
assessment of prognosis, prediction of functional recovery after myocardial infarction, and 
prediction of recovery of function in patients with ischemic cardiomyopathy. To provide the 
most objective information, only direct comparative studies on these two techniques in the 
same patients were included. Pooled analysis revealed that both techniques are clinically 
useful in the evaluation of patients with coronary artery disease, however small differences 
between accuracies exist in different settings. The local expertise and the availability are 
important factors for using a test. Also, patients' characteristics (habitus, acoustic window, 
pregnancy) influence the choice of the technique. 
In chapter 2, the prevalence of myocardial viability is assessed in a consecutive cohort 
of patients with ischemic cardiomyopathy (left ventricular ejection fraction :::;;35%). 
Dobutamine stress echocardiography demonstrated myocardial viability in 35% of the 
dysfunctional segments. \Vhen the cut-off value of ;:::4 dysfunctional but viable segments was 
applied to classify a patient as viable, 57% of the patients were considered to have substantial 
viability. Hence in 57% of the patients with ischemic cardiomyopathy and heart failure, 
dobutamine stress echocardiography showed a clinically significant amount of myocardial 
viability. Coronary revascularization may be considered as therapy for these patients. 
Previous studies have indicated that nuclear imaging teclmiques may be more sensitive 
for the detection of myocardial viability than dobutamine stress echocardiography. Therefore, 
in chapter 3 we used dual-isotope SPECT to assess the prevalence of myocardial viability. In 
a cohort of patients with ischemic cardiomyopathy (left ventricular ejection fraction :::;;35%) 
myocardial viability was assessed using perfusion imaging alone, and combined perfusion and 
metabolic imaging. \Vhen only perfusion imaging was used to indicate viable myocardium, 
54% of the patients showed significant viability, while a combination of perfusion and FDG 
metabolic imaging revealed that 61% of the patients had a clinically significant amount of 
viable myocardium. Hence the combination of perfusion and metabolic imaging identified 
more patients with viable myocardium than perfusion imaging alone. 
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Chronic electrocardiographic Q waves are often believed to reflect scarred tissue. In 
chapter 4, the relation between chronic electrocardiographic Q waves, end-diastolic wall 
thickness, and myocardial viability is addressed. A consecutive series of patients with chronic 
electrocardiographic Q wave infarction, heart failure symptoms, and chronic coronary artery 
disease underwent dobutamine stress echocardiography. In 58% of the Q wave regions viable 
tissue was present. Hence, chronic Q waves on electrocardiography do not exclude the 
presence of viable myocardium. Initial evaluation by resting echocardiography may already 
exclude the presence of viable tissue when the end-diastolic wall thickness is 6 mm or less. 
However, in regions with Q waves and an end-diastolic wall thickness >6 nun, additional 
testing is needed since 38% of this regions did not show viability during dobutamine stress 
echocardiography. 
Next, in chapter 5, myocardial viability in Q-wave regions in patients with ischemic 
cardiomyopathy, who had heart failure as the predominant symptom was assessed with dual-
isotope SPECT. The patients underwent echocardiography at rest to identify dysfunctional 
myocardial tissue and dual-isotope nuclear imaging to assess myocardial perfusion and 
metabolism. According to FDG SPECT metabolic imaging viable tissue persisted in a high 
proportion ( 61 %) of dysfunctional myocardial regions with chronic Q waves. Hence, chronic 
Q waves on electrocardiography do not necessarily imply irreversibly scarred myocardium. 
In chapter 6, the presence of contractile reserve in response to dobutamine infusion 
was studied in patients with stunned and hibernating myocardium. Dysfunctional myocardium 
was assessed by resting echocardiography, the dysfunctional segments were subsequently 
evaluated for the presence of stunning or hibernation by dual-isotope SPECT. The presence of 
contractile reserve was assessed by dobutamine stress echocardiography. Contractile reserve 
was present in 61% of the stunned segments as compared to 51% of the hibernating 
myocardium. Patients with more severe heart failure (NYHA functional class III-IV) less 
frequently showed contractile reserve as compared to patients with mild heart failure. 
Contractile reserve was absent in the majority of scar segments; only 14% of the scar 
segments exhibited contractile reserve. In addition, residual contractile reserve was related to 
the extent of scar tissue, nontransmural scar tissue more often exhibited contractile reserve 
than transmural scars. The progressive reduction of contractile reserve in stunned, 
hibernating, nontransmural and transmural scar tissue, supports the hypothesis that stunning, 
hibernation, and scar are not circumscript pathofysiological entities but represent gradual 
ultrastructural damage on the myocyte level. 
In chapter 7, the feasibility and image quality of dual-isotope SPECT imaging using 
acipimox for the evaluation of myocardial viability in patients with diabetes mellitus are 
assessed. The study population consisted of 70 patients, subsets of patients with insulin-
dependent diabetes mellitus and with non-insulin dependent diabetes mellitus were studied. 
Metabolic conditions (plasma substrate levels) were monitored. As anticipated baseline 
glucose levels were higher in patients with diabetes. In patients with plasma glucose levels >9 
mmol/L additional insulin was administered. An oral dose of acipimox effectively lowered the 
free fatty acids concentrations in patients with and without diabetes. No serious side effects of 
Acipimox were observed. The image quality (assessed by the myocardium to background 
ratio) was comparable in both patient groups. The type of diabetes (insulin dependent or non-
insulin dependent diabetes) did not influence FDG image quality. In conclusion, FDG SPECT 
is a safe and clinically useful method to assess myocardial viability that offers a good image 
quality, even in patients with diabetes mellitus. 
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In chapter 8, the clinical implications of segments with intact perfusion without 
contractile reserve are addressed. Patients with ischemic cardiomyopathy undergoing surgical 
revascularization were evaluated using nuclear perfusion imaging and low-dose dobutamine 
stress echocardiography. The findings were related to functional outcome, assessed 9-12 
months after coronary revascularization. In 51% of the chronic dysfunctional segments an 
intact perfusion was present, 31% of the dysfunctional segments showed contractile reserve. 
The majority of the segments with improvement of contractile function after revascularization 
had both preserved perfusion and contractile reserve. Segments with both characteristics 
present may thus have a high likelihood of recovery after revascularization (66% of the 
segments with both characteristics improved in function). In contrast, segments without intact 
perfusion and contractile reserve had a low likelihood of recovery after revascularization 
(95% of the segments without perfusion and contractile reserve did not improve in function). 
Segments with preserved perfusion without contractile reserve have an intermediate 
likelihood of recovery. Additional testing needs to be developed to predict functional outcome 
after revascularization in these segments. 
Part 2: Prognosis 
In chapter 9, the long-term prognostic value of dobutamine stress 99mTc-sestamibi 
SPECT in patients with limited exercise capacity is presented. The prognostic value of stress 
99mTc-sestamibi imaging has been reported in various patient-subsets at short- to intermediate-
term follow-up. The mean follow up of this study is 8 ± l A years as compared to an average 
follow up of 0.8-3.6 years after exercise and 0.8-2.3 years after pharmacological stress 99mTc-
sestamibi SPECT in previous studies. The annual event rates for cardiac death, cardiac death 
or infarction, and all events were 0.9%, 1.2%, and 1.5% respectively after a normal scan, and 
2.7%, 3.4%, and 4.4% after an abnormal scan (P<0.05). The main finding from this study is 
that the prognostic value of dobutamine stress 99mTc-sestamibi SPECT is maintained at long-
term follow-up. Univariate and multivariate Cox proportional regression analysis 
demonstrated that 99mTc-sestamibi SPECT provided incremental prognostic information in 
addition to clinical and stress test parameters all through the 8-year follow-up period. Not 
merely the presence of an abnormal perfusion pattern, but the extent and severity of the 
perfusion defect provided incremental prognostic information as well. 
In chapter 10, the value of dobutamine stress 99mTc-tetrofosmin myocardial perfusion 
imaging for the prediction of late cardiac events is assessed. A total of 721 patients with 
limited exercise capacity underwent dobutamine stress 99mTc-tetrofosmin SPECT. The cardiac 
death rate was 1% per year in patients with a normal scan and 5.1% per year in patients with 
an abnormal scan (P<O.OOOl). A multivariable Cox model showed that the presence of an 
abnormal perfusion was independently associated with an increased risk of cardiac death, 
after adjusting for clinical and stress test data (hazard ratio 8.2, CI 3.2-21). 
Diabetes mellitus is an important risk factor for coronary artery disease. In chapter 11 
we assessed the prognostic value of 99mTc myocardial perfusion imaging in 207 patients with 
diabetes mellitus unable to perform an exercise test. During 4.1 ± 2.4 year follow-up, cardiac 
death occurred in 2 of 69 (3%) patients with normal myocardial perfusion and in 34 of 125 
(27%) patients with perfusion abnormalities (P<O.OOOI). A multivariable Cox proportional-
hazards model demonstrated that the presence of an abnormal scan had an incremental 
prognostic value for the prediction of cardiac death (hazard ratio ~ 7.2, 95% CI 1.7-30), 
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additional to clinical and stress test data. The summed stress score was an important predictor 
of cardiac death as well. 
In chapter 12, the incremental value of exercise 99mTc-tetrofosmin myocardial 
perfusion imaging for the prediction of cardiac events is evaluated. A total of 655 patients 
were followed up for a period of 4 ± 1.3 years. An abnormal scan was an independent 
predictor of cardiac death, and provided incremental information over clinical and exercise 
test data. The summed stress score provided incremental prognostic information over clinical 
data as well. An abnormal scan, and the summed stress score were powerful independent 
predictors of the combined end point of any cardiac event. Hence, exercise 99mTc-tetrofosmin 
SPECT provides information incremental to clinical data, in the prediction of cardiac events 
in patients with known or suspected coronary artery disease. 
Patients with a nonnal exercise stress 99mTc-sestamibi SPECT images were shown to 
have a favorable outcome at intermediate follow-up. We assessed the incidence and predictors 
of mortality during long-term (7.4 ± 1.8 years) follow-up after a normal exercise stress 99mTc-
sestarnibi study in 218 patients. By multivariate analysis, independent predictors of cardiac 
events were history of coronary artery disease and lower exercise heart rate. Independent 
predictors of all causes of mortality were age and exercise heart rate. The annual mortality 
rate was 0.6% in the first 5 years and 1.8% between the sixth and eighth years. The annual 
hard cardiac event rate was 0. 7% in the first 5 years and 1.5% between the sixth and eighth 
years. ROC curves identified an exercise heart rate <130/min as the cut off value that 
separated patients with regards to their risk for mortality and hard cardiac events. In 
conclusion, the annual mortality and cardiac event rate is less than 1% during 5 year follow up 
after a normal exercise sestamibi study. Therefore, it is not required to repeat the test during 
that period. Follow up should be closer in patients with a history of CAD and in those who 
fail to achieve an exercise heart rate :;?:130/min. 
In chapter 14, the prognostic significance of reversible perfusion abnormalities in 
patients without angina during dobutamine stress 99mTc-sestamibi SPECT is presented. The 
study reports on cardiac events in 224 patients with completely or partially reversible 
perfusion abnormalities. Angina occurred in 93 (42%) patients during dobutamine stress test 
(symptomatic ischemia group). The 131 patients without angina represented the silent 
ischemia group. There was no significant difference between patients with and without angina 
with regards to summed stress perfusion score, or summed ischemic score. During a median 
follow up of 7.2 years, cardiac death occurred in !4 (!5%) patients with and in 2! (!6%) 
patients without angina. Non-fatal myocardial infarction occurred in 8 (9%) patients with and 
in 13 (10%) patients without angina. In a multivariate analysis model of clinical and perfusion 
data, independent predictors of cardiac events were age, diabetes mellitus, and ischemic 
perfusion score. Patients with silent ischemia defined as reversible perfusion abnormalities 
without associated angina during dobutamine stress sestamibi SPECT imaging have similar 
extent of ischemia and similar cardiac event rate compared to patients with symptomatic 
ischemia. Therefore, the absence of angina in association with reversible perfusion 
abnormalities should not be interpreted as a sign of more benign prognosis. 
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Part 3: New techniques 
In chapter 15, the influence of left ventricular myocardial contractile reserve on atrial 
natriuretic peptide and brain natriuretic peptide is addressed. Plasma atrial natriuretic peptide 
and brain natriuretic peptide were determined in 66 consecutive patients with a varying degree 
of heart failure. All patients underwent resting echocardiography to determine the left 
ventricular ejection fraction. Contractile reserve was assessed using low-dose dobutamine 
stress echocardiography. Plasma concentrations of both natriuretic peptides were higher in 
patients with a LVEF:s;35% compared to patients with a LVEF>35%. The presence of 
contractile reserve influenced the natriuretic peptide levels in patients with segmental wall 
motion abnonnalities. Patients with a preserved myocardial contractile reserve had lower 
ANP and BNP levels than patients without contractile reserve. Thus, plasma natriuretic 
peptide levels are elevated in patients with left ventricular dysfunction. However, in the 
presence of preserved myocardial contractile reserve, relatively low atrial natriuretic peptide 
and brain natriuretic peptide are present. 
In chapter 16, we tested the diagnostic potential of a hand-held ultrasound device for 
screening for left ventricular hypertrophy. Hand-held echocardiography was performed in 100 
patients with hypertension using a standard echocardiographic system as a reference. The 
mean duration of hypertension in these patients was 13 ± 11 years. The agreement between 
the standard echocardiographic system and the hand-held device for the assessment of left 
ventricular hypertrophy was 93%. Hand-held ultrasound devices can be effectively applied for 
screening for left ventricular hypertrophy in hypertensive patients. The hand-held ultrasound 
device, being ultra-portable and inexpensive could become part of the clinical examination in 
high-risk patient groups. 
Chapter 17 deals with screening for left ventricular dysfunction. The screening 
potential of an hand-carried ultrasound device was assessed. The main finding of the current 
study was that a hand-carried ultrasound device, estimating L VEF, is a sensitive tool for 
screening for LV dysfunction as assessed by echocardiography with a standard high-end 
system. Echocardiography is a most practical tool to demonstrate cardiac dysfunction. The 
hand-carried ultrasound devices lead to incorporation of echocardiography into the physical 
examination and can broaden the availability of echocardiography allowing screening 
programmes for the identification of patients with LV dysfunction. 
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Samenvatting en conclusies 
In dit proefschrift wordt bet gebruik van beeldvormend cardiaal stress onderzoek, 
zowel nucleaire beeldvorrning als dobutamine stress echocardiografie, voor bet evalueren van 
coronaire hartziekten beschreven. 
Deell: Myocardvitaliteit 
In hoofdstuk 1 wordt een systematisch overzicht gegeven van de waarde van nucleaire 
beeldvorming en dobutamine stress echocardiografie voor bet diagnostiseren van coronaire 
hartziekten, bepaling van de prognose, voorspellen van functieherstel na een myocardinfarct 
en bet voorspellen van functieherstel bij patienten met ischemische cardiomyopathie. Om 
objectieve informatie te verschaffen, werden alleen onderzoeken geanalyseerd die deze twee 
technieken in dezelfde patienten hebben vergeleken. Gecombineerde analyse liet zien dat dit 
klinisch waardevolle technieken zijn voor bet evalueren van patienten met coronaire 
hartziekten, hoewel er in verschillende situaties kleine verschillen in nauwkeurigheid bestaan. 
De plaatselijke expertise en de beschikbaarheid zijn belangrijke factoren voor het gebruiken 
van een onderzoek Ook de eigenschappen van de patient (habitus, akoestisch raam, 
zwangerschap) beinvloeden de keuze voor een van de technieken. 
In hoofdstuk 2 wordt the prevalentie van dysfunctioneel maar vitaal myocardweefsel 
bepaald in een groep van opeenvolgende patienten met ischemische cardiomyopathie (linker 
ventrikel ejectie fractie :535%). Dobutamine stress echocardiografie toonde myocardvitaliteit 
aan in 35% van de dysfunctionele segmenten. Wanneer de grenswaarde van ?4 dysfunctionele 
maar vi tale segmenten werd toegepast om een patient als vitaal the classificeren, had 57% van 
de patienten een substantiele hoeveelheid vitaal weefsel. Dus in 57% van de patienten met 
ischemische cardiomyopathie en hartfalen, liet dobutamine stress echocardiografie een 
substantiele hoeveelheid vitaal myocardweefsel zien. Coronaire revascularisatie kan als 
behandeling overwogen worden bij deze patienten. 
Eerder onderzoek heeft laten zien dat nucleaire technieken gevoeliger kunnen zijn dan 
dobutamine stress echocardiografie voor bet vaststellen van myocardvitaliteit. Daarom 
gebruikten we in hoofdstuk 3 dual-isotope SPECT om de prevalentie van myocardvitaliteit 
vast te stellen. In een cohort patienten met ischemische cardiomyopathie (linker ventrikel 
ejectie fractie :S:35%) werd myocardvitaliteit bepaald met aileen perfusie beeldvorming, en 
met gecombineerde perfusie en metabolisme beeldvorming. Wanneer alleen de perfusie 
beelden werden gebruikt, had 54% van de patienten een significante hoeveelheid 
dysfunctioneel maar vitaal weefsel, de combinatie van perfusie en metabolisme liet zien dat 
61% van de patienten een significante hoeveelheid vitaal myocardweefsel had. Dus met de 
combinatie van perfusie en metabolisme beeldvorming werden meer patienten met vitaal 
myocardweefsel ontdekt dan met aileen perfusie beeldvorming. 
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Er wordt vaak gedacht dat chronische Q golven op het electrocardiogram op 
littekenweefsel duiden. In hoofdstuk 4 werd de relatie tussen chronische Q golven, 
einddiastolische wanddikte en myocardvitaliteit onderzocht. Een opeenvolgende serie 
patienten met een chronisch Q golf infarct, hartfalen, en chronische coronaire hartziekte 
ondergingen dobutamine stress echocardiografie. In 58% van de Q golf gebieden was 
dysfunctioneel maar vitaal weefsel aanwezig. Derhalve sluiten chronische Q golven op bet 
electrocardiogram de aanwezigheid van vitaal myocard niet uit. Een eerste evaluatie met een 
rust echocardiogram kan de aanwezigheid van vitaal weefsel al uitsluiten wanneer de 
einddiastolische wanddikte 6 rnm of minder is. In gebieden met Q golven en een 
einddiastolische wanddikte grater dan 6 mm is echter een aanvullende test nodig, omdat 38% 
van deze gebieden geen vitaliteit toonde tijdens dobutamine stress echocardiografie. 
Vervolgens werd in hoofdstuk 5 de myocardvitaliteit bepaald in gebieden met Q 
golven bij patienten met ischemische cardiomyopathie, die hartfalen als het belangrijkste 
symptoom hadden, door middel van dual-isotope SPECT. De patienten ondergingen een rust 
echocardiogram om dysfunctioneel myocardweefsel vast te stellen en dual-isotope nucleaire 
beeldvorming om de myocardiale perfusie en het glucose metabolisme te bepalen. Volgens 
FDG SPECT afueeldingen van het metabolisme was er nog vitaal weefsel aanwezig in een 
groat gedeelte (61 %) van de dysfimctionele gebieden met chronische Q golven. Chronische Q 
golven op het electrocardiogram wijzen dus niet eenvoudigweg op irreversibel verlittekend 
myocardweefsel. 
In hoofdstuk 6 wordt de aanwezigheid van een contractiele reserve in respons op 
dobutamine infusie bestudeerd in patienten met stunned en hibernating myocardweefsel. 
Dysfunctioneel myocard werd vastgesteld met een echocardiogram in rust, de dysfimctionele 
segmenten werden vervolgens geevalueerd op de aanwezigheid van stunned of hibernating 
myocardweefsel met dual-isotope SPECT. De aanwezigheid van contractiele reserve werd 
vastgesteld met dobutamine stress echocardiografie. Contractiele reserve was aanwezig in 
61% van de stunned segmenten en in 51% van de hibernating segmenten. Patienten met 
emstig hartfalen (NYHA functie klasse III-IV) hadden minder vaak een behouden contractiele 
reserve vergeleken met patienten met een geringere vorm van hartfalen. Contractiele reserve 
was ahvezig in de meerderheid van de verlittekende segmenten; slechts 14% van de 
verlittekende segmenten had een contractiele reserve. Bovendien was een behouden 
contractiele reserve gerelateerd aan de uitbreiding van het Iitteken, een niet-transmuraal 
litteken liet vaker contractiele reserve zien dan een transmuraal litteken. De progressieve 
vermindering van contractiele reserve in stunned, hibernating, niet-transmuraal en transmuraal 
littekenweefsel, steunt de hypothese dat stunning, hibernation en littekenweefsel geen scherp 
omschreven pathosfysiologische begrippen zijn, maar een geleidelijke hoeveelheid schade op 
het niveau van de myocyten vertegenwoordigen. 
In hoofdstuk 7 wordt de toepasbaarheid en de beeldkwaliteit van dual-isotope SPECT 
na orale toediening van acipimox voor de evaluatie van myocardvitaliteit bij patienten met 
diabetes mellitus vastgesteld. De onderzoekspopulatie bestond uit 70 patienten, waarvan 
subgroepen van patienten met insulineafhankelijke en non-insulineafhankelijke diabetes 
mellitus werden bestudeerd. Zeals venvacht waren de uitgangsglucosewaarden hager bij 
patienten met diabetes. Bij patienten met een plasma glucosewaarde >9 mmol/L werd extra 
insuline toegediend. Een orale dosis acipimox verlaagde vrije vetzuur concentraties effectief 
bij patienten met en zonder diabetes. Er werden geen ernstige bijwerkingen van acipimox 
gezien. De beeldkwaliteit (bepaald met de myocard versus achtergrond ratio) was 
vergelijkbaar in beide groepen patienten. Ret type diabetes (insulineafhankelijke en non-
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insulineafhankelijke diabetes) had geen inv1oed op de FDG bee1dkwa1iteit. FDG SPECT is 
een veilige en klinisch nuttige methode en biedt een goede beeldbvaliteit om de 
myocardvitaliteit vast te stellen, zelfs bij patienten met diabetes mellitus. 
In hoofdstuk 8 worden de klinische implicaties van segmenten met een intacte perfusie 
zonder contractiele reserve vastgesteld. Patienten met ischemische cardiomyopathie 
ondergingen een coronaire bypass operatie en werden geevalueerd met nucleaire 
beeldvorming en lage-dosis dobutamine stress echocardiografie. De bevindingen werden 
gerelateerd aan de verbetering van functie, die 9-12 maanden na de coronaire bypass operatie 
werd bepaald. In 51% van de chronisch dysfunctionele segmenten was er een intacte perfusie 
en 31% van de dysfunctionele segmenten had een behouden contractiele reserve. De 
meerderheid van de segmenten met een verbeterde contractiele functie na de revascularisatie 
had een behouden perfusie en contractiele reserve. Segmenten met beide eigenschappen 
hadden een hoge kans op functieherstel na revascularisatie ( 66% van deze segmenten had een 
functie verbetering). Bij segmenten zonder intacte perfusie en contractiele reserve was de 
kans op functieherstel na revascularisatie laag (95% van de segmenten zonder perfusie en 
contractiele reserve hadden geen functieherstel). Segmenten met een behouden perfusie 
zonder contractiele reserve hadden ook een kans op functieherstel. Aanvullende tests moeten 
ontwikkeld worden om het functieherstel na revascularisatie in deze segmenten te 
voorspellen. 
Deel2: Prognose 
In hoofdstuk 9 wordt de lange-termijn prognostische waarde van dobutamine stress 
99mTc-sestamibi SPECT bij patienten met een beperkte inspanningscapaciteit gepresenteerd. 
De prognostische waarde van stress 99mTc-sestamibi beeldvorming is reeds onderzocht in 
verschillende patienten groepen met een korte of middellange termijn. De gemiddelde vervolg 
termijn van dit onderzoek is 8 ± 1.4 jaar in vergelijking tot een gemiddelde termijn van 0.8-
3.6 jaar na inspanning en 0.8-2.3 jaar na farmacologische stress 99mTc-sestamibi SPECT in 
eerdere onderzoeken. De jaarlijkse kans op cardiale dood, cardiale dood of een 
myocardinfarct, en cardiale dood of een myocardinfarct of een coronaire revascularisatie was 
0.9%, 1.2%, en 1.5% respectievelijk na een normale scan, en 2.7%, 3.4%, en 4.4% na een 
afwijkende scan (P<0.05). De be1angrijkste bevinding van dit onderzoek is dat de 
prognostische waarde van dobutamine stress 99mTc-sestamibi SPECT behouden blijft tijdens 
lange-termijn vervolgonderzoek. Univariabel and multivariabel Cox proportionele regressie 
analyse toonde dat 99mTc-sestamibi SPECT meer informatie biedt dan klinische en stress test 
parameters gedurende de gehele follow-up periode van 8 jaar. Niet aileen de aanwezigheid 
van een afwijkend perfusie, maar ook de uitbreiding en de ernst van een perfusie defect 
verschaffen een toegevoegde prognostische waarde. 
In hoofdstuk 10 wordt de waarde van dobutamine stress 99mTc-tetrofosmin nucleaire 
beeldvorming voor het voorspellen van late cardiale aandoeningen vastgesteld. Een groep van 
721 patienten met een beperkte inspanningscapaciteit onderging dobutamine stress 99mTc-
tetrofosmin SPECT. De kans op een cardiale dood was 1% per jaar bij patiE:nten met een 
normale scan en 5.1% per jaar bij patienten met een afwijkende scan (P<O.OOOl). Een 
multivariabel Cox model toonde dat de aanwezigheid van een afwijkende perfusie was 
gerelateerd aan een verhoogd risico op een cardiale dood, na correctie voor de klinische en 
stress test informatie (hazard ratio 8.2, CI 3.2-21). 
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Diabetes mellitus is een belangrijke risicofactor voor coronaire hartziekten. In 
hoofdstuk 11 bepaalden we de prognostische waarde van 99mTc nucleaire beeldvorming bij 
207 patienten met diabetes mellitus die niet in staat waren om een inspanningstest te 
volbrengen. Gedurende een follow-up periode van 4.1 ± 2.4 jaar, trader cardiale dood op bij 2 
van de 69 (3%) patienten met een normale myocard perfusie en bij 34 van de 125 (27%) 
patienten met perfusie afwijkingen (P<O.OOO!). Een multivariabel Cox model toonde dat de 
aanwezigheid van een afwijkende scan een toegevoegde prognostische waarde had voor bet 
voorspellen van een cardiale dood (hazard ratio~ 7.2 95% Cl 1.7-30), boven klinische en 
stress test gegevens. De stress score was ook een belangrijke voorspeller van cardiale dood. 
In hoofdstuk 12 wordt de toegevoegde waarde van inspannings 99mTc-tetrofosmin 
SPECT voor bet voorspellen van cardiale aandoeningen geevalueerd. Een groep van 655 
patienten werd gevolgd gedurende 4 ± 1.3 jaar. Een afwijkende scan was een onafhankelijke 
voospeller van cardiale dood en bood een toegevoegde waarde naast de klinische en 
inspannings test gegevens. The stress score bood ook toegevoegde prognostische informatie 
naast de klinische gegevens. Een abnormale scan en de stress score waren sterke 
onafhankelijke voorspellers voor bet gecombineerde eindpunt van cardiale dood, infarct, of 
coronaire revascularisatie. Inspannings 99mTc-tetrofosmin SPECT onderzoek, naast klinische 
gegevens, biedt een toegevoegde informatie voor bet voorspellen van cardiale aandoeningen 
bij patienten met bewezen of vermoedelijke coronaire hartziekten. 
Patienten met norma1e inspannings 99mTc-sestamibi SPECT scans hebben een gunstige 
prognose op middellange termijn. We stelden de incidentie en voorspellers van ( cardiale) 
sterfte vast, ~edurende een 1ange-termijn follow-up (7 .4 ± 1.8 jaar) na een normale 
inspannings 9 mTc-sestamibi scan bij een groep van 218 patienten. Multivariabele analyse 
toonde dat een voorgeschiedenis met coronaire hartziekte en een lage hartfrequentie tijdens 
inspanning onafhankelijke voorpellers zijn van cardiale aandoeningen. Leeftijd en 
hartfrequentie tijdens inspanning zijn onafhankelijke voorspellers voor de totale mortaliteit. 
De jaarlijkse mortaliteitskans was 0.6% in de eerste 5 jaar en 1.8% van het zesde tot bet 
achtste jaar. De kans op cardiale dood of een myocardinfarct was 0. 7% in de eerste 5 jaar en 
1.5% tussen het zesde en achtste jaar. Een hartfrequentie tijdens inspanning <130/min is de 
grenswaarde die patienten verdeelt wat betreft hun sterfterisico en de kans op een 
myocardinfarct. De jaarlijkse mortaliteit en kans op een myocardinfarct is minder dan 1% 
gedurende een vervolgperiode van 5 jaar na een nonnale inspannings sestamibi scan. Tijdens 
deze periode lijkt het daarom niet nodig om de test te herhalen bij patienten met een normale 
scan. Patienten met een voorgeschiedenis van coronaire hartziekten en zij die een 
hartfrequentie tijdens inspanning <130/min hebben dienen intensiever gevolgd te worden. 
In hoofdstuk 14 wordt bet prognostische belang van reversibele perfusie afwijkingen 
bij patienten zonder angina pectoris tijdens de dobutamine stress 99mTc-sestamibi SPECT test 
gepresenteerd. Dit onderzoekt richt zich op de cardiale aandoeningen bij 224 patienten met 
een compleet of gedeeltelijk reversibel perfusie defect. Angina tract bij 93 (42%) patienten op 
tijdens de dobutamine stress test (groep met symptomatische ischemie). De 131 patienten 
zonder angina vertegenwoordigden de groep met stille ischemie. Er was geen significant 
verschil tussen patienten met en zonder angina wat betreft de stress perfusie score, of de 
ischemie score. Tijdens een vervolgperiode van 7.2 jaar, trad cardiale dood op bij 14 (15%) 
patienten met en bij 21 (16%) patienten zonder angina. Een niet-fataal myocardinfarct trad op 
bij 8 (9%) patienten met en 13 (10%) patienten zonder angina. Een multivariabele analyse van 
klinische en perfusie gegevens, toonde dat leeftijd, diabetes mellitus en de ischemie perfusie 
score onafhankelijke voorspellers voor cardiale aandoeningen waren. Patienten met stille 
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ischemie gedefinieerd als reversibele perfusie defecten zonder angina tijdens de dobutamine 
stress sestamibi SPECT test hebben een vergelijkbare hoeveelheid ischemie en een 
vergelijkbare kans op cardiale aandoeningen als patienten met symptomatische ischemie. De 
af\vezigheid van angina pectoris bij patienten met een reversibel perfusiedefect moet daarom 
niet gezien worden als een teken dat wijst op een gunstige prognose. 
Deel3: Nieuwe technieken 
In hoofdstuk 15 wordt de invloed van contractiele reserve van het linker ventrikel op 
atrium natriuretisch peptide (ANP) en brein natriuretisch peptide (BNP) bestudeerd. De 
plasma concentraties van ANP en BNP werden bepaald bij 66 opeenvolgende patienten met 
hartfalen. Bij aile patienten werd een rust echocardiogram gemaakt om de linker ventrikel 
ejectie ftactie (L VEF) te bepalen. Contractiele reserve werd vastgesteld met lage-dosis 
dobutamine stress echocardiografie. Plasma concentraties van beide natriuretische peptiden 
waren boger in patienten met een LVEF$;35% vergeleken met patienten met een LVEF>35%. 
De aanwezigheid van contractiele reserve beinvloedde de concentratie van de natriuretische 
peptiden bij patienten met wandbewegingsstoomissen. Patienten met een behouden 
myocardiale contractiele reserve hadden lagere ANP en BNP niveaus dan patienten zonder 
contractiele reserve. Plasma natriuretische peptide concentraties zijn dus verhoogd bij 
patienten met een dysfunctie van de linker ventrikel. Echter, in aanwezigheid van een 
behouden myocardiale contractiele reserve waren de ANP en BNP concentraties relatief laag. 
In hoofdstuk 16 hebben we de diagnostische moge1ijkbeden van een draagbaar 
echoapparaat geevalueerd voor het screenen op linker ventrikel hypertrofie. Bij 100 patienten 
met hypertensie werd een echocardiogram gemaakt met een draagbaar echoapparaat. Een 
standaard echocardiografiesyteem werd gebruikt als referentiemethode. De patienten hadden 
gemiddeld 13 ± 11 jaar hypertensie. De overeenkomst tussen het standaard echocardiografie 
systeem en het draagbare apparaat voor bet vaststellen van linker ventrikelhypertrofie was 
93%. Draagbare echoapparaten kunnen effectief ingezet worden om te screenen op linker 
ventrikel hypertrofie bij patienten met hypertensie. Deze apparaten zijn relatief goedkoop en 
kunnen deel uitmaken van het klinische onderzoek bij patienten met een hoog risico voor 
linker ventrikel hypertrofie. 
Hoofdstuk 17 beschrijft de screeningsmogelijkheden van draagbare echoapparaten 
voor bet opsporen van linker ventrikel dysfunctie. De belangrijkste bevinding was dat het 
schatten van de L VEF met een draagbaar echoapparaat een gevoelig instrument is voor bet 
screenen op LV dysfunctie. Draagbare echoapparaten kunnen een onderdeel worden van bet 
lichamelijk onderzoek. Echocardiografie wordt zo voor meer patienten beschikbaar en een 
screeningsprogramma voor het opsporen van patienten met LV dysfunctie wordt mogelijk. 
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